drug_name,drug_name_en,drug_synonyms,indication,indication_en,targets,mechanism_of_action,research_institution,drug_category_1,drug_category_2,drug_category_3,drug_tag,pharmacological_type,indication_original,global_highest_phase_indication,global_highest_phase_indication_start_date,global_development_status,disease_area,npuid,originator_country,highest_phase_indication_standard,global_highest_phase_all_indication,global_highest_phase_all_indication_date,global_highest_phase_all_indication_standard,research_institution_count,is_cyclic_peptide,is_rare_disease,is_top20_mnc,top20_mnc_list,originator_company_list,count_originator,research_institution_list,therapeutic_area_norm,therapeutic_area_list,count_therapeutic_area,therapeutic_area_primary,therapeutic_area_secondary,therapeutic_area_tertiary,global_highest_phase_all_indication_sort_val,highest_phase_standard_sort_val,therapeutic_area_norm_en,therapeutic_area_primary_en,therapeutic_area_secondary_en,therapeutic_area_tertiary_en
杆菌肽,bacitracin,杆菌肽;bacitracin,细菌感染,bacterial infection,not available,多肽类抗生素,Columbia University(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,多肽类抗生素,细菌感染,批准上市,,Active,感染领域,DR004636,美国,approved,批准上市,1948/7/29,approved,1,TRUE,FALSE,FALSE,[],['Columbia University'],1,['Columbia University(原研)'],感染领域,['感染领域'],1,感染领域,,,5,5,Infectious Diseases,Infectious Diseases,,
缩宫素,oxytocin,缩宫素;oxytocin;催产素;Syntocinon;TTA-121;OT;Pitocin,催产/引产,Oxygen/induced labor,oxytocin,合成的oxytocin,Travere Therapeutics(原研),创新药,化药,多肽,环肽;First-in-Class,合成的,催产/引产,批准上市,,Active,泌尿生殖领域,DR032561,美国,approved,批准上市,1954/6/30,approved,1,TRUE,FALSE,FALSE,[],['Travere Therapeutics'],1,['Travere Therapeutics(原研)'],泌尿生殖领域,['泌尿生殖领域'],1,泌尿生殖领域,,,5,5,Genitourinary,Genitourinary,,
缩宫素,oxytocin,缩宫素;oxytocin;催产素;Syntocinon;TTA-121;OT;Pitocin,产后子宫出血,Postpartum uterine bleeding,oxytocin,合成的oxytocin,Travere Therapeutics(原研),创新药,化药,多肽,环肽;First-in-Class,合成的,产后子宫出血,批准上市,,Active,泌尿生殖领域,DR032561,美国,approved,批准上市,1954/6/30,approved,1,TRUE,FALSE,FALSE,[],['Travere Therapeutics'],1,['Travere Therapeutics(原研)'],泌尿生殖领域,['泌尿生殖领域'],1,泌尿生殖领域,,,5,5,Genitourinary,Genitourinary,,
缩宫素,oxytocin,缩宫素;oxytocin;催产素;Syntocinon;TTA-121;OT;Pitocin,孤独症谱系障碍,autism spectrum disorder,oxytocin,合成的oxytocin,Travere Therapeutics(原研),创新药,化药,多肽,环肽;First-in-Class,合成的,孤独症谱系障碍,III期临床,,Active,精神领域,DR032561,美国,phase 3,批准上市,1954/6/30,approved,1,TRUE,FALSE,FALSE,[],['Travere Therapeutics'],1,['Travere Therapeutics(原研)'],精神领域,['精神领域'],1,精神领域,,,5,3,Psychiatry,Psychiatry,,
多粘菌素B,polymyxin B,多粘菌素B;polymyxin B,细菌性肺炎,bacterial pneumonia,not available,多粘菌素类抗生素,--,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,多粘菌素类抗生素,细菌性肺炎,批准上市,,Active,感染领域;呼吸领域,DR049372,,approved,批准上市,1956/8/6,approved,0,TRUE,FALSE,FALSE,[],[],0,[],感染领域,"['感染领域', '呼吸领域']",2,感染领域,呼吸领域,,5,5,Infectious Diseases,Infectious Diseases,Respiratory,
多粘菌素B,polymyxin B,多粘菌素B;polymyxin B,菌血症,bacteremia,not available,多粘菌素类抗生素,--,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,多粘菌素类抗生素,菌血症(差异化疾病),批准上市,,Active,感染领域,DR049372,,approved,批准上市,1956/8/6,approved,0,TRUE,FALSE,FALSE,[],[],0,[],感染领域,['感染领域'],1,感染领域,,,5,5,Infectious Diseases,Infectious Diseases,,
多粘菌素B,polymyxin B,多粘菌素B;polymyxin B,细菌性心内膜炎,bacterial endocarditis,not available,多粘菌素类抗生素,--,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,多粘菌素类抗生素,细菌性心内膜炎(差异化疾病),批准上市,,Active,感染领域;心脑血管领域,DR049372,,approved,批准上市,1956/8/6,approved,0,TRUE,FALSE,FALSE,[],[],0,[],感染领域,"['感染领域', '心脑血管领域']",2,感染领域,心脑血管领域,,5,5,Infectious Diseases,Infectious Diseases,Cardiovascular & Cerebrovascular,
放线菌素D,dactinomycin,放线菌素D;dactinomycin;Cosmegen;actinomycin D;Act D,肾母细胞瘤,nephroblastoma,DNA,放线菌素抗生素,Recordati Rare Diseases(原研);Tiziana Life Sciences;Rasna(无权益),创新药,化药,其他,环肽;First-in-Class,放线菌素抗生素,肾母细胞瘤,批准上市,,Active,罕见疾病领域;肿瘤领域,DR001704,欧洲,approved,批准上市,1964/12/10,approved,3,TRUE,TRUE,FALSE,[],['Recordati Rare Diseases'],1,"['Recordati Rare Diseases(原研)', 'Tiziana Life Sciences', 'Rasna(无权益)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,
放线菌素D,dactinomycin,放线菌素D;dactinomycin;Cosmegen;actinomycin D;Act D,横纹肌肉瘤,rhabdomyosarcoma,DNA,放线菌素抗生素,Recordati Rare Diseases(原研);Tiziana Life Sciences;Rasna(无权益),创新药,化药,其他,环肽;First-in-Class,放线菌素抗生素,横纹肌肉瘤,批准上市,,Active,罕见疾病领域;肿瘤领域,DR001704,欧洲,approved,批准上市,1964/12/10,approved,3,TRUE,TRUE,FALSE,[],['Recordati Rare Diseases'],1,"['Recordati Rare Diseases(原研)', 'Tiziana Life Sciences', 'Rasna(无权益)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,
放线菌素D,dactinomycin,放线菌素D;dactinomycin;Cosmegen;actinomycin D;Act D,睾丸癌,testicular cancer,DNA,放线菌素抗生素,Recordati Rare Diseases(原研);Tiziana Life Sciences;Rasna(无权益),创新药,化药,其他,环肽;First-in-Class,放线菌素抗生素,睾丸癌,批准上市,,Active,罕见疾病领域;肿瘤领域,DR001704,欧洲,approved,批准上市,1964/12/10,approved,3,TRUE,TRUE,FALSE,[],['Recordati Rare Diseases'],1,"['Recordati Rare Diseases(原研)', 'Tiziana Life Sciences', 'Rasna(无权益)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,
放线菌素D,dactinomycin,放线菌素D;dactinomycin;Cosmegen;actinomycin D;Act D,尤文氏肉瘤,Ewing's sarcoma,DNA,放线菌素抗生素,Recordati Rare Diseases(原研);Tiziana Life Sciences;Rasna(无权益),创新药,化药,其他,环肽;First-in-Class,放线菌素抗生素,尤文氏肉瘤,批准上市,,Active,罕见疾病领域;肿瘤领域,DR001704,欧洲,approved,批准上市,1964/12/10,approved,3,TRUE,TRUE,FALSE,[],['Recordati Rare Diseases'],1,"['Recordati Rare Diseases(原研)', 'Tiziana Life Sciences', 'Rasna(无权益)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,
放线菌素D,dactinomycin,放线菌素D;dactinomycin;Cosmegen;actinomycin D;Act D,妊娠滋养细胞肿瘤,gestational trophoblastic tumor,DNA,放线菌素抗生素,Recordati Rare Diseases(原研);Tiziana Life Sciences;Rasna(无权益),创新药,化药,其他,环肽;First-in-Class,放线菌素抗生素,妊娠滋养细胞肿瘤,批准上市,,Active,罕见疾病领域;肿瘤领域,DR001704,欧洲,approved,批准上市,1964/12/10,approved,3,TRUE,TRUE,FALSE,[],['Recordati Rare Diseases'],1,"['Recordati Rare Diseases(原研)', 'Tiziana Life Sciences', 'Rasna(无权益)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,
卷曲霉素,capreomycin,卷曲霉素;capreomycin;卷须霉素;结核霉素;Capastat,肺结核,tuberculosis,not available,多肽类抗生素,Eli Lilly(Top20 MNC)(原研),创新药,化药,小分子,环肽;差异化疾病,多肽类抗生素,肺结核(差异化疾病),批准上市,,Active,感染领域,DR023297,美国,approved,批准上市,1971/6/2,approved,1,TRUE,FALSE,TRUE,['Eli Lilly'],['Eli Lilly'],1,['Eli Lilly(Top20 MNC)(原研)'],感染领域,['感染领域'],1,感染领域,,,5,5,Infectious Diseases,Infectious Diseases,,
杆菌肽+多粘菌素B,bacitracin+polymyxin B,杆菌肽+多粘菌素B;bacitracin+polymyxin B,细菌感染,bacterial infection,not available,多粘菌素类抗生素;多肽类抗生素,--,创新药,化药,复方;多肽,环肽,多粘菌素类抗生素;多肽类抗生素,细菌感染,批准上市,,Active,感染领域,DR066181,,approved,批准上市,1974/4/16,approved,0,TRUE,FALSE,FALSE,[],[],0,[],感染领域,['感染领域'],1,感染领域,,,5,5,Infectious Diseases,Infectious Diseases,,
去氨加压素,desmopressin,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,肾盂肾炎,Pyelonephritis,vasopressin,vasopressin类似物,Ferring Pharmaceuticals(原研);维健医药,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,肾盂肾炎(差异化疾病),批准上市,,Active,感染领域;泌尿生殖领域,DR032515,欧洲,approved,批准上市,1978/2/21,approved,2,TRUE,FALSE,FALSE,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', '维健医药']",感染领域,"['感染领域', '泌尿生殖领域']",2,感染领域,泌尿生殖领域,,5,5,Infectious Diseases,Infectious Diseases,Genitourinary,
去氨加压素,desmopressin,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,A型血友病,Hemophilia A,vasopressin,vasopressin类似物,Ferring Pharmaceuticals(原研);维健医药,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,A型血友病(差异化疾病),批准上市,2023/4/10,Active,血液领域;罕见疾病领域,DR032515,欧洲,approved,批准上市,1978/2/21,approved,2,TRUE,TRUE,FALSE,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', '维健医药']",血液领域,['血液领域'],1,血液领域,,,5,5,Hematology,Hematology,,
去氨加压素,desmopressin,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,血管性血友病,von Willebrand disease,vasopressin,vasopressin类似物,Ferring Pharmaceuticals(原研);维健医药,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,血管性血友病(差异化疾病),批准上市,2023/4/10,Active,血液领域;罕见疾病领域,DR032515,欧洲,approved,批准上市,1978/2/21,approved,2,TRUE,TRUE,FALSE,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', '维健医药']",血液领域,['血液领域'],1,血液领域,,,5,5,Hematology,Hematology,,
去氨加压素,desmopressin,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,血小板减少症,Thrombocytopenia,vasopressin,vasopressin类似物,Ferring Pharmaceuticals(原研);维健医药,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,血小板减少症(差异化疾病),批准上市,,Active,血液领域,DR032515,欧洲,approved,批准上市,1978/2/21,approved,2,TRUE,FALSE,FALSE,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', '维健医药']",血液领域,['血液领域'],1,血液领域,,,5,5,Hematology,Hematology,,
去氨加压素,desmopressin,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,中枢性尿崩症,central diabetes insipidus,vasopressin,vasopressin类似物,Ferring Pharmaceuticals(原研);维健医药,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,中枢性尿崩症,批准上市,,Active,内分泌及代谢领域,DR032515,欧洲,approved,批准上市,1978/2/21,approved,2,TRUE,FALSE,FALSE,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', '维健医药']",内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,5,Endocrinology & Metabolism,Endocrinology & Metabolism,,
去氨加压素,desmopressin,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,遗尿症,enuresis,vasopressin,vasopressin类似物,Ferring Pharmaceuticals(原研);维健医药,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,遗尿症(差异化疾病),批准上市,1995/6/1,Active,精神领域,DR032515,欧洲,approved,批准上市,1978/2/21,approved,2,TRUE,FALSE,FALSE,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', '维健医药']",精神领域,['精神领域'],1,精神领域,,,5,5,Psychiatry,Psychiatry,,
去氨加压素,desmopressin,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,肝硬化,Cirrhosis,vasopressin,vasopressin类似物,Ferring Pharmaceuticals(原研);维健医药,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,肝硬化(差异化疾病),批准上市,,Active,消化领域,DR032515,欧洲,approved,批准上市,1978/2/21,approved,2,TRUE,FALSE,FALSE,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', '维健医药']",消化领域,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,
去氨加压素,desmopressin,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,膀胱炎,Cystitis,vasopressin,vasopressin类似物,Ferring Pharmaceuticals(原研);维健医药,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,膀胱炎(差异化疾病),批准上市,,Active,泌尿生殖领域,DR032515,欧洲,approved,批准上市,1978/2/21,approved,2,TRUE,FALSE,FALSE,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', '维健医药']",泌尿生殖领域,['泌尿生殖领域'],1,泌尿生殖领域,,,5,5,Genitourinary,Genitourinary,,
去氨加压素,desmopressin,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,尿频,Frequent urination,vasopressin,vasopressin类似物,Ferring Pharmaceuticals(原研);维健医药,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,尿频(差异化疾病),批准上市,,Active,泌尿生殖领域,DR032515,欧洲,approved,批准上市,1978/2/21,approved,2,TRUE,FALSE,FALSE,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', '维健医药']",泌尿生殖领域,['泌尿生殖领域'],1,泌尿生殖领域,,,5,5,Genitourinary,Genitourinary,,
去氨加压素,desmopressin,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,出血,Bleeding,vasopressin,vasopressin类似物,Ferring Pharmaceuticals(原研);维健医药,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,出血,批准上市,2023/4/10,Active,其他领域,DR032515,欧洲,approved,批准上市,1978/2/21,approved,2,TRUE,FALSE,FALSE,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', '维健医药']",其他领域,['其他领域'],1,其他领域,,,5,5,Others,Others,,
去氨加压素,desmopressin,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,夜尿症,Nocturia,vasopressin,vasopressin类似物,Ferring Pharmaceuticals(原研);维健医药,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,夜尿症(差异化疾病),批准上市,,Active,泌尿生殖领域,DR032515,欧洲,approved,批准上市,1978/2/21,approved,2,TRUE,FALSE,FALSE,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', '维健医药']",泌尿生殖领域,['泌尿生殖领域'],1,泌尿生殖领域,,,5,5,Genitourinary,Genitourinary,,
去氨加压素,desmopressin,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,低钠血症,Hyponatremia,vasopressin,vasopressin类似物,Ferring Pharmaceuticals(原研);维健医药,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,低钠血症(差异化疾病),III期临床,2023/8/31,Active,内分泌及代谢领域,DR032515,欧洲,phase 3,批准上市,1978/2/21,approved,2,TRUE,FALSE,FALSE,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', '维健医药']",内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,3,Endocrinology & Metabolism,Endocrinology & Metabolism,,
去氨加压素,desmopressin,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,维生素D缺乏,Vitamin D deficiency,vasopressin,vasopressin类似物,Ferring Pharmaceuticals(原研);维健医药,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,维生素D缺乏(差异化疾病),I期临床,2025/12/18,Active,内分泌及代谢领域,DR032515,欧洲,phase 1,批准上市,1978/2/21,approved,2,TRUE,FALSE,FALSE,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', '维健医药']",内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,1,Endocrinology & Metabolism,Endocrinology & Metabolism,,
去氨加压素,desmopressin,去氨加压素;desmopressin;Ddavp;Concentraid;desmopresin;Nocdurna,低血压,hypotension,vasopressin,vasopressin类似物,Ferring Pharmaceuticals(原研);维健医药,创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,低血压(差异化疾病),I期临床,2025/10/28,Active,心脑血管领域,DR032515,欧洲,phase 1,批准上市,1978/2/21,approved,2,TRUE,FALSE,FALSE,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', '维健医药']",心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,5,1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
粘菌素,colistin,粘菌素;colistin;抗敌素;COL,志贺杆菌病,shigellosis,not available,多粘菌素类抗生素,Par Pharmaceutical(Endo International)(原研),创新药,化药,其他,环肽;差异化疾病,多粘菌素类抗生素,志贺杆菌病(差异化疾病),批准上市,,Active,感染领域;消化领域,DR049240,美国,approved,批准上市,1982/1/1,approved,1,TRUE,FALSE,FALSE,[],['Par Pharmaceutical(Endo International)'],1,['Par Pharmaceutical(Endo International)(原研)'],感染领域,"['感染领域', '消化领域']",2,感染领域,消化领域,,5,5,Infectious Diseases,Infectious Diseases,Digestive System,
紫霉素,viomycin,紫霉素;viomycin,结核病,tuberculosis,not available,多肽类抗生素,Pfizer(Top20 MNC)(原研),创新药,化药,小分子,环肽,多肽类抗生素,结核病,批准上市,,Active,感染领域,DR051819,美国,approved,批准上市,1982/1/1,approved,1,TRUE,FALSE,TRUE,['Pfizer'],['Pfizer'],1,['Pfizer(Top20 MNC)(原研)'],感染领域,['感染领域'],1,感染领域,,,5,5,Infectious Diseases,Infectious Diseases,,
血管加压素,vasopressin,血管加压素;vasopressin;arginine vasopressin;精氨酸加压素;抗利尿激素;Vasostrict;Vasopressins;argipressin,中枢性尿崩症,central diabetes insipidus,vasopressin,vasopressin,Par Sterile Products(原研),创新药,化药,多肽,环肽;差异化疾病,原形,中枢性尿崩症,批准上市,,Active,内分泌及代谢领域,DR001309,美国,approved,批准上市,1982/1/1,approved,1,TRUE,FALSE,FALSE,[],['Par Sterile Products'],1,['Par Sterile Products(原研)'],内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,5,Endocrinology & Metabolism,Endocrinology & Metabolism,,
血管加压素,vasopressin,血管加压素;vasopressin;arginine vasopressin;精氨酸加压素;抗利尿激素;Vasostrict;Vasopressins;argipressin,血管扩张性休克,vasodilatory shock,vasopressin,vasopressin,Par Sterile Products(原研),创新药,化药,多肽,环肽;差异化疾病,原形,血管扩张性休克(差异化疾病),批准上市,,Active,其他领域,DR001309,美国,approved,批准上市,1982/1/1,approved,1,TRUE,FALSE,FALSE,[],['Par Sterile Products'],1,['Par Sterile Products(原研)'],其他领域,['其他领域'],1,其他领域,,,5,5,Others,Others,,
环孢素,cyclosporine,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,再生障碍性贫血,aplastic anemia,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Sandoz(原研),创新药,化药,多肽,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,再生障碍性贫血(差异化疾病),批准上市,,Active,血液领域;罕见疾病领域,DR032554,欧洲,approved,批准上市,1983/11/14,approved,1,TRUE,TRUE,FALSE,[],['Sandoz'],1,['Sandoz(原研)'],血液领域,['血液领域'],1,血液领域,,,5,5,Hematology,Hematology,,
环孢素,cyclosporine,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,类风湿性关节炎,rheumatoid arthritis,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Sandoz(原研),创新药,化药,多肽,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,类风湿性关节炎(差异化疾病),批准上市,,Active,骨骼肌肉领域;免疫领域,DR032554,欧洲,approved,批准上市,1983/11/14,approved,1,TRUE,FALSE,FALSE,[],['Sandoz'],1,['Sandoz(原研)'],骨骼肌肉领域,"['骨骼肌肉领域', '免疫领域']",2,骨骼肌肉领域,免疫领域,,5,5,Musculoskeletal,Musculoskeletal,Immunology,
环孢素,cyclosporine,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,银屑病,psoriasis,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Sandoz(原研),创新药,化药,多肽,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,银屑病,批准上市,,Active,免疫领域;皮肤领域,DR032554,欧洲,approved,批准上市,1983/11/14,approved,1,TRUE,FALSE,FALSE,[],['Sandoz'],1,['Sandoz(原研)'],免疫领域,"['免疫领域', '皮肤领域']",2,免疫领域,皮肤领域,,5,5,Immunology,Immunology,Dermatology,
环孢素,cyclosporine,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,器官移植排斥,organ transplant rejection,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Sandoz(原研),创新药,化药,多肽,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,器官移植排斥,批准上市,,Active,罕见疾病领域;免疫领域,DR032554,欧洲,approved,批准上市,1983/11/14,approved,1,TRUE,TRUE,FALSE,[],['Sandoz'],1,['Sandoz(原研)'],免疫领域,['免疫领域'],1,免疫领域,,,5,5,Immunology,Immunology,,
环孢素,cyclosporine,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,移植物抗宿主病,graft versus host disease,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Sandoz(原研),创新药,化药,多肽,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,移植物抗宿主病(差异化疾病),批准上市,,Active,罕见疾病领域;免疫领域,DR032554,欧洲,approved,批准上市,1983/11/14,approved,1,TRUE,TRUE,FALSE,[],['Sandoz'],1,['Sandoz(原研)'],免疫领域,['免疫领域'],1,免疫领域,,,5,5,Immunology,Immunology,,
环孢素,cyclosporine,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,特应性皮炎,atopic dermatitis,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Sandoz(原研),创新药,化药,多肽,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,特应性皮炎(差异化疾病),批准上市,,Active,免疫领域;皮肤领域,DR032554,欧洲,approved,批准上市,1983/11/14,approved,1,TRUE,FALSE,FALSE,[],['Sandoz'],1,['Sandoz(原研)'],免疫领域,"['免疫领域', '皮肤领域']",2,免疫领域,皮肤领域,,5,5,Immunology,Immunology,Dermatology,
环孢素,cyclosporine,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,狼疮性肾炎,lupus nephritis,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Sandoz(原研),创新药,化药,多肽,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,狼疮性肾炎,批准上市,,Active,免疫领域;泌尿生殖领域,DR032554,欧洲,approved,批准上市,1983/11/14,approved,1,TRUE,FALSE,FALSE,[],['Sandoz'],1,['Sandoz(原研)'],免疫领域,"['免疫领域', '泌尿生殖领域']",2,免疫领域,泌尿生殖领域,,5,5,Immunology,Immunology,Genitourinary,
环孢素,cyclosporine,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,肾病综合征,nephrotic syndrome,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Sandoz(原研),创新药,化药,多肽,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,肾病综合征(差异化疾病),批准上市,,Active,泌尿生殖领域,DR032554,欧洲,approved,批准上市,1983/11/14,approved,1,TRUE,FALSE,FALSE,[],['Sandoz'],1,['Sandoz(原研)'],泌尿生殖领域,['泌尿生殖领域'],1,泌尿生殖领域,,,5,5,Genitourinary,Genitourinary,,
环孢素,cyclosporine,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,干眼病,dry eye disease,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Sandoz(原研),创新药,化药,多肽,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,干眼病,批准上市,,Active,眼科领域,DR032554,欧洲,approved,批准上市,1983/11/14,approved,1,TRUE,FALSE,FALSE,[],['Sandoz'],1,['Sandoz(原研)'],眼科领域,['眼科领域'],1,眼科领域,,,5,5,Ophthalmology,Ophthalmology,,
环孢素,cyclosporine,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,角结膜炎,keratoconjunctivitis,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Sandoz(原研),创新药,化药,多肽,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,角结膜炎,批准上市,,Active,眼科领域,DR032554,欧洲,approved,批准上市,1983/11/14,approved,1,TRUE,FALSE,FALSE,[],['Sandoz'],1,['Sandoz(原研)'],眼科领域,['眼科领域'],1,眼科领域,,,5,5,Ophthalmology,Ophthalmology,,
环孢素,cyclosporine,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,非感染性葡萄膜炎,noninfectious uveitis,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Sandoz(原研),创新药,化药,多肽,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,非感染性葡萄膜炎,批准上市,,Active,眼科领域;免疫领域,DR032554,欧洲,approved,批准上市,1983/11/14,approved,1,TRUE,FALSE,FALSE,[],['Sandoz'],1,['Sandoz(原研)'],眼科领域,"['眼科领域', '免疫领域']",2,眼科领域,免疫领域,,5,5,Ophthalmology,Ophthalmology,Immunology,
环孢素,cyclosporine,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,溃疡性结肠炎,ulcerative colitis,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Sandoz(原研),创新药,化药,多肽,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,溃疡性结肠炎(差异化疾病),III期临床,,Active,消化领域;免疫领域,DR032554,欧洲,phase 3,批准上市,1983/11/14,approved,1,TRUE,FALSE,FALSE,[],['Sandoz'],1,['Sandoz(原研)'],消化领域,"['消化领域', '免疫领域']",2,消化领域,免疫领域,,5,3,Digestive System,Digestive System,Immunology,
环孢素,cyclosporine,环孢素;cyclosporine;环孢菌素;ciclosporin;ciclosprin A;Sandimmun;cyclosporin;cyclosporin A;cyclosporine A;cyclosporione A;ciclosporine;NSC #290193;Neoral,章鱼壶心肌症,Takotsubo cardiomyopathy,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Sandoz(原研),创新药,化药,多肽,环肽;胆汁酸通路;First-in-Class;差异化疾病;非降解型分子胶,抑制剂;分子胶,章鱼壶心肌症(差异化疾病),II期临床,,Active,罕见疾病领域;心脑血管领域,DR032554,欧洲,phase 2,批准上市,1983/11/14,approved,1,TRUE,TRUE,FALSE,[],['Sandoz'],1,['Sandoz(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,5,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
奥曲肽,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,类癌,carcinoid,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,类癌,批准上市,1988/10/21,Active,肿瘤领域;罕见疾病领域,DR066054,欧洲,approved,批准上市,1988/10/21,approved,1,TRUE,TRUE,TRUE,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,
奥曲肽,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,类癌综合征,carcinoid syndrome,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,类癌综合征,批准上市,2003/7/8,Active,肿瘤领域;罕见疾病领域,DR066054,欧洲,approved,批准上市,1988/10/21,approved,1,TRUE,TRUE,TRUE,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,
奥曲肽,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,低血糖症,hypoglycemia,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,低血糖症,批准上市,2024/6/3,Active,内分泌及代谢领域,DR066054,欧洲,approved,批准上市,1988/10/21,approved,1,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,5,Endocrinology & Metabolism,Endocrinology & Metabolism,,
奥曲肽,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,肢端肥大症,acromegaly,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,肢端肥大症,批准上市,1988/10/21,Active,内分泌及代谢领域;罕见疾病领域,DR066054,欧洲,approved,批准上市,1988/10/21,approved,1,TRUE,TRUE,TRUE,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,5,Endocrinology & Metabolism,Endocrinology & Metabolism,,
奥曲肽,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,甲状腺肿,goiter,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,甲状腺肿(差异化疾病),批准上市,,Active,内分泌及代谢领域,DR066054,欧洲,approved,批准上市,1988/10/21,approved,1,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,5,Endocrinology & Metabolism,Endocrinology & Metabolism,,
奥曲肽,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,消化性溃疡,peptic ulcer,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,消化性溃疡,批准上市,,Active,消化领域,DR066054,欧洲,approved,批准上市,1988/10/21,approved,1,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],消化领域,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,
奥曲肽,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,肝硬化,Cirrhosis,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,肝硬化(差异化疾病),批准上市,,Active,消化领域,DR066054,欧洲,approved,批准上市,1988/10/21,approved,1,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],消化领域,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,
奥曲肽,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,出血,Bleeding,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,出血(差异化疾病),批准上市,2023/1/29,Active,其他领域,DR066054,欧洲,approved,批准上市,1988/10/21,approved,1,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],其他领域,['其他领域'],1,其他领域,,,5,5,Others,Others,,
奥曲肽,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,胃泌素瘤,gastrinoma,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,胃泌素瘤(差异化疾病),批准上市,2003/7/8,Active,肿瘤领域;罕见疾病领域,DR066054,欧洲,approved,批准上市,1988/10/21,approved,1,TRUE,TRUE,TRUE,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,
奥曲肽,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,食管静脉曲张出血,Esophageal variceal bleeding,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,食管静脉曲张出血,批准上市,2023/1/5,Active,消化领域,DR066054,欧洲,approved,批准上市,1988/10/21,approved,1,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],消化领域,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,
奥曲肽,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,消化性溃疡出血,peptic ulcer bleeding,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,消化性溃疡出血,批准上市,,Active,消化领域,DR066054,欧洲,approved,批准上市,1988/10/21,approved,1,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],消化领域,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,
奥曲肽,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,十二指肠溃疡出血,duodenal ulcer bleeding,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,十二指肠溃疡出血,批准上市,,Active,消化领域,DR066054,欧洲,approved,批准上市,1988/10/21,approved,1,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],消化领域,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,
奥曲肽,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,胰瘘,pancreatic fistula,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,胰瘘,批准上市,,Active,消化领域,DR066054,欧洲,approved,批准上市,1988/10/21,approved,1,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],消化领域,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,
奥曲肽,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,胰岛细胞瘤,islet cell tumor,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,胰岛细胞瘤(差异化疾病),批准上市,2003/7/8,Active,肿瘤领域;罕见疾病领域,DR066054,欧洲,approved,批准上市,1988/10/21,approved,1,TRUE,TRUE,TRUE,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,
奥曲肽,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,胃肠胰神经内分泌肿瘤,批准上市,1988/10/21,Active,肿瘤领域;罕见疾病领域,DR066054,欧洲,approved,批准上市,1988/10/21,approved,1,TRUE,TRUE,TRUE,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,
奥曲肽,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,食管静脉曲张,Esophageal varices,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,食管静脉曲张,批准上市,2023/1/29,Active,消化领域,DR066054,欧洲,approved,批准上市,1988/10/21,approved,1,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],消化领域,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,
奥曲肽,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,急性胰腺炎,acute pancreatitis,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,急性胰腺炎(差异化疾病),批准上市,,Active,消化领域,DR066054,欧洲,approved,批准上市,1988/10/21,approved,1,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],消化领域,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,
奥曲肽,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,血管活性肠肽瘤,vasoactive intestinal peptide tumor,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,血管活性肠肽瘤(差异化疾病),批准上市,2003/7/8,Active,肿瘤领域;罕见疾病领域,DR066054,欧洲,approved,批准上市,1988/10/21,approved,1,TRUE,TRUE,TRUE,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,
奥曲肽,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,神经内分泌肿瘤,neuroendocrine tumors,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,神经内分泌肿瘤,III期临床,2005/9/15,Active,肿瘤领域;罕见疾病领域,DR066054,欧洲,phase 3,批准上市,1988/10/21,approved,1,TRUE,TRUE,TRUE,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,3,Oncology,Oncology,,
奥曲肽,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,消化道出血,gastrointestinal bleeding,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,消化道出血,III期临床,2015/3/10,Active,消化领域,DR066054,欧洲,phase 3,批准上市,1988/10/21,approved,1,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],消化领域,['消化领域'],1,消化领域,,,5,3,Digestive System,Digestive System,,
奥曲肽,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,增殖性糖尿病视网膜病变,proliferative diabetic retinopathy,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,增殖性糖尿病视网膜病变(差异化疾病),III期临床,2005/8/16,Active,眼科领域,DR066054,欧洲,phase 3,批准上市,1988/10/21,approved,1,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],眼科领域,['眼科领域'],1,眼科领域,,,5,3,Ophthalmology,Ophthalmology,,
奥曲肽,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,多囊肝病,polycystic liver disease,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,多囊肝病,II/III期临床,2007/1/24,Active,消化领域;罕见疾病领域,DR066054,欧洲,phase 3,批准上市,1988/10/21,approved,1,TRUE,TRUE,TRUE,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],消化领域,['消化领域'],1,消化领域,,,5,3,Digestive System,Digestive System,,
奥曲肽,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,肿瘤,tumor,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,肿瘤,II期临床,2023/9/21,Active,肿瘤领域,DR066054,欧洲,phase 2,批准上市,1988/10/21,approved,1,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,
奥曲肽,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,胰腺神经内分泌肿瘤,pancreatic neuroendocrine tumors,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,胰腺神经内分泌肿瘤,II期临床,2005/6/8,Active,肿瘤领域;罕见疾病领域,DR066054,欧洲,phase 2,批准上市,1988/10/21,approved,1,TRUE,TRUE,TRUE,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,
奥曲肽,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,胃肠道神经内分泌肿瘤,gastrointestinal neuroendocrine tumors,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,胃肠道神经内分泌肿瘤,II期临床,2005/9/28,Active,肿瘤领域;罕见疾病领域,DR066054,欧洲,phase 2,批准上市,1988/10/21,approved,1,TRUE,TRUE,TRUE,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,
奥曲肽,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,脑膜瘤,Meningioma,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,脑膜瘤,II期临床,2015/1/7,Active,肿瘤领域,DR066054,欧洲,phase 2,批准上市,1988/10/21,approved,1,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,
奥曲肽,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,十二指肠疾病,duodenal disease,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,十二指肠疾病,II期临床,2023/9/21,Active,消化领域,DR066054,欧洲,phase 2,批准上市,1988/10/21,approved,1,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],消化领域,['消化领域'],1,消化领域,,,5,2,Digestive System,Digestive System,,
奥曲肽,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,脑膜血管外皮细胞瘤,Meningeal hemangiopericytoma,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,脑膜血管外皮细胞瘤(差异化疾病),II期临床,,Active,肿瘤领域,DR066054,欧洲,phase 2,批准上市,1988/10/21,approved,1,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,
奥曲肽,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,2型糖尿病,type 2 diabetes,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,2型糖尿病(差异化疾病),I期临床,2024/6/21,Active,内分泌及代谢领域,DR066054,欧洲,phase 1,批准上市,1988/10/21,approved,1,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,1,Endocrinology & Metabolism,Endocrinology & Metabolism,,
奥曲肽,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,代谢相关脂肪性肝病,metabolic related fatty liver disease,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,代谢相关脂肪性肝病(差异化疾病),I期临床,2023/11/13,Active,消化领域,DR066054,欧洲,phase 1,批准上市,1988/10/21,approved,1,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],消化领域,['消化领域'],1,消化领域,,,5,1,Digestive System,Digestive System,,
奥曲肽,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,糖尿病黄斑水肿,diabetic macular edema,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,糖尿病黄斑水肿(差异化疾病),I期临床,2025/3/18,Active,眼科领域,DR066054,欧洲,phase 1,批准上市,1988/10/21,approved,1,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],眼科领域,['眼科领域'],1,眼科领域,,,5,1,Ophthalmology,Ophthalmology,,
奥曲肽,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,腹泻,diarrhea,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,腹泻,I期临床,2001/8/31,Active,消化领域,DR066054,欧洲,phase 1,批准上市,1988/10/21,approved,1,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],消化领域,['消化领域'],1,消化领域,,,5,1,Digestive System,Digestive System,,
奥曲肽,octreotide,奥曲肽;octreotide;Sandostatin LAR;Sandostatin;octeotride;SMS995;SMS 201-995;善龙;善宁,原发性神经外胚层肿瘤,primary neuroectodermal tumor,somatostatin,somatostatin类似物,Novartis(Top20 MNC)(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,原发性神经外胚层肿瘤(差异化疾病),I期临床,2023/10/12,Active,肿瘤领域;罕见疾病领域,DR066054,欧洲,phase 1,批准上市,1988/10/21,approved,1,TRUE,TRUE,TRUE,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,
铟[111In]喷曲肽,indium In-111 pentetreotide,铟[111In]喷曲肽;indium In-111 pentetreotide;Octreoscan;In111-pentetréotide;pentetreotide;indium-111 pentetreotide;indium-111-Octreoscan;indium-111 pentreotide;111In-DTPA-octreotide;111In-octreotide,放射性核素显像,radionuclide imaging,SSTR,含铟放射性示踪剂;anti-SSTR多肽偶联核素,Keenova Therapeutics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,含铟放射性示踪剂;多肽偶联核素,放射性核素显像,批准上市,2015/9/28,Active,诊断试剂领域,DR020836,欧洲,approved,批准上市,1994/6/2,approved,1,TRUE,FALSE,FALSE,[],['Keenova Therapeutics'],1,['Keenova Therapeutics(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,5,5,Diagnostic Reagents,Diagnostic Reagents,,
铟[111In]喷曲肽,indium In-111 pentetreotide,铟[111In]喷曲肽;indium In-111 pentetreotide;Octreoscan;In111-pentetréotide;pentetreotide;indium-111 pentetreotide;indium-111-Octreoscan;indium-111 pentreotide;111In-DTPA-octreotide;111In-octreotide,神经内分泌肿瘤,neuroendocrine tumors,SSTR,含铟放射性示踪剂;anti-SSTR多肽偶联核素,Keenova Therapeutics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,含铟放射性示踪剂;多肽偶联核素,神经内分泌肿瘤,批准上市,2015/9/28,Active,肿瘤领域;罕见疾病领域,DR020836,欧洲,approved,批准上市,1994/6/2,approved,1,TRUE,TRUE,FALSE,[],['Keenova Therapeutics'],1,['Keenova Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,
卡培立肽,carperitide,卡培立肽;carperitide;卡哌利汀;recombinant human atrial natriuretic polypeptide,急性心力衰竭,acute heart failure,ANP,重组ANP,Astellas Pharma(Top20 MNC);Daiichi Sankyo(原研),创新药,生物,多肽,环肽;First-in-Class,重组,急性心力衰竭,批准上市,,Active,心脑血管领域,DR007785,日本,approved,批准上市,1995/1/20,approved,2,TRUE,FALSE,TRUE,['Astellas Pharma'],['Daiichi Sankyo'],1,"['Astellas Pharma(Top20 MNC)', 'Daiichi Sankyo(原研)']",心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,5,5,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
来匹卢定,lepirudin,来匹卢定;lepirudin;Refludan;HBW 023;来匹芦定,肝素引起的血小板减少症,Heparin-induced thrombocytopenia,thrombin;hirudin,hirudin类似物;thrombin抑制剂,Bayer(Top20 MNC);Hoechst(Sanofi)(Top20 MNC)(原研)(无权益),创新药,生物,多肽,环肽;First-in-Class;差异化疾病,抑制剂;类似物,肝素引起的血小板减少症(差异化疾病),批准上市,,Active,血液领域,DR057151,欧洲,approved,批准上市,1997/3/12,approved,2,TRUE,FALSE,TRUE,"['Bayer', 'Hoechst(Sanofi)']",['Hoechst(Sanofi)'],1,"['Bayer(Top20 MNC)', 'Hoechst(Sanofi)(Top20 MNC)(原研)(无权益)']",血液领域,['血液领域'],1,血液领域,,,5,5,Hematology,Hematology,,
地西卢定,desirudin,地西卢定;desirudin;Iprivask;recombinant desulphatohirudin;CGP 39393;地西芦定,深静脉血栓,deep vein thrombosis,thrombin;hirudin,hirudin类似物;thrombin抑制剂,Novartis(Top20 MNC)(原研);Kacefa,创新药,生物,多肽,环肽;差异化疾病,抑制剂;类似物,深静脉血栓(差异化疾病),批准上市,2003/4/4,Active,心脑血管领域,DR044002,欧洲,approved,批准上市,1997/7/8,approved,2,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'Kacefa']",心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,5,5,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
地西卢定,desirudin,地西卢定;desirudin;Iprivask;recombinant desulphatohirudin;CGP 39393;地西芦定,肺栓塞,pulmonary embolism,thrombin;hirudin,hirudin类似物;thrombin抑制剂,Novartis(Top20 MNC)(原研);Kacefa,创新药,生物,多肽,环肽;差异化疾病,抑制剂;类似物,肺栓塞(差异化疾病),批准上市,,Active,心脑血管领域,DR044002,欧洲,approved,批准上市,1997/7/8,approved,2,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'Kacefa']",心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,5,5,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
地西卢定,desirudin,地西卢定;desirudin;Iprivask;recombinant desulphatohirudin;CGP 39393;地西芦定,髋关节置换术,hip replacement,thrombin;hirudin,hirudin类似物;thrombin抑制剂,Novartis(Top20 MNC)(原研);Kacefa,创新药,生物,多肽,环肽;差异化疾病,抑制剂;类似物,髋关节置换术(差异化疾病),批准上市,,Active,骨骼肌肉领域,DR044002,欧洲,approved,批准上市,1997/7/8,approved,2,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'Kacefa']",骨骼肌肉领域,['骨骼肌肉领域'],1,骨骼肌肉领域,,,5,5,Musculoskeletal,Musculoskeletal,,
依替巴肽,eptifibatide,依替巴肽;eptifibatide;依非巴特;依替非巴肽;爱啡肽;Integrilin;eptifibitide,血栓(抗凝或抗血小板),Thrombosis (anticoagulant or antiplatelet),GPIIb/IIIa,GPIIb/IIIa抑制剂,Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研);Schering-Plough(Merck & Co.)(Top20 MNC),创新药,化药,多肽,环肽;差异化疾病,抑制剂,血栓(抗凝或抗血小板),批准上市,,Active,心脑血管领域,DR028356,美国,approved,批准上市,1998/5/18,approved,2,TRUE,FALSE,TRUE,"['Millennium Pharmaceuticals(Takeda Pharmaceuticals)', 'Schering-Plough(Merck & Co.)']",['Millennium Pharmaceuticals(Takeda Pharmaceuticals)'],1,"['Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研)', 'Schering-Plough(Merck & Co.)(Top20 MNC)']",心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,5,5,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
依替巴肽,eptifibatide,依替巴肽;eptifibatide;依非巴特;依替非巴肽;爱啡肽;Integrilin;eptifibitide,经皮冠状动脉介入治疗,percutaneous coronary intervention,GPIIb/IIIa,GPIIb/IIIa抑制剂,Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研);Schering-Plough(Merck & Co.)(Top20 MNC),创新药,化药,多肽,环肽;差异化疾病,抑制剂,经皮冠状动脉介入治疗,批准上市,2020/11/19,Active,心脑血管领域,DR028356,美国,approved,批准上市,1998/5/18,approved,2,TRUE,FALSE,TRUE,"['Millennium Pharmaceuticals(Takeda Pharmaceuticals)', 'Schering-Plough(Merck & Co.)']",['Millennium Pharmaceuticals(Takeda Pharmaceuticals)'],1,"['Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研)', 'Schering-Plough(Merck & Co.)(Top20 MNC)']",心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,5,5,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
依替巴肽,eptifibatide,依替巴肽;eptifibatide;依非巴特;依替非巴肽;爱啡肽;Integrilin;eptifibitide,急性冠脉综合征,acute coronary syndrome,GPIIb/IIIa,GPIIb/IIIa抑制剂,Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研);Schering-Plough(Merck & Co.)(Top20 MNC),创新药,化药,多肽,环肽;差异化疾病,抑制剂,急性冠脉综合征,批准上市,2020/11/19,Active,心脑血管领域,DR028356,美国,approved,批准上市,1998/5/18,approved,2,TRUE,FALSE,TRUE,"['Millennium Pharmaceuticals(Takeda Pharmaceuticals)', 'Schering-Plough(Merck & Co.)']",['Millennium Pharmaceuticals(Takeda Pharmaceuticals)'],1,"['Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研)', 'Schering-Plough(Merck & Co.)(Top20 MNC)']",心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,5,5,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
依替巴肽,eptifibatide,依替巴肽;eptifibatide;依非巴特;依替非巴肽;爱啡肽;Integrilin;eptifibitide,心肌梗塞,myocardial infarction,GPIIb/IIIa,GPIIb/IIIa抑制剂,Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研);Schering-Plough(Merck & Co.)(Top20 MNC),创新药,化药,多肽,环肽;差异化疾病,抑制剂,心肌梗塞,批准上市,2021/4/23,Active,心脑血管领域,DR028356,美国,approved,批准上市,1998/5/18,approved,2,TRUE,FALSE,TRUE,"['Millennium Pharmaceuticals(Takeda Pharmaceuticals)', 'Schering-Plough(Merck & Co.)']",['Millennium Pharmaceuticals(Takeda Pharmaceuticals)'],1,"['Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研)', 'Schering-Plough(Merck & Co.)(Top20 MNC)']",心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,5,5,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
依替巴肽,eptifibatide,依替巴肽;eptifibatide;依非巴特;依替非巴肽;爱啡肽;Integrilin;eptifibitide,缺血性卒中,ischemic stroke,GPIIb/IIIa,GPIIb/IIIa抑制剂,Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研);Schering-Plough(Merck & Co.)(Top20 MNC),创新药,化药,多肽,环肽;差异化疾病,抑制剂,缺血性卒中,III期临床,2018/11/8,Active,心脑血管领域,DR028356,美国,phase 3,批准上市,1998/5/18,approved,2,TRUE,FALSE,TRUE,"['Millennium Pharmaceuticals(Takeda Pharmaceuticals)', 'Schering-Plough(Merck & Co.)']",['Millennium Pharmaceuticals(Takeda Pharmaceuticals)'],1,"['Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研)', 'Schering-Plough(Merck & Co.)(Top20 MNC)']",心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,5,3,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
依替巴肽,eptifibatide,依替巴肽;eptifibatide;依非巴特;依替非巴肽;爱啡肽;Integrilin;eptifibitide,不稳定性心绞痛,unstable angina,GPIIb/IIIa,GPIIb/IIIa抑制剂,Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研);Schering-Plough(Merck & Co.)(Top20 MNC),创新药,化药,多肽,环肽;差异化疾病,抑制剂,不稳定性心绞痛,III期临床,2010/2/26,Active,心脑血管领域,DR028356,美国,phase 3,批准上市,1998/5/18,approved,2,TRUE,FALSE,TRUE,"['Millennium Pharmaceuticals(Takeda Pharmaceuticals)', 'Schering-Plough(Merck & Co.)']",['Millennium Pharmaceuticals(Takeda Pharmaceuticals)'],1,"['Millennium Pharmaceuticals(Takeda Pharmaceuticals)(Top20 MNC)(原研)', 'Schering-Plough(Merck & Co.)(Top20 MNC)']",心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,5,3,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
锝[99mTc]地普奥肽,technetium Tc-99m depreotide,锝[99mTc]地普奥肽;technetium Tc-99m depreotide;NeoSpect;depreotide;地普奥肽,癌症,cancer,SSTR,anti-SSTR多肽偶联核素;含锝放射性示踪剂,Bayer(Top20 MNC)(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,含锝放射性示踪剂;多肽偶联核素,癌症,批准上市,,Active,肿瘤领域,DR017965,欧洲,approved,批准上市,1999/8/3,approved,1,TRUE,FALSE,TRUE,['Bayer'],['Bayer'],1,['Bayer(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,
阿托西班,atosiban,阿托西班;atosiban;Tractocile;依保;dTVT;RWJ-22164,推迟早产,postpone premature birth,OXTR;AVPR,AVPR拮抗剂;OXTR拮抗剂,Johnson & Johnson(Top20 MNC);Ferring Pharmaceuticals(原研),创新药,化药,多肽,环肽;First-in-Class;G蛋白偶联受体,拮抗剂,推迟早产,批准上市,,Active,泌尿生殖领域,DR042554,欧洲,approved,批准上市,2000/1/19,approved,2,TRUE,FALSE,TRUE,['Johnson & Johnson'],['Ferring Pharmaceuticals'],1,"['Johnson & Johnson(Top20 MNC)', 'Ferring Pharmaceuticals(原研)']",泌尿生殖领域,['泌尿生殖领域'],1,泌尿生殖领域,,,5,5,Genitourinary,Genitourinary,,
特利加压素,terlipressin,特利加压素;terlipressin;Glypressin;可利新;Terlivaz;LUCASSIN;Remestyp,肝肾综合征,Hepatorenal syndrome,vasopressin,vasopressin类似物,Ferring Pharmaceuticals;Ikaria(Keenova Therapeutics);Orphan Therapeutics(原研);ESP Pharma(PDL BioPharma)(无权益),创新药,化药,多肽,环肽;差异化疾病,类似物,肝肾综合征(差异化疾病),批准上市,,Active,泌尿生殖领域,DR032590,美国,approved,批准上市,2001/1/22,approved,4,TRUE,FALSE,FALSE,[],['Orphan Therapeutics'],1,"['Ferring Pharmaceuticals', 'Ikaria(Keenova Therapeutics)', 'Orphan Therapeutics(原研)', 'ESP Pharma(PDL BioPharma)(无权益)']",泌尿生殖领域,['泌尿生殖领域'],1,泌尿生殖领域,,,5,5,Genitourinary,Genitourinary,,
特利加压素,terlipressin,特利加压素;terlipressin;Glypressin;可利新;Terlivaz;LUCASSIN;Remestyp,产后子宫出血,Postpartum uterine bleeding,vasopressin,vasopressin类似物,Ferring Pharmaceuticals;Ikaria(Keenova Therapeutics);Orphan Therapeutics(原研);ESP Pharma(PDL BioPharma)(无权益),创新药,化药,多肽,环肽;差异化疾病,类似物,产后子宫出血(差异化疾病),批准上市,,Active,泌尿生殖领域,DR032590,美国,approved,批准上市,2001/1/22,approved,4,TRUE,FALSE,FALSE,[],['Orphan Therapeutics'],1,"['Ferring Pharmaceuticals', 'Ikaria(Keenova Therapeutics)', 'Orphan Therapeutics(原研)', 'ESP Pharma(PDL BioPharma)(无权益)']",泌尿生殖领域,['泌尿生殖领域'],1,泌尿生殖领域,,,5,5,Genitourinary,Genitourinary,,
特利加压素,terlipressin,特利加压素;terlipressin;Glypressin;可利新;Terlivaz;LUCASSIN;Remestyp,休克,shock,vasopressin,vasopressin类似物,Ferring Pharmaceuticals;Ikaria(Keenova Therapeutics);Orphan Therapeutics(原研);ESP Pharma(PDL BioPharma)(无权益),创新药,化药,多肽,环肽;差异化疾病,类似物,休克,批准上市,,Active,其他领域,DR032590,美国,approved,批准上市,2001/1/22,approved,4,TRUE,FALSE,FALSE,[],['Orphan Therapeutics'],1,"['Ferring Pharmaceuticals', 'Ikaria(Keenova Therapeutics)', 'Orphan Therapeutics(原研)', 'ESP Pharma(PDL BioPharma)(无权益)']",其他领域,['其他领域'],1,其他领域,,,5,5,Others,Others,,
特利加压素,terlipressin,特利加压素;terlipressin;Glypressin;可利新;Terlivaz;LUCASSIN;Remestyp,食管静脉曲张出血,Esophageal variceal bleeding,vasopressin,vasopressin类似物,Ferring Pharmaceuticals;Ikaria(Keenova Therapeutics);Orphan Therapeutics(原研);ESP Pharma(PDL BioPharma)(无权益),创新药,化药,多肽,环肽;差异化疾病,类似物,食管静脉曲张出血(差异化疾病),批准上市,,Active,消化领域,DR032590,美国,approved,批准上市,2001/1/22,approved,4,TRUE,FALSE,FALSE,[],['Orphan Therapeutics'],1,"['Ferring Pharmaceuticals', 'Ikaria(Keenova Therapeutics)', 'Orphan Therapeutics(原研)', 'ESP Pharma(PDL BioPharma)(无权益)']",消化领域,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,
特利加压素,terlipressin,特利加压素;terlipressin;Glypressin;可利新;Terlivaz;LUCASSIN;Remestyp,消化性溃疡出血,peptic ulcer bleeding,vasopressin,vasopressin类似物,Ferring Pharmaceuticals;Ikaria(Keenova Therapeutics);Orphan Therapeutics(原研);ESP Pharma(PDL BioPharma)(无权益),创新药,化药,多肽,环肽;差异化疾病,类似物,消化性溃疡出血(差异化疾病),批准上市,,Active,消化领域,DR032590,美国,approved,批准上市,2001/1/22,approved,4,TRUE,FALSE,FALSE,[],['Orphan Therapeutics'],1,"['Ferring Pharmaceuticals', 'Ikaria(Keenova Therapeutics)', 'Orphan Therapeutics(原研)', 'ESP Pharma(PDL BioPharma)(无权益)']",消化领域,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,
特利加压素,terlipressin,特利加压素;terlipressin;Glypressin;可利新;Terlivaz;LUCASSIN;Remestyp,术后出血,postoperative bleeding,vasopressin,vasopressin类似物,Ferring Pharmaceuticals;Ikaria(Keenova Therapeutics);Orphan Therapeutics(原研);ESP Pharma(PDL BioPharma)(无权益),创新药,化药,多肽,环肽;差异化疾病,类似物,术后出血,批准上市,,Active,其他领域,DR032590,美国,approved,批准上市,2001/1/22,approved,4,TRUE,FALSE,FALSE,[],['Orphan Therapeutics'],1,"['Ferring Pharmaceuticals', 'Ikaria(Keenova Therapeutics)', 'Orphan Therapeutics(原研)', 'ESP Pharma(PDL BioPharma)(无权益)']",其他领域,['其他领域'],1,其他领域,,,5,5,Others,Others,,
卡泊芬净,caspofungin,"卡泊芬净;caspofungin;Cancidas;科赛斯;MK-0991;L-743,872",真菌感染,fungal infection,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,Merck & Co.(Top20 MNC)(原研),创新药,化药,多肽,环肽;First-in-Class,棘白菌素类抗真菌药;脂肽类抗真菌药,真菌感染,批准上市,,Active,感染领域,DR014100,美国,approved,批准上市,2001/1/26,approved,1,TRUE,FALSE,TRUE,['Merck & Co.'],['Merck & Co.'],1,['Merck & Co.(Top20 MNC)(原研)'],感染领域,['感染领域'],1,感染领域,,,5,5,Infectious Diseases,Infectious Diseases,,
卡泊芬净,caspofungin,"卡泊芬净;caspofungin;Cancidas;科赛斯;MK-0991;L-743,872",曲霉病,Aspergillosis,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,Merck & Co.(Top20 MNC)(原研),创新药,化药,多肽,环肽;First-in-Class,棘白菌素类抗真菌药;脂肽类抗真菌药,曲霉病,批准上市,,Active,感染领域,DR014100,美国,approved,批准上市,2001/1/26,approved,1,TRUE,FALSE,TRUE,['Merck & Co.'],['Merck & Co.'],1,['Merck & Co.(Top20 MNC)(原研)'],感染领域,['感染领域'],1,感染领域,,,5,5,Infectious Diseases,Infectious Diseases,,
卡泊芬净,caspofungin,"卡泊芬净;caspofungin;Cancidas;科赛斯;MK-0991;L-743,872",念珠菌病,candidiasis,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,Merck & Co.(Top20 MNC)(原研),创新药,化药,多肽,环肽;First-in-Class,棘白菌素类抗真菌药;脂肽类抗真菌药,念珠菌病,批准上市,,Active,感染领域,DR014100,美国,approved,批准上市,2001/1/26,approved,1,TRUE,FALSE,TRUE,['Merck & Co.'],['Merck & Co.'],1,['Merck & Co.(Top20 MNC)(原研)'],感染领域,['感染领域'],1,感染领域,,,5,5,Infectious Diseases,Infectious Diseases,,
卡泊芬净,caspofungin,"卡泊芬净;caspofungin;Cancidas;科赛斯;MK-0991;L-743,872",念珠菌血症,candidemia,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,Merck & Co.(Top20 MNC)(原研),创新药,化药,多肽,环肽;First-in-Class,棘白菌素类抗真菌药;脂肽类抗真菌药,念珠菌血症,批准上市,,Active,感染领域,DR014100,美国,approved,批准上市,2001/1/26,approved,1,TRUE,FALSE,TRUE,['Merck & Co.'],['Merck & Co.'],1,['Merck & Co.(Top20 MNC)(原研)'],感染领域,['感染领域'],1,感染领域,,,5,5,Infectious Diseases,Infectious Diseases,,
卡泊芬净,caspofungin,"卡泊芬净;caspofungin;Cancidas;科赛斯;MK-0991;L-743,872",侵袭性念珠菌病,Invasive candidiasis,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,Merck & Co.(Top20 MNC)(原研),创新药,化药,多肽,环肽;First-in-Class,棘白菌素类抗真菌药;脂肽类抗真菌药,侵袭性念珠菌病,批准上市,,Active,感染领域,DR014100,美国,approved,批准上市,2001/1/26,approved,1,TRUE,FALSE,TRUE,['Merck & Co.'],['Merck & Co.'],1,['Merck & Co.(Top20 MNC)(原研)'],感染领域,['感染领域'],1,感染领域,,,5,5,Infectious Diseases,Infectious Diseases,,
卡泊芬净,caspofungin,"卡泊芬净;caspofungin;Cancidas;科赛斯;MK-0991;L-743,872",侵袭性曲霉病,Invasive aspergillosis,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,Merck & Co.(Top20 MNC)(原研),创新药,化药,多肽,环肽;First-in-Class,棘白菌素类抗真菌药;脂肽类抗真菌药,侵袭性曲霉病,批准上市,,Active,感染领域,DR014100,美国,approved,批准上市,2001/1/26,approved,1,TRUE,FALSE,TRUE,['Merck & Co.'],['Merck & Co.'],1,['Merck & Co.(Top20 MNC)(原研)'],感染领域,['感染领域'],1,感染领域,,,5,5,Infectious Diseases,Infectious Diseases,,
卡泊芬净,caspofungin,"卡泊芬净;caspofungin;Cancidas;科赛斯;MK-0991;L-743,872",食管念珠菌感染,Esophageal Candida Infection,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,Merck & Co.(Top20 MNC)(原研),创新药,化药,多肽,环肽;First-in-Class,棘白菌素类抗真菌药;脂肽类抗真菌药,食管念珠菌感染,批准上市,,Active,感染领域,DR014100,美国,approved,批准上市,2001/1/26,approved,1,TRUE,FALSE,TRUE,['Merck & Co.'],['Merck & Co.'],1,['Merck & Co.(Top20 MNC)(原研)'],感染领域,['感染领域'],1,感染领域,,,5,5,Infectious Diseases,Infectious Diseases,,
生长抑素,somatostatin,生长抑素;somatostatin;Modustatine;Stilamin;赛得;思他宁,食管静脉曲张出血,Esophageal variceal bleeding,somatostatin,somatostatin,Merck KGaA(Top20 MNC)(原研);海森生物,创新药,化药,多肽,环肽;差异化疾病,原形,食管静脉曲张出血,批准上市,,Active,消化领域,DR011297,欧洲,approved,批准上市,2002/3/6,approved,2,TRUE,FALSE,TRUE,['Merck KGaA'],['Merck KGaA'],1,"['Merck KGaA(Top20 MNC)(原研)', '海森生物']",消化领域,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,
生长抑素,somatostatin,生长抑素;somatostatin;Modustatine;Stilamin;赛得;思他宁,消化性溃疡出血,peptic ulcer bleeding,somatostatin,somatostatin,Merck KGaA(Top20 MNC)(原研);海森生物,创新药,化药,多肽,环肽;差异化疾病,原形,消化性溃疡出血,批准上市,,Active,消化领域,DR011297,欧洲,approved,批准上市,2002/3/6,approved,2,TRUE,FALSE,TRUE,['Merck KGaA'],['Merck KGaA'],1,"['Merck KGaA(Top20 MNC)(原研)', '海森生物']",消化领域,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,
生长抑素,somatostatin,生长抑素;somatostatin;Modustatine;Stilamin;赛得;思他宁,十二指肠溃疡出血,duodenal ulcer bleeding,somatostatin,somatostatin,Merck KGaA(Top20 MNC)(原研);海森生物,创新药,化药,多肽,环肽;差异化疾病,原形,十二指肠溃疡出血,批准上市,,Active,消化领域,DR011297,欧洲,approved,批准上市,2002/3/6,approved,2,TRUE,FALSE,TRUE,['Merck KGaA'],['Merck KGaA'],1,"['Merck KGaA(Top20 MNC)(原研)', '海森生物']",消化领域,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,
生长抑素,somatostatin,生长抑素;somatostatin;Modustatine;Stilamin;赛得;思他宁,胰瘘,pancreatic fistula,somatostatin,somatostatin,Merck KGaA(Top20 MNC)(原研);海森生物,创新药,化药,多肽,环肽;差异化疾病,原形,胰瘘,批准上市,,Active,消化领域,DR011297,欧洲,approved,批准上市,2002/3/6,approved,2,TRUE,FALSE,TRUE,['Merck KGaA'],['Merck KGaA'],1,"['Merck KGaA(Top20 MNC)(原研)', '海森生物']",消化领域,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,
生长抑素,somatostatin,生长抑素;somatostatin;Modustatine;Stilamin;赛得;思他宁,胆瘘,bile fistula,somatostatin,somatostatin,Merck KGaA(Top20 MNC)(原研);海森生物,创新药,化药,多肽,环肽;差异化疾病,原形,胆瘘(差异化疾病),批准上市,,Active,消化领域,DR011297,欧洲,approved,批准上市,2002/3/6,approved,2,TRUE,FALSE,TRUE,['Merck KGaA'],['Merck KGaA'],1,"['Merck KGaA(Top20 MNC)(原研)', '海森生物']",消化领域,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,
生长抑素,somatostatin,生长抑素;somatostatin;Modustatine;Stilamin;赛得;思他宁,肠瘘,intestinal fistula,somatostatin,somatostatin,Merck KGaA(Top20 MNC)(原研);海森生物,创新药,化药,多肽,环肽;差异化疾病,原形,肠瘘,批准上市,,Active,消化领域,DR011297,欧洲,approved,批准上市,2002/3/6,approved,2,TRUE,FALSE,TRUE,['Merck KGaA'],['Merck KGaA'],1,"['Merck KGaA(Top20 MNC)(原研)', '海森生物']",消化领域,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,
生长抑素,somatostatin,生长抑素;somatostatin;Modustatine;Stilamin;赛得;思他宁,糖尿病酮症酸中毒,diabetic ketoacidosis,somatostatin,somatostatin,Merck KGaA(Top20 MNC)(原研);海森生物,创新药,化药,多肽,环肽;差异化疾病,原形,糖尿病酮症酸中毒(差异化疾病),批准上市,,Active,内分泌及代谢领域,DR011297,欧洲,approved,批准上市,2002/3/6,approved,2,TRUE,FALSE,TRUE,['Merck KGaA'],['Merck KGaA'],1,"['Merck KGaA(Top20 MNC)(原研)', '海森生物']",内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,5,Endocrinology & Metabolism,Endocrinology & Metabolism,,
兰瑞肽,lanreotide,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,类癌,carcinoid,somatostatin,somatostatin类似物,Ipsen;Teijin;Biomeasure;Tulane University(原研),创新药,化药,多肽,环肽;差异化疾病,类似物,类癌,批准上市,,Active,肿瘤领域;罕见疾病领域,DR015935,美国,approved,批准上市,2002/3/14,approved,4,TRUE,TRUE,FALSE,[],['Tulane University'],1,"['Ipsen', 'Teijin', 'Biomeasure', 'Tulane University(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,
兰瑞肽,lanreotide,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,类癌综合征,carcinoid syndrome,somatostatin,somatostatin类似物,Ipsen;Teijin;Biomeasure;Tulane University(原研),创新药,化药,多肽,环肽;差异化疾病,类似物,类癌综合征,批准上市,2002/3/14,Active,肿瘤领域;罕见疾病领域,DR015935,美国,approved,批准上市,2002/3/14,approved,4,TRUE,TRUE,FALSE,[],['Tulane University'],1,"['Ipsen', 'Teijin', 'Biomeasure', 'Tulane University(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,
兰瑞肽,lanreotide,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,肢端肥大症,acromegaly,somatostatin,somatostatin类似物,Ipsen;Teijin;Biomeasure;Tulane University(原研),创新药,化药,多肽,环肽;差异化疾病,类似物,肢端肥大症,批准上市,2002/3/14,Active,内分泌及代谢领域;罕见疾病领域,DR015935,美国,approved,批准上市,2002/3/14,approved,4,TRUE,TRUE,FALSE,[],['Tulane University'],1,"['Ipsen', 'Teijin', 'Biomeasure', 'Tulane University(原研)']",内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,5,Endocrinology & Metabolism,Endocrinology & Metabolism,,
兰瑞肽,lanreotide,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,垂体瘤,Pituitary tumor,somatostatin,somatostatin类似物,Ipsen;Teijin;Biomeasure;Tulane University(原研),创新药,化药,多肽,环肽;差异化疾病,类似物,垂体瘤,批准上市,,Active,肿瘤领域;罕见疾病领域,DR015935,美国,approved,批准上市,2002/3/14,approved,4,TRUE,TRUE,FALSE,[],['Tulane University'],1,"['Ipsen', 'Teijin', 'Biomeasure', 'Tulane University(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,
兰瑞肽,lanreotide,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,somatostatin,somatostatin类似物,Ipsen;Teijin;Biomeasure;Tulane University(原研),创新药,化药,多肽,环肽;差异化疾病,类似物,胃肠胰神经内分泌肿瘤,批准上市,2014/12/16,Active,肿瘤领域;罕见疾病领域,DR015935,美国,approved,批准上市,2002/3/14,approved,4,TRUE,TRUE,FALSE,[],['Tulane University'],1,"['Ipsen', 'Teijin', 'Biomeasure', 'Tulane University(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,
兰瑞肽,lanreotide,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,神经内分泌肿瘤,neuroendocrine tumors,somatostatin,somatostatin类似物,Ipsen;Teijin;Biomeasure;Tulane University(原研),创新药,化药,多肽,环肽;差异化疾病,类似物,神经内分泌肿瘤,III期临床,2016/2/17,Active,肿瘤领域;罕见疾病领域,DR015935,美国,phase 3,批准上市,2002/3/14,approved,4,TRUE,TRUE,FALSE,[],['Tulane University'],1,"['Ipsen', 'Teijin', 'Biomeasure', 'Tulane University(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,3,Oncology,Oncology,,
兰瑞肽,lanreotide,兰瑞肽;lanreotide;Somatuline;索马杜林;ITM-014N;BIM23014C;BIM 23014C;BIM 23014;BIM-23014 C;Somatuline® Autogel®;Somatuline Autogel,胃肠道神经内分泌肿瘤,gastrointestinal neuroendocrine tumors,somatostatin,somatostatin类似物,Ipsen;Teijin;Biomeasure;Tulane University(原研),创新药,化药,多肽,环肽;差异化疾病,类似物,胃肠道神经内分泌肿瘤,III期临床,2025/3/17,Active,肿瘤领域;罕见疾病领域,DR015935,美国,phase 3,批准上市,2002/3/14,approved,4,TRUE,TRUE,FALSE,[],['Tulane University'],1,"['Ipsen', 'Teijin', 'Biomeasure', 'Tulane University(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,3,Oncology,Oncology,,
米卡芬净,micafungin,米卡芬净;micafungin;Mycamine;FK463;FR179642;Funguard,曲霉病,Aspergillosis,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,Sandoz;Astellas Pharma(Top20 MNC)(原研)(无权益),创新药,化药,多肽,环肽,棘白菌素类抗真菌药;脂肽类抗真菌药,曲霉病,批准上市,,Active,感染领域,DR042817,日本,approved,批准上市,2002/10/8,approved,2,TRUE,FALSE,TRUE,['Astellas Pharma'],['Astellas Pharma'],1,"['Sandoz', 'Astellas Pharma(Top20 MNC)(原研)(无权益)']",感染领域,['感染领域'],1,感染领域,,,5,5,Infectious Diseases,Infectious Diseases,,
米卡芬净,micafungin,米卡芬净;micafungin;Mycamine;FK463;FR179642;Funguard,念珠菌病,candidiasis,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,Sandoz;Astellas Pharma(Top20 MNC)(原研)(无权益),创新药,化药,多肽,环肽,棘白菌素类抗真菌药;脂肽类抗真菌药,念珠菌病,批准上市,,Active,感染领域,DR042817,日本,approved,批准上市,2002/10/8,approved,2,TRUE,FALSE,TRUE,['Astellas Pharma'],['Astellas Pharma'],1,"['Sandoz', 'Astellas Pharma(Top20 MNC)(原研)(无权益)']",感染领域,['感染领域'],1,感染领域,,,5,5,Infectious Diseases,Infectious Diseases,,
米卡芬净,micafungin,米卡芬净;micafungin;Mycamine;FK463;FR179642;Funguard,侵袭性念珠菌病,Invasive candidiasis,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,Sandoz;Astellas Pharma(Top20 MNC)(原研)(无权益),创新药,化药,多肽,环肽,棘白菌素类抗真菌药;脂肽类抗真菌药,侵袭性念珠菌病,批准上市,,Active,感染领域,DR042817,日本,approved,批准上市,2002/10/8,approved,2,TRUE,FALSE,TRUE,['Astellas Pharma'],['Astellas Pharma'],1,"['Sandoz', 'Astellas Pharma(Top20 MNC)(原研)(无权益)']",感染领域,['感染领域'],1,感染领域,,,5,5,Infectious Diseases,Infectious Diseases,,
米卡芬净,micafungin,米卡芬净;micafungin;Mycamine;FK463;FR179642;Funguard,食管念珠菌感染,Esophageal Candida Infection,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,Sandoz;Astellas Pharma(Top20 MNC)(原研)(无权益),创新药,化药,多肽,环肽,棘白菌素类抗真菌药;脂肽类抗真菌药,食管念珠菌感染,批准上市,,Active,感染领域,DR042817,日本,approved,批准上市,2002/10/8,approved,2,TRUE,FALSE,TRUE,['Astellas Pharma'],['Astellas Pharma'],1,"['Sandoz', 'Astellas Pharma(Top20 MNC)(原研)(无权益)']",感染领域,['感染领域'],1,感染领域,,,5,5,Infectious Diseases,Infectious Diseases,,
Restasis,Restasis (cyclosporine A),Restasis;Restasis (环孢素);Restasis (cyclosporine A),干眼病,dry eye disease,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Allergan(AbbVie)(Top20 MNC)(原研),微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,干眼病,批准上市,2002/12/23,Active,眼科领域,DR031879,欧洲,approved,批准上市,2002/12/23,approved,1,TRUE,FALSE,TRUE,['Allergan(AbbVie)'],['Allergan(AbbVie)'],1,['Allergan(AbbVie)(Top20 MNC)(原研)'],眼科领域,['眼科领域'],1,眼科领域,,,5,5,Ophthalmology,Ophthalmology,,
Restasis,Restasis (cyclosporine A),Restasis;Restasis (环孢素);Restasis (cyclosporine A),流泪,shed tears,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Allergan(AbbVie)(Top20 MNC)(原研),微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,流泪,II/III期临床,2020/11/20,Active,其他领域,DR031879,欧洲,phase 3,批准上市,2002/12/23,approved,1,TRUE,FALSE,TRUE,['Allergan(AbbVie)'],['Allergan(AbbVie)'],1,['Allergan(AbbVie)(Top20 MNC)(原研)'],其他领域,['其他领域'],1,其他领域,,,5,3,Others,Others,,
Restasis,Restasis (cyclosporine A),Restasis;Restasis (环孢素);Restasis (cyclosporine A),眼科疾病,Eye diseases,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Allergan(AbbVie)(Top20 MNC)(原研),微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,眼科疾病,I期临床,2024/10/3,Active,眼科领域,DR031879,欧洲,phase 1,批准上市,2002/12/23,approved,1,TRUE,FALSE,TRUE,['Allergan(AbbVie)'],['Allergan(AbbVie)'],1,['Allergan(AbbVie)(Top20 MNC)(原研)'],眼科领域,['眼科领域'],1,眼科领域,,,5,1,Ophthalmology,Ophthalmology,,
达托霉素,daptomycin,达托霉素;daptomycin;Cubicin;克必信;MK-3009;LY146032;Cidecin,皮肤/皮肤结构感染,Skin/skin structure infection,not available,脂肽类抗生素,Gilead Sciences(Top20 MNC);Eli Lilly(Top20 MNC)(原研);Cubist Pharmaceuticals(Merck & Co.)(Top20 MNC),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,脂肽类抗生素,皮肤/皮肤结构感染,批准上市,,Active,感染领域;皮肤领域,DR038793,美国,approved,批准上市,2003/9/12,approved,3,TRUE,FALSE,TRUE,"['Gilead Sciences', 'Eli Lilly', 'Cubist Pharmaceuticals(Merck & Co.)']",['Eli Lilly'],1,"['Gilead Sciences(Top20 MNC)', 'Eli Lilly(Top20 MNC)(原研)', 'Cubist Pharmaceuticals(Merck & Co.)(Top20 MNC)']",感染领域,"['感染领域', '皮肤领域']",2,感染领域,皮肤领域,,5,5,Infectious Diseases,Infectious Diseases,Dermatology,
达托霉素,daptomycin,达托霉素;daptomycin;Cubicin;克必信;MK-3009;LY146032;Cidecin,菌血症,bacteremia,not available,脂肽类抗生素,Gilead Sciences(Top20 MNC);Eli Lilly(Top20 MNC)(原研);Cubist Pharmaceuticals(Merck & Co.)(Top20 MNC),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,脂肽类抗生素,菌血症(差异化疾病),批准上市,,Active,感染领域,DR038793,美国,approved,批准上市,2003/9/12,approved,3,TRUE,FALSE,TRUE,"['Gilead Sciences', 'Eli Lilly', 'Cubist Pharmaceuticals(Merck & Co.)']",['Eli Lilly'],1,"['Gilead Sciences(Top20 MNC)', 'Eli Lilly(Top20 MNC)(原研)', 'Cubist Pharmaceuticals(Merck & Co.)(Top20 MNC)']",感染领域,['感染领域'],1,感染领域,,,5,5,Infectious Diseases,Infectious Diseases,,
达托霉素,daptomycin,达托霉素;daptomycin;Cubicin;克必信;MK-3009;LY146032;Cidecin,细菌性心内膜炎,bacterial endocarditis,not available,脂肽类抗生素,Gilead Sciences(Top20 MNC);Eli Lilly(Top20 MNC)(原研);Cubist Pharmaceuticals(Merck & Co.)(Top20 MNC),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,脂肽类抗生素,细菌性心内膜炎(差异化疾病),批准上市,,Active,感染领域;心脑血管领域,DR038793,美国,approved,批准上市,2003/9/12,approved,3,TRUE,FALSE,TRUE,"['Gilead Sciences', 'Eli Lilly', 'Cubist Pharmaceuticals(Merck & Co.)']",['Eli Lilly'],1,"['Gilead Sciences(Top20 MNC)', 'Eli Lilly(Top20 MNC)(原研)', 'Cubist Pharmaceuticals(Merck & Co.)(Top20 MNC)']",感染领域,"['感染领域', '心脑血管领域']",2,感染领域,心脑血管领域,,5,5,Infectious Diseases,Infectious Diseases,Cardiovascular & Cerebrovascular,
卡贝缩宫素,carbetocin,卡贝缩宫素;carbetocin;卡比托辛;Duratocin;巧特欣,产后子宫收缩乏力,Postpartum uterine atony,oxytocin,oxytocin类似物,Ferring Pharmaceuticals(原研),创新药,化药,小分子,环肽;First-in-Class;差异化疾病,类似物,产后子宫收缩乏力(差异化疾病),批准上市,,Active,泌尿生殖领域,DR016036,欧洲,approved,批准上市,2004/10/20,approved,1,TRUE,FALSE,FALSE,[],['Ferring Pharmaceuticals'],1,['Ferring Pharmaceuticals(原研)'],泌尿生殖领域,['泌尿生殖领域'],1,泌尿生殖领域,,,5,5,Genitourinary,Genitourinary,,
卡贝缩宫素,carbetocin,卡贝缩宫素;carbetocin;卡比托辛;Duratocin;巧特欣,产后子宫出血,Postpartum uterine bleeding,oxytocin,oxytocin类似物,Ferring Pharmaceuticals(原研),创新药,化药,小分子,环肽;First-in-Class;差异化疾病,类似物,产后子宫出血(差异化疾病),批准上市,,Active,泌尿生殖领域,DR016036,欧洲,approved,批准上市,2004/10/20,approved,1,TRUE,FALSE,FALSE,[],['Ferring Pharmaceuticals'],1,['Ferring Pharmaceuticals(原研)'],泌尿生殖领域,['泌尿生殖领域'],1,泌尿生殖领域,,,5,5,Genitourinary,Genitourinary,,
齐考诺肽,ziconotide,齐考诺肽;ziconotide;Prialt;SNX-111,慢性疼痛,chronic pain,N-type calcium channel,N-type calcium channel阻断剂,Tersera;Neurex(Perrigo)(原研);Jazz Pharmaceuticals(无权益),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,阻断剂,慢性疼痛,批准上市,2004/12/28,Active,麻醉镇痛领域,DR026760,美国,approved,批准上市,2004/12/28,approved,3,TRUE,FALSE,FALSE,[],['Neurex(Perrigo)'],1,"['Tersera', 'Neurex(Perrigo)(原研)', 'Jazz Pharmaceuticals(无权益)']",麻醉镇痛领域,['麻醉镇痛领域'],1,麻醉镇痛领域,,,5,5,Anesthesia & Analgesia,Anesthesia & Analgesia,,
普兰林肽,pramlintide,普兰林肽;pramlintide;Symlin;AC137,1型糖尿病,type 1 diabetes,amylin,amylin类似物,Bristol-Myers Squibb(Top20 MNC);Amylin Pharmaceuticals(AstraZeneca)(Top20 MNC)(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,1型糖尿病(差异化疾病),批准上市,2005/3/16,Active,内分泌及代谢领域,DR062469,美国,approved,批准上市,2005/3/16,approved,2,TRUE,FALSE,TRUE,"['Bristol-Myers Squibb', 'Amylin Pharmaceuticals(AstraZeneca)']",['Amylin Pharmaceuticals(AstraZeneca)'],1,"['Bristol-Myers Squibb(Top20 MNC)', 'Amylin Pharmaceuticals(AstraZeneca)(Top20 MNC)(原研)']",内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,5,Endocrinology & Metabolism,Endocrinology & Metabolism,,
普兰林肽,pramlintide,普兰林肽;pramlintide;Symlin;AC137,2型糖尿病,type 2 diabetes,amylin,amylin类似物,Bristol-Myers Squibb(Top20 MNC);Amylin Pharmaceuticals(AstraZeneca)(Top20 MNC)(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,2型糖尿病,批准上市,2005/3/16,Active,内分泌及代谢领域,DR062469,美国,approved,批准上市,2005/3/16,approved,2,TRUE,FALSE,TRUE,"['Bristol-Myers Squibb', 'Amylin Pharmaceuticals(AstraZeneca)']",['Amylin Pharmaceuticals(AstraZeneca)'],1,"['Bristol-Myers Squibb(Top20 MNC)', 'Amylin Pharmaceuticals(AstraZeneca)(Top20 MNC)(原研)']",内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,5,Endocrinology & Metabolism,Endocrinology & Metabolism,,
普兰林肽,pramlintide,普兰林肽;pramlintide;Symlin;AC137,糖尿病前期,prediabetes,amylin,amylin类似物,Bristol-Myers Squibb(Top20 MNC);Amylin Pharmaceuticals(AstraZeneca)(Top20 MNC)(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,糖尿病前期(差异化疾病),II/III期临床,2024/10/1,Active,内分泌及代谢领域,DR062469,美国,phase 3,批准上市,2005/3/16,approved,2,TRUE,FALSE,TRUE,"['Bristol-Myers Squibb', 'Amylin Pharmaceuticals(AstraZeneca)']",['Amylin Pharmaceuticals(AstraZeneca)'],1,"['Bristol-Myers Squibb(Top20 MNC)', 'Amylin Pharmaceuticals(AstraZeneca)(Top20 MNC)(原研)']",内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,3,Endocrinology & Metabolism,Endocrinology & Metabolism,,
普兰林肽,pramlintide,普兰林肽;pramlintide;Symlin;AC137,代谢性骨病,metabolic bone disease,amylin,amylin类似物,Bristol-Myers Squibb(Top20 MNC);Amylin Pharmaceuticals(AstraZeneca)(Top20 MNC)(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,类似物,代谢性骨病(差异化疾病),I期临床,2023/12/29,Active,骨骼肌肉领域;内分泌及代谢领域,DR062469,美国,phase 1,批准上市,2005/3/16,approved,2,TRUE,FALSE,TRUE,"['Bristol-Myers Squibb', 'Amylin Pharmaceuticals(AstraZeneca)']",['Amylin Pharmaceuticals(AstraZeneca)'],1,"['Bristol-Myers Squibb(Top20 MNC)', 'Amylin Pharmaceuticals(AstraZeneca)(Top20 MNC)(原研)']",骨骼肌肉领域,"['骨骼肌肉领域', '内分泌及代谢领域']",2,骨骼肌肉领域,内分泌及代谢领域,,5,1,Musculoskeletal,Musculoskeletal,Endocrinology & Metabolism,
脑利钠肽,nesiritide biosimilar,脑利钠肽;新活素(重组人脑利钠肽);nesiritide biosimilar;新活素,心力衰竭,heart failure,BNP,重组BNP,西藏药业(康哲药业)(原研),生物类似药,生物,多肽,环肽;差异化疾病,重组,心力衰竭(差异化疾病),批准上市,,Active,心脑血管领域,DR014028,中国(内地),approved,批准上市,2005/3/31,approved,1,TRUE,FALSE,FALSE,[],['西藏药业(康哲药业)'],1,['西藏药业(康哲药业)(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,5,5,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
脑利钠肽,nesiritide biosimilar,脑利钠肽;新活素(重组人脑利钠肽);nesiritide biosimilar;新活素,急性心力衰竭,acute heart failure,BNP,重组BNP,西藏药业(康哲药业)(原研),生物类似药,生物,多肽,环肽;差异化疾病,重组,急性心力衰竭,I期临床,2025/11/16,Active,心脑血管领域,DR014028,中国(内地),phase 1,批准上市,2005/3/31,approved,1,TRUE,FALSE,FALSE,[],['西藏药业(康哲药业)'],1,['西藏药业(康哲药业)(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,5,1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
脑利钠肽,nesiritide biosimilar,脑利钠肽;新活素(重组人脑利钠肽);nesiritide biosimilar;新活素,慢性心力衰竭,chronic heart failure,BNP,重组BNP,西藏药业(康哲药业)(原研),生物类似药,生物,多肽,环肽;差异化疾病,重组,慢性心力衰竭(差异化疾病),I期临床,2025/12/17,Active,心脑血管领域,DR014028,中国(内地),phase 1,批准上市,2005/3/31,approved,1,TRUE,FALSE,FALSE,[],['西藏药业(康哲药业)'],1,['西藏药业(康哲药业)(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,5,1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
脑利钠肽,nesiritide biosimilar,脑利钠肽;新活素(重组人脑利钠肽);nesiritide biosimilar;新活素,心脏病,heart disease,BNP,重组BNP,西藏药业(康哲药业)(原研),生物类似药,生物,多肽,环肽;差异化疾病,重组,心脏病(差异化疾病),I期临床,2023/1/28,Active,心脑血管领域,DR014028,中国(内地),phase 1,批准上市,2005/3/31,approved,1,TRUE,FALSE,FALSE,[],['西藏药业(康哲药业)'],1,['西藏药业(康哲药业)(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,5,1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
脑利钠肽,nesiritide biosimilar,脑利钠肽;新活素(重组人脑利钠肽);nesiritide biosimilar;新活素,急性失代偿性心力衰竭,acute decompensated heart failure,BNP,重组BNP,西藏药业(康哲药业)(原研),生物类似药,生物,多肽,环肽;差异化疾病,重组,急性失代偿性心力衰竭,I期临床,2025/6/11,Active,心脑血管领域,DR014028,中国(内地),phase 1,批准上市,2005/3/31,approved,1,TRUE,FALSE,FALSE,[],['西藏药业(康哲药业)'],1,['西藏药业(康哲药业)(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,5,1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
脑利钠肽,nesiritide biosimilar,脑利钠肽;布罗纳泰(重组人脑利钠肽);nesiritide biosimilar;布罗纳泰,参考原研,Reference original research,BNP,重组BNP,苏兰生物(原研),生物类似药,生物,多肽,环肽,重组,参考原研,批准上市,,Active,其他领域,DR015076,中国(内地),approved,批准上市,2005/5/10,approved,1,TRUE,FALSE,FALSE,[],['苏兰生物'],1,['苏兰生物(原研)'],其他领域,['其他领域'],1,其他领域,,,5,5,Others,Others,,
Ikervis/Verkazia,Ikervis/Verkazia (cyclosporine eye drop),Ikervis/Verkazia;Ikervis/Verkazia (环孢素滴眼液);Ikervis/Verkazia (cyclosporine eye drop);Ikervis;NOVA22007;DE-076B;DE-076C;Verkazia;STN1007603;Cyclokat;维卡思,干眼病,dry eye disease,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Novagali Pharma(Santen Pharmaceutical)(原研);Harrow,微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,干眼病,批准上市,,Active,眼科领域,DR015576,欧洲,approved,批准上市,2005/10/11,approved,2,TRUE,FALSE,FALSE,[],['Novagali Pharma(Santen Pharmaceutical)'],1,"['Novagali Pharma(Santen Pharmaceutical)(原研)', 'Harrow']",眼科领域,['眼科领域'],1,眼科领域,,,5,5,Ophthalmology,Ophthalmology,,
Ikervis/Verkazia,Ikervis/Verkazia (cyclosporine eye drop),Ikervis/Verkazia;Ikervis/Verkazia (环孢素滴眼液);Ikervis/Verkazia (cyclosporine eye drop);Ikervis;NOVA22007;DE-076B;DE-076C;Verkazia;STN1007603;Cyclokat;维卡思,春季角结膜炎,Vernal keratoconjunctivitis,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Novagali Pharma(Santen Pharmaceutical)(原研);Harrow,微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,春季角结膜炎,批准上市,2018/7/6,Active,眼科领域;罕见疾病领域,DR015576,欧洲,approved,批准上市,2005/10/11,approved,2,TRUE,TRUE,FALSE,[],['Novagali Pharma(Santen Pharmaceutical)'],1,"['Novagali Pharma(Santen Pharmaceutical)(原研)', 'Harrow']",眼科领域,['眼科领域'],1,眼科领域,,,5,5,Ophthalmology,Ophthalmology,,
Ikervis/Verkazia,Ikervis/Verkazia (cyclosporine eye drop),Ikervis/Verkazia;Ikervis/Verkazia (环孢素滴眼液);Ikervis/Verkazia (cyclosporine eye drop);Ikervis;NOVA22007;DE-076B;DE-076C;Verkazia;STN1007603;Cyclokat;维卡思,角结膜炎,keratoconjunctivitis,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Novagali Pharma(Santen Pharmaceutical)(原研);Harrow,微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,角结膜炎,II期临床,2023/12/13,Active,眼科领域,DR015576,欧洲,phase 2,批准上市,2005/10/11,approved,2,TRUE,FALSE,FALSE,[],['Novagali Pharma(Santen Pharmaceutical)'],1,"['Novagali Pharma(Santen Pharmaceutical)(原研)', 'Harrow']",眼科领域,['眼科领域'],1,眼科领域,,,5,2,Ophthalmology,Ophthalmology,,
阿尼芬净,anidulafungin,阿尼芬净;anidulafungin;Eraxis;Ecalta;LY303366;VER002,念珠菌病,candidiasis,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,Pfizer(Top20 MNC);Eli Lilly(Top20 MNC)(原研);Vicuron Pharmaceuticals(AbbVie)(Top20 MNC),创新药,化药,多肽,环肽;差异化疾病,棘白菌素类抗真菌药;脂肽类抗真菌药,念珠菌病,批准上市,2006/2/17,Active,感染领域,DR031838,美国,approved,批准上市,2006/2/17,approved,3,TRUE,FALSE,TRUE,"['Pfizer', 'Eli Lilly', 'Vicuron\xa0Pharmaceuticals(AbbVie)']",['Eli Lilly'],1,"['Pfizer(Top20 MNC)', 'Eli Lilly(Top20 MNC)(原研)', 'Vicuron\xa0Pharmaceuticals(AbbVie)(Top20 MNC)']",感染领域,['感染领域'],1,感染领域,,,5,5,Infectious Diseases,Infectious Diseases,,
阿尼芬净,anidulafungin,阿尼芬净;anidulafungin;Eraxis;Ecalta;LY303366;VER002,念珠菌血症,candidemia,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,Pfizer(Top20 MNC);Eli Lilly(Top20 MNC)(原研);Vicuron Pharmaceuticals(AbbVie)(Top20 MNC),创新药,化药,多肽,环肽;差异化疾病,棘白菌素类抗真菌药;脂肽类抗真菌药,念珠菌血症,批准上市,2006/2/17,Active,感染领域,DR031838,美国,approved,批准上市,2006/2/17,approved,3,TRUE,FALSE,TRUE,"['Pfizer', 'Eli Lilly', 'Vicuron\xa0Pharmaceuticals(AbbVie)']",['Eli Lilly'],1,"['Pfizer(Top20 MNC)', 'Eli Lilly(Top20 MNC)(原研)', 'Vicuron\xa0Pharmaceuticals(AbbVie)(Top20 MNC)']",感染领域,['感染领域'],1,感染领域,,,5,5,Infectious Diseases,Infectious Diseases,,
阿尼芬净,anidulafungin,阿尼芬净;anidulafungin;Eraxis;Ecalta;LY303366;VER002,侵袭性曲霉病,Invasive aspergillosis,glucan synthase,棘白菌素类抗真菌药;脂肽类抗真菌药,Pfizer(Top20 MNC);Eli Lilly(Top20 MNC)(原研);Vicuron Pharmaceuticals(AbbVie)(Top20 MNC),创新药,化药,多肽,环肽;差异化疾病,棘白菌素类抗真菌药;脂肽类抗真菌药,侵袭性曲霉病,III期临床,2007/9/18,Active,感染领域,DR031838,美国,phase 3,批准上市,2006/2/17,approved,3,TRUE,FALSE,TRUE,"['Pfizer', 'Eli Lilly', 'Vicuron\xa0Pharmaceuticals(AbbVie)']",['Eli Lilly'],1,"['Pfizer(Top20 MNC)', 'Eli Lilly(Top20 MNC)(原研)', 'Vicuron\xa0Pharmaceuticals(AbbVie)(Top20 MNC)']",感染领域,['感染领域'],1,感染领域,,,5,3,Infectious Diseases,Infectious Diseases,,
罗米地辛,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,皮肤T细胞淋巴瘤,Cutaneous T-cell lymphoma,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),创新药,化药,小分子,环肽;差异化疾病;表观遗传,抑制剂,皮肤T细胞淋巴瘤,批准上市,2009/11/5,Active,肿瘤领域;罕见疾病领域,DR057058,日本,approved,批准上市,2009/11/5,approved,2,TRUE,TRUE,TRUE,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,
罗米地辛,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,胰腺导管癌,pancreatic ductal carcinoma,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),创新药,化药,小分子,环肽;差异化疾病;表观遗传,抑制剂,胰腺导管癌,I/II期临床,2020/2/6,Active,肿瘤领域,DR057058,日本,phase 2,批准上市,2009/11/5,approved,2,TRUE,FALSE,TRUE,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,
罗米地辛,romidepsin,罗米地辛;romidepsin;Istodax;FR901228;FK228;NSC 630176;depsipeptide,肌层浸润性膀胱癌,muscle invasive bladder cancer,HDAC,HDAC抑制剂,Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研);Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC),创新药,化药,小分子,环肽;差异化疾病;表观遗传,抑制剂,肌层浸润性膀胱癌,I期临床,2025/5/9,Active,肿瘤领域,DR057058,日本,phase 1,批准上市,2009/11/5,approved,2,TRUE,FALSE,TRUE,"['Fujisawa Pharmaceutical(Astellas Pharma)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)']",['Fujisawa Pharmaceutical(Astellas Pharma)'],1,"['Fujisawa Pharmaceutical(Astellas Pharma)(Top20 MNC)(原研)', 'Gloucester Pharmaceuticals(Bristol-Myers Squibb)(Top20 MNC)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,
艾卡拉肽,ecallantide,艾卡拉肽;ecallantide;Kalbitor;DX-88;FOV2302,遗传性血管性水肿,hereditary angioedema,PKK,PKK抑制剂,Dyax(Takeda Pharmaceuticals)(Top20 MNC)(原研);CVie Therapeutics(Windtree Therapeutics);Fovea Pharmaceuticals(Sanofi)(Top20 MNC),创新药,生物,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,遗传性血管性水肿,批准上市,2009/12/1,Active,皮肤领域;罕见疾病领域,DR003372,美国,approved,批准上市,2009/12/1,approved,3,TRUE,TRUE,TRUE,"['Dyax(Takeda Pharmaceuticals)', 'Fovea Pharmaceuticals(Sanofi)']",['Dyax(Takeda Pharmaceuticals)'],1,"['Dyax(Takeda Pharmaceuticals)(Top20 MNC)(原研)', 'CVie Therapeutics(Windtree Therapeutics)', 'Fovea Pharmaceuticals(Sanofi)(Top20 MNC)']",皮肤领域,['皮肤领域'],1,皮肤领域,,,5,5,Dermatology,Dermatology,,
艾卡拉肽,ecallantide,艾卡拉肽;ecallantide;Kalbitor;DX-88;FOV2302,ACE抑制剂引起的血管性水肿,Angioedema caused by ACE inhibitors,PKK,PKK抑制剂,Dyax(Takeda Pharmaceuticals)(Top20 MNC)(原研);CVie Therapeutics(Windtree Therapeutics);Fovea Pharmaceuticals(Sanofi)(Top20 MNC),创新药,生物,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,ACE抑制剂引起的血管性水肿(差异化疾病),II期临床,2009/12/21,Active,心脑血管领域,DR003372,美国,phase 2,批准上市,2009/12/1,approved,3,TRUE,FALSE,TRUE,"['Dyax(Takeda Pharmaceuticals)', 'Fovea Pharmaceuticals(Sanofi)']",['Dyax(Takeda Pharmaceuticals)'],1,"['Dyax(Takeda Pharmaceuticals)(Top20 MNC)(原研)', 'CVie Therapeutics(Windtree Therapeutics)', 'Fovea Pharmaceuticals(Sanofi)(Top20 MNC)']",心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,5,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
帕瑞肽,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,肢端肥大症,acromegaly,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),创新药,化药,多肽,环肽;差异化疾病,类似物,肢端肥大症,批准上市,2014/11/24,Active,内分泌及代谢领域;罕见疾病领域,DR015961,欧洲,approved,批准上市,2012/4/24,approved,2,TRUE,TRUE,TRUE,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,5,Endocrinology & Metabolism,Endocrinology & Metabolism,,
帕瑞肽,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,库欣综合征,Cushing's syndrome,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),创新药,化药,多肽,环肽;差异化疾病,类似物,库欣综合征(差异化疾病),批准上市,2012/4/24,Active,内分泌及代谢领域;罕见疾病领域,DR015961,欧洲,approved,批准上市,2012/4/24,approved,2,TRUE,TRUE,TRUE,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,5,Endocrinology & Metabolism,Endocrinology & Metabolism,,
帕瑞肽,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,胰瘘,pancreatic fistula,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),创新药,化药,多肽,环肽;差异化疾病,类似物,胰瘘,III期临床,2009/10/14,Active,消化领域,DR015961,欧洲,phase 3,批准上市,2012/4/24,approved,2,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",消化领域,['消化领域'],1,消化领域,,,5,3,Digestive System,Digestive System,,
帕瑞肽,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,泌乳素瘤,prolactinoma,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),创新药,化药,多肽,环肽;差异化疾病,类似物,泌乳素瘤(差异化疾病),II/III期临床,2012/6/15,Active,肿瘤领域;罕见疾病领域,DR015961,欧洲,phase 3,批准上市,2012/4/24,approved,2,TRUE,TRUE,TRUE,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,3,Oncology,Oncology,,
帕瑞肽,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,乳腺癌,breast cancer,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),创新药,化药,多肽,环肽;差异化疾病,类似物,乳腺癌,II期临床,2011/5/20,Active,肿瘤领域,DR015961,欧洲,phase 2,批准上市,2012/4/24,approved,2,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,
帕瑞肽,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,胰腺癌,pancreatic cancer,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),创新药,化药,多肽,环肽;差异化疾病,类似物,胰腺癌,II期临床,2009/8/13,Active,肿瘤领域;罕见疾病领域,DR015961,欧洲,phase 2,批准上市,2012/4/24,approved,2,TRUE,TRUE,TRUE,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,
帕瑞肽,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,髓样甲状腺癌,medullary thyroid cancer,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),创新药,化药,多肽,环肽;差异化疾病,类似物,髓样甲状腺癌(差异化疾病),II期临床,2011/1/5,Active,肿瘤领域;罕见疾病领域,DR015961,欧洲,phase 2,批准上市,2012/4/24,approved,2,TRUE,TRUE,TRUE,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,
帕瑞肽,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,低血糖症,hypoglycemia,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),创新药,化药,多肽,环肽;差异化疾病,类似物,低血糖症,II期临床,,Active,内分泌及代谢领域,DR015961,欧洲,phase 2,批准上市,2012/4/24,approved,2,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,
帕瑞肽,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,多囊肾病,polycystic kidney disease,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),创新药,化药,多肽,环肽;差异化疾病,类似物,多囊肾病,II期临床,2012/8/21,Active,泌尿生殖领域;罕见疾病领域,DR015961,欧洲,phase 2,批准上市,2012/4/24,approved,2,TRUE,TRUE,TRUE,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",泌尿生殖领域,['泌尿生殖领域'],1,泌尿生殖领域,,,5,2,Genitourinary,Genitourinary,,
帕瑞肽,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,神经内分泌肿瘤,neuroendocrine tumors,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),创新药,化药,多肽,环肽;差异化疾病,类似物,神经内分泌肿瘤,II期临床,2010/12/3,Active,肿瘤领域;罕见疾病领域,DR015961,欧洲,phase 2,批准上市,2012/4/24,approved,2,TRUE,TRUE,TRUE,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,
帕瑞肽,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,滑膜肉瘤,synovial sarcoma,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),创新药,化药,多肽,环肽;差异化疾病,类似物,滑膜肉瘤(差异化疾病),II期临床,2024/6/13,Active,肿瘤领域;罕见疾病领域,DR015961,欧洲,phase 2,批准上市,2012/4/24,approved,2,TRUE,TRUE,TRUE,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,
帕瑞肽,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,促结缔组织增生性小圆细胞瘤,desmoplastic small round cell tumor,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),创新药,化药,多肽,环肽;差异化疾病,类似物,促结缔组织增生性小圆细胞瘤(差异化疾病),II期临床,2024/6/13,Active,肿瘤领域;罕见疾病领域,DR015961,欧洲,phase 2,批准上市,2012/4/24,approved,2,TRUE,TRUE,TRUE,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,
帕瑞肽,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,脑膜瘤,Meningioma,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),创新药,化药,多肽,环肽;差异化疾病,类似物,脑膜瘤,II期临床,2008/12/23,Active,肿瘤领域,DR015961,欧洲,phase 2,批准上市,2012/4/24,approved,2,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,
帕瑞肽,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,肺和胸腺类癌,Lung and thymic carcinoid tumors,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),创新药,化药,多肽,环肽;差异化疾病,类似物,肺和胸腺类癌(差异化疾病),II期临床,,Active,肿瘤领域;罕见疾病领域,DR015961,欧洲,phase 2,批准上市,2012/4/24,approved,2,TRUE,TRUE,TRUE,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,
帕瑞肽,pasireotide,帕瑞肽;pasireotide;帕西瑞肽;Signifor;丝尼芬;SOM230;SOM230B;SOM230LAR;SOM230C LAR;SOM 230;SOM230C,减肥术后低血糖症,Hypoglycemia after bariatric surgery,somatostatin,somatostatin类似物,Recordati;Novartis(Top20 MNC)(原研)(无权益),创新药,化药,多肽,环肽;差异化疾病,类似物,减肥术后低血糖症(差异化疾病),II期临床,2023/7/3,Active,消化领域,DR015961,欧洲,phase 2,批准上市,2012/4/24,approved,2,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,"['Recordati', 'Novartis(Top20 MNC)(原研)(无权益)']",消化领域,['消化领域'],1,消化领域,,,5,2,Digestive System,Digestive System,,
利那洛肽,linaclotide,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,便秘型肠易激综合征,constipation irritable bowel syndrome,GC-C,GC-C激动剂,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,激动剂,便秘型肠易激综合征,批准上市,2012/8/30,Active,消化领域,DR031924,美国,approved,批准上市,2012/8/30,approved,4,TRUE,FALSE,TRUE,"['AstraZeneca', 'Astellas Pharma', 'Forest Laboratories(AbbVie)']",['Ironwood Pharmaceuticals'],1,"['AstraZeneca(Top20 MNC)', 'Astellas Pharma(Top20 MNC)', 'Forest Laboratories(AbbVie)(Top20 MNC)', 'Ironwood Pharmaceuticals(原研)']",消化领域,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,
利那洛肽,linaclotide,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,便秘,constipate,GC-C,GC-C激动剂,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,激动剂,便秘,批准上市,2023/6/12,Active,消化领域,DR031924,美国,approved,批准上市,2012/8/30,approved,4,TRUE,FALSE,TRUE,"['AstraZeneca', 'Astellas Pharma', 'Forest Laboratories(AbbVie)']",['Ironwood Pharmaceuticals'],1,"['AstraZeneca(Top20 MNC)', 'Astellas Pharma(Top20 MNC)', 'Forest Laboratories(AbbVie)(Top20 MNC)', 'Ironwood Pharmaceuticals(原研)']",消化领域,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,
利那洛肽,linaclotide,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,慢性特发性便秘,chronic idiopathic constipation,GC-C,GC-C激动剂,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,激动剂,慢性特发性便秘,批准上市,2012/8/30,Active,消化领域,DR031924,美国,approved,批准上市,2012/8/30,approved,4,TRUE,FALSE,TRUE,"['AstraZeneca', 'Astellas Pharma', 'Forest Laboratories(AbbVie)']",['Ironwood Pharmaceuticals'],1,"['AstraZeneca(Top20 MNC)', 'Astellas Pharma(Top20 MNC)', 'Forest Laboratories(AbbVie)(Top20 MNC)', 'Ironwood Pharmaceuticals(原研)']",消化领域,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,
利那洛肽,linaclotide,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,结直肠癌,colorectal cancer,GC-C,GC-C激动剂,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,激动剂,结直肠癌(差异化疾病),II期临床,2019/1/8,Active,肿瘤领域,DR031924,美国,phase 2,批准上市,2012/8/30,approved,4,TRUE,FALSE,TRUE,"['AstraZeneca', 'Astellas Pharma', 'Forest Laboratories(AbbVie)']",['Ironwood Pharmaceuticals'],1,"['AstraZeneca(Top20 MNC)', 'Astellas Pharma(Top20 MNC)', 'Forest Laboratories(AbbVie)(Top20 MNC)', 'Ironwood Pharmaceuticals(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,
利那洛肽,linaclotide,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,肠易激综合征,irritable bowel syndrome,GC-C,GC-C激动剂,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,激动剂,肠易激综合征,I/II期临床,2024/11/18,Active,消化领域,DR031924,美国,phase 2,批准上市,2012/8/30,approved,4,TRUE,FALSE,TRUE,"['AstraZeneca', 'Astellas Pharma', 'Forest Laboratories(AbbVie)']",['Ironwood Pharmaceuticals'],1,"['AstraZeneca(Top20 MNC)', 'Astellas Pharma(Top20 MNC)', 'Forest Laboratories(AbbVie)(Top20 MNC)', 'Ironwood Pharmaceuticals(原研)']",消化领域,['消化领域'],1,消化领域,,,5,2,Digestive System,Digestive System,,
利那洛肽,linaclotide,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,肠道清洗,bowel cleansing,GC-C,GC-C激动剂,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,激动剂,肠道清洗(差异化疾病),I期临床,2021/11/30,Active,消化领域,DR031924,美国,phase 1,批准上市,2012/8/30,approved,4,TRUE,FALSE,TRUE,"['AstraZeneca', 'Astellas Pharma', 'Forest Laboratories(AbbVie)']",['Ironwood Pharmaceuticals'],1,"['AstraZeneca(Top20 MNC)', 'Astellas Pharma(Top20 MNC)', 'Forest Laboratories(AbbVie)(Top20 MNC)', 'Ironwood Pharmaceuticals(原研)']",消化领域,['消化领域'],1,消化领域,,,5,1,Digestive System,Digestive System,,
利那洛肽,linaclotide,利那洛肽;linaclotide;Linzess;Constella;ASP0456;MD-1100;令泽舒;MD-7246,急性胰腺炎,acute pancreatitis,GC-C,GC-C激动剂,AstraZeneca(Top20 MNC);Astellas Pharma(Top20 MNC);Forest Laboratories(AbbVie)(Top20 MNC);Ironwood Pharmaceuticals(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,激动剂,急性胰腺炎(差异化疾病),I期临床,2024/1/26,Active,消化领域,DR031924,美国,phase 1,批准上市,2012/8/30,approved,4,TRUE,FALSE,TRUE,"['AstraZeneca', 'Astellas Pharma', 'Forest Laboratories(AbbVie)']",['Ironwood Pharmaceuticals'],1,"['AstraZeneca(Top20 MNC)', 'Astellas Pharma(Top20 MNC)', 'Forest Laboratories(AbbVie)(Top20 MNC)', 'Ironwood Pharmaceuticals(原研)']",消化领域,['消化领域'],1,消化领域,,,5,1,Digestive System,Digestive System,,
gallium Ga-68 dotatate,gallium Ga-68 dotatate,gallium Ga-68 dotatate;Netspot;Somakit-TATE;68Ga-DOTA TATE;gallium-68 DOTA TATE;Ga-68-DOTATATE;gallium Ga 68-DOTATATE;68Ga-DOTATATE;68Ga-DOTA-TATE;[68Ga]Ga-DOTA-TATE;68Ga-DOTA-octreotate,PET显像,PET imaging,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,PET显像,批准上市,,Active,诊断试剂领域,DR009499,欧洲,approved,批准上市,2016/6/1,approved,1,TRUE,FALSE,TRUE,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,5,5,Diagnostic Reagents,Diagnostic Reagents,,
gallium Ga-68 dotatate,gallium Ga-68 dotatate,gallium Ga-68 dotatate;Netspot;Somakit-TATE;68Ga-DOTA TATE;gallium-68 DOTA TATE;Ga-68-DOTATATE;gallium Ga 68-DOTATATE;68Ga-DOTATATE;68Ga-DOTA-TATE;[68Ga]Ga-DOTA-TATE;68Ga-DOTA-octreotate,神经内分泌肿瘤,neuroendocrine tumors,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,神经内分泌肿瘤,批准上市,,Active,罕见疾病领域;肿瘤领域,DR009499,欧洲,approved,批准上市,2016/6/1,approved,1,TRUE,TRUE,TRUE,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,
gallium Ga-68 dotatate,gallium Ga-68 dotatate,gallium Ga-68 dotatate;Netspot;Somakit-TATE;68Ga-DOTA TATE;gallium-68 DOTA TATE;Ga-68-DOTATATE;gallium Ga 68-DOTATATE;68Ga-DOTATATE;68Ga-DOTA-TATE;[68Ga]Ga-DOTA-TATE;68Ga-DOTA-octreotate,HR阳性乳腺癌,HR positive breast cancer,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,HR阳性乳腺癌(差异化疾病),II期临床,,Active,肿瘤领域,DR009499,欧洲,phase 2,批准上市,2016/6/1,approved,1,TRUE,FALSE,TRUE,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,
gallium Ga-68 dotatate,gallium Ga-68 dotatate,gallium Ga-68 dotatate;Netspot;Somakit-TATE;68Ga-DOTA TATE;gallium-68 DOTA TATE;Ga-68-DOTATATE;gallium Ga 68-DOTATATE;68Ga-DOTATATE;68Ga-DOTA-TATE;[68Ga]Ga-DOTA-TATE;68Ga-DOTA-octreotate,鼻咽癌,Nasopharyngeal cancer,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,鼻咽癌,I/II期临床,,Active,罕见疾病领域;肿瘤领域,DR009499,欧洲,phase 2,批准上市,2016/6/1,approved,1,TRUE,TRUE,TRUE,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,
gallium Ga-68 dotatate,gallium Ga-68 dotatate,gallium Ga-68 dotatate;Netspot;Somakit-TATE;68Ga-DOTA TATE;gallium-68 DOTA TATE;Ga-68-DOTATATE;gallium Ga 68-DOTATATE;68Ga-DOTATATE;68Ga-DOTA-TATE;[68Ga]Ga-DOTA-TATE;68Ga-DOTA-octreotate,小细胞肺癌,small cell lung cancer,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,小细胞肺癌,I期临床,,Active,罕见疾病领域;肿瘤领域,DR009499,欧洲,phase 1,批准上市,2016/6/1,approved,1,TRUE,TRUE,TRUE,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,
镓[68Ga]伊索曲肽,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,PET显像,PET imaging,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,PET显像,批准上市,2019/8/21,Active,诊断试剂领域,DR055026,欧洲,approved,批准上市,2016/12/8,approved,4,TRUE,FALSE,TRUE,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,5,5,Diagnostic Reagents,Diagnostic Reagents,,
镓[68Ga]伊索曲肽,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,神经内分泌肿瘤,neuroendocrine tumors,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,神经内分泌肿瘤,批准上市,2016/12/8,Active,肿瘤领域;罕见疾病领域,DR055026,欧洲,approved,批准上市,2016/12/8,approved,4,TRUE,TRUE,TRUE,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,
镓[68Ga]伊索曲肽,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,乳腺癌,breast cancer,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,乳腺癌,III期临床,2024/9/25,Active,肿瘤领域,DR055026,欧洲,phase 3,批准上市,2016/12/8,approved,4,TRUE,FALSE,TRUE,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,3,Oncology,Oncology,,
镓[68Ga]伊索曲肽,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,胃肠胰神经内分泌肿瘤,III期临床,2023/10/19,Active,肿瘤领域;罕见疾病领域,DR055026,欧洲,phase 3,批准上市,2016/12/8,approved,4,TRUE,TRUE,TRUE,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,3,Oncology,Oncology,,
镓[68Ga]伊索曲肽,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,细菌性心内膜炎,bacterial endocarditis,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,细菌性心内膜炎(差异化疾病),II期临床,2021/12/23,Active,感染领域;心脑血管领域,DR055026,欧洲,phase 2,批准上市,2016/12/8,approved,4,TRUE,FALSE,TRUE,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",感染领域,"['感染领域', '心脑血管领域']",2,感染领域,心脑血管领域,,5,2,Infectious Diseases,Infectious Diseases,Cardiovascular & Cerebrovascular,
镓[68Ga]伊索曲肽,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,HER2阳性乳腺癌,HER2-positive breast cancer,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,HER2阳性乳腺癌(差异化疾病),II期临床,2025/9/17,Active,肿瘤领域,DR055026,欧洲,phase 2,批准上市,2016/12/8,approved,4,TRUE,FALSE,TRUE,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,
镓[68Ga]伊索曲肽,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,神经母细胞瘤,Neuroblastoma,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,神经母细胞瘤,II期临床,2015/5/12,Active,肿瘤领域;罕见疾病领域,DR055026,欧洲,phase 2,批准上市,2016/12/8,approved,4,TRUE,TRUE,TRUE,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,
镓[68Ga]伊索曲肽,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,癌症脑转移,cancer brain metastasis,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,癌症脑转移(差异化疾病),II期临床,2025/9/17,Active,肿瘤领域,DR055026,欧洲,phase 2,批准上市,2016/12/8,approved,4,TRUE,FALSE,TRUE,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,
镓[68Ga]伊索曲肽,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,鼻咽癌,Nasopharyngeal cancer,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,鼻咽癌,I/II期临床,2025/5/21,Active,肿瘤领域;罕见疾病领域,DR055026,欧洲,phase 2,批准上市,2016/12/8,approved,4,TRUE,TRUE,TRUE,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,
镓[68Ga]伊索曲肽,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,副神经节瘤,paraganglioma,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,副神经节瘤,I/II期临床,2014/6/30,Active,肿瘤领域;罕见疾病领域,DR055026,欧洲,phase 2,批准上市,2016/12/8,approved,4,TRUE,TRUE,TRUE,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,
镓[68Ga]伊索曲肽,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,抑郁症,depression,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,抑郁症,I期临床,2025/9/26,Active,精神领域,DR055026,欧洲,phase 1,批准上市,2016/12/8,approved,4,TRUE,FALSE,TRUE,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",精神领域,['精神领域'],1,精神领域,,,5,1,Psychiatry,Psychiatry,,
镓[68Ga]伊索曲肽,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,不孕不育,Infertility,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,不孕不育,I期临床,2025/9/26,Active,泌尿生殖领域,DR055026,欧洲,phase 1,批准上市,2016/12/8,approved,4,TRUE,FALSE,TRUE,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",泌尿生殖领域,['泌尿生殖领域'],1,泌尿生殖领域,,,5,1,Genitourinary,Genitourinary,,
镓[68Ga]伊索曲肽,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,嗜铬细胞瘤,Pheochromocytoma,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,嗜铬细胞瘤,I期临床,2018/7/11,Active,肿瘤领域;罕见疾病领域,DR055026,欧洲,phase 1,批准上市,2016/12/8,approved,4,TRUE,TRUE,TRUE,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,
镓[68Ga]伊索曲肽,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,骨转移疼痛,bone metastasis pain,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,骨转移疼痛,I期临床,2025/9/26,Active,肿瘤领域,DR055026,欧洲,phase 1,批准上市,2016/12/8,approved,4,TRUE,FALSE,TRUE,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,
镓[68Ga]伊索曲肽,68Ga-edotreotide,镓[68Ga]伊索曲肽;68Ga-edotreotide;SomaKit TOC;gallium (Ga 68) edotreotide;gallium Ga 68-edotreotide;68Ga-DOTATOC;DOTATOC-68Ga;[68Ga]-DOTA-tyr3-Octreotide;gallium-68 DOTATOC;Sogacin;TOCscan;[68Ga]Ga-DOTA-TOC;IASOtoc;[68Ga]-DOTATOC;ITM-14D;ITM-14;镓[68Ga]依度曲肽,胃肠道神经内分泌肿瘤,gastrointestinal neuroendocrine tumors,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研);ITM Isotope;远大医药;IASON(Curium Austria),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;68Ga标记的PET药物,胃肠道神经内分泌肿瘤(差异化疾病),I期临床,2025/1/14,Active,肿瘤领域;罕见疾病领域,DR055026,欧洲,phase 1,批准上市,2016/12/8,approved,4,TRUE,TRUE,TRUE,['Advanced Accelerator Applications(Siemens Healthineers)'],['Advanced Accelerator Applications(Siemens Healthineers)'],1,"['Advanced Accelerator Applications(Siemens Healthineers)(Top20 MNC)(原研)', 'ITM Isotope', '远大医药', 'IASON(Curium Austria)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,
普卡那肽,plecanatide,普卡那肽;plecanatide;SP-304;Trulance;pirnabin,便秘型肠易激综合征,constipation irritable bowel syndrome,GC-C,GC-C激动剂,Bausch Health;罗欣药业;Synergy Pharmaceuticals(原研)(无权益),创新药,化药,多肽,环肽,激动剂,便秘型肠易激综合征,批准上市,2018/1/24,Active,消化领域,DR041066,美国,approved,批准上市,2017/1/19,approved,3,TRUE,FALSE,FALSE,[],['Synergy Pharmaceuticals'],1,"['Bausch Health', '罗欣药业', 'Synergy Pharmaceuticals(原研)(无权益)']",消化领域,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,
普卡那肽,plecanatide,普卡那肽;plecanatide;SP-304;Trulance;pirnabin,慢性特发性便秘,chronic idiopathic constipation,GC-C,GC-C激动剂,Bausch Health;罗欣药业;Synergy Pharmaceuticals(原研)(无权益),创新药,化药,多肽,环肽,激动剂,慢性特发性便秘,批准上市,2017/1/19,Active,消化领域,DR041066,美国,approved,批准上市,2017/1/19,approved,3,TRUE,FALSE,FALSE,[],['Synergy Pharmaceuticals'],1,"['Bausch Health', '罗欣药业', 'Synergy Pharmaceuticals(原研)(无权益)']",消化领域,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,
Noctiva,Noctiva (desmopressin),Noctiva;Noctiva (去氨加压素);Noctiva (desmopressin);AV002;SER120,夜尿症,Nocturia,vasopressin,vasopressin类似物,Avadel Pharmaceuticals(原研);Serenity Pharmaceuticals(Acerus Pharmaceuticals),微创新,化药,多肽,环肽;中国无申报,类似物,夜尿症,批准上市,2017/3/3,Active,泌尿生殖领域,DR037313,欧洲,approved,批准上市,2017/3/3,approved,2,TRUE,FALSE,FALSE,[],['Avadel Pharmaceuticals'],1,"['Avadel Pharmaceuticals(原研)', 'Serenity Pharmaceuticals(Acerus Pharmaceuticals)']",泌尿生殖领域,['泌尿生殖领域'],1,泌尿生殖领域,,,5,5,Genitourinary,Genitourinary,,
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,胃肠胰神经内分泌肿瘤,批准上市,2017/9/26,Active,肿瘤领域;罕见疾病领域,DR030635,欧洲,approved,批准上市,2017/9/26,approved,2,TRUE,TRUE,TRUE,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,胰腺神经内分泌肿瘤,pancreatic neuroendocrine tumors,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,胰腺神经内分泌肿瘤,III期临床,2025/9/22,Active,肿瘤领域;罕见疾病领域,DR030635,欧洲,phase 3,批准上市,2017/9/26,approved,2,TRUE,TRUE,TRUE,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,3,Oncology,Oncology,,
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,胃肠道神经内分泌肿瘤,gastrointestinal neuroendocrine tumors,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,胃肠道神经内分泌肿瘤(差异化疾病),III期临床,2013/5/23,Active,肿瘤领域;罕见疾病领域,DR030635,欧洲,phase 3,批准上市,2017/9/26,approved,2,TRUE,TRUE,TRUE,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,3,Oncology,Oncology,,
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,神经内分泌肿瘤,neuroendocrine tumors,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,神经内分泌肿瘤,II/III期临床,2024/4/24,Active,肿瘤领域;罕见疾病领域,DR030635,欧洲,phase 3,批准上市,2017/9/26,approved,2,TRUE,TRUE,TRUE,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,3,Oncology,Oncology,,
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,实体瘤,solid tumors,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,实体瘤,II期临床,2024/9/23,Active,肿瘤领域,DR030635,欧洲,phase 2,批准上市,2017/9/26,approved,2,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,小细胞肺癌,small cell lung cancer,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,小细胞肺癌(差异化疾病),II期临床,,Active,肿瘤领域;罕见疾病领域,DR030635,欧洲,phase 2,批准上市,2017/9/26,approved,2,TRUE,TRUE,TRUE,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,乳腺癌,breast cancer,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,乳腺癌(差异化疾病),II期临床,,Active,肿瘤领域,DR030635,欧洲,phase 2,批准上市,2017/9/26,approved,2,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,Merkel细胞瘤,Merkel cell tumor,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,Merkel细胞瘤(差异化疾病),II期临床,2022/10/18,Active,肿瘤领域;罕见疾病领域,DR030635,欧洲,phase 2,批准上市,2017/9/26,approved,2,TRUE,TRUE,TRUE,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,前列腺癌,prostate cancer,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,前列腺癌,II期临床,2023/1/20,Active,肿瘤领域,DR030635,欧洲,phase 2,批准上市,2017/9/26,approved,2,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,胶质母细胞瘤,glioblastoma,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,胶质母细胞瘤(差异化疾病),II期临床,,Active,肿瘤领域;罕见疾病领域,DR030635,欧洲,phase 2,批准上市,2017/9/26,approved,2,TRUE,TRUE,TRUE,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,髓样甲状腺癌,medullary thyroid cancer,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,髓样甲状腺癌(差异化疾病),II期临床,2023/11/7,Active,肿瘤领域;罕见疾病领域,DR030635,欧洲,phase 2,批准上市,2017/9/26,approved,2,TRUE,TRUE,TRUE,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,嗜铬细胞瘤,Pheochromocytoma,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,嗜铬细胞瘤,II期临床,2017/7/2,Active,肿瘤领域;罕见疾病领域,DR030635,欧洲,phase 2,批准上市,2017/9/26,approved,2,TRUE,TRUE,TRUE,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,副神经节瘤,paraganglioma,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,副神经节瘤,II期临床,2017/7/2,Active,肿瘤领域;罕见疾病领域,DR030635,欧洲,phase 2,批准上市,2017/9/26,approved,2,TRUE,TRUE,TRUE,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,癌症肝转移,cancer liver metastasis,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,癌症肝转移(差异化疾病),II期临床,2019/8/1,Active,肿瘤领域,DR030635,欧洲,phase 2,批准上市,2017/9/26,approved,2,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,脑膜瘤,Meningioma,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,脑膜瘤,II期临床,2019/9/9,Active,肿瘤领域,DR030635,欧洲,phase 2,批准上市,2017/9/26,approved,2,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,胸腺癌,thymic cancer,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,胸腺癌(差异化疾病),II期临床,,Active,肿瘤领域;罕见疾病领域,DR030635,欧洲,phase 2,批准上市,2017/9/26,approved,2,TRUE,TRUE,TRUE,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,神经内分泌前列腺癌,neuroendocrine prostate cancer,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,神经内分泌前列腺癌(差异化疾病),II期临床,,Active,肿瘤领域,DR030635,欧洲,phase 2,批准上市,2017/9/26,approved,2,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,弥漫性内因性脑桥神经胶质瘤,Diffuse intrinsic pontine glioma,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,弥漫性内因性脑桥神经胶质瘤(差异化疾病),I/II期临床,,Active,肿瘤领域;罕见疾病领域,DR030635,欧洲,phase 2,批准上市,2017/9/26,approved,2,TRUE,TRUE,TRUE,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,
镥[177lu]氧奥曲肽,lutetium Lu-177 dotatate,镥[177lu]氧奥曲肽;lutetium Lu-177 dotatate;177Lu-DOTA0-Tyr3-octreotate;177lutetium dotatate;Lutathera;Lu-177-DOTATATE;Lu-177 DOTA-TATE;177Lu-DOTATATE;[177]Lu-DOTA-TATE;Lu-DOTA-TATE;lutetium (177Lu) oxodotreotide;177Lu-DOTA-TATE;177Lu-octreotate;F-1515;(177镥)镥氧奥曲肽;177Lu-oxodotreotide;AAA601;Lu-177-DOTA-Octreotide;[177Lu]Lu-DOTA-TATE;lutetium[177Lu] oxodotreotide;lutetium Lu 177 dotatate;XTR008,非霍奇金淋巴瘤,non-hodgkin lymphoma,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);FUJIFILM Toyama(PeptiDream),创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,非霍奇金淋巴瘤(差异化疾病),I期临床,2023/8/16,Active,肿瘤领域;血液领域;罕见疾病领域,DR030635,欧洲,phase 1,批准上市,2017/9/26,approved,2,TRUE,TRUE,TRUE,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'FUJIFILM Toyama(PeptiDream)']",肿瘤领域,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,5,1,Oncology,Oncology,Hematology,
Cequa,Cequa (cyclosporine A),Cequa;Cequa (环孢素);Cequa (cyclosporine A);Seciera;OTX-101,干眼病,dry eye disease,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,康哲药业;Ocular Technologies(Sun Pharma);Auven Therapeutics(原研)(无权益),微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,干眼病,批准上市,2018/8/14,Active,眼科领域,DR038984,欧洲,approved,批准上市,2018/8/14,approved,3,TRUE,FALSE,FALSE,[],['Auven Therapeutics'],1,"['康哲药业', 'Ocular Technologies(Sun Pharma)', 'Auven Therapeutics(原研)(无权益)']",眼科领域,['眼科领域'],1,眼科领域,,,5,5,Ophthalmology,Ophthalmology,,
Cequa,Cequa (cyclosporine A),Cequa;Cequa (环孢素);Cequa (cyclosporine A);Seciera;OTX-101,炎症(未指明),Inflammation (unspecified),CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,康哲药业;Ocular Technologies(Sun Pharma);Auven Therapeutics(原研)(无权益),微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,炎症(未指明),I期临床,2023/7/24,Active,免疫领域,DR038984,欧洲,phase 1,批准上市,2018/8/14,approved,3,TRUE,FALSE,FALSE,[],['Auven Therapeutics'],1,"['康哲药业', 'Ocular Technologies(Sun Pharma)', 'Auven Therapeutics(原研)(无权益)']",免疫领域,['免疫领域'],1,免疫领域,,,5,1,Immunology,Immunology,,
普利肽新,普利肽新,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine,多发性骨髓瘤,multiple myeloma,EEF1A1,EEF1A1抑制剂,Boryung Pharmaceutical;Chugai Pharmaceutical(Top20 MNC);PharmaMar(原研);Specialised Therapeutics,创新药,化药,其他,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,多发性骨髓瘤(差异化疾病),批准上市,2018/12/11,Active,肿瘤领域;血液领域;罕见疾病领域,DR011563,欧洲,approved,批准上市,2018/12/11,approved,4,TRUE,TRUE,TRUE,['Chugai Pharmaceutical'],['PharmaMar'],1,"['Boryung Pharmaceutical', 'Chugai Pharmaceutical(Top20 MNC)', 'PharmaMar(原研)', 'Specialised Therapeutics']",肿瘤领域,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,5,5,Oncology,Oncology,Hematology,
普利肽新,普利肽新,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine,新型冠状病毒感染,novel coronavirus infection,EEF1A1,EEF1A1抑制剂,Boryung Pharmaceutical;Chugai Pharmaceutical(Top20 MNC);PharmaMar(原研);Specialised Therapeutics,创新药,化药,其他,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,新型冠状病毒感染,III期临床,2021/3/5,Active,感染领域,DR011563,欧洲,phase 3,批准上市,2018/12/11,approved,4,TRUE,FALSE,TRUE,['Chugai Pharmaceutical'],['PharmaMar'],1,"['Boryung Pharmaceutical', 'Chugai Pharmaceutical(Top20 MNC)', 'PharmaMar(原研)', 'Specialised Therapeutics']",感染领域,['感染领域'],1,感染领域,,,5,3,Infectious Diseases,Infectious Diseases,,
普利肽新,普利肽新,普利肽新;plitidepsin;dehydrodidemnin B;Aplidin;plitidepsine,长新冠,Long new crown,EEF1A1,EEF1A1抑制剂,Boryung Pharmaceutical;Chugai Pharmaceutical(Top20 MNC);PharmaMar(原研);Specialised Therapeutics,创新药,化药,其他,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,长新冠(差异化疾病),II期临床,2024/12/5,Active,感染领域,DR011563,欧洲,phase 2,批准上市,2018/12/11,approved,4,TRUE,FALSE,TRUE,['Chugai Pharmaceutical'],['PharmaMar'],1,"['Boryung Pharmaceutical', 'Chugai Pharmaceutical(Top20 MNC)', 'PharmaMar(原研)', 'Specialised Therapeutics']",感染领域,['感染领域'],1,感染领域,,,5,2,Infectious Diseases,Infectious Diseases,,
布美诺肽,bremelanotide,布美诺肽;bremelanotide;Rekynda;PT-141;Vyleesi,低反应性性欲障碍,hyporesponsive sexual desire disorder,MC4R,MC4R激动剂,KwangDong Pharmaceutical;复星医药;Cosette Pharmaceuticals;Gedeon Richter(无权益);AMAG Pharmaceuticals(Azurity Pharmaceuticals)(无权益);Palatin Technologies(原研)(无权益),创新药,化药,多肽,环肽;First-in-Class;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,低反应性性欲障碍(差异化疾病),批准上市,2019/6/21,Active,精神领域;泌尿生殖领域,DR015256,美国,approved,批准上市,2019/6/21,approved,6,TRUE,FALSE,FALSE,[],['Palatin Technologies'],1,"['KwangDong Pharmaceutical', '复星医药', 'Cosette Pharmaceuticals', 'Gedeon Richter(无权益)', 'AMAG Pharmaceuticals(Azurity Pharmaceuticals)(无权益)', 'Palatin Technologies(原研)(无权益)']",精神领域,"['精神领域', '泌尿生殖领域']",2,精神领域,泌尿生殖领域,,5,5,Psychiatry,Psychiatry,Genitourinary,
布美诺肽,bremelanotide,布美诺肽;bremelanotide;Rekynda;PT-141;Vyleesi,肥胖,obesity,MC4R,MC4R激动剂,KwangDong Pharmaceutical;复星医药;Cosette Pharmaceuticals;Gedeon Richter(无权益);AMAG Pharmaceuticals(Azurity Pharmaceuticals)(无权益);Palatin Technologies(原研)(无权益),创新药,化药,多肽,环肽;First-in-Class;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,肥胖,II期临床,2024/6/12,Active,内分泌及代谢领域,DR015256,美国,phase 2,批准上市,2019/6/21,approved,6,TRUE,FALSE,FALSE,[],['Palatin Technologies'],1,"['KwangDong Pharmaceutical', '复星医药', 'Cosette Pharmaceuticals', 'Gedeon Richter(无权益)', 'AMAG Pharmaceuticals(Azurity Pharmaceuticals)(无权益)', 'Palatin Technologies(原研)(无权益)']",内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,
布美诺肽,bremelanotide,布美诺肽;bremelanotide;Rekynda;PT-141;Vyleesi,糖尿病肾病,diabetic nephropathy,MC4R,MC4R激动剂,KwangDong Pharmaceutical;复星医药;Cosette Pharmaceuticals;Gedeon Richter(无权益);AMAG Pharmaceuticals(Azurity Pharmaceuticals)(无权益);Palatin Technologies(原研)(无权益),创新药,化药,多肽,环肽;First-in-Class;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,糖尿病肾病(差异化疾病),II期临床,2023/2/2,Active,泌尿生殖领域,DR015256,美国,phase 2,批准上市,2019/6/21,approved,6,TRUE,FALSE,FALSE,[],['Palatin Technologies'],1,"['KwangDong Pharmaceutical', '复星医药', 'Cosette Pharmaceuticals', 'Gedeon Richter(无权益)', 'AMAG Pharmaceuticals(Azurity Pharmaceuticals)(无权益)', 'Palatin Technologies(原研)(无权益)']",泌尿生殖领域,['泌尿生殖领域'],1,泌尿生殖领域,,,5,2,Genitourinary,Genitourinary,,
布美诺肽,bremelanotide,布美诺肽;bremelanotide;Rekynda;PT-141;Vyleesi,勃起功能障碍,erectile dysfunction,MC4R,MC4R激动剂,KwangDong Pharmaceutical;复星医药;Cosette Pharmaceuticals;Gedeon Richter(无权益);AMAG Pharmaceuticals(Azurity Pharmaceuticals)(无权益);Palatin Technologies(原研)(无权益),创新药,化药,多肽,环肽;First-in-Class;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,勃起功能障碍(差异化疾病),II期临床,2024/6/20,Active,泌尿生殖领域,DR015256,美国,phase 2,批准上市,2019/6/21,approved,6,TRUE,FALSE,FALSE,[],['Palatin Technologies'],1,"['KwangDong Pharmaceutical', '复星医药', 'Cosette Pharmaceuticals', 'Gedeon Richter(无权益)', 'AMAG Pharmaceuticals(Azurity Pharmaceuticals)(无权益)', 'Palatin Technologies(原研)(无权益)']",泌尿生殖领域,['泌尿生殖领域'],1,泌尿生殖领域,,,5,2,Genitourinary,Genitourinary,,
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,PET显像,PET imaging,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,PET显像,批准上市,2020/9/3,Active,诊断试剂领域,DR039127,欧洲,approved,批准上市,2020/9/3,approved,3,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'RadioMedix', 'Curium Pharma']",诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,5,5,Diagnostic Reagents,Diagnostic Reagents,,
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,神经内分泌肿瘤,neuroendocrine tumors,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,神经内分泌肿瘤,批准上市,2020/9/3,Active,肿瘤领域;罕见疾病领域,DR039127,欧洲,approved,批准上市,2020/9/3,approved,3,TRUE,TRUE,TRUE,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'RadioMedix', 'Curium Pharma']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,5,Oncology,Oncology,,
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,胃肠胰神经内分泌肿瘤,II期临床,2023/2/2,Active,肿瘤领域;罕见疾病领域,DR039127,欧洲,phase 2,批准上市,2020/9/3,approved,3,TRUE,TRUE,TRUE,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'RadioMedix', 'Curium Pharma']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,前列腺癌,prostate cancer,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,前列腺癌,I期临床,2023/1/11,Active,肿瘤领域,DR039127,欧洲,phase 1,批准上市,2020/9/3,approved,3,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'RadioMedix', 'Curium Pharma']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,神经母细胞瘤,Neuroblastoma,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,神经母细胞瘤,I期临床,2025/9/26,Active,肿瘤领域;罕见疾病领域,DR039127,欧洲,phase 1,批准上市,2020/9/3,approved,3,TRUE,TRUE,TRUE,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'RadioMedix', 'Curium Pharma']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,抑郁症,depression,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,抑郁症,I期临床,2025/9/26,Active,精神领域,DR039127,欧洲,phase 1,批准上市,2020/9/3,approved,3,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'RadioMedix', 'Curium Pharma']",精神领域,['精神领域'],1,精神领域,,,5,1,Psychiatry,Psychiatry,,
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,不孕不育,Infertility,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,不孕不育,I期临床,2025/9/26,Active,泌尿生殖领域,DR039127,欧洲,phase 1,批准上市,2020/9/3,approved,3,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'RadioMedix', 'Curium Pharma']",泌尿生殖领域,['泌尿生殖领域'],1,泌尿生殖领域,,,5,1,Genitourinary,Genitourinary,,
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,嗜铬细胞瘤,Pheochromocytoma,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,嗜铬细胞瘤,I期临床,2025/9/26,Active,肿瘤领域;罕见疾病领域,DR039127,欧洲,phase 1,批准上市,2020/9/3,approved,3,TRUE,TRUE,TRUE,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'RadioMedix', 'Curium Pharma']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,骨转移疼痛,bone metastasis pain,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,骨转移疼痛,I期临床,2025/9/26,Active,肿瘤领域,DR039127,欧洲,phase 1,批准上市,2020/9/3,approved,3,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'RadioMedix', 'Curium Pharma']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,副神经节瘤,paraganglioma,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,副神经节瘤,I期临床,2025/9/26,Active,肿瘤领域;罕见疾病领域,DR039127,欧洲,phase 1,批准上市,2020/9/3,approved,3,TRUE,TRUE,TRUE,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'RadioMedix', 'Curium Pharma']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,1,Oncology,Oncology,,
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,莱姆病,Lyme disease,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,莱姆病,I期临床,2024/4/30,Active,感染领域,DR039127,欧洲,phase 1,批准上市,2020/9/3,approved,3,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'RadioMedix', 'Curium Pharma']",感染领域,['感染领域'],1,感染领域,,,5,1,Infectious Diseases,Infectious Diseases,,
铜[64Cu]氧奥曲肽,64Cu-DOTATATE,铜[64Cu]氧奥曲肽;64Cu-DOTATATE;Cu-64 DOTATATE;NETMedix;Detectnet;copper Cu 64 dotatate;copper (64Cu) oxodotreotide,心脏结节病,cardiac sarcoidosis,SSTR,anti-SSTR多肽偶联核素;64Cu标记的放射性示踪剂,Novartis(Top20 MNC)(原研);RadioMedix;Curium Pharma,创新药,化药,多肽;放射性药物;偶联药物,环肽;First-in-Class;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,心脏结节病,I期临床,2023/11/14,Active,心脑血管领域;免疫领域,DR039127,欧洲,phase 1,批准上市,2020/9/3,approved,3,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,"['Novartis(Top20 MNC)(原研)', 'RadioMedix', 'Curium Pharma']",心脑血管领域,"['心脑血管领域', '免疫领域']",2,心脑血管领域,免疫领域,,5,1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,Immunology,
setmelanotide,setmelanotide,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,肥胖,obesity,MC4R,MC4R激动剂,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,肥胖,批准上市,2024/7/31,Active,内分泌及代谢领域,DR064607,欧洲,approved,批准上市,2020/11/25,approved,4,TRUE,FALSE,FALSE,[],['Ipsen'],1,"['Ipsen(原研)', 'Rhythm Pharmaceuticals', 'Camurus(无权益)', '琅钰集团(无权益)']",内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,5,Endocrinology & Metabolism,Endocrinology & Metabolism,,
setmelanotide,setmelanotide,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,阿黑皮素原缺乏症,proopiomelanocortin deficiency,MC4R,MC4R激动剂,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,阿黑皮素原缺乏症,批准上市,2020/11/25,Active,内分泌及代谢领域;罕见疾病领域,DR064607,欧洲,approved,批准上市,2020/11/25,approved,4,TRUE,TRUE,FALSE,[],['Ipsen'],1,"['Ipsen(原研)', 'Rhythm Pharmaceuticals', 'Camurus(无权益)', '琅钰集团(无权益)']",内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,5,Endocrinology & Metabolism,Endocrinology & Metabolism,,
setmelanotide,setmelanotide,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,瘦素受体缺乏,leptin receptor deficiency,MC4R,MC4R激动剂,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,瘦素受体缺乏,批准上市,2020/11/25,Active,内分泌及代谢领域;罕见疾病领域,DR064607,欧洲,approved,批准上市,2020/11/25,approved,4,TRUE,TRUE,FALSE,[],['Ipsen'],1,"['Ipsen(原研)', 'Rhythm Pharmaceuticals', 'Camurus(无权益)', '琅钰集团(无权益)']",内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,5,Endocrinology & Metabolism,Endocrinology & Metabolism,,
setmelanotide,setmelanotide,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,巴德-毕德氏症候群,Budd-Bide syndrome,MC4R,MC4R激动剂,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,巴德-毕德氏症候群(差异化疾病),批准上市,2022/6/16,Active,罕见疾病领域,DR064607,欧洲,approved,批准上市,2020/11/25,approved,4,TRUE,TRUE,FALSE,[],['Ipsen'],1,"['Ipsen(原研)', 'Rhythm Pharmaceuticals', 'Camurus(无权益)', '琅钰集团(无权益)']",,[],0,,,,5,5,,,,
setmelanotide,setmelanotide,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,PCSK1缺乏症,PCSK1 deficiency,MC4R,MC4R激动剂,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,PCSK1缺乏症(差异化疾病),批准上市,2021/7/23,Active,罕见疾病领域;内分泌及代谢领域,DR064607,欧洲,approved,批准上市,2020/11/25,approved,4,TRUE,TRUE,FALSE,[],['Ipsen'],1,"['Ipsen(原研)', 'Rhythm Pharmaceuticals', 'Camurus(无权益)', '琅钰集团(无权益)']",内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,5,Endocrinology & Metabolism,Endocrinology & Metabolism,,
setmelanotide,setmelanotide,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,下丘脑性肥胖,hypothalamic obesity,MC4R,MC4R激动剂,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,下丘脑性肥胖,申请上市,2025/8/20,Active,内分泌及代谢领域,DR064607,欧洲,pre-registration,批准上市,2020/11/25,approved,4,TRUE,FALSE,FALSE,[],['Ipsen'],1,"['Ipsen(原研)', 'Rhythm Pharmaceuticals', 'Camurus(无权益)', '琅钰集团(无权益)']",内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,4,Endocrinology & Metabolism,Endocrinology & Metabolism,,
setmelanotide,setmelanotide,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,Alström综合征,Alström syndrome,MC4R,MC4R激动剂,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,Alström综合征(差异化疾病),申请上市,2021/9/20,Active,罕见疾病领域,DR064607,欧洲,pre-registration,批准上市,2020/11/25,approved,4,TRUE,TRUE,FALSE,[],['Ipsen'],1,"['Ipsen(原研)', 'Rhythm Pharmaceuticals', 'Camurus(无权益)', '琅钰集团(无权益)']",,[],0,,,,5,4,,,,
setmelanotide,setmelanotide,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,联合垂体激素缺乏症,combined pituitary hormone deficiency,MC4R,MC4R激动剂,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,联合垂体激素缺乏症(差异化疾病),III期临床,2025/1/7,Active,内分泌及代谢领域,DR064607,欧洲,phase 3,批准上市,2020/11/25,approved,4,TRUE,FALSE,FALSE,[],['Ipsen'],1,"['Ipsen(原研)', 'Rhythm Pharmaceuticals', 'Camurus(无权益)', '琅钰集团(无权益)']",内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,3,Endocrinology & Metabolism,Endocrinology & Metabolism,,
setmelanotide,setmelanotide,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,视-隔发育不良,Opto-septal dysplasia,MC4R,MC4R激动剂,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,视-隔发育不良(差异化疾病),III期临床,2025/1/7,Active,罕见疾病领域,DR064607,欧洲,phase 3,批准上市,2020/11/25,approved,4,TRUE,TRUE,FALSE,[],['Ipsen'],1,"['Ipsen(原研)', 'Rhythm Pharmaceuticals', 'Camurus(无权益)', '琅钰集团(无权益)']",,[],0,,,,5,3,,,,
setmelanotide,setmelanotide,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,Prader-Willi综合征,Prader-Willi syndrome,MC4R,MC4R激动剂,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,Prader-Willi综合征(差异化疾病),II期临床,2014/12/8,Active,内分泌及代谢领域;罕见疾病领域,DR064607,欧洲,phase 2,批准上市,2020/11/25,approved,4,TRUE,TRUE,FALSE,[],['Ipsen'],1,"['Ipsen(原研)', 'Rhythm Pharmaceuticals', 'Camurus(无权益)', '琅钰集团(无权益)']",内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,
setmelanotide,setmelanotide,setmelanotide;RM-493;BIM-22493;IRC-022493;Imcivree;CAM4072,多食症,polyphagia,MC4R,MC4R激动剂,Ipsen(原研);Rhythm Pharmaceuticals;Camurus(无权益);琅钰集团(无权益),创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,多食症(差异化疾病),II期临床,2025/1/13,Active,精神领域;内分泌及代谢领域,DR064607,欧洲,phase 2,批准上市,2020/11/25,approved,4,TRUE,FALSE,FALSE,[],['Ipsen'],1,"['Ipsen(原研)', 'Rhythm Pharmaceuticals', 'Camurus(无权益)', '琅钰集团(无权益)']",精神领域,"['精神领域', '内分泌及代谢领域']",2,精神领域,内分泌及代谢领域,,5,2,Psychiatry,Psychiatry,Endocrinology & Metabolism,
pegcetacoplan,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,阵发性睡眠性血红蛋白尿症,paroxysmal nocturnal hemoglobinuria,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,阵发性睡眠性血红蛋白尿症(差异化疾病),批准上市,2021/5/14,Active,罕见疾病领域;血液领域,DR035939,美国,approved,批准上市,2021/5/14,approved,2,TRUE,TRUE,FALSE,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",血液领域,['血液领域'],1,血液领域,,,5,5,Hematology,Hematology,,
pegcetacoplan,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,C3肾小球病,C3 glomerulopathy,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,C3肾小球病(差异化疾病),批准上市,2025/7/28,Active,罕见疾病领域;免疫领域;泌尿生殖领域,DR035939,美国,approved,批准上市,2021/5/14,approved,2,TRUE,TRUE,FALSE,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",免疫领域,"['免疫领域', '泌尿生殖领域']",2,免疫领域,泌尿生殖领域,,5,5,Immunology,Immunology,Genitourinary,
pegcetacoplan,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,地图样萎缩,geographical atrophy,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,地图样萎缩(差异化疾病),批准上市,2023/2/17,Active,眼科领域,DR035939,美国,approved,批准上市,2021/5/14,approved,2,TRUE,FALSE,FALSE,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",眼科领域,['眼科领域'],1,眼科领域,,,5,5,Ophthalmology,Ophthalmology,,
pegcetacoplan,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,免疫复合物介导的膜增生性肾小球肾炎,Immune complex-mediated membranoproliferative glomerulonephritis,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,免疫复合物介导的膜增生性肾小球肾炎(差异化疾病),批准上市,2025/7/28,Active,泌尿生殖领域;罕见疾病领域,DR035939,美国,approved,批准上市,2021/5/14,approved,2,TRUE,TRUE,FALSE,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",泌尿生殖领域,['泌尿生殖领域'],1,泌尿生殖领域,,,5,5,Genitourinary,Genitourinary,,
pegcetacoplan,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,肾移植后移植物功能延迟恢复,Delayed recovery of graft function after kidney transplantation,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,肾移植后移植物功能延迟恢复(差异化疾病),III期临床,2025/6/13,Active,免疫领域;罕见疾病领域,DR035939,美国,phase 3,批准上市,2021/5/14,approved,2,TRUE,TRUE,FALSE,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",免疫领域,['免疫领域'],1,免疫领域,,,5,3,Immunology,Immunology,,
pegcetacoplan,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,冷凝集素病,cold agglutinin disease,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,冷凝集素病(差异化疾病),III期临床,2021/10/27,Active,血液领域;罕见疾病领域;免疫领域,DR035939,美国,phase 3,批准上市,2021/5/14,approved,2,TRUE,TRUE,FALSE,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",血液领域,"['血液领域', '免疫领域']",2,血液领域,免疫领域,,5,3,Hematology,Hematology,Immunology,
pegcetacoplan,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,局灶性节段性肾小球硬化,focal segmental glomerulosclerosis,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,局灶性节段性肾小球硬化(差异化疾病),II/III期临床,2025/10/9,Active,泌尿生殖领域,DR035939,美国,phase 3,批准上市,2021/5/14,approved,2,TRUE,FALSE,FALSE,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",泌尿生殖领域,['泌尿生殖领域'],1,泌尿生殖领域,,,5,3,Genitourinary,Genitourinary,,
pegcetacoplan,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,狼疮性肾炎,lupus nephritis,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,狼疮性肾炎(差异化疾病),II期临床,2018/3/5,Active,泌尿生殖领域;免疫领域,DR035939,美国,phase 2,批准上市,2021/5/14,approved,2,TRUE,FALSE,FALSE,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",泌尿生殖领域,"['泌尿生殖领域', '免疫领域']",2,泌尿生殖领域,免疫领域,,5,2,Genitourinary,Genitourinary,Immunology,
pegcetacoplan,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,IgA肾病,IgA nephropathy,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,IgA肾病(差异化疾病),II期临床,2018/3/5,Active,泌尿生殖领域;免疫领域,DR035939,美国,phase 2,批准上市,2021/5/14,approved,2,TRUE,FALSE,FALSE,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",泌尿生殖领域,"['泌尿生殖领域', '免疫领域']",2,泌尿生殖领域,免疫领域,,5,2,Genitourinary,Genitourinary,Immunology,
pegcetacoplan,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,膜性肾病,membranous nephropathy,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,膜性肾病(差异化疾病),II期临床,2018/3/5,Active,泌尿生殖领域,DR035939,美国,phase 2,批准上市,2021/5/14,approved,2,TRUE,FALSE,FALSE,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",泌尿生殖领域,['泌尿生殖领域'],1,泌尿生殖领域,,,5,2,Genitourinary,Genitourinary,,
pegcetacoplan,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,温抗体型自身免疫溶血性贫血,Warm antibody autoimmune hemolytic anemia,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,温抗体型自身免疫溶血性贫血(差异化疾病),II期临床,2017/7/24,Active,罕见疾病领域;血液领域;免疫领域,DR035939,美国,phase 2,批准上市,2021/5/14,approved,2,TRUE,TRUE,FALSE,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",血液领域,"['血液领域', '免疫领域']",2,血液领域,免疫领域,,5,2,Hematology,Hematology,Immunology,
pegcetacoplan,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,造血干细胞移植后血栓性微血管病,Thrombotic microangiopathy after hematopoietic stem cell transplantation,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,造血干细胞移植后血栓性微血管病(差异化疾病),II期临床,2021/12/8,Active,血液领域,DR035939,美国,phase 2,批准上市,2021/5/14,approved,2,TRUE,FALSE,FALSE,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",血液领域,['血液领域'],1,血液领域,,,5,2,Hematology,Hematology,,
pegcetacoplan,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,恶性胸水,malignant pleural effusion,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,恶性胸水(差异化疾病),I/II期临床,2025/10/9,Active,肿瘤领域;罕见疾病领域,DR035939,美国,phase 2,批准上市,2021/5/14,approved,2,TRUE,TRUE,FALSE,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,
pegcetacoplan,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,血栓(抗凝或抗血小板),Thrombosis (anticoagulant or antiplatelet),C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,血栓(抗凝或抗血小板)(差异化疾病),I/II期临床,2025/10/9,Active,心脑血管领域,DR035939,美国,phase 2,批准上市,2021/5/14,approved,2,TRUE,FALSE,FALSE,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,5,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
pegcetacoplan,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,心肌梗塞,myocardial infarction,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,心肌梗塞(差异化疾病),I/II期临床,2025/10/9,Active,心脑血管领域,DR035939,美国,phase 2,批准上市,2021/5/14,approved,2,TRUE,FALSE,FALSE,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,5,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
pegcetacoplan,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,卒中,Stroke,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,卒中,I/II期临床,2025/10/9,Active,心脑血管领域,DR035939,美国,phase 2,批准上市,2021/5/14,approved,2,TRUE,FALSE,FALSE,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,5,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
pegcetacoplan,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,腹水,ascites,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,腹水(差异化疾病),I/II期临床,2025/10/9,Active,泌尿生殖领域,DR035939,美国,phase 2,批准上市,2021/5/14,approved,2,TRUE,FALSE,FALSE,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",泌尿生殖领域,['泌尿生殖领域'],1,泌尿生殖领域,,,5,2,Genitourinary,Genitourinary,,
pegcetacoplan,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,年龄相关性黄斑变性,age-related macular degeneration,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,年龄相关性黄斑变性,I/II期临床,2018/3/14,Active,眼科领域,DR035939,美国,phase 2,批准上市,2021/5/14,approved,2,TRUE,FALSE,FALSE,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",眼科领域,['眼科领域'],1,眼科领域,,,5,2,Ophthalmology,Ophthalmology,,
pegcetacoplan,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,湿性年龄相关性黄斑变性,Wet age-related macular degeneration,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,湿性年龄相关性黄斑变性(差异化疾病),I/II期临床,,Active,眼科领域,DR035939,美国,phase 2,批准上市,2021/5/14,approved,2,TRUE,FALSE,FALSE,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",眼科领域,['眼科领域'],1,眼科领域,,,5,2,Ophthalmology,Ophthalmology,,
pegcetacoplan,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,干性年龄相关性黄斑变性,Dry age-related macular degeneration,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,干性年龄相关性黄斑变性,I/II期临床,2025/9/8,Active,眼科领域,DR035939,美国,phase 2,批准上市,2021/5/14,approved,2,TRUE,FALSE,FALSE,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",眼科领域,['眼科领域'],1,眼科领域,,,5,2,Ophthalmology,Ophthalmology,,
pegcetacoplan,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,胰腺导管癌,pancreatic ductal carcinoma,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,胰腺导管癌(差异化疾病),I/II期临床,2025/10/9,Active,肿瘤领域,DR035939,美国,phase 2,批准上市,2021/5/14,approved,2,TRUE,FALSE,FALSE,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,
pegcetacoplan,pegcetacoplan,pegcetacoplan;APL-2;Empaveli;Aspaveli;Syfovre,移植物抗宿主病,graft versus host disease,C3,C3抑制剂,Apellis Pharmaceuticals(原研);Swedish Orphan Biovitrum,创新药,化药,多肽,环肽;First-in-Class;差异化疾病;中国无申报,抑制剂,移植物抗宿主病(差异化疾病),临床前,,Active,免疫领域;罕见疾病领域,DR035939,美国,pre-clinical,批准上市,2021/5/14,approved,2,TRUE,TRUE,FALSE,[],['Apellis Pharmaceuticals'],1,"['Apellis Pharmaceuticals(原研)', 'Swedish Orphan Biovitrum']",免疫领域,['免疫领域'],1,免疫领域,,,5,-1,Immunology,Immunology,,
伏索利肽,vosoritide,伏索利肽;vosoritide;BMN 111;BMN111;Voxzogo,软骨发育不全,Achondroplasia,CNP,CNP类似物,BioMarin Pharmaceutical(原研);Samoh Pharm,创新药,生物,多肽,环肽;First-in-Class;差异化疾病,类似物,软骨发育不全,批准上市,2021/8/27,Active,骨骼肌肉领域;罕见疾病领域,DR003025,美国,approved,批准上市,2021/8/26,approved,2,TRUE,TRUE,FALSE,[],['BioMarin Pharmaceutical'],1,"['BioMarin Pharmaceutical(原研)', 'Samoh Pharm']",骨骼肌肉领域,['骨骼肌肉领域'],1,骨骼肌肉领域,,,5,5,Musculoskeletal,Musculoskeletal,,
伏索利肽,vosoritide,伏索利肽;vosoritide;BMN 111;BMN111;Voxzogo,矮小,short,CNP,CNP类似物,BioMarin Pharmaceutical(原研);Samoh Pharm,创新药,生物,多肽,环肽;First-in-Class;差异化疾病,类似物,矮小,II期临床,2023/5/8,Active,内分泌及代谢领域,DR003025,美国,phase 2,批准上市,2021/8/26,approved,2,TRUE,FALSE,FALSE,[],['BioMarin Pharmaceutical'],1,"['BioMarin Pharmaceutical(原研)', 'Samoh Pharm']",内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,
伏索利肽,vosoritide,伏索利肽;vosoritide;BMN 111;BMN111;Voxzogo,特纳综合征,Turner syndrome,CNP,CNP类似物,BioMarin Pharmaceutical(原研);Samoh Pharm,创新药,生物,多肽,环肽;First-in-Class;差异化疾病,类似物,特纳综合征(差异化疾病),II期临床,2023/5/8,Active,罕见疾病领域,DR003025,美国,phase 2,批准上市,2021/8/26,approved,2,TRUE,TRUE,FALSE,[],['BioMarin Pharmaceutical'],1,"['BioMarin Pharmaceutical(原研)', 'Samoh Pharm']",,[],0,,,,5,2,,,,
伏索利肽,vosoritide,伏索利肽;vosoritide;BMN 111;BMN111;Voxzogo,努南综合征,Noonan syndrome,CNP,CNP类似物,BioMarin Pharmaceutical(原研);Samoh Pharm,创新药,生物,多肽,环肽;First-in-Class;差异化疾病,类似物,努南综合征(差异化疾病),II期临床,2024/10/31,Active,罕见疾病领域,DR003025,美国,phase 2,批准上市,2021/8/26,approved,2,TRUE,TRUE,FALSE,[],['BioMarin Pharmaceutical'],1,"['BioMarin Pharmaceutical(原研)', 'Samoh Pharm']",,[],0,,,,5,2,,,,
伏索利肽,vosoritide,伏索利肽;vosoritide;BMN 111;BMN111;Voxzogo,特发性矮小,idiopathic short stature,CNP,CNP类似物,BioMarin Pharmaceutical(原研);Samoh Pharm,创新药,生物,多肽,环肽;First-in-Class;差异化疾病,类似物,特发性矮小(差异化疾病),II期临床,2024/4/24,Active,内分泌及代谢领域,DR003025,美国,phase 2,批准上市,2021/8/26,approved,2,TRUE,FALSE,FALSE,[],['BioMarin Pharmaceutical'],1,"['BioMarin Pharmaceutical(原研)', 'Samoh Pharm']",内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,
伏索利肽,vosoritide,伏索利肽;vosoritide;BMN 111;BMN111;Voxzogo,SHOX缺陷,SHOX defects,CNP,CNP类似物,BioMarin Pharmaceutical(原研);Samoh Pharm,创新药,生物,多肽,环肽;First-in-Class;差异化疾病,类似物,SHOX缺陷(差异化疾病),II期临床,2024/10/31,Active,内分泌及代谢领域;罕见疾病领域,DR003025,美国,phase 2,批准上市,2021/8/26,approved,2,TRUE,TRUE,FALSE,[],['BioMarin Pharmaceutical'],1,"['BioMarin Pharmaceutical(原研)', 'Samoh Pharm']",内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,
伏索利肽,vosoritide,伏索利肽;vosoritide;BMN 111;BMN111;Voxzogo,VI型黏多糖贮积症,Mucopolysaccharidosis type VI,CNP,CNP类似物,BioMarin Pharmaceutical(原研);Samoh Pharm,创新药,生物,多肽,环肽;First-in-Class;差异化疾病,类似物,VI型黏多糖贮积症(差异化疾病),I/II期临床,2023/5/6,Active,内分泌及代谢领域;罕见疾病领域,DR003025,美国,phase 2,批准上市,2021/8/26,approved,2,TRUE,TRUE,FALSE,[],['BioMarin Pharmaceutical'],1,"['BioMarin Pharmaceutical(原研)', 'Samoh Pharm']",内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,
伏索利肽,vosoritide,伏索利肽;vosoritide;BMN 111;BMN111;Voxzogo,IVA型黏多糖贮积症,Mucopolysaccharidosis type IVA,CNP,CNP类似物,BioMarin Pharmaceutical(原研);Samoh Pharm,创新药,生物,多肽,环肽;First-in-Class;差异化疾病,类似物,IVA型黏多糖贮积症(差异化疾病),I/II期临床,2023/5/6,Active,内分泌及代谢领域;罕见疾病领域,DR003025,美国,phase 2,批准上市,2021/8/26,approved,2,TRUE,TRUE,FALSE,[],['BioMarin Pharmaceutical'],1,"['BioMarin Pharmaceutical(原研)', 'Samoh Pharm']",内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,
CyclASol,CyclASol (cyclosporine A),CyclASol;CyclASol (环孢素);CyclASol (cyclosporine A);SHR8028;Vevye;Vevizye,干眼病,dry eye disease,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,恒瑞医药;Novaliq(原研);Harrow,微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,干眼病,批准上市,2023/5/30,Active,眼科领域,DR015549,欧洲,approved,批准上市,2023/5/30,approved,3,TRUE,FALSE,FALSE,[],['Novaliq'],1,"['恒瑞医药', 'Novaliq(原研)', 'Harrow']",眼科领域,['眼科领域'],1,眼科领域,,,5,5,Ophthalmology,Ophthalmology,,
培莫沙肽,Pegol-sihematide,培莫沙肽;Pegol-sihematide;培化西海马肽;pegol-sihematide;EPO-018B;HS-20039;圣罗莱;pegmolesatide,慢性肾病贫血,chronic kidney disease anemia,EPO receptor,EPO receptor激动剂,翰森制药(原研),创新药,化药,多肽,环肽;差异化疾病,激动剂,慢性肾病贫血,批准上市,2023/6/30,Active,血液领域;泌尿生殖领域,DR032372,中国(内地),approved,批准上市,2023/6/30,approved,1,TRUE,FALSE,FALSE,[],['翰森制药'],1,['翰森制药(原研)'],血液领域,"['血液领域', '泌尿生殖领域']",2,血液领域,泌尿生殖领域,,5,5,Hematology,Hematology,Genitourinary,
莫替福肽,motixafortide,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,多发性骨髓瘤,multiple myeloma,CXCR4,CXCR4拮抗剂,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,多发性骨髓瘤,批准上市,2023/9/11,Active,肿瘤领域;血液领域;罕见疾病领域,DR041695,以色列,approved,批准上市,2023/9/8,approved,5,TRUE,TRUE,FALSE,[],['Biokine Therapeutics'],1,"['BioLineRx', '劲方医药', 'Biokine Therapeutics(原研)', '誉衡生物', 'Ayrmid']",肿瘤领域,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,5,5,Oncology,Oncology,Hematology,
莫替福肽,motixafortide,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,干细胞动员,stem cell mobilization,CXCR4,CXCR4拮抗剂,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,干细胞动员,批准上市,2023/9/11,Active,血液领域;罕见疾病领域,DR041695,以色列,approved,批准上市,2023/9/8,approved,5,TRUE,TRUE,FALSE,[],['Biokine Therapeutics'],1,"['BioLineRx', '劲方医药', 'Biokine Therapeutics(原研)', '誉衡生物', 'Ayrmid']",血液领域,['血液领域'],1,血液领域,,,5,5,Hematology,Hematology,,
莫替福肽,motixafortide,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,胰腺癌,pancreatic cancer,CXCR4,CXCR4拮抗剂,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,胰腺癌,II期临床,2016/7/11,Active,肿瘤领域;罕见疾病领域,DR041695,以色列,phase 2,批准上市,2023/9/8,approved,5,TRUE,TRUE,FALSE,[],['Biokine Therapeutics'],1,"['BioLineRx', '劲方医药', 'Biokine Therapeutics(原研)', '誉衡生物', 'Ayrmid']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,
莫替福肽,motixafortide,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,急性髓系白血病,acute myeloid leukemia,CXCR4,CXCR4拮抗剂,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,急性髓系白血病,II期临床,2013/4/24,Active,肿瘤领域;血液领域;罕见疾病领域,DR041695,以色列,phase 2,批准上市,2023/9/8,approved,5,TRUE,TRUE,FALSE,[],['Biokine Therapeutics'],1,"['BioLineRx', '劲方医药', 'Biokine Therapeutics(原研)', '誉衡生物', 'Ayrmid']",肿瘤领域,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,5,2,Oncology,Oncology,Hematology,
莫替福肽,motixafortide,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,胃癌,stomach cancer,CXCR4,CXCR4拮抗剂,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,胃癌(差异化疾病),I/II期临床,2017/9/13,Active,肿瘤领域,DR041695,以色列,phase 2,批准上市,2023/9/8,approved,5,TRUE,FALSE,FALSE,[],['Biokine Therapeutics'],1,"['BioLineRx', '劲方医药', 'Biokine Therapeutics(原研)', '誉衡生物', 'Ayrmid']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,2,Oncology,Oncology,,
莫替福肽,motixafortide,莫替福肽;motixafortide;BL-8040;BKT140;4F-benzoyl-TN14003;BKT-140;T140;GFH168;Aphexda,镰状细胞病,sickle cell disease,CXCR4,CXCR4拮抗剂,BioLineRx;劲方医药;Biokine Therapeutics(原研);誉衡生物;Ayrmid,创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,镰状细胞病,I期临床,2022/11/16,Active,血液领域;罕见疾病领域,DR041695,以色列,phase 1,批准上市,2023/9/8,approved,5,TRUE,TRUE,FALSE,[],['Biokine Therapeutics'],1,"['BioLineRx', '劲方医药', 'Biokine Therapeutics(原研)', '誉衡生物', 'Ayrmid']",血液领域,['血液领域'],1,血液领域,,,5,1,Hematology,Hematology,,
泽卢克布仑钠,zilucoplan,泽卢克布仑钠;zilucoplan;RA101495;Zilbrysq;泽勒普肽;卓倍可,重症肌无力,myasthenia gravis,C5,C5抑制剂,Ra Pharmaceuticals(UCB)(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,抑制剂,重症肌无力,批准上市,2023/9/25,Active,罕见疾病领域;免疫领域,DR046869,美国,approved,批准上市,2023/9/25,approved,1,TRUE,TRUE,FALSE,[],['Ra Pharmaceuticals(UCB)'],1,['Ra Pharmaceuticals(UCB)(原研)'],免疫领域,['免疫领域'],1,免疫领域,,,5,5,Immunology,Immunology,,
泽卢克布仑钠,zilucoplan,泽卢克布仑钠;zilucoplan;RA101495;Zilbrysq;泽勒普肽;卓倍可,脑膜炎,meningitis,C5,C5抑制剂,Ra Pharmaceuticals(UCB)(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,抑制剂,脑膜炎(差异化疾病),III期临床,2025/10/14,Active,神经领域,DR046869,美国,phase 3,批准上市,2023/9/25,approved,1,TRUE,FALSE,FALSE,[],['Ra Pharmaceuticals(UCB)'],1,['Ra Pharmaceuticals(UCB)(原研)'],神经领域,['神经领域'],1,神经领域,,,5,3,Neurology,Neurology,,
泽卢克布仑钠,zilucoplan,泽卢克布仑钠;zilucoplan;RA101495;Zilbrysq;泽勒普肽;卓倍可,新型冠状病毒感染,novel coronavirus infection,C5,C5抑制剂,Ra Pharmaceuticals(UCB)(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,抑制剂,新型冠状病毒感染(差异化疾病),III期临床,2020/10/19,Active,感染领域,DR046869,美国,phase 3,批准上市,2023/9/25,approved,1,TRUE,FALSE,FALSE,[],['Ra Pharmaceuticals(UCB)'],1,['Ra Pharmaceuticals(UCB)(原研)'],感染领域,['感染领域'],1,感染领域,,,5,3,Infectious Diseases,Infectious Diseases,,
泽卢克布仑钠,zilucoplan,泽卢克布仑钠;zilucoplan;RA101495;Zilbrysq;泽勒普肽;卓倍可,肌萎缩侧索硬化症,amyotrophic lateral sclerosis,C5,C5抑制剂,Ra Pharmaceuticals(UCB)(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,抑制剂,肌萎缩侧索硬化症(差异化疾病),II/III期临床,2020/3/5,Active,神经领域;罕见疾病领域,DR046869,美国,phase 3,批准上市,2023/9/25,approved,1,TRUE,TRUE,FALSE,[],['Ra Pharmaceuticals(UCB)'],1,['Ra Pharmaceuticals(UCB)(原研)'],神经领域,['神经领域'],1,神经领域,,,5,3,Neurology,Neurology,,
泽卢克布仑钠,zilucoplan,泽卢克布仑钠;zilucoplan;RA101495;Zilbrysq;泽勒普肽;卓倍可,狼疮性肾炎,lupus nephritis,C5,C5抑制剂,Ra Pharmaceuticals(UCB)(原研),创新药,化药,多肽,环肽;First-in-Class;差异化疾病,抑制剂,狼疮性肾炎(差异化疾病),临床前,,Active,泌尿生殖领域;免疫领域,DR046869,美国,pre-clinical,批准上市,2023/9/25,approved,1,TRUE,FALSE,FALSE,[],['Ra Pharmaceuticals(UCB)'],1,['Ra Pharmaceuticals(UCB)(原研)'],泌尿生殖领域,"['泌尿生殖领域', '免疫领域']",2,泌尿生殖领域,免疫领域,,5,-1,Genitourinary,Genitourinary,Immunology,
倍维巴肽,bevifibatide,倍维巴肽;bevifibatide;巴替非班;batifiban;BAT2094;贝塔宁;Betagrin,血栓(抗凝或抗血小板),Thrombosis (anticoagulant or antiplatelet),GPIIb/IIIa,GPIIb/IIIa拮抗剂,百奥泰(原研),创新药,化药,多肽,环肽;差异化疾病,拮抗剂,血栓(抗凝或抗血小板),批准上市,2024/6/28,Active,心脑血管领域,DR030700,中国(内地),approved,批准上市,2024/6/25,approved,1,TRUE,FALSE,FALSE,[],['百奥泰'],1,['百奥泰(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,5,5,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
倍维巴肽,bevifibatide,倍维巴肽;bevifibatide;巴替非班;batifiban;BAT2094;贝塔宁;Betagrin,急性冠脉综合征,acute coronary syndrome,GPIIb/IIIa,GPIIb/IIIa拮抗剂,百奥泰(原研),创新药,化药,多肽,环肽;差异化疾病,拮抗剂,急性冠脉综合征,批准上市,2024/6/28,Active,心脑血管领域,DR030700,中国(内地),approved,批准上市,2024/6/25,approved,1,TRUE,FALSE,FALSE,[],['百奥泰'],1,['百奥泰(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,5,5,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
倍维巴肽,bevifibatide,倍维巴肽;bevifibatide;巴替非班;batifiban;BAT2094;贝塔宁;Betagrin,心肌梗塞,myocardial infarction,GPIIb/IIIa,GPIIb/IIIa拮抗剂,百奥泰(原研),创新药,化药,多肽,环肽;差异化疾病,拮抗剂,心肌梗塞,III期临床,2024/11/14,Active,心脑血管领域,DR030700,中国(内地),phase 3,批准上市,2024/6/25,approved,1,TRUE,FALSE,FALSE,[],['百奥泰'],1,['百奥泰(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,5,3,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
倍维巴肽,bevifibatide,倍维巴肽;bevifibatide;巴替非班;batifiban;BAT2094;贝塔宁;Betagrin,不稳定性心绞痛,unstable angina,GPIIb/IIIa,GPIIb/IIIa拮抗剂,百奥泰(原研),创新药,化药,多肽,环肽;差异化疾病,拮抗剂,不稳定性心绞痛,III期临床,2018/5/2,Active,心脑血管领域,DR030700,中国(内地),phase 3,批准上市,2024/6/25,approved,1,TRUE,FALSE,FALSE,[],['百奥泰'],1,['百奥泰(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,5,3,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
倍维巴肽,bevifibatide,倍维巴肽;bevifibatide;巴替非班;batifiban;BAT2094;贝塔宁;Betagrin,非ST段抬高型心肌梗死,Non-ST segment elevation myocardial infarction,GPIIb/IIIa,GPIIb/IIIa拮抗剂,百奥泰(原研),创新药,化药,多肽,环肽;差异化疾病,拮抗剂,非ST段抬高型心肌梗死,III期临床,2018/5/2,Active,心脑血管领域,DR030700,中国(内地),phase 3,批准上市,2024/6/25,approved,1,TRUE,FALSE,FALSE,[],['百奥泰'],1,['百奥泰(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,5,3,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
倍维巴肽,bevifibatide,倍维巴肽;bevifibatide;巴替非班;batifiban;BAT2094;贝塔宁;Betagrin,缺血性卒中,ischemic stroke,GPIIb/IIIa,GPIIb/IIIa拮抗剂,百奥泰(原研),创新药,化药,多肽,环肽;差异化疾病,拮抗剂,缺血性卒中,II期临床,2024/12/2,Active,心脑血管领域,DR030700,中国(内地),phase 2,批准上市,2024/6/25,approved,1,TRUE,FALSE,FALSE,[],['百奥泰'],1,['百奥泰(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,5,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
倍维巴肽,bevifibatide,倍维巴肽;bevifibatide;巴替非班;batifiban;BAT2094;贝塔宁;Betagrin,血栓闭塞性脉管炎,Thromboangitis obliterans,GPIIb/IIIa,GPIIb/IIIa拮抗剂,百奥泰(原研),创新药,化药,多肽,环肽;差异化疾病,拮抗剂,血栓闭塞性脉管炎(差异化疾病),I期临床,2025/1/22,Active,心脑血管领域,DR030700,中国(内地),phase 1,批准上市,2024/6/25,approved,1,TRUE,FALSE,FALSE,[],['百奥泰'],1,['百奥泰(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,5,1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
CAM2029,CAM2029 (octreotide),CAM2029;CAM2029 (奥曲肽);CAM2029 (octreotide);Oczyesa,肢端肥大症,acromegaly,somatostatin,somatostatin类似物,Novartis(Top20 MNC);Camurus(原研),微创新,化药,多肽,环肽,类似物,肢端肥大症,批准上市,2025/6/30,Active,内分泌及代谢领域;罕见疾病领域,DR031328,欧洲,approved,批准上市,2025/6/30,approved,2,TRUE,TRUE,TRUE,['Novartis'],['Camurus'],1,"['Novartis(Top20 MNC)', 'Camurus(原研)']",内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,5,Endocrinology & Metabolism,Endocrinology & Metabolism,,
CAM2029,CAM2029 (octreotide),CAM2029;CAM2029 (奥曲肽);CAM2029 (octreotide);Oczyesa,胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,somatostatin,somatostatin类似物,Novartis(Top20 MNC);Camurus(原研),微创新,化药,多肽,环肽,类似物,胃肠胰神经内分泌肿瘤,III期临床,2021/9/21,Active,肿瘤领域;罕见疾病领域,DR031328,欧洲,phase 3,批准上市,2025/6/30,approved,2,TRUE,TRUE,TRUE,['Novartis'],['Camurus'],1,"['Novartis(Top20 MNC)', 'Camurus(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,5,3,Oncology,Oncology,,
CAM2029,CAM2029 (octreotide),CAM2029;CAM2029 (奥曲肽);CAM2029 (octreotide);Oczyesa,多囊肝病,polycystic liver disease,somatostatin,somatostatin类似物,Novartis(Top20 MNC);Camurus(原研),微创新,化药,多肽,环肽,类似物,多囊肝病,II/III期临床,2022/3/16,Active,消化领域;罕见疾病领域,DR031328,欧洲,phase 3,批准上市,2025/6/30,approved,2,TRUE,TRUE,TRUE,['Novartis'],['Camurus'],1,"['Novartis(Top20 MNC)', 'Camurus(原研)']",消化领域,['消化领域'],1,消化领域,,,5,3,Digestive System,Digestive System,,
CAM2029,CAM2029 (octreotide),CAM2029;CAM2029 (奥曲肽);CAM2029 (octreotide);Oczyesa,多囊肾病,polycystic kidney disease,somatostatin,somatostatin类似物,Novartis(Top20 MNC);Camurus(原研),微创新,化药,多肽,环肽,类似物,多囊肾病,临床前,,Active,泌尿生殖领域;罕见疾病领域,DR031328,欧洲,pre-clinical,批准上市,2025/6/30,approved,2,TRUE,TRUE,TRUE,['Novartis'],['Camurus'],1,"['Novartis(Top20 MNC)', 'Camurus(原研)']",泌尿生殖领域,['泌尿生殖领域'],1,泌尿生殖领域,,,5,-1,Genitourinary,Genitourinary,,
Cyporin N,Cyporin N (cyclosporine nanoemulsion),Cyporin N;Cyporin N (环孢素纳米乳);Cyporin N (cyclosporine nanoemulsion);TJO-087,干眼病,dry eye disease,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Taejoon Pharm(原研),微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶;中国无申报,抑制剂;分子胶,干眼病,批准上市,,Active,眼科领域,DR022738,韩国,approved,批准上市,,approved,1,TRUE,FALSE,FALSE,[],['Taejoon Pharm'],1,['Taejoon Pharm(原研)'],眼科领域,['眼科领域'],1,眼科领域,,,5,5,Ophthalmology,Ophthalmology,,
Octreonax,Octreonax (octreotide injectable microsphere),Octreonax;Octreonax(注射用奥曲肽微球);Octreonax (octreotide injectable microsphere),肢端肥大症,acromegaly,somatostatin,somatostatin类似物,Nanox Release Technology(原研),微创新,化药,多肽,环肽;中国无申报,类似物,肢端肥大症,批准上市,,Active,内分泌及代谢领域;罕见疾病领域,DR047438,阿根廷,approved,批准上市,,approved,1,TRUE,TRUE,FALSE,[],['Nanox Release Technology'],1,['Nanox Release Technology(原研)'],内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,5,Endocrinology & Metabolism,Endocrinology & Metabolism,,
Octreonax,Octreonax (octreotide injectable microsphere),Octreonax;Octreonax(注射用奥曲肽微球);Octreonax (octreotide injectable microsphere),巨人症,gigantism,somatostatin,somatostatin类似物,Nanox Release Technology(原研),微创新,化药,多肽,环肽;中国无申报,类似物,巨人症,批准上市,,Active,内分泌及代谢领域,DR047438,阿根廷,approved,批准上市,,approved,1,TRUE,FALSE,FALSE,[],['Nanox Release Technology'],1,['Nanox Release Technology(原研)'],内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,5,5,Endocrinology & Metabolism,Endocrinology & Metabolism,,
伐普肽,vapreotide,伐普肽;vapreotide;Sanvar;RC-160,食管静脉曲张出血,Esophageal variceal bleeding,somatostatin,somatostatin类似物,Debiopharm(原研),创新药,化药,多肽,环肽,类似物,食管静脉曲张出血,批准上市,,Active,消化领域,DR010387,欧洲,approved,批准上市,,approved,1,TRUE,FALSE,FALSE,[],['Debiopharm'],1,['Debiopharm(原研)'],消化领域,['消化领域'],1,消化领域,,,5,5,Digestive System,Digestive System,,
夫沙芬净,fusafungin,夫沙芬净;fusafungin;fusafungine;S-314;Bioparox;Locabiotal,上呼吸道感染,upper respiratory tract infection,not available,,Servier(原研),创新药,化药,小分子,环肽,其他,上呼吸道感染,批准上市,,Active,感染领域;呼吸领域,DR001193,欧洲,approved,批准上市,,approved,1,TRUE,FALSE,FALSE,[],['Servier'],1,['Servier(原研)'],感染领域,"['感染领域', '呼吸领域']",2,感染领域,呼吸领域,,5,5,Infectious Diseases,Infectious Diseases,Respiratory,
普那霉素,pristinamycin,普那霉素;pristinamycin;Pyostacine;pristinamycine;RP 7293;原始霉素,细菌感染,bacterial infection,50S subunit,链阳性菌素类抗生素,Rhône-Poulenc(Sanofi)(Top20 MNC)(原研),创新药,化药,其他,环肽;First-in-Class;差异化疾病,链阳性菌素类抗生素,细菌感染,批准上市,,Active,感染领域,DR044796,欧洲,approved,批准上市,,approved,1,TRUE,FALSE,TRUE,['Rhône-Poulenc(Sanofi)'],['Rhône-Poulenc(Sanofi)'],1,['Rhône-Poulenc(Sanofi)(Top20 MNC)(原研)'],感染领域,['感染领域'],1,感染领域,,,5,5,Infectious Diseases,Infectious Diseases,,
苯赖加压素,felypressin,苯赖加压素;felypressin;Octapressin,局部麻醉,local anesthesia,vasopressin,vasopressin类似物,Sandoz(原研),创新药,化药,多肽,环肽;差异化疾病,类似物,局部麻醉(差异化疾病),批准上市,,Active,麻醉镇痛领域,DR051774,欧洲,approved,批准上市,,approved,1,TRUE,FALSE,FALSE,[],['Sandoz'],1,['Sandoz(原研)'],麻醉镇痛领域,['麻醉镇痛领域'],1,麻醉镇痛领域,,,5,5,Anesthesia & Analgesia,Anesthesia & Analgesia,,
重组水蛭素,recombinant hirudin,重组水蛭素;recombinant hirudin;Thrombexx;Extrauma;r-hirudin,深静脉血栓,deep vein thrombosis,hirudin,重组hirudin,Minapharm(原研);Rhein biotech(Top20 MNC)(原研),创新药,生物,多肽,环肽;First-in-Class;差异化疾病,重组,深静脉血栓,批准上市,,Active,心脑血管领域,DR010644,欧洲;埃及,approved,批准上市,,approved,2,TRUE,FALSE,TRUE,['Rhein biotech'],"['Minapharm', 'Rhein biotech']",2,"['Minapharm(原研)', 'Rhein biotech(Top20 MNC)(原研)']",心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,5,5,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
重组水蛭素,recombinant hirudin,重组水蛭素;recombinant hirudin;Thrombexx;Extrauma;r-hirudin,静脉曲张,Varicose veins,hirudin,重组hirudin,Minapharm(原研);Rhein biotech(Top20 MNC)(原研),创新药,生物,多肽,环肽;First-in-Class;差异化疾病,重组,静脉曲张(差异化疾病),批准上市,,Active,心脑血管领域,DR010644,欧洲;埃及,approved,批准上市,,approved,2,TRUE,FALSE,TRUE,['Rhein biotech'],"['Minapharm', 'Rhein biotech']",2,"['Minapharm(原研)', 'Rhein biotech(Top20 MNC)(原研)']",心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,5,5,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
重组水蛭素,recombinant hirudin,重组水蛭素;recombinant hirudin;Thrombexx;Extrauma;r-hirudin,血栓性静脉炎,thrombophlebitis,hirudin,重组hirudin,Minapharm(原研);Rhein biotech(Top20 MNC)(原研),创新药,生物,多肽,环肽;First-in-Class;差异化疾病,重组,血栓性静脉炎(差异化疾病),批准上市,,Active,心脑血管领域,DR010644,欧洲;埃及,approved,批准上市,,approved,2,TRUE,FALSE,TRUE,['Rhein biotech'],"['Minapharm', 'Rhein biotech']",2,"['Minapharm(原研)', 'Rhein biotech(Top20 MNC)(原研)']",心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,5,5,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
重组水蛭素,recombinant hirudin,重组水蛭素;recombinant hirudin;Thrombexx;Extrauma;r-hirudin,血肿,hematoma,hirudin,重组hirudin,Minapharm(原研);Rhein biotech(Top20 MNC)(原研),创新药,生物,多肽,环肽;First-in-Class;差异化疾病,重组,血肿(差异化疾病),批准上市,,Active,其他领域,DR010644,欧洲;埃及,approved,批准上市,,approved,2,TRUE,FALSE,TRUE,['Rhein biotech'],"['Minapharm', 'Rhein biotech']",2,"['Minapharm(原研)', 'Rhein biotech(Top20 MNC)(原研)']",其他领域,['其他领域'],1,其他领域,,,5,5,Others,Others,,
环孢素A眼凝胶,cyclosporine A ophthalmic gel,环孢素A眼凝胶;cyclosporine A ophthalmic gel,干眼病,dry eye disease,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,兆科眼科(原研),微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,干眼病,申请上市,2022/6/9,Active,眼科领域,DR049927,中国(内地),pre-registration,申请上市,2022/6/9,pre-registration,1,TRUE,FALSE,FALSE,[],['兆科眼科'],1,['兆科眼科(原研)'],眼科领域,['眼科领域'],1,眼科领域,,,4,4,Ophthalmology,Ophthalmology,,
那韦培肽,navepegritide,那韦培肽;navepegritide;TransCon CNP,软骨发育不全,Achondroplasia,CNP,CNP类似物,Teijin;Ascendis Pharma(原研);维昇药业,创新药,化药,多肽,环肽;差异化疾病,类似物,软骨发育不全,申请上市,2025/3/31,Active,骨骼肌肉领域;罕见疾病领域,DR011859,欧洲,pre-registration,申请上市,2025/3/31,pre-registration,3,TRUE,TRUE,FALSE,[],['Ascendis Pharma'],1,"['Teijin', 'Ascendis Pharma(原研)', '维昇药业']",骨骼肌肉领域,['骨骼肌肉领域'],1,骨骼肌肉领域,,,4,4,Musculoskeletal,Musculoskeletal,,
ET-600,ET-600 (desmopressin oral solution),ET-600;ET-600 (去氨加压素口服溶液);ET-600 (desmopressin oral solution),中枢性尿崩症,central diabetes insipidus,vasopressin,vasopressin类似物,Eton Pharmaceuticals(原研),微创新,化药,多肽,环肽,类似物,中枢性尿崩症,申请上市,2025/4/28,Active,内分泌及代谢领域,DR068510,美国,pre-registration,申请上市,2025/4/28,pre-registration,1,TRUE,FALSE,FALSE,[],['Eton Pharmaceuticals'],1,['Eton Pharmaceuticals(原研)'],内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,4,4,Endocrinology & Metabolism,Endocrinology & Metabolism,,
镥[177Lu]依多曲肽,177Lu-edotreotide,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,ITM Isotope(原研);远大医药;Duchembio,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,胃肠胰神经内分泌肿瘤,申请上市,2025/11/13,Active,肿瘤领域;罕见疾病领域,DR064918,欧洲,pre-registration,申请上市,2025/11/13,pre-registration,3,TRUE,TRUE,FALSE,[],['ITM Isotope'],1,"['ITM Isotope(原研)', '远大医药', 'Duchembio']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,4,4,Oncology,Oncology,,
镥[177Lu]依多曲肽,177Lu-edotreotide,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,神经内分泌肿瘤,neuroendocrine tumors,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,ITM Isotope(原研);远大医药;Duchembio,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,神经内分泌肿瘤,III期临床,2022/5/24,Active,肿瘤领域;罕见疾病领域,DR064918,欧洲,phase 3,申请上市,2025/11/13,pre-registration,3,TRUE,TRUE,FALSE,[],['ITM Isotope'],1,"['ITM Isotope(原研)', '远大医药', 'Duchembio']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,4,3,Oncology,Oncology,,
镥[177Lu]依多曲肽,177Lu-edotreotide,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,嗜铬细胞瘤,Pheochromocytoma,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,ITM Isotope(原研);远大医药;Duchembio,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,嗜铬细胞瘤,II期临床,2019/8/20,Active,肿瘤领域;罕见疾病领域,DR064918,欧洲,phase 2,申请上市,2025/11/13,pre-registration,3,TRUE,TRUE,FALSE,[],['ITM Isotope'],1,"['ITM Isotope(原研)', '远大医药', 'Duchembio']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,4,2,Oncology,Oncology,,
镥[177Lu]依多曲肽,177Lu-edotreotide,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,副神经节瘤,paraganglioma,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,ITM Isotope(原研);远大医药;Duchembio,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,副神经节瘤,II期临床,2020/2/19,Active,肿瘤领域;罕见疾病领域,DR064918,欧洲,phase 2,申请上市,2025/11/13,pre-registration,3,TRUE,TRUE,FALSE,[],['ITM Isotope'],1,"['ITM Isotope(原研)', '远大医药', 'Duchembio']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,4,2,Oncology,Oncology,,
镥[177Lu]依多曲肽,177Lu-edotreotide,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,脑膜瘤,Meningioma,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,ITM Isotope(原研);远大医药;Duchembio,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,脑膜瘤,II期临床,,Active,肿瘤领域,DR064918,欧洲,phase 2,申请上市,2025/11/13,pre-registration,3,TRUE,FALSE,FALSE,[],['ITM Isotope'],1,"['ITM Isotope(原研)', '远大医药', 'Duchembio']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,4,2,Oncology,Oncology,,
镥[177Lu]依多曲肽,177Lu-edotreotide,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,实体瘤,solid tumors,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,ITM Isotope(原研);远大医药;Duchembio,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,实体瘤,I期临床,2025/3/19,Active,肿瘤领域,DR064918,欧洲,phase 1,申请上市,2025/11/13,pre-registration,3,TRUE,FALSE,FALSE,[],['ITM Isotope'],1,"['ITM Isotope(原研)', '远大医药', 'Duchembio']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,4,1,Oncology,Oncology,,
镥[177Lu]依多曲肽,177Lu-edotreotide,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,脑癌,brain cancer,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,ITM Isotope(原研);远大医药;Duchembio,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,脑癌,I期临床,2024/6/4,Active,肿瘤领域,DR064918,欧洲,phase 1,申请上市,2025/11/13,pre-registration,3,TRUE,FALSE,FALSE,[],['ITM Isotope'],1,"['ITM Isotope(原研)', '远大医药', 'Duchembio']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,4,1,Oncology,Oncology,,
镥[177Lu]依多曲肽,177Lu-edotreotide,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,淋巴瘤,Lymphoma,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,ITM Isotope(原研);远大医药;Duchembio,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,淋巴瘤,I期临床,2024/6/4,Active,肿瘤领域;血液领域,DR064918,欧洲,phase 1,申请上市,2025/11/13,pre-registration,3,TRUE,FALSE,FALSE,[],['ITM Isotope'],1,"['ITM Isotope(原研)', '远大医药', 'Duchembio']",肿瘤领域,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,4,1,Oncology,Oncology,Hematology,
镥[177Lu]依多曲肽,177Lu-edotreotide,镥[177Lu]依多曲肽;177Lu-edotreotide;177Lu-DOTATOC;Solucin;ITM-11;镥[177Lu]依度曲肽,胰腺神经内分泌肿瘤,pancreatic neuroendocrine tumors,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,ITM Isotope(原研);远大医药;Duchembio,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,胰腺神经内分泌肿瘤,申报临床,2024/9/27,Active,肿瘤领域;罕见疾病领域,DR064918,欧洲,ind,申请上市,2025/11/13,pre-registration,3,TRUE,TRUE,FALSE,[],['ITM Isotope'],1,"['ITM Isotope(原研)', '远大医药', 'Duchembio']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,4,0,Oncology,Oncology,,
LV-101,LV-101 (intranasal carbetocin),LV-101;LV-101 (卡贝缩宫素);LV-101 (intranasal carbetocin);ACP-101,Prader-Willi综合征,Prader-Willi syndrome,oxytocin,oxytocin类似物,Ferring Pharmaceuticals(原研);Levo Therapeutics(Acadia Pharmaceuticals),微创新,化药,多肽,环肽;中国无申报,类似物,Prader-Willi综合征,申请上市,,Active,内分泌及代谢领域;罕见疾病领域,DR000577,欧洲,pre-registration,申请上市,,pre-registration,2,TRUE,TRUE,FALSE,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', 'Levo Therapeutics(Acadia Pharmaceuticals)']",内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,4,4,Endocrinology & Metabolism,Endocrinology & Metabolism,,
LV-101,LV-101 (intranasal carbetocin),LV-101;LV-101 (卡贝缩宫素);LV-101 (intranasal carbetocin);ACP-101,多食症,polyphagia,oxytocin,oxytocin类似物,Ferring Pharmaceuticals(原研);Levo Therapeutics(Acadia Pharmaceuticals),微创新,化药,多肽,环肽;中国无申报,类似物,多食症,III期临床,2024/5/20,Active,精神领域;内分泌及代谢领域,DR000577,欧洲,phase 3,申请上市,,pre-registration,2,TRUE,FALSE,FALSE,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', 'Levo Therapeutics(Acadia Pharmaceuticals)']",精神领域,"['精神领域', '内分泌及代谢领域']",2,精神领域,内分泌及代谢领域,,4,3,Psychiatry,Psychiatry,Endocrinology & Metabolism,
CMS I-neb,CMS I-neb (colistimethate sodium powder for nebulization),CMS I-neb;CMS I-neb (多粘菌素E甲磺酸钠雾化剂);CMS I-neb (colistimethate sodium powder for nebulization);Promixin,支气管扩张,bronchiectasis,not available,多粘菌素类抗生素,Zambon(原研),微创新,化药,其他,环肽,多粘菌素类抗生素,支气管扩张,III期临床,2017/2/10,Active,呼吸领域,DR055713,欧洲,phase 3,III期临床,2017/2/10,phase 3,1,TRUE,FALSE,FALSE,[],['Zambon'],1,['Zambon(原研)'],呼吸领域,['呼吸领域'],1,呼吸领域,,,3,3,Respiratory,Respiratory,,
莫瑞伐定,murepavadin,莫瑞伐定;murepavadin;POL7080;RG7929;RO7033877,囊性纤维化,cystic fibrosis,LptD,抗生素,Polyphor(Spexis)(原研);Roche(Top20 MNC)(无权益),创新药,化药,多肽,环肽;Potential First-in-Class,抗生素,囊性纤维化,申报临床,,Active,呼吸领域;罕见疾病领域,DR030039,欧洲,ind,III期临床,2018/1/24,phase 3,2,TRUE,TRUE,TRUE,['Roche'],['Polyphor(Spexis)'],1,"['Polyphor(Spexis)(原研)', 'Roche(Top20 MNC)(无权益)']",呼吸领域,['呼吸领域'],1,呼吸领域,,,3,0,Respiratory,Respiratory,,
Liposomal cyclosporine A,Liposomal cyclosporine A,Liposomal cyclosporine A;环孢素A脂质体 (Breath Therapeutics);L-CsA-i,闭塞性细支气管炎,bronchiolitis obliterans,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Breath Therapeutics(Zambon)(原研),微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,闭塞性细支气管炎,III期临床,2018/9/4,Active,呼吸领域;罕见疾病领域,DR019246,欧洲,phase 3,III期临床,2018/9/4,phase 3,1,TRUE,TRUE,FALSE,[],['Breath Therapeutics(Zambon)'],1,['Breath Therapeutics(Zambon)(原研)'],呼吸领域,['呼吸领域'],1,呼吸领域,,,3,3,Respiratory,Respiratory,,
巴利福肽,balixafortide,巴利福肽;balixafortide;POL6326;SPX6326,乳腺癌,breast cancer,CXCR4,CXCR4拮抗剂,复星医药;Polyphor(Spexis)(原研);University of Zurich(原研)(无权益),创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,乳腺癌,III期临床,2018/12/24,Active,肿瘤领域,DR042535,欧洲,phase 3,III期临床,2018/12/24,phase 3,3,TRUE,FALSE,FALSE,[],"['Polyphor(Spexis)', 'University of Zurich']",2,"['复星医药', 'Polyphor(Spexis)(原研)', 'University of Zurich(原研)(无权益)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,3,Oncology,Oncology,,
巴利福肽,balixafortide,巴利福肽;balixafortide;POL6326;SPX6326,心肌梗塞,myocardial infarction,CXCR4,CXCR4拮抗剂,复星医药;Polyphor(Spexis)(原研);University of Zurich(原研)(无权益),创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,心肌梗塞,II期临床,,Active,心脑血管领域,DR042535,欧洲,phase 2,III期临床,2018/12/24,phase 3,3,TRUE,FALSE,FALSE,[],"['Polyphor(Spexis)', 'University of Zurich']",2,"['复星医药', 'Polyphor(Spexis)(原研)', 'University of Zurich(原研)(无权益)']",心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,3,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
巴利福肽,balixafortide,巴利福肽;balixafortide;POL6326;SPX6326,胰腺导管癌,pancreatic ductal carcinoma,CXCR4,CXCR4拮抗剂,复星医药;Polyphor(Spexis)(原研);University of Zurich(原研)(无权益),创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,胰腺导管癌,I期临床,2025/5/21,Active,肿瘤领域,DR042535,欧洲,phase 1,III期临床,2018/12/24,phase 3,3,TRUE,FALSE,FALSE,[],"['Polyphor(Spexis)', 'University of Zurich']",2,"['复星医药', 'Polyphor(Spexis)(原研)', 'University of Zurich(原研)(无权益)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,
巴利福肽,balixafortide,巴利福肽;balixafortide;POL6326;SPX6326,B细胞淋巴瘤,B cell lymphoma,CXCR4,CXCR4拮抗剂,复星医药;Polyphor(Spexis)(原研);University of Zurich(原研)(无权益),创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,B细胞淋巴瘤,临床前,,Active,肿瘤领域;血液领域,DR042535,欧洲,pre-clinical,III期临床,2018/12/24,phase 3,3,TRUE,FALSE,FALSE,[],"['Polyphor(Spexis)', 'University of Zurich']",2,"['复星医药', 'Polyphor(Spexis)(原研)', 'University of Zurich(原研)(无权益)']",肿瘤领域,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,3,-1,Oncology,Oncology,Hematology,
巴利福肽,balixafortide,巴利福肽;balixafortide;POL6326;SPX6326,新型冠状病毒感染,novel coronavirus infection,CXCR4,CXCR4拮抗剂,复星医药;Polyphor(Spexis)(原研);University of Zurich(原研)(无权益),创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,拮抗剂,新型冠状病毒感染,临床前,,Active,感染领域,DR042535,欧洲,pre-clinical,III期临床,2018/12/24,phase 3,3,TRUE,FALSE,FALSE,[],"['Polyphor(Spexis)', 'University of Zurich']",2,"['复星医药', 'Polyphor(Spexis)(原研)', 'University of Zurich(原研)(无权益)']",感染领域,['感染领域'],1,感染领域,,,3,-1,Infectious Diseases,Infectious Diseases,,
TNX-2900,TNX-2900 (intranasal potentiated oxytocin),TNX-2900;TNX-2900 (缩宫素鼻喷雾);TNX-2900 (intranasal potentiated oxytocin),Prader-Willi综合征,Prader-Willi syndrome,oxytocin,合成的oxytocin,Tonix Pharmaceuticals(原研);Institut National de la Sante et de la Recherche Medicale (INSERM),微创新,化药,多肽,环肽;中国无申报,合成的,Prader-Willi综合征,III期临床,2020/2/25,Active,内分泌及代谢领域;罕见疾病领域,DR003204,美国,phase 3,III期临床,2020/2/25,phase 3,2,TRUE,TRUE,FALSE,[],['Tonix Pharmaceuticals'],1,"['Tonix Pharmaceuticals(原研)', 'Institut National de la Sante et de la Recherche Medicale (INSERM)']",内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,3,3,Endocrinology & Metabolism,Endocrinology & Metabolism,,
氟[18F]阿法肽,alfatide F-18,氟[18F]阿法肽;alfatide F-18;18F-alfatide;(18)F-AlF-NOTA-PRGD2;18F-Al-NOTA-PRGD2;[18F]AlF-NOTA-PRGD2;18F-LNC1016,非小细胞肺癌,non-small cell lung cancer,αvβ3,anti-αvβ3多肽偶联核素;18F标记的PET药物,东诚药业;National Institute of Biomedical Imaging and Bioengineering;施美康(无权益);厦门大学(原研)(无权益),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;18F标记的PET药物,非小细胞肺癌,III期临床,2021/12/10,Active,肿瘤领域,DR043061,中国(内地),phase 3,III期临床,2020/8/6,phase 3,4,TRUE,FALSE,FALSE,[],['厦门大学'],1,"['东诚药业', 'National Institute of Biomedical Imaging and Bioengineering', '施美康(无权益)', '厦门大学(原研)(无权益)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,3,Oncology,Oncology,,
氟[18F]阿法肽,alfatide F-18,氟[18F]阿法肽;alfatide F-18;18F-alfatide;(18)F-AlF-NOTA-PRGD2;18F-Al-NOTA-PRGD2;[18F]AlF-NOTA-PRGD2;18F-LNC1016,PET显像,PET imaging,αvβ3,anti-αvβ3多肽偶联核素;18F标记的PET药物,东诚药业;National Institute of Biomedical Imaging and Bioengineering;施美康(无权益);厦门大学(原研)(无权益),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;18F标记的PET药物,PET显像,III期临床,2021/12/10,Active,诊断试剂领域,DR043061,中国(内地),phase 3,III期临床,2020/8/6,phase 3,4,TRUE,FALSE,FALSE,[],['厦门大学'],1,"['东诚药业', 'National Institute of Biomedical Imaging and Bioengineering', '施美康(无权益)', '厦门大学(原研)(无权益)']",诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,3,3,Diagnostic Reagents,Diagnostic Reagents,,
PL-8331,PL-8331,PL-8331;PL-9643;PL9643;PL8331,干眼病,dry eye disease,MC1R;MC5R,MC5R激动剂;MC1R激动剂,Palatin Technologies(原研),创新药,其他,多肽,环肽;差异化疾病;G蛋白偶联受体;Potential First-in-Class;Melanogenesis,激动剂,干眼病(差异化疾病),III期临床,2022/1/21,Active,眼科领域,DR054606,美国,phase 3,III期临床,2022/1/21,phase 3,1,TRUE,FALSE,FALSE,[],['Palatin Technologies'],1,['Palatin Technologies(原研)'],眼科领域,['眼科领域'],1,眼科领域,,,3,3,Ophthalmology,Ophthalmology,,
PL-8331,PL-8331,PL-8331;PL-9643;PL9643;PL8331,葡萄膜炎,uveitis,MC1R;MC5R,MC5R激动剂;MC1R激动剂,Palatin Technologies(原研),创新药,其他,多肽,环肽;差异化疾病;G蛋白偶联受体;Potential First-in-Class;Melanogenesis,激动剂,葡萄膜炎(差异化疾病),临床前,,Active,眼科领域,DR054606,美国,pre-clinical,III期临床,2022/1/21,phase 3,1,TRUE,FALSE,FALSE,[],['Palatin Technologies'],1,['Palatin Technologies(原研)'],眼科领域,['眼科领域'],1,眼科领域,,,3,-1,Ophthalmology,Ophthalmology,,
PL-8331,PL-8331,PL-8331;PL-9643;PL9643;PL8331,糖尿病视网膜病变,diabetic retinopathy,MC1R;MC5R,MC5R激动剂;MC1R激动剂,Palatin Technologies(原研),创新药,其他,多肽,环肽;差异化疾病;G蛋白偶联受体;Potential First-in-Class;Melanogenesis,激动剂,糖尿病视网膜病变(差异化疾病),临床前,,Active,眼科领域,DR054606,美国,pre-clinical,III期临床,2022/1/21,phase 3,1,TRUE,FALSE,FALSE,[],['Palatin Technologies'],1,['Palatin Technologies(原研)'],眼科领域,['眼科领域'],1,眼科领域,,,3,-1,Ophthalmology,Ophthalmology,,
rusfertide,rusfertide,rusfertide;PTG-300;鲁斯费尔肽;TAK-121,真性红细胞增多症,polycythemia vera,Hepc,合成的Hepc,Takeda Pharmaceuticals(Top20 MNC);Protagonist Therapeutics(原研),创新药,化药,多肽,环肽;差异化疾病;铁代谢;中国无申报;Potential First-in-Class,合成的,真性红细胞增多症(差异化疾病),III期临床,2022/1/27,Active,肿瘤领域;血液领域;罕见疾病领域,DR043844,美国,phase 3,III期临床,2022/1/27,phase 3,2,TRUE,TRUE,TRUE,['Takeda Pharmaceuticals'],['Protagonist Therapeutics'],1,"['Takeda Pharmaceuticals(Top20 MNC)', 'Protagonist Therapeutics(原研)']",肿瘤领域,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,3,3,Oncology,Oncology,Hematology,
rusfertide,rusfertide,rusfertide;PTG-300;鲁斯费尔肽;TAK-121,铁负荷过载,iron load overload,Hepc,合成的Hepc,Takeda Pharmaceuticals(Top20 MNC);Protagonist Therapeutics(原研),创新药,化药,多肽,环肽;差异化疾病;铁代谢;中国无申报;Potential First-in-Class,合成的,铁负荷过载,II期临床,,Active,内分泌及代谢领域;罕见疾病领域,DR043844,美国,phase 2,III期临床,2022/1/27,phase 3,2,TRUE,TRUE,TRUE,['Takeda Pharmaceuticals'],['Protagonist Therapeutics'],1,"['Takeda Pharmaceuticals(Top20 MNC)', 'Protagonist Therapeutics(原研)']",内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,3,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,
rusfertide,rusfertide,rusfertide;PTG-300;鲁斯费尔肽;TAK-121,遗传性血色素沉着病,hereditary hemochromatosis,Hepc,合成的Hepc,Takeda Pharmaceuticals(Top20 MNC);Protagonist Therapeutics(原研),创新药,化药,多肽,环肽;差异化疾病;铁代谢;中国无申报;Potential First-in-Class,合成的,遗传性血色素沉着病,II期临床,2019/12/18,Active,罕见疾病领域;内分泌及代谢领域,DR043844,美国,phase 2,III期临床,2022/1/27,phase 3,2,TRUE,TRUE,TRUE,['Takeda Pharmaceuticals'],['Protagonist Therapeutics'],1,"['Takeda Pharmaceuticals(Top20 MNC)', 'Protagonist Therapeutics(原研)']",内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,3,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,
RYZ101,RYZ101,RYZ101;225Ac-DOTATATE;Actinium-225 DOTATATE;Ac225 DOTATATE;锕[225Ac]-氧奥曲肽,胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,SSTR2,225Ac标记的放射性药物;anti-SSTR2多肽偶联核素,RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,胃肠胰神经内分泌肿瘤,III期临床,2022/7/28,Active,肿瘤领域;罕见疾病领域,DR055976,美国,phase 3,III期临床,2022/7/28,phase 3,1,TRUE,TRUE,TRUE,['RayzeBio(Bristol-Myers Squibb)'],['RayzeBio(Bristol-Myers Squibb)'],1,['RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,3,Oncology,Oncology,,
RYZ101,RYZ101,RYZ101;225Ac-DOTATATE;Actinium-225 DOTATATE;Ac225 DOTATATE;锕[225Ac]-氧奥曲肽,HR阳性乳腺癌,HR positive breast cancer,SSTR2,225Ac标记的放射性药物;anti-SSTR2多肽偶联核素,RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,HR阳性乳腺癌(差异化疾病),I/II期临床,2024/9/19,Active,肿瘤领域,DR055976,美国,phase 2,III期临床,2022/7/28,phase 3,1,TRUE,FALSE,TRUE,['RayzeBio(Bristol-Myers Squibb)'],['RayzeBio(Bristol-Myers Squibb)'],1,['RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,2,Oncology,Oncology,,
RYZ101,RYZ101,RYZ101;225Ac-DOTATATE;Actinium-225 DOTATATE;Ac225 DOTATATE;锕[225Ac]-氧奥曲肽,脑膜瘤,Meningioma,SSTR2,225Ac标记的放射性药物;anti-SSTR2多肽偶联核素,RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,脑膜瘤(差异化疾病),I/II期临床,2025/9/2,Active,肿瘤领域,DR055976,美国,phase 2,III期临床,2022/7/28,phase 3,1,TRUE,FALSE,TRUE,['RayzeBio(Bristol-Myers Squibb)'],['RayzeBio(Bristol-Myers Squibb)'],1,['RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,2,Oncology,Oncology,,
RYZ101,RYZ101,RYZ101;225Ac-DOTATATE;Actinium-225 DOTATATE;Ac225 DOTATATE;锕[225Ac]-氧奥曲肽,小细胞肺癌,small cell lung cancer,SSTR2,225Ac标记的放射性药物;anti-SSTR2多肽偶联核素,RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,小细胞肺癌,I期临床,2022/10/27,Active,肿瘤领域;罕见疾病领域,DR055976,美国,phase 1,III期临床,2022/7/28,phase 3,1,TRUE,TRUE,TRUE,['RayzeBio(Bristol-Myers Squibb)'],['RayzeBio(Bristol-Myers Squibb)'],1,['RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,
RYZ101,RYZ101,RYZ101;225Ac-DOTATATE;Actinium-225 DOTATATE;Ac225 DOTATATE;锕[225Ac]-氧奥曲肽,多发性骨髓瘤,multiple myeloma,SSTR2,225Ac标记的放射性药物;anti-SSTR2多肽偶联核素,RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,多发性骨髓瘤(差异化疾病),I期临床,2024/5/13,Active,肿瘤领域;血液领域;罕见疾病领域,DR055976,美国,phase 1,III期临床,2022/7/28,phase 3,1,TRUE,TRUE,TRUE,['RayzeBio(Bristol-Myers Squibb)'],['RayzeBio(Bristol-Myers Squibb)'],1,['RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研)'],肿瘤领域,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,3,1,Oncology,Oncology,Hematology,
[68Ga]CBP8,[68Ga]CBP8,[68Ga]CBP8;68Ga-CBP8,PET显像,PET imaging,COL1,anti-COL1多肽偶联核素;68Ga标记的PET药物,Massachusetts General Hospital(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,PET显像,III期临床,2022/11/16,Active,诊断试剂领域,DR022856,美国,phase 3,III期临床,2022/11/16,phase 3,1,TRUE,FALSE,FALSE,[],['Massachusetts General Hospital'],1,['Massachusetts General Hospital(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,3,3,Diagnostic Reagents,Diagnostic Reagents,,
[68Ga]CBP8,[68Ga]CBP8,[68Ga]CBP8;68Ga-CBP8,心脏淀粉样变性,cardiac amyloidosis,COL1,anti-COL1多肽偶联核素;68Ga标记的PET药物,Massachusetts General Hospital(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,心脏淀粉样变性,III期临床,2022/11/16,Active,罕见疾病领域;心脑血管领域,DR022856,美国,phase 3,III期临床,2022/11/16,phase 3,1,TRUE,TRUE,FALSE,[],['Massachusetts General Hospital'],1,['Massachusetts General Hospital(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,3,3,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
[68Ga]CBP8,[68Ga]CBP8,[68Ga]CBP8;68Ga-CBP8,肺癌,lung cancer,COL1,anti-COL1多肽偶联核素;68Ga标记的PET药物,Massachusetts General Hospital(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,肺癌,II期临床,,Active,肿瘤领域,DR022856,美国,phase 2,III期临床,2022/11/16,phase 3,1,TRUE,FALSE,FALSE,[],['Massachusetts General Hospital'],1,['Massachusetts General Hospital(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,2,Oncology,Oncology,,
[68Ga]CBP8,[68Ga]CBP8,[68Ga]CBP8;68Ga-CBP8,特发性肺纤维化,idiopathic pulmonary fibrosis,COL1,anti-COL1多肽偶联核素;68Ga标记的PET药物,Massachusetts General Hospital(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,特发性肺纤维化,II期临床,,Active,呼吸领域;罕见疾病领域,DR022856,美国,phase 2,III期临床,2022/11/16,phase 3,1,TRUE,TRUE,FALSE,[],['Massachusetts General Hospital'],1,['Massachusetts General Hospital(原研)'],呼吸领域,['呼吸领域'],1,呼吸领域,,,3,2,Respiratory,Respiratory,,
[68Ga]CBP8,[68Ga]CBP8,[68Ga]CBP8;68Ga-CBP8,间质性肺病,interstitial lung disease,COL1,anti-COL1多肽偶联核素;68Ga标记的PET药物,Massachusetts General Hospital(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,间质性肺病,II期临床,2022/6/14,Active,呼吸领域,DR022856,美国,phase 2,III期临床,2022/11/16,phase 3,1,TRUE,FALSE,FALSE,[],['Massachusetts General Hospital'],1,['Massachusetts General Hospital(原研)'],呼吸领域,['呼吸领域'],1,呼吸领域,,,3,2,Respiratory,Respiratory,,
[68Ga]CBP8,[68Ga]CBP8,[68Ga]CBP8;68Ga-CBP8,进展性肺纤维化,progressive pulmonary fibrosis,COL1,anti-COL1多肽偶联核素;68Ga标记的PET药物,Massachusetts General Hospital(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,进展性肺纤维化,II期临床,2024/8/1,Active,呼吸领域;罕见疾病领域,DR022856,美国,phase 2,III期临床,2022/11/16,phase 3,1,TRUE,TRUE,FALSE,[],['Massachusetts General Hospital'],1,['Massachusetts General Hospital(原研)'],呼吸领域,['呼吸领域'],1,呼吸领域,,,3,2,Respiratory,Respiratory,,
[68Ga]CBP8,[68Ga]CBP8,[68Ga]CBP8;68Ga-CBP8,原发性硬化性胆管炎,primary sclerosing cholangitis,COL1,anti-COL1多肽偶联核素;68Ga标记的PET药物,Massachusetts General Hospital(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,原发性硬化性胆管炎,I期临床,2024/2/9,Active,消化领域;罕见疾病领域,DR022856,美国,phase 1,III期临床,2022/11/16,phase 3,1,TRUE,TRUE,FALSE,[],['Massachusetts General Hospital'],1,['Massachusetts General Hospital(原研)'],消化领域,['消化领域'],1,消化领域,,,3,1,Digestive System,Digestive System,,
[68Ga]CBP8,[68Ga]CBP8,[68Ga]CBP8;68Ga-CBP8,克罗恩病,Crohn's disease,COL1,anti-COL1多肽偶联核素;68Ga标记的PET药物,Massachusetts General Hospital(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,克罗恩病,I期临床,2024/2/9,Active,消化领域;免疫领域,DR022856,美国,phase 1,III期临床,2022/11/16,phase 3,1,TRUE,FALSE,FALSE,[],['Massachusetts General Hospital'],1,['Massachusetts General Hospital(原研)'],消化领域,"['消化领域', '免疫领域']",2,消化领域,免疫领域,,3,1,Digestive System,Digestive System,Immunology,
[68Ga]CBP8,[68Ga]CBP8,[68Ga]CBP8;68Ga-CBP8,子宫内膜异位,endometriosis,COL1,anti-COL1多肽偶联核素;68Ga标记的PET药物,Massachusetts General Hospital(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,子宫内膜异位,I期临床,2024/4/22,Active,泌尿生殖领域,DR022856,美国,phase 1,III期临床,2022/11/16,phase 3,1,TRUE,FALSE,FALSE,[],['Massachusetts General Hospital'],1,['Massachusetts General Hospital(原研)'],泌尿生殖领域,['泌尿生殖领域'],1,泌尿生殖领域,,,3,1,Genitourinary,Genitourinary,,
solnatide,solnatide,solnatide;AP301;AP-301;TIP-peptide,慢性肾病高磷血症,Chronic kidney disease hyperphosphatemia,ENaC,ENaC激活剂,Apeptico(原研),创新药,化药,多肽,环肽;Potential First-in-Class,激活剂,慢性肾病高磷血症,III期临床,2023/6/30,Active,泌尿生殖领域,DR019331,欧洲,phase 3,III期临床,2023/6/30,phase 3,1,TRUE,FALSE,FALSE,[],['Apeptico'],1,['Apeptico(原研)'],泌尿生殖领域,['泌尿生殖领域'],1,泌尿生殖领域,,,3,3,Genitourinary,Genitourinary,,
enlicitide,enlicitide,enlicitide;MK-0616;[14C]MK-0616;[14C]enlicitide;enlicitide decanoate,血脂异常,dyslipidemia,PCSK9,PCSK9抑制剂,Merck & Co.(Top20 MNC)(原研),创新药,化药,多肽,环肽;2021年转化医学TOP25;Potential First-in-Class,抑制剂,血脂异常,III期临床,2025/11/19,Active,心脑血管领域,DR041755,美国,phase 3,III期临床,2023/7/19,phase 3,1,TRUE,FALSE,TRUE,['Merck & Co.'],['Merck & Co.'],1,['Merck & Co.(Top20 MNC)(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,3,3,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
enlicitide,enlicitide,enlicitide;MK-0616;[14C]MK-0616;[14C]enlicitide;enlicitide decanoate,高胆固醇血症,hypercholesterolemia,PCSK9,PCSK9抑制剂,Merck & Co.(Top20 MNC)(原研),创新药,化药,多肽,环肽;2021年转化医学TOP25;Potential First-in-Class,抑制剂,高胆固醇血症,III期临床,2023/8/25,Active,心脑血管领域,DR041755,美国,phase 3,III期临床,2023/7/19,phase 3,1,TRUE,FALSE,TRUE,['Merck & Co.'],['Merck & Co.'],1,['Merck & Co.(Top20 MNC)(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,3,3,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
enlicitide,enlicitide,enlicitide;MK-0616;[14C]MK-0616;[14C]enlicitide;enlicitide decanoate,家族性高胆固醇血症,familial hypercholesterolemia,PCSK9,PCSK9抑制剂,Merck & Co.(Top20 MNC)(原研),创新药,化药,多肽,环肽;2021年转化医学TOP25;Potential First-in-Class,抑制剂,家族性高胆固醇血症,III期临床,2023/7/19,Active,心脑血管领域,DR041755,美国,phase 3,III期临床,2023/7/19,phase 3,1,TRUE,FALSE,TRUE,['Merck & Co.'],['Merck & Co.'],1,['Merck & Co.(Top20 MNC)(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,3,3,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
enlicitide,enlicitide,enlicitide;MK-0616;[14C]MK-0616;[14C]enlicitide;enlicitide decanoate,心血管风险,cardiovascular risk,PCSK9,PCSK9抑制剂,Merck & Co.(Top20 MNC)(原研),创新药,化药,多肽,环肽;2021年转化医学TOP25;Potential First-in-Class,抑制剂,心血管风险,III期临床,2023/8/24,Active,心脑血管领域,DR041755,美国,phase 3,III期临床,2023/7/19,phase 3,1,TRUE,FALSE,TRUE,['Merck & Co.'],['Merck & Co.'],1,['Merck & Co.(Top20 MNC)(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,3,3,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
enlicitide,enlicitide,enlicitide;MK-0616;[14C]MK-0616;[14C]enlicitide;enlicitide decanoate,杂合子型家族性高胆固醇血症,Heterozygous familial hypercholesterolemia,PCSK9,PCSK9抑制剂,Merck & Co.(Top20 MNC)(原研),创新药,化药,多肽,环肽;2021年转化医学TOP25;Potential First-in-Class,抑制剂,杂合子型家族性高胆固醇血症,III期临床,2023/7/19,Active,心脑血管领域,DR041755,美国,phase 3,III期临床,2023/7/19,phase 3,1,TRUE,FALSE,TRUE,['Merck & Co.'],['Merck & Co.'],1,['Merck & Co.(Top20 MNC)(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,3,3,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
enlicitide,enlicitide,enlicitide;MK-0616;[14C]MK-0616;[14C]enlicitide;enlicitide decanoate,动脉粥样硬化性心血管疾病,atherosclerotic cardiovascular disease,PCSK9,PCSK9抑制剂,Merck & Co.(Top20 MNC)(原研),创新药,化药,多肽,环肽;2021年转化医学TOP25;Potential First-in-Class,抑制剂,动脉粥样硬化性心血管疾病,III期临床,2023/11/6,Active,心脑血管领域,DR041755,美国,phase 3,III期临床,2023/7/19,phase 3,1,TRUE,FALSE,TRUE,['Merck & Co.'],['Merck & Co.'],1,['Merck & Co.(Top20 MNC)(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,3,3,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
68Ga-pentixafor,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,PET显像,PET imaging,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,PET显像,III期临床,2023/11/9,Active,诊断试剂领域,DR016804,欧洲,phase 3,III期临床,2023/11/9,phase 3,2,TRUE,FALSE,FALSE,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,3,3,Diagnostic Reagents,Diagnostic Reagents,,
68Ga-pentixafor,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,边缘区淋巴瘤,marginal zone lymphoma,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,边缘区淋巴瘤,III期临床,2023/11/9,Active,肿瘤领域;血液领域;罕见疾病领域,DR016804,欧洲,phase 3,III期临床,2023/11/9,phase 3,2,TRUE,TRUE,FALSE,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",肿瘤领域,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,3,3,Oncology,Oncology,Hematology,
68Ga-pentixafor,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,肾上腺疾病,Adrenal gland disease,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,肾上腺疾病,II/III期临床,2021/4/26,Active,内分泌及代谢领域,DR016804,欧洲,phase 3,III期临床,2023/11/9,phase 3,2,TRUE,FALSE,FALSE,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,3,3,Endocrinology & Metabolism,Endocrinology & Metabolism,,
68Ga-pentixafor,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,醛固酮过多症,Hyperaldosteronism,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,醛固酮过多症,II/III期临床,2024/3/18,Active,内分泌及代谢领域,DR016804,欧洲,phase 3,III期临床,2023/11/9,phase 3,2,TRUE,FALSE,FALSE,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,3,3,Endocrinology & Metabolism,Endocrinology & Metabolism,,
68Ga-pentixafor,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,多发性骨髓瘤,multiple myeloma,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,多发性骨髓瘤,II期临床,2020/9/23,Active,肿瘤领域;血液领域;罕见疾病领域,DR016804,欧洲,phase 2,III期临床,2023/11/9,phase 3,2,TRUE,TRUE,FALSE,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",肿瘤领域,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,3,2,Oncology,Oncology,Hematology,
68Ga-pentixafor,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,库欣综合征,Cushing's syndrome,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,库欣综合征,II期临床,2024/2/7,Active,内分泌及代谢领域;罕见疾病领域,DR016804,欧洲,phase 2,III期临床,2023/11/9,phase 3,2,TRUE,TRUE,FALSE,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,3,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,
68Ga-pentixafor,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,B细胞淋巴瘤,B cell lymphoma,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,B细胞淋巴瘤,II期临床,2024/6/14,Active,肿瘤领域;血液领域,DR016804,欧洲,phase 2,III期临床,2023/11/9,phase 3,2,TRUE,FALSE,FALSE,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",肿瘤领域,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,3,2,Oncology,Oncology,Hematology,
68Ga-pentixafor,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,心脏移植排斥,heart transplant rejection,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,心脏移植排斥,II期临床,,Active,免疫领域;罕见疾病领域,DR016804,欧洲,phase 2,III期临床,2023/11/9,phase 3,2,TRUE,TRUE,FALSE,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",免疫领域,['免疫领域'],1,免疫领域,,,3,2,Immunology,Immunology,,
68Ga-pentixafor,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,惰性非霍奇金淋巴瘤,indolent non-Hodgkin lymphoma,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,惰性非霍奇金淋巴瘤,II期临床,2024/6/14,Active,血液领域;肿瘤领域;罕见疾病领域,DR016804,欧洲,phase 2,III期临床,2023/11/9,phase 3,2,TRUE,TRUE,FALSE,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",肿瘤领域,"['血液领域', '肿瘤领域']",2,血液领域,肿瘤领域,,3,2,Oncology,Hematology,Oncology,
68Ga-pentixafor,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,中枢神经系统淋巴瘤,central nervous system lymphoma,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,中枢神经系统淋巴瘤,II期临床,,Active,血液领域;肿瘤领域,DR016804,欧洲,phase 2,III期临床,2023/11/9,phase 3,2,TRUE,FALSE,FALSE,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",肿瘤领域,"['血液领域', '肿瘤领域']",2,血液领域,肿瘤领域,,3,2,Oncology,Hematology,Oncology,
68Ga-pentixafor,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,心脏结节病,cardiac sarcoidosis,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,心脏结节病,II期临床,,Active,心脑血管领域;免疫领域,DR016804,欧洲,phase 2,III期临床,2023/11/9,phase 3,2,TRUE,FALSE,FALSE,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",心脑血管领域,"['心脑血管领域', '免疫领域']",2,心脑血管领域,免疫领域,,3,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,Immunology,
68Ga-pentixafor,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,免疫检查点抑制剂引起的心肌炎,Myocarditis caused by immune checkpoint inhibitors,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,免疫检查点抑制剂引起的心肌炎,II期临床,,Active,肿瘤领域,DR016804,欧洲,phase 2,III期临床,2023/11/9,phase 3,2,TRUE,FALSE,FALSE,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,2,Oncology,Oncology,,
68Ga-pentixafor,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,小细胞肺癌,small cell lung cancer,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,小细胞肺癌,I期临床,2025/6/5,Active,肿瘤领域;罕见疾病领域,DR016804,欧洲,phase 1,III期临床,2023/11/9,phase 3,2,TRUE,TRUE,FALSE,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,
68Ga-pentixafor,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,三阴性乳腺癌,triple negative breast cancer,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,三阴性乳腺癌,I期临床,2025/5/8,Active,肿瘤领域,DR016804,欧洲,phase 1,III期临床,2023/11/9,phase 3,2,TRUE,FALSE,FALSE,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,
68Ga-pentixafor,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,分化型甲状腺癌,differentiated thyroid cancer,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,分化型甲状腺癌,I期临床,2024/5/14,Active,肿瘤领域,DR016804,欧洲,phase 1,III期临床,2023/11/9,phase 3,2,TRUE,FALSE,FALSE,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,
68Ga-pentixafor,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,非霍奇金淋巴瘤,non-hodgkin lymphoma,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,非霍奇金淋巴瘤,I期临床,2021/10/26,Active,肿瘤领域;血液领域;罕见疾病领域,DR016804,欧洲,phase 1,III期临床,2023/11/9,phase 3,2,TRUE,TRUE,FALSE,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",肿瘤领域,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,3,1,Oncology,Oncology,Hematology,
68Ga-pentixafor,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,高血压,hypertension,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,高血压,I期临床,2025/6/18,Active,心脑血管领域,DR016804,欧洲,phase 1,III期临床,2023/11/9,phase 3,2,TRUE,FALSE,FALSE,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,3,1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
68Ga-pentixafor,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,神经内分泌肿瘤,neuroendocrine tumors,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,神经内分泌肿瘤,I期临床,2017/11/8,Active,肿瘤领域;罕见疾病领域,DR016804,欧洲,phase 1,III期临床,2023/11/9,phase 3,2,TRUE,TRUE,FALSE,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,
68Ga-pentixafor,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,肾上腺皮质癌,adrenocortical carcinoma,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,肾上腺皮质癌,I期临床,2025/9/19,Active,肿瘤领域;罕见疾病领域,DR016804,欧洲,phase 1,III期临床,2023/11/9,phase 3,2,TRUE,TRUE,FALSE,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,
68Ga-pentixafor,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,小淋巴细胞性淋巴瘤,small lymphocytic lymphoma,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,小淋巴细胞性淋巴瘤,I期临床,2024/3/1,Active,肿瘤领域;血液领域,DR016804,欧洲,phase 1,III期临床,2023/11/9,phase 3,2,TRUE,FALSE,FALSE,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",肿瘤领域,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,3,1,Oncology,Oncology,Hematology,
68Ga-pentixafor,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,Erdheim-Chester病,Erdheim-Chester disease,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,Erdheim-Chester病,I期临床,,Active,肿瘤领域;罕见疾病领域,DR016804,欧洲,phase 1,III期临床,2023/11/9,phase 3,2,TRUE,TRUE,FALSE,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,
68Ga-pentixafor,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,胸腺瘤,thymoma,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,胸腺瘤,I期临床,2023/10/17,Active,肿瘤领域;罕见疾病领域,DR016804,欧洲,phase 1,III期临床,2023/11/9,phase 3,2,TRUE,TRUE,FALSE,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,
68Ga-pentixafor,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,假性醛固酮减少症,pseudohypoaldosteronism,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,假性醛固酮减少症,I期临床,2025/1/3,Active,内分泌及代谢领域,DR016804,欧洲,phase 1,III期临床,2023/11/9,phase 3,2,TRUE,FALSE,FALSE,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,3,1,Endocrinology & Metabolism,Endocrinology & Metabolism,,
68Ga-pentixafor,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,罗道病,Rhododendron,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,罗道病,I期临床,,Active,罕见疾病领域,DR016804,欧洲,phase 1,III期临床,2023/11/9,phase 3,2,TRUE,TRUE,FALSE,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",,[],0,,,,3,1,,,,
68Ga-pentixafor,68Ga-pentixafor,68Ga-pentixafor;[68Ga]pentixafor;[68Ga]Ga-PentixaFor;Gallium-68 Pentixafor;[68Ga]-Pentixafor;68Ga-PTF;68Ga-CPCR4.2;(68)Ga-CPCR4-2;[68Ga]Ga-PTF,自主皮质醇分泌,Autonomous cortisol secretion,CXCR4,anti-CXCR4多肽偶联核素;68Ga标记的PET药物,PentixaPharm;Scintomics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,自主皮质醇分泌,I期临床,2024/10/10,Active,内分泌及代谢领域,DR016804,欧洲,phase 1,III期临床,2023/11/9,phase 3,2,TRUE,FALSE,FALSE,[],['Scintomics'],1,"['PentixaPharm', 'Scintomics(原研)']",内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,3,1,Endocrinology & Metabolism,Endocrinology & Metabolism,,
emodepside,emodepside,emodepside;BAY 44-4400,蛔虫病,Ascariasis,not available,,Bayer(Top20 MNC);Astellas Pharma(Top20 MNC)(原研);DNDi,创新药,化药,小分子,环肽;中国无申报,其他,蛔虫病,III期临床,2024/12/17,Active,感染领域,DR066507,日本,phase 3,III期临床,2024/12/17,phase 3,3,TRUE,FALSE,TRUE,"['Bayer', 'Astellas Pharma']",['Astellas Pharma'],1,"['Bayer(Top20 MNC)', 'Astellas Pharma(Top20 MNC)(原研)', 'DNDi']",感染领域,['感染领域'],1,感染领域,,,3,3,Infectious Diseases,Infectious Diseases,,
emodepside,emodepside,emodepside;BAY 44-4400,钩虫病,hookworm disease,not available,,Bayer(Top20 MNC);Astellas Pharma(Top20 MNC)(原研);DNDi,创新药,化药,小分子,环肽;中国无申报,其他,钩虫病,III期临床,2024/12/17,Active,感染领域,DR066507,日本,phase 3,III期临床,2024/12/17,phase 3,3,TRUE,FALSE,TRUE,"['Bayer', 'Astellas Pharma']",['Astellas Pharma'],1,"['Bayer(Top20 MNC)', 'Astellas Pharma(Top20 MNC)(原研)', 'DNDi']",感染领域,['感染领域'],1,感染领域,,,3,3,Infectious Diseases,Infectious Diseases,,
emodepside,emodepside,emodepside;BAY 44-4400,鞭虫病,Trichuris,not available,,Bayer(Top20 MNC);Astellas Pharma(Top20 MNC)(原研);DNDi,创新药,化药,小分子,环肽;中国无申报,其他,鞭虫病,III期临床,2024/12/17,Active,感染领域,DR066507,日本,phase 3,III期临床,2024/12/17,phase 3,3,TRUE,FALSE,TRUE,"['Bayer', 'Astellas Pharma']",['Astellas Pharma'],1,"['Bayer(Top20 MNC)', 'Astellas Pharma(Top20 MNC)(原研)', 'DNDi']",感染领域,['感染领域'],1,感染领域,,,3,3,Infectious Diseases,Infectious Diseases,,
emodepside,emodepside,emodepside;BAY 44-4400,类圆线虫病,strongyloidiasis,not available,,Bayer(Top20 MNC);Astellas Pharma(Top20 MNC)(原研);DNDi,创新药,化药,小分子,环肽;中国无申报,其他,类圆线虫病,II期临床,2024/4/18,Active,感染领域,DR066507,日本,phase 2,III期临床,2024/12/17,phase 3,3,TRUE,FALSE,TRUE,"['Bayer', 'Astellas Pharma']",['Astellas Pharma'],1,"['Bayer(Top20 MNC)', 'Astellas Pharma(Top20 MNC)(原研)', 'DNDi']",感染领域,['感染领域'],1,感染领域,,,3,2,Infectious Diseases,Infectious Diseases,,
emodepside,emodepside,emodepside;BAY 44-4400,盘尾丝虫病,onchocerciasis,not available,,Bayer(Top20 MNC);Astellas Pharma(Top20 MNC)(原研);DNDi,创新药,化药,小分子,环肽;中国无申报,其他,盘尾丝虫病,II期临床,2022/1/6,Active,感染领域,DR066507,日本,phase 2,III期临床,2024/12/17,phase 3,3,TRUE,FALSE,TRUE,"['Bayer', 'Astellas Pharma']",['Astellas Pharma'],1,"['Bayer(Top20 MNC)', 'Astellas Pharma(Top20 MNC)(原研)', 'DNDi']",感染领域,['感染领域'],1,感染领域,,,3,2,Infectious Diseases,Infectious Diseases,,
脑利钠肽,nesiritide biosimilar,脑利钠肽;重组人脑利钠肽(沃泰生物);nesiritide biosimilar,急性心力衰竭,acute heart failure,BNP,重组BNP,沃泰生物(原研),生物类似药,生物,多肽,环肽,重组,急性心力衰竭,III期临床,2025/4/3,Active,心脑血管领域,DR077616,中国(内地),phase 3,III期临床,2025/4/3,phase 3,1,TRUE,FALSE,FALSE,[],['沃泰生物'],1,['沃泰生物(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,3,3,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
Debio 4126,Debio 4126 (12-week prolonged-release octreotide),Debio 4126;Debio 4126 (12周缓释奥曲肽);Debio 4126 (12-week prolonged-release octreotide),肢端肥大症,acromegaly,somatostatin,somatostatin类似物,Debiopharm(原研),微创新,化药,多肽,环肽,类似物,肢端肥大症,III期临床,2025/4/16,Active,内分泌及代谢领域;罕见疾病领域,DR003491,欧洲,phase 3,III期临床,2025/4/16,phase 3,1,TRUE,TRUE,FALSE,[],['Debiopharm'],1,['Debiopharm(原研)'],内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,3,3,Endocrinology & Metabolism,Endocrinology & Metabolism,,
Debio 4126,Debio 4126 (12-week prolonged-release octreotide),Debio 4126;Debio 4126 (12周缓释奥曲肽);Debio 4126 (12-week prolonged-release octreotide),胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,somatostatin,somatostatin类似物,Debiopharm(原研),微创新,化药,多肽,环肽,类似物,胃肠胰神经内分泌肿瘤,II期临床,,Active,肿瘤领域;罕见疾病领域,DR003491,欧洲,phase 2,III期临床,2025/4/16,phase 3,1,TRUE,TRUE,FALSE,[],['Debiopharm'],1,['Debiopharm(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,2,Oncology,Oncology,,
SYHX2008,SYHX2008 (long-acting octreotide),SYHX2008;SYHX2008 (长效奥曲肽);SYHX2008 (long-acting octreotide),神经内分泌肿瘤,neuroendocrine tumors,somatostatin,somatostatin类似物,石药集团(原研),微创新,化药,多肽,环肽,类似物,神经内分泌肿瘤,III期临床,2025/11/12,Active,肿瘤领域;罕见疾病领域,DR064549,中国(内地),phase 3,III期临床,2025/10/10,phase 3,1,TRUE,TRUE,FALSE,[],['石药集团'],1,['石药集团(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,3,Oncology,Oncology,,
SYHX2008,SYHX2008 (long-acting octreotide),SYHX2008;SYHX2008 (长效奥曲肽);SYHX2008 (long-acting octreotide),胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,somatostatin,somatostatin类似物,石药集团(原研),微创新,化药,多肽,环肽,类似物,胃肠胰神经内分泌肿瘤,II/III期临床,2025/9/10,Active,肿瘤领域;罕见疾病领域,DR064549,中国(内地),phase 3,III期临床,2025/10/10,phase 3,1,TRUE,TRUE,FALSE,[],['石药集团'],1,['石药集团(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,3,Oncology,Oncology,,
SYHX2008,SYHX2008 (long-acting octreotide),SYHX2008;SYHX2008 (长效奥曲肽);SYHX2008 (long-acting octreotide),肢端肥大症,acromegaly,somatostatin,somatostatin类似物,石药集团(原研),微创新,化药,多肽,环肽,类似物,肢端肥大症,II期临床,2024/1/30,Active,内分泌及代谢领域;罕见疾病领域,DR064549,中国(内地),phase 2,III期临床,2025/10/10,phase 3,1,TRUE,TRUE,FALSE,[],['石药集团'],1,['石药集团(原研)'],内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,3,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,
SYHX2008,SYHX2008 (long-acting octreotide),SYHX2008;SYHX2008 (长效奥曲肽);SYHX2008 (long-acting octreotide),胃肠道神经内分泌肿瘤,gastrointestinal neuroendocrine tumors,somatostatin,somatostatin类似物,石药集团(原研),微创新,化药,多肽,环肽,类似物,胃肠道神经内分泌肿瘤,II期临床,2024/7/17,Active,肿瘤领域;罕见疾病领域,DR064549,中国(内地),phase 2,III期临床,2025/10/10,phase 3,1,TRUE,TRUE,FALSE,[],['石药集团'],1,['石药集团(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,2,Oncology,Oncology,,
PNT2003,PNT2003,PNT2003;177Lu-PNT2003,神经内分泌肿瘤,neuroendocrine tumors,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,Lantheus;POINT Biopharma(Eli Lilly)(Top20 MNC)(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;中国无申报,177Lu标记的放射性药物;多肽偶联核素,神经内分泌肿瘤,III期临床,,Active,肿瘤领域;罕见疾病领域,DR053445,加拿大,phase 3,III期临床,,phase 3,2,TRUE,TRUE,TRUE,['POINT Biopharma(Eli Lilly)'],['POINT Biopharma(Eli Lilly)'],1,"['Lantheus', 'POINT Biopharma(Eli Lilly)(Top20 MNC)(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,3,Oncology,Oncology,,
68Ga-DOTA-NOC,68Ga-DOTA-NOC,68Ga-DOTA-NOC;68Ga-DOTANOC;[68Ga]-DOTANOC,神经母细胞瘤,Neuroblastoma,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,--,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,神经母细胞瘤,I期临床,2025/9/26,Active,肿瘤领域;罕见疾病领域,DR002623,,phase 1,II/III期临床,2016/7/6,phase 3,0,TRUE,TRUE,FALSE,[],[],0,[],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,
68Ga-DOTA-NOC,68Ga-DOTA-NOC,68Ga-DOTA-NOC;68Ga-DOTANOC;[68Ga]-DOTANOC,抑郁症,depression,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,--,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,抑郁症,I期临床,2025/9/26,Active,精神领域,DR002623,,phase 1,II/III期临床,2016/7/6,phase 3,0,TRUE,FALSE,FALSE,[],[],0,[],精神领域,['精神领域'],1,精神领域,,,3,1,Psychiatry,Psychiatry,,
68Ga-DOTA-NOC,68Ga-DOTA-NOC,68Ga-DOTA-NOC;68Ga-DOTANOC;[68Ga]-DOTANOC,不孕不育,Infertility,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,--,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,不孕不育,I期临床,2025/9/26,Active,泌尿生殖领域,DR002623,,phase 1,II/III期临床,2016/7/6,phase 3,0,TRUE,FALSE,FALSE,[],[],0,[],泌尿生殖领域,['泌尿生殖领域'],1,泌尿生殖领域,,,3,1,Genitourinary,Genitourinary,,
68Ga-DOTA-NOC,68Ga-DOTA-NOC,68Ga-DOTA-NOC;68Ga-DOTANOC;[68Ga]-DOTANOC,嗜铬细胞瘤,Pheochromocytoma,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,--,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,嗜铬细胞瘤,I期临床,2025/9/26,Active,肿瘤领域;罕见疾病领域,DR002623,,phase 1,II/III期临床,2016/7/6,phase 3,0,TRUE,TRUE,FALSE,[],[],0,[],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,
68Ga-DOTA-NOC,68Ga-DOTA-NOC,68Ga-DOTA-NOC;68Ga-DOTANOC;[68Ga]-DOTANOC,骨转移疼痛,bone metastasis pain,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,--,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,骨转移疼痛,I期临床,2025/9/26,Active,肿瘤领域,DR002623,,phase 1,II/III期临床,2016/7/6,phase 3,0,TRUE,FALSE,FALSE,[],[],0,[],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,
68Ga-DOTA-NOC,68Ga-DOTA-NOC,68Ga-DOTA-NOC;68Ga-DOTANOC;[68Ga]-DOTANOC,副神经节瘤,paraganglioma,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,--,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,副神经节瘤,I期临床,2025/9/26,Active,肿瘤领域;罕见疾病领域,DR002623,,phase 1,II/III期临床,2016/7/6,phase 3,0,TRUE,TRUE,FALSE,[],[],0,[],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,
VT1021,VT1021,VT1021,实体瘤,solid tumors,THBS1,THBS1诱导剂,Vigeo Therapeutics(原研),创新药,化药,多肽,环肽;Potential First-in-Class,诱导剂,实体瘤,I/II期临床,,Active,肿瘤领域,DR023742,美国,phase 2,II/III期临床,2019/5/31,phase 3,1,TRUE,FALSE,FALSE,[],['Vigeo Therapeutics'],1,['Vigeo Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,2,Oncology,Oncology,,
18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,PET显像,PET imaging,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,中南大学湘雅医院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,PET显像,II/III期临床,2020/9/17,Active,诊断试剂领域,DR002664,中国(内地),phase 3,II/III期临床,2020/9/17,phase 3,1,TRUE,FALSE,FALSE,[],['中南大学湘雅医院'],1,['中南大学湘雅医院(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,3,3,Diagnostic Reagents,Diagnostic Reagents,,
18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,神经内分泌肿瘤,neuroendocrine tumors,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,中南大学湘雅医院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,神经内分泌肿瘤,II/III期临床,2020/9/17,Active,肿瘤领域;罕见疾病领域,DR002664,中国(内地),phase 3,II/III期临床,2020/9/17,phase 3,1,TRUE,TRUE,FALSE,[],['中南大学湘雅医院'],1,['中南大学湘雅医院(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,3,Oncology,Oncology,,
18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,心肌梗塞,myocardial infarction,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,中南大学湘雅医院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,心肌梗塞(差异化疾病),II期临床,2025/8/5,Active,心脑血管领域,DR002664,中国(内地),phase 2,II/III期临床,2020/9/17,phase 3,1,TRUE,FALSE,FALSE,[],['中南大学湘雅医院'],1,['中南大学湘雅医院(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,3,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,动脉粥样硬化,atherosclerosis,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,中南大学湘雅医院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,动脉粥样硬化(差异化疾病),II期临床,2024/11/18,Active,心脑血管领域,DR002664,中国(内地),phase 2,II/III期临床,2020/9/17,phase 3,1,TRUE,FALSE,FALSE,[],['中南大学湘雅医院'],1,['中南大学湘雅医院(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,3,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,卒中,Stroke,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,中南大学湘雅医院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,卒中(差异化疾病),II期临床,2025/8/5,Active,心脑血管领域,DR002664,中国(内地),phase 2,II/III期临床,2020/9/17,phase 3,1,TRUE,FALSE,FALSE,[],['中南大学湘雅医院'],1,['中南大学湘雅医院(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,3,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,心脏停搏,cardiac arrest,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,中南大学湘雅医院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,心脏停搏(差异化疾病),II期临床,2025/8/5,Active,心脑血管领域,DR002664,中国(内地),phase 2,II/III期临床,2020/9/17,phase 3,1,TRUE,FALSE,FALSE,[],['中南大学湘雅医院'],1,['中南大学湘雅医院(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,3,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,不稳定性心绞痛,unstable angina,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,中南大学湘雅医院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,不稳定性心绞痛(差异化疾病),II期临床,2025/8/5,Active,心脑血管领域,DR002664,中国(内地),phase 2,II/III期临床,2020/9/17,phase 3,1,TRUE,FALSE,FALSE,[],['中南大学湘雅医院'],1,['中南大学湘雅医院(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,3,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,颈动脉疾病,carotid artery disease,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,中南大学湘雅医院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,颈动脉疾病,II期临床,2024/11/18,Active,心脑血管领域,DR002664,中国(内地),phase 2,II/III期临床,2020/9/17,phase 3,1,TRUE,FALSE,FALSE,[],['中南大学湘雅医院'],1,['中南大学湘雅医院(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,3,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,颈动脉狭窄,Carotid artery stenosis,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,中南大学湘雅医院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,颈动脉狭窄(差异化疾病),II期临床,2025/8/5,Active,心脑血管领域,DR002664,中国(内地),phase 2,II/III期临床,2020/9/17,phase 3,1,TRUE,FALSE,FALSE,[],['中南大学湘雅医院'],1,['中南大学湘雅医院(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,3,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,神经母细胞瘤,Neuroblastoma,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,中南大学湘雅医院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,神经母细胞瘤,I期临床,2025/9/26,Active,肿瘤领域;罕见疾病领域,DR002664,中国(内地),phase 1,II/III期临床,2020/9/17,phase 3,1,TRUE,TRUE,FALSE,[],['中南大学湘雅医院'],1,['中南大学湘雅医院(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,
18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,抑郁症,depression,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,中南大学湘雅医院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,抑郁症,I期临床,2025/9/26,Active,精神领域,DR002664,中国(内地),phase 1,II/III期临床,2020/9/17,phase 3,1,TRUE,FALSE,FALSE,[],['中南大学湘雅医院'],1,['中南大学湘雅医院(原研)'],精神领域,['精神领域'],1,精神领域,,,3,1,Psychiatry,Psychiatry,,
18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,不孕不育,Infertility,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,中南大学湘雅医院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,不孕不育,I期临床,2025/9/26,Active,泌尿生殖领域,DR002664,中国(内地),phase 1,II/III期临床,2020/9/17,phase 3,1,TRUE,FALSE,FALSE,[],['中南大学湘雅医院'],1,['中南大学湘雅医院(原研)'],泌尿生殖领域,['泌尿生殖领域'],1,泌尿生殖领域,,,3,1,Genitourinary,Genitourinary,,
18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,嗜铬细胞瘤,Pheochromocytoma,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,中南大学湘雅医院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,嗜铬细胞瘤,I期临床,2025/9/26,Active,肿瘤领域;罕见疾病领域,DR002664,中国(内地),phase 1,II/III期临床,2020/9/17,phase 3,1,TRUE,TRUE,FALSE,[],['中南大学湘雅医院'],1,['中南大学湘雅医院(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,
18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,骨转移疼痛,bone metastasis pain,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,中南大学湘雅医院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,骨转移疼痛,I期临床,2025/9/26,Active,肿瘤领域,DR002664,中国(内地),phase 1,II/III期临床,2020/9/17,phase 3,1,TRUE,FALSE,FALSE,[],['中南大学湘雅医院'],1,['中南大学湘雅医院(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,
18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide,18F-AlF-NOTA-octreotide;18F-IMP466;Al18F-NOTA-octreotide;Al18F-octreotide;Al18F-NOTA-TATE,副神经节瘤,paraganglioma,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,中南大学湘雅医院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,副神经节瘤,I期临床,2025/9/26,Active,肿瘤领域;罕见疾病领域,DR002664,中国(内地),phase 1,II/III期临床,2020/9/17,phase 3,1,TRUE,TRUE,FALSE,[],['中南大学湘雅医院'],1,['中南大学湘雅医院(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,
18F-AlF-NOTA-FAPI,18F-AlF-NOTA-FAPI,18F-AlF-NOTA-FAPI;Al18F-NOTA-FAPI,癌症,cancer,FAP,18F标记的PET药物,北京大学(原研),创新药,化药,放射性药物;其他,环肽;诊断用放射性药物,18F标记的PET药物,癌症,II/III期临床,2023/3/1,Active,肿瘤领域,DR057490,中国(内地),phase 3,II/III期临床,2023/3/1,phase 3,1,TRUE,FALSE,FALSE,[],['北京大学'],1,['北京大学(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,3,Oncology,Oncology,,
18F-AlF-NOTA-FAPI,18F-AlF-NOTA-FAPI,18F-AlF-NOTA-FAPI;Al18F-NOTA-FAPI,PET显像,PET imaging,FAP,18F标记的PET药物,北京大学(原研),创新药,化药,放射性药物;其他,环肽;诊断用放射性药物,18F标记的PET药物,PET显像,II/III期临床,2023/3/1,Active,诊断试剂领域,DR057490,中国(内地),phase 3,II/III期临床,2023/3/1,phase 3,1,TRUE,FALSE,FALSE,[],['北京大学'],1,['北京大学(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,3,3,Diagnostic Reagents,Diagnostic Reagents,,
18F-AlF-NOTA-FAPI,18F-AlF-NOTA-FAPI,18F-AlF-NOTA-FAPI;Al18F-NOTA-FAPI,胃癌,stomach cancer,FAP,18F标记的PET药物,北京大学(原研),创新药,化药,放射性药物;其他,环肽;诊断用放射性药物,18F标记的PET药物,胃癌,I期临床,2022/6/24,Active,肿瘤领域,DR057490,中国(内地),phase 1,II/III期临床,2023/3/1,phase 3,1,TRUE,FALSE,FALSE,[],['北京大学'],1,['北京大学(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,
zelenectide pevedotin,zelenectide pevedotin,zelenectide pevedotin;BT8009,尿路上皮癌,urothelial carcinoma,nectin-4,多肽偶联药物,Bicycle Therapeutics(原研),创新药,化药,多肽;偶联药物,环肽;2022 AACR新机会;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];Potential First-in-Class;可降解连接子,多肽偶联药物,尿路上皮癌(差异化疾病),II/III期临床,2024/1/26,Active,肿瘤领域,DR052156,欧洲,phase 3,II/III期临床,2024/1/26,phase 3,1,TRUE,FALSE,FALSE,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,3,Oncology,Oncology,,
zelenectide pevedotin,zelenectide pevedotin,zelenectide pevedotin;BT8009,HR阳性乳腺癌,HR positive breast cancer,nectin-4,多肽偶联药物,Bicycle Therapeutics(原研),创新药,化药,多肽;偶联药物,环肽;2022 AACR新机会;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];Potential First-in-Class;可降解连接子,多肽偶联药物,HR阳性乳腺癌(差异化疾病),II期临床,2025/2/21,Active,肿瘤领域,DR052156,欧洲,phase 2,II/III期临床,2024/1/26,phase 3,1,TRUE,FALSE,FALSE,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,2,Oncology,Oncology,,
zelenectide pevedotin,zelenectide pevedotin,zelenectide pevedotin;BT8009,三阴性乳腺癌,triple negative breast cancer,nectin-4,多肽偶联药物,Bicycle Therapeutics(原研),创新药,化药,多肽;偶联药物,环肽;2022 AACR新机会;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];Potential First-in-Class;可降解连接子,多肽偶联药物,三阴性乳腺癌,II期临床,2025/2/21,Active,肿瘤领域,DR052156,欧洲,phase 2,II/III期临床,2024/1/26,phase 3,1,TRUE,FALSE,FALSE,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,2,Oncology,Oncology,,
zelenectide pevedotin,zelenectide pevedotin,zelenectide pevedotin;BT8009,鳞状非小细胞肺癌,Squamous non-small cell lung cancer,nectin-4,多肽偶联药物,Bicycle Therapeutics(原研),创新药,化药,多肽;偶联药物,环肽;2022 AACR新机会;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];Potential First-in-Class;可降解连接子,多肽偶联药物,鳞状非小细胞肺癌(差异化疾病),II期临床,2025/4/18,Active,肿瘤领域,DR052156,欧洲,phase 2,II/III期临床,2024/1/26,phase 3,1,TRUE,FALSE,FALSE,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,2,Oncology,Oncology,,
zelenectide pevedotin,zelenectide pevedotin,zelenectide pevedotin;BT8009,非鳞状非小细胞肺癌,non-squamous non-small cell lung cancer,nectin-4,多肽偶联药物,Bicycle Therapeutics(原研),创新药,化药,多肽;偶联药物,环肽;2022 AACR新机会;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];Potential First-in-Class;可降解连接子,多肽偶联药物,非鳞状非小细胞肺癌(差异化疾病),II期临床,2025/4/18,Active,肿瘤领域,DR052156,欧洲,phase 2,II/III期临床,2024/1/26,phase 3,1,TRUE,FALSE,FALSE,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,2,Oncology,Oncology,,
zelenectide pevedotin,zelenectide pevedotin,zelenectide pevedotin;BT8009,癌症,cancer,nectin-4,多肽偶联药物,Bicycle Therapeutics(原研),创新药,化药,多肽;偶联药物,环肽;2022 AACR新机会;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];Potential First-in-Class;可降解连接子,多肽偶联药物,癌症,I/II期临床,2024/5/28,Active,肿瘤领域,DR052156,欧洲,phase 2,II/III期临床,2024/1/26,phase 3,1,TRUE,FALSE,FALSE,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,2,Oncology,Oncology,,
zelenectide pevedotin,zelenectide pevedotin,zelenectide pevedotin;BT8009,非小细胞肺癌,non-small cell lung cancer,nectin-4,多肽偶联药物,Bicycle Therapeutics(原研),创新药,化药,多肽;偶联药物,环肽;2022 AACR新机会;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];Potential First-in-Class;可降解连接子,多肽偶联药物,非小细胞肺癌,I/II期临床,2020/9/23,Active,肿瘤领域,DR052156,欧洲,phase 2,II/III期临床,2024/1/26,phase 3,1,TRUE,FALSE,FALSE,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,2,Oncology,Oncology,,
zelenectide pevedotin,zelenectide pevedotin,zelenectide pevedotin;BT8009,胃癌,stomach cancer,nectin-4,多肽偶联药物,Bicycle Therapeutics(原研),创新药,化药,多肽;偶联药物,环肽;2022 AACR新机会;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];Potential First-in-Class;可降解连接子,多肽偶联药物,胃癌(差异化疾病),I/II期临床,,Active,肿瘤领域,DR052156,欧洲,phase 2,II/III期临床,2024/1/26,phase 3,1,TRUE,FALSE,FALSE,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,2,Oncology,Oncology,,
zelenectide pevedotin,zelenectide pevedotin,zelenectide pevedotin;BT8009,食管癌,Esophageal cancer,nectin-4,多肽偶联药物,Bicycle Therapeutics(原研),创新药,化药,多肽;偶联药物,环肽;2022 AACR新机会;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];Potential First-in-Class;可降解连接子,多肽偶联药物,食管癌,I/II期临床,,Active,肿瘤领域,DR052156,欧洲,phase 2,II/III期临床,2024/1/26,phase 3,1,TRUE,FALSE,FALSE,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,2,Oncology,Oncology,,
zelenectide pevedotin,zelenectide pevedotin,zelenectide pevedotin;BT8009,胰腺癌,pancreatic cancer,nectin-4,多肽偶联药物,Bicycle Therapeutics(原研),创新药,化药,多肽;偶联药物,环肽;2022 AACR新机会;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];Potential First-in-Class;可降解连接子,多肽偶联药物,胰腺癌(差异化疾病),I/II期临床,,Active,肿瘤领域;罕见疾病领域,DR052156,欧洲,phase 2,II/III期临床,2024/1/26,phase 3,1,TRUE,TRUE,FALSE,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,2,Oncology,Oncology,,
zelenectide pevedotin,zelenectide pevedotin,zelenectide pevedotin;BT8009,卵巢癌,ovarian cancer,nectin-4,多肽偶联药物,Bicycle Therapeutics(原研),创新药,化药,多肽;偶联药物,环肽;2022 AACR新机会;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];Potential First-in-Class;可降解连接子,多肽偶联药物,卵巢癌(差异化疾病),I/II期临床,2020/9/23,Active,肿瘤领域;罕见疾病领域,DR052156,欧洲,phase 2,II/III期临床,2024/1/26,phase 3,1,TRUE,TRUE,FALSE,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,2,Oncology,Oncology,,
zelenectide pevedotin,zelenectide pevedotin,zelenectide pevedotin;BT8009,膀胱癌,bladder cancer,nectin-4,多肽偶联药物,Bicycle Therapeutics(原研),创新药,化药,多肽;偶联药物,环肽;2022 AACR新机会;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];Potential First-in-Class;可降解连接子,多肽偶联药物,膀胱癌,I/II期临床,2020/9/23,Active,肿瘤领域,DR052156,欧洲,phase 2,II/III期临床,2024/1/26,phase 3,1,TRUE,FALSE,FALSE,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,2,Oncology,Oncology,,
zelenectide pevedotin,zelenectide pevedotin,zelenectide pevedotin;BT8009,实体瘤,solid tumors,nectin-4,多肽偶联药物,Bicycle Therapeutics(原研),创新药,化药,多肽;偶联药物,环肽;2022 AACR新机会;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];Potential First-in-Class;可降解连接子,多肽偶联药物,实体瘤,I期临床,2024/7/26,Active,肿瘤领域,DR052156,欧洲,phase 1,II/III期临床,2024/1/26,phase 3,1,TRUE,FALSE,FALSE,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,3,1,Oncology,Oncology,,
脑利钠肽,nesiritide biosimilar,脑利钠肽;BC003 (重组人脑利钠肽);nesiritide biosimilar,急性失代偿性心力衰竭,acute decompensated heart failure,BNP,重组BNP,步长制药(原研),生物类似药,生物,多肽,环肽,重组,急性失代偿性心力衰竭,II/III期临床,2025/3/4,Active,心脑血管领域,DR075838,中国(内地),phase 3,II/III期临床,2025/3/4,phase 3,1,TRUE,FALSE,FALSE,[],['步长制药'],1,['步长制药(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,3,3,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
Tc99m-maraciclatide,Tc99m-maraciclatide,Tc99m-maraciclatide;99mTc-NC100692;Tc-99m-NC100692;99mTc-maraciclatide,间质性肺病,interstitial lung disease,αvβ3,含锝放射性示踪剂;anti-αvβ3多肽偶联核素,GE Healthcare(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,含锝放射性示踪剂;多肽偶联核素,间质性肺病(差异化疾病),II期临床,2024/9/10,Active,呼吸领域,DR016896,美国,phase 2,II期临床,2004/11/10,phase 2,1,TRUE,FALSE,FALSE,[],['GE Healthcare'],1,['GE Healthcare(原研)'],呼吸领域,['呼吸领域'],1,呼吸领域,,,2,2,Respiratory,Respiratory,,
Tc99m-maraciclatide,Tc99m-maraciclatide,Tc99m-maraciclatide;99mTc-NC100692;Tc-99m-NC100692;99mTc-maraciclatide,类风湿性关节炎,rheumatoid arthritis,αvβ3,含锝放射性示踪剂;anti-αvβ3多肽偶联核素,GE Healthcare(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,含锝放射性示踪剂;多肽偶联核素,类风湿性关节炎,I期临床,2023/8/9,Active,免疫领域;骨骼肌肉领域,DR016896,美国,phase 1,II期临床,2004/11/10,phase 2,1,TRUE,FALSE,FALSE,[],['GE Healthcare'],1,['GE Healthcare(原研)'],免疫领域,"['免疫领域', '骨骼肌肉领域']",2,免疫领域,骨骼肌肉领域,,2,1,Immunology,Immunology,Musculoskeletal,
Tc99m-maraciclatide,Tc99m-maraciclatide,Tc99m-maraciclatide;99mTc-NC100692;Tc-99m-NC100692;99mTc-maraciclatide,子宫内膜异位,endometriosis,αvβ3,含锝放射性示踪剂;anti-αvβ3多肽偶联核素,GE Healthcare(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,含锝放射性示踪剂;多肽偶联核素,子宫内膜异位(差异化疾病),临床前,2024/7/2,Active,泌尿生殖领域,DR016896,美国,pre-clinical,II期临床,2004/11/10,phase 2,1,TRUE,FALSE,FALSE,[],['GE Healthcare'],1,['GE Healthcare(原研)'],泌尿生殖领域,['泌尿生殖领域'],1,泌尿生殖领域,,,2,-1,Genitourinary,Genitourinary,,
TI-001,TI-001,TI-001;TI-001 (oxytocin solution for intranasal delivery);TNX-1900,肥胖,obesity,oxytocin,合成的oxytocin,Tonix Pharmaceuticals;University of Geneva;Trigemina(原研)(无权益),微创新,化药,多肽,环肽;中国无申报,合成的,肥胖,II期临床,2022/12/23,Active,内分泌及代谢领域,DR057077,美国,phase 2,II期临床,2013/4/24,phase 2,3,TRUE,FALSE,FALSE,[],['Trigemina'],1,"['Tonix Pharmaceuticals', 'University of Geneva', 'Trigemina(原研)(无权益)']",内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,2,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,
TI-001,TI-001,TI-001;TI-001 (oxytocin solution for intranasal delivery);TNX-1900,社交恐惧症,social phobia,oxytocin,合成的oxytocin,Tonix Pharmaceuticals;University of Geneva;Trigemina(原研)(无权益),微创新,化药,多肽,环肽;中国无申报,合成的,社交恐惧症,II期临床,,Active,精神领域,DR057077,美国,phase 2,II期临床,2013/4/24,phase 2,3,TRUE,FALSE,FALSE,[],['Trigemina'],1,"['Tonix Pharmaceuticals', 'University of Geneva', 'Trigemina(原研)(无权益)']",精神领域,['精神领域'],1,精神领域,,,2,2,Psychiatry,Psychiatry,,
TI-001,TI-001,TI-001;TI-001 (oxytocin solution for intranasal delivery);TNX-1900,自闭症,autism,oxytocin,合成的oxytocin,Tonix Pharmaceuticals;University of Geneva;Trigemina(原研)(无权益),微创新,化药,多肽,环肽;中国无申报,合成的,自闭症,II期临床,2024/3/21,Active,精神领域,DR057077,美国,phase 2,II期临床,2013/4/24,phase 2,3,TRUE,FALSE,FALSE,[],['Trigemina'],1,"['Tonix Pharmaceuticals', 'University of Geneva', 'Trigemina(原研)(无权益)']",精神领域,['精神领域'],1,精神领域,,,2,2,Psychiatry,Psychiatry,,
TI-001,TI-001,TI-001;TI-001 (oxytocin solution for intranasal delivery);TNX-1900,暴食症,Bulimia,oxytocin,合成的oxytocin,Tonix Pharmaceuticals;University of Geneva;Trigemina(原研)(无权益),微创新,化药,多肽,环肽;中国无申报,合成的,暴食症,II期临床,2022/12/23,Active,精神领域,DR057077,美国,phase 2,II期临床,2013/4/24,phase 2,3,TRUE,FALSE,FALSE,[],['Trigemina'],1,"['Tonix Pharmaceuticals', 'University of Geneva', 'Trigemina(原研)(无权益)']",精神领域,['精神领域'],1,精神领域,,,2,2,Psychiatry,Psychiatry,,
TI-001,TI-001,TI-001;TI-001 (oxytocin solution for intranasal delivery);TNX-1900,偏头痛,Migraine,oxytocin,合成的oxytocin,Tonix Pharmaceuticals;University of Geneva;Trigemina(原研)(无权益),微创新,化药,多肽,环肽;中国无申报,合成的,偏头痛,II期临床,2013/4/24,Active,麻醉镇痛领域;神经领域,DR057077,美国,phase 2,II期临床,2013/4/24,phase 2,3,TRUE,FALSE,FALSE,[],['Trigemina'],1,"['Tonix Pharmaceuticals', 'University of Geneva', 'Trigemina(原研)(无权益)']",麻醉镇痛领域,"['麻醉镇痛领域', '神经领域']",2,麻醉镇痛领域,神经领域,,2,2,Anesthesia & Analgesia,Anesthesia & Analgesia,Neurology,
TI-001,TI-001,TI-001;TI-001 (oxytocin solution for intranasal delivery);TNX-1900,骨密度低,low bone density,oxytocin,合成的oxytocin,Tonix Pharmaceuticals;University of Geneva;Trigemina(原研)(无权益),微创新,化药,多肽,环肽;中国无申报,合成的,骨密度低,II期临床,2023/11/13,Active,骨骼肌肉领域;内分泌及代谢领域,DR057077,美国,phase 2,II期临床,2013/4/24,phase 2,3,TRUE,FALSE,FALSE,[],['Trigemina'],1,"['Tonix Pharmaceuticals', 'University of Geneva', 'Trigemina(原研)(无权益)']",骨骼肌肉领域,"['骨骼肌肉领域', '内分泌及代谢领域']",2,骨骼肌肉领域,内分泌及代谢领域,,2,2,Musculoskeletal,Musculoskeletal,Endocrinology & Metabolism,
TI-001,TI-001,TI-001;TI-001 (oxytocin solution for intranasal delivery);TNX-1900,面部神经痛,Facial neuralgia,oxytocin,合成的oxytocin,Tonix Pharmaceuticals;University of Geneva;Trigemina(原研)(无权益),微创新,化药,多肽,环肽;中国无申报,合成的,面部神经痛,临床前,,Active,神经领域;麻醉镇痛领域,DR057077,美国,pre-clinical,II期临床,2013/4/24,phase 2,3,TRUE,FALSE,FALSE,[],['Trigemina'],1,"['Tonix Pharmaceuticals', 'University of Geneva', 'Trigemina(原研)(无权益)']",神经领域,"['神经领域', '麻醉镇痛领域']",2,神经领域,麻醉镇痛领域,,2,-1,Neurology,Neurology,Anesthesia & Analgesia,
68Ga-satoreotide trizoxetan,68Ga-satoreotide trizoxetan,68Ga-satoreotide trizoxetan;68Ga-OPS202;68Ga-IPN01070;satoreotide trizoxetan;68Ga-NODAGA-JR11;Gallium-68 NODAGA-JR11;Ga68 NODAGA-JR11;SSO120;68Ga-SSO-120,小细胞肺癌,small cell lung cancer,SSTR2,anti-SSTR2多肽偶联核素;68Ga标记的PET药物,Ariceum Therapeutics;Ipsen(原研)(无权益),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,小细胞肺癌,II期临床,2023/5/10,Active,肿瘤领域;罕见疾病领域,DR002657,欧洲,phase 2,II期临床,2017/7/18,phase 2,2,TRUE,TRUE,FALSE,[],['Ipsen'],1,"['Ariceum Therapeutics', 'Ipsen(原研)(无权益)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
68Ga-satoreotide trizoxetan,68Ga-satoreotide trizoxetan,68Ga-satoreotide trizoxetan;68Ga-OPS202;68Ga-IPN01070;satoreotide trizoxetan;68Ga-NODAGA-JR11;Gallium-68 NODAGA-JR11;Ga68 NODAGA-JR11;SSO120;68Ga-SSO-120,PET显像,PET imaging,SSTR2,anti-SSTR2多肽偶联核素;68Ga标记的PET药物,Ariceum Therapeutics;Ipsen(原研)(无权益),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,PET显像,II期临床,2017/7/18,Active,诊断试剂领域,DR002657,欧洲,phase 2,II期临床,2017/7/18,phase 2,2,TRUE,FALSE,FALSE,[],['Ipsen'],1,"['Ariceum Therapeutics', 'Ipsen(原研)(无权益)']",诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,2,2,Diagnostic Reagents,Diagnostic Reagents,,
68Ga-satoreotide trizoxetan,68Ga-satoreotide trizoxetan,68Ga-satoreotide trizoxetan;68Ga-OPS202;68Ga-IPN01070;satoreotide trizoxetan;68Ga-NODAGA-JR11;Gallium-68 NODAGA-JR11;Ga68 NODAGA-JR11;SSO120;68Ga-SSO-120,神经内分泌肿瘤,neuroendocrine tumors,SSTR2,anti-SSTR2多肽偶联核素;68Ga标记的PET药物,Ariceum Therapeutics;Ipsen(原研)(无权益),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,神经内分泌肿瘤,II期临床,2020/7/29,Active,肿瘤领域;罕见疾病领域,DR002657,欧洲,phase 2,II期临床,2017/7/18,phase 2,2,TRUE,TRUE,FALSE,[],['Ipsen'],1,"['Ariceum Therapeutics', 'Ipsen(原研)(无权益)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
68Ga-satoreotide trizoxetan,68Ga-satoreotide trizoxetan,68Ga-satoreotide trizoxetan;68Ga-OPS202;68Ga-IPN01070;satoreotide trizoxetan;68Ga-NODAGA-JR11;Gallium-68 NODAGA-JR11;Ga68 NODAGA-JR11;SSO120;68Ga-SSO-120,肺神经内分泌肿瘤,Pulmonary neuroendocrine tumors,SSTR2,anti-SSTR2多肽偶联核素;68Ga标记的PET药物,Ariceum Therapeutics;Ipsen(原研)(无权益),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,肺神经内分泌肿瘤(差异化疾病),II期临床,2023/5/10,Active,肿瘤领域;罕见疾病领域,DR002657,欧洲,phase 2,II期临床,2017/7/18,phase 2,2,TRUE,TRUE,FALSE,[],['Ipsen'],1,"['Ariceum Therapeutics', 'Ipsen(原研)(无权益)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
68Ga-NODAGA-E[c(RGDyK)]2,68Ga-NODAGA-E[c(RGDyK)]2,68Ga-NODAGA-E[c(RGDyK)]2,PET显像,PET imaging,αvβ3,anti-αvβ3多肽偶联核素;68Ga标记的PET药物,Rigshospitalet(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,PET显像,II期临床,2017/9/5,Active,诊断试剂领域,DR062251,欧洲,phase 2,II期临床,2017/9/5,phase 2,1,TRUE,FALSE,FALSE,[],['Rigshospitalet'],1,['Rigshospitalet(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,2,2,Diagnostic Reagents,Diagnostic Reagents,,
[68]Ga-HA-DOTATATE,[68]Ga-HA-DOTATATE,[68]Ga-HA-DOTATATE;gallium-68 high affinity-DOTATATE;gallium-68 DOTA-3-iodo-Tyr(3)-octreotate;68Ga-HA-DOTATATE,PET显像,PET imaging,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,University of Alberta(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;中国无申报,68Ga标记的PET药物;多肽偶联核素,PET显像,II期临床,2019/1/23,Active,诊断试剂领域,DR062261,加拿大,phase 2,II期临床,2019/1/23,phase 2,1,TRUE,FALSE,FALSE,[],['University of Alberta'],1,['University of Alberta(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,2,2,Diagnostic Reagents,Diagnostic Reagents,,
[68]Ga-HA-DOTATATE,[68]Ga-HA-DOTATATE,[68]Ga-HA-DOTATATE;gallium-68 high affinity-DOTATATE;gallium-68 DOTA-3-iodo-Tyr(3)-octreotate;68Ga-HA-DOTATATE,神经内分泌肿瘤,neuroendocrine tumors,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,University of Alberta(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;中国无申报,68Ga标记的PET药物;多肽偶联核素,神经内分泌肿瘤,II期临床,2021/5/17,Active,肿瘤领域;罕见疾病领域,DR062261,加拿大,phase 2,II期临床,2019/1/23,phase 2,1,TRUE,TRUE,FALSE,[],['University of Alberta'],1,['University of Alberta(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
cRGD-ZW800-1 ,cRGD-ZW800-1 ,cRGD-ZW800-1 ;cRGD-ZW800-1,胰腺癌,pancreatic cancer,αvβ6;αvβ3;αvβ5,荧光显像剂,Leiden University;Curadel(原研),创新药,化药,多肽,环肽;中国无申报;Potential First-in-Class,荧光显像剂,胰腺癌,II期临床,2022/8/26,Active,肿瘤领域;罕见疾病领域,DR058158,美国,phase 2,II期临床,2019/12/9,phase 2,2,TRUE,TRUE,FALSE,[],['Curadel'],1,"['Leiden University', 'Curadel(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
cRGD-ZW800-1 ,cRGD-ZW800-1 ,cRGD-ZW800-1 ;cRGD-ZW800-1,光学成像剂,optical imaging agent,αvβ6;αvβ3;αvβ5,荧光显像剂,Leiden University;Curadel(原研),创新药,化药,多肽,环肽;中国无申报;Potential First-in-Class,荧光显像剂,光学成像剂,II期临床,2022/8/26,Active,诊断试剂领域,DR058158,美国,phase 2,II期临床,2019/12/9,phase 2,2,TRUE,FALSE,FALSE,[],['Curadel'],1,"['Leiden University', 'Curadel(原研)']",诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,2,2,Diagnostic Reagents,Diagnostic Reagents,,
cRGD-ZW800-1 ,cRGD-ZW800-1 ,cRGD-ZW800-1 ;cRGD-ZW800-1,喉癌,Throat cancer,αvβ6;αvβ3;αvβ5,荧光显像剂,Leiden University;Curadel(原研),创新药,化药,多肽,环肽;中国无申报;Potential First-in-Class,荧光显像剂,喉癌,II期临床,2023/3/2,Active,肿瘤领域,DR058158,美国,phase 2,II期临床,2019/12/9,phase 2,2,TRUE,FALSE,FALSE,[],['Curadel'],1,"['Leiden University', 'Curadel(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
cRGD-ZW800-1 ,cRGD-ZW800-1 ,cRGD-ZW800-1 ;cRGD-ZW800-1,口腔癌,oral cancer,αvβ6;αvβ3;αvβ5,荧光显像剂,Leiden University;Curadel(原研),创新药,化药,多肽,环肽;中国无申报;Potential First-in-Class,荧光显像剂,口腔癌,II期临床,2019/12/9,Active,肿瘤领域;罕见疾病领域,DR058158,美国,phase 2,II期临床,2019/12/9,phase 2,2,TRUE,TRUE,FALSE,[],['Curadel'],1,"['Leiden University', 'Curadel(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
cRGD-ZW800-1 ,cRGD-ZW800-1 ,cRGD-ZW800-1 ;cRGD-ZW800-1,胆管癌,cholangiocarcinoma,αvβ6;αvβ3;αvβ5,荧光显像剂,Leiden University;Curadel(原研),创新药,化药,多肽,环肽;中国无申报;Potential First-in-Class,荧光显像剂,胆管癌,II期临床,,Active,肿瘤领域;罕见疾病领域,DR058158,美国,phase 2,II期临床,2019/12/9,phase 2,2,TRUE,TRUE,FALSE,[],['Curadel'],1,"['Leiden University', 'Curadel(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
cRGD-ZW800-1 ,cRGD-ZW800-1 ,cRGD-ZW800-1 ;cRGD-ZW800-1,下咽癌,hypopharyngeal cancer,αvβ6;αvβ3;αvβ5,荧光显像剂,Leiden University;Curadel(原研),创新药,化药,多肽,环肽;中国无申报;Potential First-in-Class,荧光显像剂,下咽癌,II期临床,2023/3/2,Active,肿瘤领域,DR058158,美国,phase 2,II期临床,2019/12/9,phase 2,2,TRUE,FALSE,FALSE,[],['Curadel'],1,"['Leiden University', 'Curadel(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
cRGD-ZW800-1 ,cRGD-ZW800-1 ,cRGD-ZW800-1 ;cRGD-ZW800-1,结肠癌,colon cancer,αvβ6;αvβ3;αvβ5,荧光显像剂,Leiden University;Curadel(原研),创新药,化药,多肽,环肽;中国无申报;Potential First-in-Class,荧光显像剂,结肠癌,I期临床,,Active,肿瘤领域,DR058158,美国,phase 1,II期临床,2019/12/9,phase 2,2,TRUE,FALSE,FALSE,[],['Curadel'],1,"['Leiden University', 'Curadel(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,1,Oncology,Oncology,,
PL-8177,PL-8177,PL-8177;PL8177,溃疡性结肠炎,ulcerative colitis,MC1R,MC1R激动剂,Palatin Technologies(原研),创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;Melanogenesis,激动剂,溃疡性结肠炎(差异化疾病),II期临床,2022/7/20,Active,免疫领域;消化领域,DR054605,美国,phase 2,II期临床,2020/1/20,phase 2,1,TRUE,FALSE,FALSE,[],['Palatin Technologies'],1,['Palatin Technologies(原研)'],免疫领域,"['免疫领域', '消化领域']",2,免疫领域,消化领域,,2,2,Immunology,Immunology,Digestive System,
PL-8177,PL-8177,PL-8177;PL8177,糖尿病肾病,diabetic nephropathy,MC1R,MC1R激动剂,Palatin Technologies(原研),创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;Melanogenesis,激动剂,糖尿病肾病(差异化疾病),临床前,,Active,泌尿生殖领域,DR054605,美国,pre-clinical,II期临床,2020/1/20,phase 2,1,TRUE,FALSE,FALSE,[],['Palatin Technologies'],1,['Palatin Technologies(原研)'],泌尿生殖领域,['泌尿生殖领域'],1,泌尿生殖领域,,,2,-1,Genitourinary,Genitourinary,,
68Ga-NODAGA-LM3,68Ga-NODAGA-LM3,68Ga-NODAGA-LM3;(68)Ga-NODAGA-LM3;Gallium-68 NODAGA-LM3,PET显像,PET imaging,SSTR2,68Ga标记的PET药物;anti-SSTR2多肽偶联核素,University Hospital of Basel(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,PET显像,II期临床,2020/7/29,Active,诊断试剂领域,DR014961,欧洲,phase 2,II期临床,2020/7/29,phase 2,1,TRUE,FALSE,FALSE,[],['University Hospital of Basel'],1,['University Hospital of Basel(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,2,2,Diagnostic Reagents,Diagnostic Reagents,,
68Ga-NODAGA-LM3,68Ga-NODAGA-LM3,68Ga-NODAGA-LM3;(68)Ga-NODAGA-LM3;Gallium-68 NODAGA-LM3,神经内分泌肿瘤,neuroendocrine tumors,SSTR2,68Ga标记的PET药物;anti-SSTR2多肽偶联核素,University Hospital of Basel(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,神经内分泌肿瘤,II期临床,2020/7/29,Active,肿瘤领域;罕见疾病领域,DR014961,欧洲,phase 2,II期临床,2020/7/29,phase 2,1,TRUE,TRUE,FALSE,[],['University Hospital of Basel'],1,['University Hospital of Basel(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
68Ga-NODAGA-LM3,68Ga-NODAGA-LM3,68Ga-NODAGA-LM3;(68)Ga-NODAGA-LM3;Gallium-68 NODAGA-LM3,希佩尔-林道综合征,Hippel-Lindau syndrome,SSTR2,68Ga标记的PET药物;anti-SSTR2多肽偶联核素,University Hospital of Basel(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,希佩尔-林道综合征(差异化疾病),II期临床,2023/4/12,Active,罕见疾病领域;肿瘤领域,DR014961,欧洲,phase 2,II期临床,2020/7/29,phase 2,1,TRUE,TRUE,FALSE,[],['University Hospital of Basel'],1,['University Hospital of Basel(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
THR-149,THR-149,THR-149,糖尿病黄斑水肿,diabetic macular edema,PKK,PKK抑制剂,Oxurion;Bicycle Therapeutics(原研),创新药,化药,多肽,环肽,抑制剂,糖尿病黄斑水肿,II期临床,2020/8/26,Active,眼科领域,DR044097,欧洲,phase 2,II期临床,2020/8/26,phase 2,2,TRUE,FALSE,FALSE,[],['Bicycle Therapeutics'],1,"['Oxurion', 'Bicycle Therapeutics(原研)']",眼科领域,['眼科领域'],1,眼科领域,,,2,2,Ophthalmology,Ophthalmology,,
certepetide,certepetide,certepetide;CEND-1;iRGD;QLC12102;LSTA1,胰腺癌,pancreatic cancer,CD51,CD51结合剂,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,胰腺癌,II期临床,,Active,肿瘤领域;罕见疾病领域,DR051234,美国,phase 2,II期临床,2021/9/13,phase 2,4,TRUE,TRUE,FALSE,[],['Lisata Therapeutics'],1,"['齐鲁制药', 'Lisata Therapeutics(原研)', 'GATC Health', 'Kuva Labs']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
certepetide,certepetide,certepetide;CEND-1;iRGD;QLC12102;LSTA1,胶质瘤,glioma,CD51,CD51结合剂,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,胶质瘤,II期临床,,Active,肿瘤领域;罕见疾病领域,DR051234,美国,phase 2,II期临床,2021/9/13,phase 2,4,TRUE,TRUE,FALSE,[],['Lisata Therapeutics'],1,"['齐鲁制药', 'Lisata Therapeutics(原研)', 'GATC Health', 'Kuva Labs']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
certepetide,certepetide,certepetide;CEND-1;iRGD;QLC12102;LSTA1,胶质母细胞瘤,glioblastoma,CD51,CD51结合剂,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,胶质母细胞瘤,II期临床,2023/10/17,Active,肿瘤领域;罕见疾病领域,DR051234,美国,phase 2,II期临床,2021/9/13,phase 2,4,TRUE,TRUE,FALSE,[],['Lisata Therapeutics'],1,"['齐鲁制药', 'Lisata Therapeutics(原研)', 'GATC Health', 'Kuva Labs']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
certepetide,certepetide,certepetide;CEND-1;iRGD;QLC12102;LSTA1,胰腺导管癌,pancreatic ductal carcinoma,CD51,CD51结合剂,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,胰腺导管癌,II期临床,2021/9/13,Active,肿瘤领域,DR051234,美国,phase 2,II期临床,2021/9/13,phase 2,4,TRUE,FALSE,FALSE,[],['Lisata Therapeutics'],1,"['齐鲁制药', 'Lisata Therapeutics(原研)', 'GATC Health', 'Kuva Labs']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
certepetide,certepetide,certepetide;CEND-1;iRGD;QLC12102;LSTA1,头颈部鳞状细胞癌,Head and neck squamous cell carcinoma,CD51,CD51结合剂,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,头颈部鳞状细胞癌,II期临床,2023/2/3,Active,肿瘤领域,DR051234,美国,phase 2,II期临床,2021/9/13,phase 2,4,TRUE,FALSE,FALSE,[],['Lisata Therapeutics'],1,"['齐鲁制药', 'Lisata Therapeutics(原研)', 'GATC Health', 'Kuva Labs']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
certepetide,certepetide,certepetide;CEND-1;iRGD;QLC12102;LSTA1,肝内胆管癌,intrahepatic cholangiocarcinoma,CD51,CD51结合剂,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,肝内胆管癌,II期临床,,Active,肿瘤领域,DR051234,美国,phase 2,II期临床,2021/9/13,phase 2,4,TRUE,FALSE,FALSE,[],['Lisata Therapeutics'],1,"['齐鲁制药', 'Lisata Therapeutics(原研)', 'GATC Health', 'Kuva Labs']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
certepetide,certepetide,certepetide;CEND-1;iRGD;QLC12102;LSTA1,胆囊癌,gallbladder cancer,CD51,CD51结合剂,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,胆囊癌,II期临床,,Active,肿瘤领域;罕见疾病领域,DR051234,美国,phase 2,II期临床,2021/9/13,phase 2,4,TRUE,TRUE,FALSE,[],['Lisata Therapeutics'],1,"['齐鲁制药', 'Lisata Therapeutics(原研)', 'GATC Health', 'Kuva Labs']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
certepetide,certepetide,certepetide;CEND-1;iRGD;QLC12102;LSTA1,胆管癌,cholangiocarcinoma,CD51,CD51结合剂,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,胆管癌,II期临床,2023/2/3,Active,肿瘤领域;罕见疾病领域,DR051234,美国,phase 2,II期临床,2021/9/13,phase 2,4,TRUE,TRUE,FALSE,[],['Lisata Therapeutics'],1,"['齐鲁制药', 'Lisata Therapeutics(原研)', 'GATC Health', 'Kuva Labs']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
certepetide,certepetide,certepetide;CEND-1;iRGD;QLC12102;LSTA1,肝外胆管癌,extrahepatic cholangiocarcinoma,CD51,CD51结合剂,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,肝外胆管癌,II期临床,,Active,肿瘤领域;罕见疾病领域,DR051234,美国,phase 2,II期临床,2021/9/13,phase 2,4,TRUE,TRUE,FALSE,[],['Lisata Therapeutics'],1,"['齐鲁制药', 'Lisata Therapeutics(原研)', 'GATC Health', 'Kuva Labs']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
certepetide,certepetide,certepetide;CEND-1;iRGD;QLC12102;LSTA1,食管鳞状细胞癌,Esophageal squamous cell carcinoma,CD51,CD51结合剂,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,食管鳞状细胞癌,II期临床,2023/2/3,Active,肿瘤领域,DR051234,美国,phase 2,II期临床,2021/9/13,phase 2,4,TRUE,FALSE,FALSE,[],['Lisata Therapeutics'],1,"['齐鲁制药', 'Lisata Therapeutics(原研)', 'GATC Health', 'Kuva Labs']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
certepetide,certepetide,certepetide;CEND-1;iRGD;QLC12102;LSTA1,结肠癌,colon cancer,CD51,CD51结合剂,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,结肠癌,I/II期临床,2021/11/16,Active,肿瘤领域,DR051234,美国,phase 2,II期临床,2021/9/13,phase 2,4,TRUE,FALSE,FALSE,[],['Lisata Therapeutics'],1,"['齐鲁制药', 'Lisata Therapeutics(原研)', 'GATC Health', 'Kuva Labs']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
certepetide,certepetide,certepetide;CEND-1;iRGD;QLC12102;LSTA1,阑尾癌,appendix cancer,CD51,CD51结合剂,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,阑尾癌,I/II期临床,2021/11/16,Active,肿瘤领域;罕见疾病领域,DR051234,美国,phase 2,II期临床,2021/9/13,phase 2,4,TRUE,TRUE,FALSE,[],['Lisata Therapeutics'],1,"['齐鲁制药', 'Lisata Therapeutics(原研)', 'GATC Health', 'Kuva Labs']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
certepetide,certepetide,certepetide;CEND-1;iRGD;QLC12102;LSTA1,腹膜转移癌,peritoneal metastasis cancer,CD51,CD51结合剂,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,腹膜转移癌,I期临床,2024/1/22,Active,肿瘤领域,DR051234,美国,phase 1,II期临床,2021/9/13,phase 2,4,TRUE,FALSE,FALSE,[],['Lisata Therapeutics'],1,"['齐鲁制药', 'Lisata Therapeutics(原研)', 'GATC Health', 'Kuva Labs']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,1,Oncology,Oncology,,
certepetide,certepetide,certepetide;CEND-1;iRGD;QLC12102;LSTA1,骨肉瘤,Osteosarcoma,CD51,CD51结合剂,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,骨肉瘤,临床前,2024/3/21,Active,肿瘤领域;罕见疾病领域,DR051234,美国,pre-clinical,II期临床,2021/9/13,phase 2,4,TRUE,TRUE,FALSE,[],['Lisata Therapeutics'],1,"['齐鲁制药', 'Lisata Therapeutics(原研)', 'GATC Health', 'Kuva Labs']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,-1,Oncology,Oncology,,
certepetide,certepetide,certepetide;CEND-1;iRGD;QLC12102;LSTA1,腹膜癌,peritoneal cancer,CD51,CD51结合剂,齐鲁制药;Lisata Therapeutics(原研);GATC Health;Kuva Labs,创新药,化药,多肽,环肽;Potential First-in-Class,结合剂,腹膜癌,临床前,,Active,肿瘤领域;罕见疾病领域,DR051234,美国,pre-clinical,II期临床,2021/9/13,phase 2,4,TRUE,TRUE,FALSE,[],['Lisata Therapeutics'],1,"['齐鲁制药', 'Lisata Therapeutics(原研)', 'GATC Health', 'Kuva Labs']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,-1,Oncology,Oncology,,
212Pb-dotamtate,212Pb-dotamtate,212Pb-dotamtate;AlphaMedix;212Pb-DOTAMTATE;212Pb-AR-RMX;ORM2110;SAR447873,神经内分泌肿瘤,neuroendocrine tumors,SSTR,212Pb标记的放射性药物;anti-SSTR多肽偶联核素,Sanofi(Top20 MNC);Orano Med(原研)(无权益);RadioMedix(原研)(无权益),创新药,化药,多肽;放射性药物;偶联药物,环肽;2024年转化医学TOP25;中国无申报;Potential First-in-Class;2024 ASCO新机会,多肽偶联核素;212Pb标记的放射性药物,神经内分泌肿瘤,II期临床,2021/12/10,Active,肿瘤领域;罕见疾病领域,DR056969,美国,phase 2,II期临床,2021/12/10,phase 2,3,TRUE,TRUE,TRUE,['Sanofi'],"['Orano Med', 'RadioMedix']",2,"['Sanofi(Top20 MNC)', 'Orano Med(原研)(无权益)', 'RadioMedix(原研)(无权益)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
212Pb-dotamtate,212Pb-dotamtate,212Pb-dotamtate;AlphaMedix;212Pb-DOTAMTATE;212Pb-AR-RMX;ORM2110;SAR447873,胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,SSTR,212Pb标记的放射性药物;anti-SSTR多肽偶联核素,Sanofi(Top20 MNC);Orano Med(原研)(无权益);RadioMedix(原研)(无权益),创新药,化药,多肽;放射性药物;偶联药物,环肽;2024年转化医学TOP25;中国无申报;Potential First-in-Class;2024 ASCO新机会,多肽偶联核素;212Pb标记的放射性药物,胃肠胰神经内分泌肿瘤,II期临床,2024/2/12,Active,肿瘤领域;罕见疾病领域,DR056969,美国,phase 2,II期临床,2021/12/10,phase 2,3,TRUE,TRUE,TRUE,['Sanofi'],"['Orano Med', 'RadioMedix']",2,"['Sanofi(Top20 MNC)', 'Orano Med(原研)(无权益)', 'RadioMedix(原研)(无权益)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
GT-02037,GT-02037,GT-02037,肢端肥大症,acromegaly,somatostatin;SSTR1;SSTR2;SSTR4;SSTR5;SSTR3,SSTR1激动剂;SSTR4激动剂;SSTR2激动剂;SSTR3激动剂;SSTR5激动剂;somatostatin类似物,永信药品;GlyTech(原研),创新药,化药,多肽,环肽;中国无申报;Potential First-in-Class,类似物;激动剂,肢端肥大症,II期临床,2022/6/22,Active,内分泌及代谢领域;罕见疾病领域,DR024863,日本,phase 2,II期临床,2022/6/22,phase 2,2,TRUE,TRUE,FALSE,[],['GlyTech'],1,"['永信药品', 'GlyTech(原研)']",内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,2,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,
SCAI-001,SCAI-001 (cyclosporine),SCAI-001;SCAI-001 (环孢素);SCAI-001 (cyclosporine),干眼病,dry eye disease,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,SCAI Therapeutics(原研),微创新,化药,小分子,环肽;胆汁酸通路;非降解型分子胶;中国无申报,抑制剂;分子胶,干眼病,II期临床,2023/2/17,Active,眼科领域,DR013209,韩国,phase 2,II期临床,2023/2/17,phase 2,1,TRUE,FALSE,FALSE,[],['SCAI Therapeutics'],1,['SCAI Therapeutics(原研)'],眼科领域,['眼科领域'],1,眼科领域,,,2,2,Ophthalmology,Ophthalmology,,
thiostrepton,thiostrepton,thiostrepton;RSO-021,恶性胸水,malignant pleural effusion,FOXM1;PRDX3,FOXM1抑制剂;PRDX3抑制剂;多肽类抗生素,RS Oncology(原研),创新药,化药,多肽,环肽;Potential First-in-Class,多肽类抗生素;抑制剂,恶性胸水,II期临床,2024/2/1,Active,肿瘤领域;罕见疾病领域,DR054387,美国,phase 2,II期临床,2024/2/1,phase 2,1,TRUE,TRUE,FALSE,[],['RS Oncology'],1,['RS Oncology(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
thiostrepton,thiostrepton,thiostrepton;RSO-021,胸膜间皮瘤,Pleural mesothelioma,FOXM1;PRDX3,FOXM1抑制剂;PRDX3抑制剂;多肽类抗生素,RS Oncology(原研),创新药,化药,多肽,环肽;Potential First-in-Class,多肽类抗生素;抑制剂,胸膜间皮瘤,II期临床,2024/2/1,Active,肿瘤领域;罕见疾病领域,DR054387,美国,phase 2,II期临床,2024/2/1,phase 2,1,TRUE,TRUE,FALSE,[],['RS Oncology'],1,['RS Oncology(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
M-ANP,M-ANP,M-ANP;MANP;M-Atrial Natriuretic Peptide,高血压,hypertension,NPR1,NPR1激活剂,Mayo Clinic(原研);E-Star BioTech,创新药,化药,多肽,环肽;差异化疾病;Potential First-in-Class,激活剂,高血压,II期临床,2024/4/2,Active,心脑血管领域,DR005045,美国,phase 2,II期临床,2024/4/2,phase 2,2,TRUE,FALSE,FALSE,[],['Mayo Clinic'],1,"['Mayo Clinic(原研)', 'E-Star BioTech']",心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,2,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
M-ANP,M-ANP,M-ANP;MANP;M-Atrial Natriuretic Peptide,射血分数保留的心力衰竭,heart failure with preserved ejection fraction,NPR1,NPR1激活剂,Mayo Clinic(原研);E-Star BioTech,创新药,化药,多肽,环肽;差异化疾病;Potential First-in-Class,激活剂,射血分数保留的心力衰竭(差异化疾病),I/II期临床,,Active,心脑血管领域,DR005045,美国,phase 2,II期临床,2024/4/2,phase 2,2,TRUE,FALSE,FALSE,[],['Mayo Clinic'],1,"['Mayo Clinic(原研)', 'E-Star BioTech']",心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,2,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
DD01,DD01,DD01;SAL0125,肥胖,obesity,GLP-1R;GCGR,GLP-1R×GCGR激动剂,信立泰;D&D Pharmatech(原研),创新药,化药,多肽,环肽;肠促胰岛素通路,激动剂,肥胖,II期临床,2024/5/13,Active,内分泌及代谢领域,DR016577,韩国,phase 2,II期临床,2024/5/13,phase 2,2,TRUE,FALSE,FALSE,[],['D&D Pharmatech'],1,"['信立泰', 'D&D Pharmatech(原研)']",内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,2,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,
DD01,DD01,DD01;SAL0125,代谢相关脂肪性肝炎,Metabolic related steatohepatitis,GLP-1R;GCGR,GLP-1R×GCGR激动剂,信立泰;D&D Pharmatech(原研),创新药,化药,多肽,环肽;肠促胰岛素通路,激动剂,代谢相关脂肪性肝炎,II期临床,2024/5/13,Active,消化领域,DR016577,韩国,phase 2,II期临床,2024/5/13,phase 2,2,TRUE,FALSE,FALSE,[],['D&D Pharmatech'],1,"['信立泰', 'D&D Pharmatech(原研)']",消化领域,['消化领域'],1,消化领域,,,2,2,Digestive System,Digestive System,,
DD01,DD01,DD01;SAL0125,超重,overweight,GLP-1R;GCGR,GLP-1R×GCGR激动剂,信立泰;D&D Pharmatech(原研),创新药,化药,多肽,环肽;肠促胰岛素通路,激动剂,超重,II期临床,2024/5/13,Active,内分泌及代谢领域,DR016577,韩国,phase 2,II期临床,2024/5/13,phase 2,2,TRUE,FALSE,FALSE,[],['D&D Pharmatech'],1,"['信立泰', 'D&D Pharmatech(原研)']",内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,2,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,
DD01,DD01,DD01;SAL0125,2型糖尿病,type 2 diabetes,GLP-1R;GCGR,GLP-1R×GCGR激动剂,信立泰;D&D Pharmatech(原研),创新药,化药,多肽,环肽;肠促胰岛素通路,激动剂,2型糖尿病,I期临床,2021/3/23,Active,内分泌及代谢领域,DR016577,韩国,phase 1,II期临床,2024/5/13,phase 2,2,TRUE,FALSE,FALSE,[],['D&D Pharmatech'],1,"['信立泰', 'D&D Pharmatech(原研)']",内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,2,1,Endocrinology & Metabolism,Endocrinology & Metabolism,,
DD01,DD01,DD01;SAL0125,代谢相关脂肪性肝病,metabolic related fatty liver disease,GLP-1R;GCGR,GLP-1R×GCGR激动剂,信立泰;D&D Pharmatech(原研),创新药,化药,多肽,环肽;肠促胰岛素通路,激动剂,代谢相关脂肪性肝病,I期临床,2021/3/23,Active,消化领域,DR016577,韩国,phase 1,II期临床,2024/5/13,phase 2,2,TRUE,FALSE,FALSE,[],['D&D Pharmatech'],1,"['信立泰', 'D&D Pharmatech(原研)']",消化领域,['消化领域'],1,消化领域,,,2,1,Digestive System,Digestive System,,
咔喏霉素,kynomycin,咔喏霉素;kynomycin;YB211;YBD211,急性细菌性皮肤和皮肤结构感染,Acute bacterial skin and skin structure infections,not available,脂肽类抗生素,友搏药业(九芝堂);香港大学(原研),创新药,化药,多肽,环肽;差异化疾病,脂肽类抗生素,急性细菌性皮肤和皮肤结构感染(差异化疾病),II期临床,2025/3/7,Active,感染领域;皮肤领域,DR049191,中国(港澳台),phase 2,II期临床,2025/3/7,phase 2,2,TRUE,FALSE,FALSE,[],['香港大学'],1,"['友搏药业(九芝堂)', '香港大学(原研)']",感染领域,"['感染领域', '皮肤领域']",2,感染领域,皮肤领域,,2,2,Infectious Diseases,Infectious Diseases,Dermatology,
咔喏霉素,kynomycin,咔喏霉素;kynomycin;YB211;YBD211,皮肤/皮肤结构感染,Skin/skin structure infection,not available,脂肽类抗生素,友搏药业(九芝堂);香港大学(原研),创新药,化药,多肽,环肽;差异化疾病,脂肽类抗生素,皮肤/皮肤结构感染,I期临床,2023/11/20,Active,感染领域;皮肤领域,DR049191,中国(港澳台),phase 1,II期临床,2025/3/7,phase 2,2,TRUE,FALSE,FALSE,[],['香港大学'],1,"['友搏药业(九芝堂)', '香港大学(原研)']",感染领域,"['感染领域', '皮肤领域']",2,感染领域,皮肤领域,,2,1,Infectious Diseases,Infectious Diseases,Dermatology,
咔喏霉素,kynomycin,咔喏霉素;kynomycin;YB211;YBD211,复杂性皮肤和皮肤结构感染,Complicated skin and skin structure infections,not available,脂肽类抗生素,友搏药业(九芝堂);香港大学(原研),创新药,化药,多肽,环肽;差异化疾病,脂肽类抗生素,复杂性皮肤和皮肤结构感染(差异化疾病),I期临床,2023/12/14,Active,感染领域;皮肤领域,DR049191,中国(港澳台),phase 1,II期临床,2025/3/7,phase 2,2,TRUE,FALSE,FALSE,[],['香港大学'],1,"['友搏药业(九芝堂)', '香港大学(原研)']",感染领域,"['感染领域', '皮肤领域']",2,感染领域,皮肤领域,,2,1,Infectious Diseases,Infectious Diseases,Dermatology,
咔喏霉素,kynomycin,咔喏霉素;kynomycin;YB211;YBD211,感染,Infect,not available,脂肽类抗生素,友搏药业(九芝堂);香港大学(原研),创新药,化药,多肽,环肽;差异化疾病,脂肽类抗生素,感染,申报临床,2023/7/7,Active,感染领域,DR049191,中国(港澳台),ind,II期临床,2025/3/7,phase 2,2,TRUE,FALSE,FALSE,[],['香港大学'],1,"['友搏药业(九芝堂)', '香港大学(原研)']",感染领域,['感染领域'],1,感染领域,,,2,0,Infectious Diseases,Infectious Diseases,,
177Lu-FAP-2286,177Lu-FAP-2286,177Lu-FAP-2286;3B-201;AAA614;[177Lu]Lu-FAPI-2286,非小细胞肺癌,non-small cell lung cancer,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC);Clovis Oncology(无权益);3B Pharmaceuticals(原研)(无权益),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,非小细胞肺癌,II期临床,2025/8/26,Active,肿瘤领域,DR056891,欧洲,phase 2,II期临床,2025/3/18,phase 2,3,TRUE,FALSE,TRUE,['Novartis'],['3B Pharmaceuticals'],1,"['Novartis(Top20 MNC)', 'Clovis Oncology(无权益)', '3B Pharmaceuticals(原研)(无权益)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
177Lu-FAP-2286,177Lu-FAP-2286,177Lu-FAP-2286;3B-201;AAA614;[177Lu]Lu-FAPI-2286,乳腺癌,breast cancer,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC);Clovis Oncology(无权益);3B Pharmaceuticals(原研)(无权益),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,乳腺癌,II期临床,2025/8/26,Active,肿瘤领域,DR056891,欧洲,phase 2,II期临床,2025/3/18,phase 2,3,TRUE,FALSE,TRUE,['Novartis'],['3B Pharmaceuticals'],1,"['Novartis(Top20 MNC)', 'Clovis Oncology(无权益)', '3B Pharmaceuticals(原研)(无权益)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
177Lu-FAP-2286,177Lu-FAP-2286,177Lu-FAP-2286;3B-201;AAA614;[177Lu]Lu-FAPI-2286,尿路上皮癌,urothelial carcinoma,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC);Clovis Oncology(无权益);3B Pharmaceuticals(原研)(无权益),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,尿路上皮癌(差异化疾病),II期临床,2025/3/18,Active,肿瘤领域,DR056891,欧洲,phase 2,II期临床,2025/3/18,phase 2,3,TRUE,FALSE,TRUE,['Novartis'],['3B Pharmaceuticals'],1,"['Novartis(Top20 MNC)', 'Clovis Oncology(无权益)', '3B Pharmaceuticals(原研)(无权益)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
177Lu-FAP-2286,177Lu-FAP-2286,177Lu-FAP-2286;3B-201;AAA614;[177Lu]Lu-FAPI-2286,胰腺导管癌,pancreatic ductal carcinoma,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC);Clovis Oncology(无权益);3B Pharmaceuticals(原研)(无权益),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,胰腺导管癌,II期临床,2025/8/26,Active,肿瘤领域,DR056891,欧洲,phase 2,II期临床,2025/3/18,phase 2,3,TRUE,FALSE,TRUE,['Novartis'],['3B Pharmaceuticals'],1,"['Novartis(Top20 MNC)', 'Clovis Oncology(无权益)', '3B Pharmaceuticals(原研)(无权益)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
177Lu-FAP-2286,177Lu-FAP-2286,177Lu-FAP-2286;3B-201;AAA614;[177Lu]Lu-FAPI-2286,实体瘤,solid tumors,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC);Clovis Oncology(无权益);3B Pharmaceuticals(原研)(无权益),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,实体瘤,I/II期临床,2021/6/25,Active,肿瘤领域,DR056891,欧洲,phase 2,II期临床,2025/3/18,phase 2,3,TRUE,FALSE,TRUE,['Novartis'],['3B Pharmaceuticals'],1,"['Novartis(Top20 MNC)', 'Clovis Oncology(无权益)', '3B Pharmaceuticals(原研)(无权益)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
177Lu-FAP-2286,177Lu-FAP-2286,177Lu-FAP-2286;3B-201;AAA614;[177Lu]Lu-FAPI-2286,骨转移疼痛,bone metastasis pain,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC);Clovis Oncology(无权益);3B Pharmaceuticals(原研)(无权益),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,骨转移疼痛(差异化疾病),I期临床,2025/5/12,Active,肿瘤领域,DR056891,欧洲,phase 1,II期临床,2025/3/18,phase 2,3,TRUE,FALSE,TRUE,['Novartis'],['3B Pharmaceuticals'],1,"['Novartis(Top20 MNC)', 'Clovis Oncology(无权益)', '3B Pharmaceuticals(原研)(无权益)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,1,Oncology,Oncology,,
TCMCB07,TCMCB07,TCMCB07,恶病质,Cachexia,MC4R,MC4R拮抗剂,Endevica(原研),创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;Potential First-in-Class;瘦素-黑皮素通路,拮抗剂,恶病质(差异化疾病),II期临床,2025/4/17,Active,内分泌及代谢领域,DR034281,美国,phase 2,II期临床,2025/4/17,phase 2,1,TRUE,FALSE,FALSE,[],['Endevica'],1,['Endevica(原研)'],内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,2,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,
TCMCB07,TCMCB07,TCMCB07,癌性恶病质,cancer cachexia,MC4R,MC4R拮抗剂,Endevica(原研),创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;Potential First-in-Class;瘦素-黑皮素通路,拮抗剂,癌性恶病质,II期临床,2025/4/22,Active,肿瘤领域,DR034281,美国,phase 2,II期临床,2025/4/17,phase 2,1,TRUE,FALSE,FALSE,[],['Endevica'],1,['Endevica(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
ALXN2420,ALXN2420,ALXN2420,肢端肥大症,acromegaly,GHR,GHR拮抗剂,Alexion Pharmaceuticals(AstraZeneca)(Top20 MNC)(原研),创新药,化药,多肽,环肽,拮抗剂,肢端肥大症,II期临床,2025/6/25,Active,内分泌及代谢领域;罕见疾病领域,DR081373,美国,phase 2,II期临床,2025/6/25,phase 2,1,TRUE,TRUE,TRUE,['Alexion Pharmaceuticals(AstraZeneca)'],['Alexion Pharmaceuticals(AstraZeneca)'],1,['Alexion Pharmaceuticals(AstraZeneca)(Top20 MNC)(原研)'],内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,2,2,Endocrinology & Metabolism,Endocrinology & Metabolism,,
68Ga-FAP-2286,68Ga-FAP-2286,68Ga-FAP-2286;3B-202,非小细胞肺癌,non-small cell lung cancer,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,非小细胞肺癌(差异化疾病),II期临床,2025/8/26,Active,肿瘤领域,DR033759,欧洲,phase 2,II期临床,2025/8/26,phase 2,3,TRUE,FALSE,TRUE,['Novartis'],['3B Pharmaceuticals'],1,"['Novartis(Top20 MNC)', '3B Pharmaceuticals(原研)', 'Clovis Oncology(无权益)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
68Ga-FAP-2286,68Ga-FAP-2286,68Ga-FAP-2286;3B-202,乳腺癌,breast cancer,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,乳腺癌(差异化疾病),II期临床,2025/8/26,Active,肿瘤领域,DR033759,欧洲,phase 2,II期临床,2025/8/26,phase 2,3,TRUE,FALSE,TRUE,['Novartis'],['3B Pharmaceuticals'],1,"['Novartis(Top20 MNC)', '3B Pharmaceuticals(原研)', 'Clovis Oncology(无权益)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
68Ga-FAP-2286,68Ga-FAP-2286,68Ga-FAP-2286;3B-202,胰腺导管癌,pancreatic ductal carcinoma,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,胰腺导管癌(差异化疾病),II期临床,2025/8/26,Active,肿瘤领域,DR033759,欧洲,phase 2,II期临床,2025/8/26,phase 2,3,TRUE,FALSE,TRUE,['Novartis'],['3B Pharmaceuticals'],1,"['Novartis(Top20 MNC)', '3B Pharmaceuticals(原研)', 'Clovis Oncology(无权益)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
68Ga-FAP-2286,68Ga-FAP-2286,68Ga-FAP-2286;3B-202,实体瘤,solid tumors,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,实体瘤,I/II期临床,2021/6/25,Active,肿瘤领域,DR033759,欧洲,phase 2,II期临床,2025/8/26,phase 2,3,TRUE,FALSE,TRUE,['Novartis'],['3B Pharmaceuticals'],1,"['Novartis(Top20 MNC)', '3B Pharmaceuticals(原研)', 'Clovis Oncology(无权益)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
68Ga-FAP-2286,68Ga-FAP-2286,68Ga-FAP-2286;3B-202,肿瘤,tumor,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,肿瘤,I期临床,2025/8/27,Active,肿瘤领域,DR033759,欧洲,phase 1,II期临床,2025/8/26,phase 2,3,TRUE,FALSE,TRUE,['Novartis'],['3B Pharmaceuticals'],1,"['Novartis(Top20 MNC)', '3B Pharmaceuticals(原研)', 'Clovis Oncology(无权益)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,1,Oncology,Oncology,,
68Ga-FAP-2286,68Ga-FAP-2286,68Ga-FAP-2286;3B-202,肺纤维化,pulmonary fibrosis,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,肺纤维化,I期临床,,Active,呼吸领域,DR033759,欧洲,phase 1,II期临床,2025/8/26,phase 2,3,TRUE,FALSE,TRUE,['Novartis'],['3B Pharmaceuticals'],1,"['Novartis(Top20 MNC)', '3B Pharmaceuticals(原研)', 'Clovis Oncology(无权益)']",呼吸领域,['呼吸领域'],1,呼吸领域,,,2,1,Respiratory,Respiratory,,
68Ga-FAP-2286,68Ga-FAP-2286,68Ga-FAP-2286;3B-202,肝纤维化,liver fibrosis,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,肝纤维化(差异化疾病),I期临床,2022/1/6,Active,消化领域,DR033759,欧洲,phase 1,II期临床,2025/8/26,phase 2,3,TRUE,FALSE,TRUE,['Novartis'],['3B Pharmaceuticals'],1,"['Novartis(Top20 MNC)', '3B Pharmaceuticals(原研)', 'Clovis Oncology(无权益)']",消化领域,['消化领域'],1,消化领域,,,2,1,Digestive System,Digestive System,,
68Ga-FAP-2286,68Ga-FAP-2286,68Ga-FAP-2286;3B-202,PET显像,PET imaging,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,PET显像,I期临床,2020/11/9,Active,诊断试剂领域,DR033759,欧洲,phase 1,II期临床,2025/8/26,phase 2,3,TRUE,FALSE,TRUE,['Novartis'],['3B Pharmaceuticals'],1,"['Novartis(Top20 MNC)', '3B Pharmaceuticals(原研)', 'Clovis Oncology(无权益)']",诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,2,1,Diagnostic Reagents,Diagnostic Reagents,,
LS301,LS301,LS301;LS301-IT,非小细胞肺癌,non-small cell lung cancer,ANXA2,荧光显像剂,Washington University in St. Louis;Integro Theranostics(原研),创新药,化药,多肽,环肽;Potential First-in-Class,荧光显像剂,非小细胞肺癌,II期临床,2025/12/11,Active,肿瘤领域,DR050488,美国,phase 2,II期临床,2025/12/11,phase 2,2,TRUE,FALSE,FALSE,[],['Integro Theranostics'],1,"['Washington University in St. Louis', 'Integro Theranostics(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
LS301,LS301,LS301;LS301-IT,光学成像剂,optical imaging agent,ANXA2,荧光显像剂,Washington University in St. Louis;Integro Theranostics(原研),创新药,化药,多肽,环肽;Potential First-in-Class,荧光显像剂,光学成像剂,II期临床,2025/12/11,Active,诊断试剂领域,DR050488,美国,phase 2,II期临床,2025/12/11,phase 2,2,TRUE,FALSE,FALSE,[],['Integro Theranostics'],1,"['Washington University in St. Louis', 'Integro Theranostics(原研)']",诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,2,2,Diagnostic Reagents,Diagnostic Reagents,,
LS301,LS301,LS301;LS301-IT,原位导管癌,Ductal carcinoma in situ,ANXA2,荧光显像剂,Washington University in St. Louis;Integro Theranostics(原研),创新药,化药,多肽,环肽;Potential First-in-Class,荧光显像剂,原位导管癌,I/II期临床,2023/6/13,Active,肿瘤领域,DR050488,美国,phase 2,II期临床,2025/12/11,phase 2,2,TRUE,FALSE,FALSE,[],['Integro Theranostics'],1,"['Washington University in St. Louis', 'Integro Theranostics(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
LS301,LS301,LS301;LS301-IT,肺癌,lung cancer,ANXA2,荧光显像剂,Washington University in St. Louis;Integro Theranostics(原研),创新药,化药,多肽,环肽;Potential First-in-Class,荧光显像剂,肺癌,I期临床,2024/12/3,Active,肿瘤领域,DR050488,美国,phase 1,II期临床,2025/12/11,phase 2,2,TRUE,FALSE,FALSE,[],['Integro Theranostics'],1,"['Washington University in St. Louis', 'Integro Theranostics(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,1,Oncology,Oncology,,
68Ga-BOT5035,68Ga-BOT5035,68Ga-BOT5035,射血分数保留的心力衰竭,heart failure with preserved ejection fraction,PDGFRβ,anti-PDGFRβ多肽偶联核素;68Ga标记的PET药物,BiOrion(原研);Cortalix,创新药,其他,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;受体酪氨酸激酶;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,射血分数保留的心力衰竭,II期临床,,Active,心脑血管领域,DR047985,欧洲,phase 2,II期临床,,phase 2,2,TRUE,FALSE,FALSE,[],['BiOrion'],1,"['BiOrion(原研)', 'Cortalix']",心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,2,2,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
68Ga-BOT5035,68Ga-BOT5035,68Ga-BOT5035,特发性肺纤维化,idiopathic pulmonary fibrosis,PDGFRβ,anti-PDGFRβ多肽偶联核素;68Ga标记的PET药物,BiOrion(原研);Cortalix,创新药,其他,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;受体酪氨酸激酶;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,特发性肺纤维化,临床前,,Active,呼吸领域;罕见疾病领域,DR047985,欧洲,pre-clinical,II期临床,,phase 2,2,TRUE,TRUE,FALSE,[],['BiOrion'],1,"['BiOrion(原研)', 'Cortalix']",呼吸领域,['呼吸领域'],1,呼吸领域,,,2,-1,Respiratory,Respiratory,,
OTX-CSI,OTX-CSI (cyclosporine A intracanalicular insert),OTX-CSI;OTX-CSI (环孢素);OTX-CSI (cyclosporine A intracanalicular insert),干眼病,dry eye disease,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Ocular Therapeutix(原研),微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,干眼病,II期临床,,Active,眼科领域,DR028223,美国,phase 2,II期临床,,phase 2,1,TRUE,FALSE,FALSE,[],['Ocular Therapeutix'],1,['Ocular Therapeutix(原研)'],眼科领域,['眼科领域'],1,眼科领域,,,2,2,Ophthalmology,Ophthalmology,,
SomaDex,SomaDex,SomaDex,去势抵抗前列腺癌,Castration-resistant prostate cancer,somatostatin,somatostatin类似物,DexTech(原研),创新药,化药,其他,环肽,类似物,去势抵抗前列腺癌,II期临床,,Active,肿瘤领域,DR024975,欧洲,phase 2,II期临床,,phase 2,1,TRUE,FALSE,FALSE,[],['DexTech'],1,['DexTech(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
SomaDex,SomaDex,SomaDex,肢端肥大症,acromegaly,somatostatin,somatostatin类似物,DexTech(原研),创新药,化药,其他,环肽,类似物,肢端肥大症,临床前,,Active,内分泌及代谢领域;罕见疾病领域,DR024975,欧洲,pre-clinical,II期临床,,phase 2,1,TRUE,TRUE,FALSE,[],['DexTech'],1,['DexTech(原研)'],内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,2,-1,Endocrinology & Metabolism,Endocrinology & Metabolism,,
SomaDex,SomaDex,SomaDex,神经内分泌肿瘤,neuroendocrine tumors,somatostatin,somatostatin类似物,DexTech(原研),创新药,化药,其他,环肽,类似物,神经内分泌肿瘤,临床前,,Active,肿瘤领域;罕见疾病领域,DR024975,欧洲,pre-clinical,II期临床,,phase 2,1,TRUE,TRUE,FALSE,[],['DexTech'],1,['DexTech(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,-1,Oncology,Oncology,,
177Lu-satoreotide tetraxetan,177Lu-satoreotide tetraxetan,177Lu-satoreotide tetraxetan;177Lu-OPS201;177Lu-DOTA-JR11;177Lu-IPN01072;SSO110;[177Lu]Lu-SSO110,神经内分泌肿瘤,neuroendocrine tumors,SSTR2,177Lu标记的放射性药物;anti-SSTR2多肽偶联核素,Ariceum Therapeutics;Ipsen(原研)(无权益),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,神经内分泌肿瘤,I/II期临床,2015/10/29,Active,肿瘤领域;罕见疾病领域,DR016814,欧洲,phase 2,I/II期临床,2015/10/29,phase 2,2,TRUE,TRUE,FALSE,[],['Ipsen'],1,"['Ariceum Therapeutics', 'Ipsen(原研)(无权益)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
177Lu-satoreotide tetraxetan,177Lu-satoreotide tetraxetan,177Lu-satoreotide tetraxetan;177Lu-OPS201;177Lu-DOTA-JR11;177Lu-IPN01072;SSO110;[177Lu]Lu-SSO110,脑膜瘤,Meningioma,SSTR2,177Lu标记的放射性药物;anti-SSTR2多肽偶联核素,Ariceum Therapeutics;Ipsen(原研)(无权益),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,脑膜瘤(差异化疾病),I/II期临床,2021/8/9,Active,肿瘤领域,DR016814,欧洲,phase 2,I/II期临床,2015/10/29,phase 2,2,TRUE,FALSE,FALSE,[],['Ipsen'],1,"['Ariceum Therapeutics', 'Ipsen(原研)(无权益)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
177Lu-satoreotide tetraxetan,177Lu-satoreotide tetraxetan,177Lu-satoreotide tetraxetan;177Lu-OPS201;177Lu-DOTA-JR11;177Lu-IPN01072;SSO110;[177Lu]Lu-SSO110,小细胞肺癌,small cell lung cancer,SSTR2,177Lu标记的放射性药物;anti-SSTR2多肽偶联核素,Ariceum Therapeutics;Ipsen(原研)(无权益),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,小细胞肺癌(差异化疾病),I期临床,2023/2/22,Active,肿瘤领域;罕见疾病领域,DR016814,欧洲,phase 1,I/II期临床,2015/10/29,phase 2,2,TRUE,TRUE,FALSE,[],['Ipsen'],1,"['Ariceum Therapeutics', 'Ipsen(原研)(无权益)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,1,Oncology,Oncology,,
lonodelestat,lonodelestat,lonodelestat;POL6014,α1-抗胰蛋白酶缺乏症,α1-antitrypsin deficiency,ELA2,ELA2抑制剂,Polyphor(Spexis)(原研);Santhera Pharmaceuticals(无权益),创新药,化药,多肽,环肽;差异化疾病,抑制剂,α1-抗胰蛋白酶缺乏症,I期临床,,Active,罕见疾病领域;呼吸领域,DR043769,欧洲,phase 1,I/II期临床,2017/6/23,phase 2,2,TRUE,TRUE,FALSE,[],['Polyphor(Spexis)'],1,"['Polyphor(Spexis)(原研)', 'Santhera Pharmaceuticals(无权益)']",呼吸领域,['呼吸领域'],1,呼吸领域,,,2,1,Respiratory,Respiratory,,
lonodelestat,lonodelestat,lonodelestat;POL6014,原发性纤毛运动障碍,primary ciliary dyskinesia,ELA2,ELA2抑制剂,Polyphor(Spexis)(原研);Santhera Pharmaceuticals(无权益),创新药,化药,多肽,环肽;差异化疾病,抑制剂,原发性纤毛运动障碍(差异化疾病),I期临床,,Active,呼吸领域;罕见疾病领域,DR043769,欧洲,phase 1,I/II期临床,2017/6/23,phase 2,2,TRUE,TRUE,FALSE,[],['Polyphor(Spexis)'],1,"['Polyphor(Spexis)(原研)', 'Santhera Pharmaceuticals(无权益)']",呼吸领域,['呼吸领域'],1,呼吸领域,,,2,1,Respiratory,Respiratory,,
67Cu-SARTATE,67Cu-SARTATE,67Cu-SARTATE;67Cu-MeCOSar-Tyr3-octreotate;67Cu-CuSarTATE,神经母细胞瘤,Neuroblastoma,SSTR,anti-SSTR多肽偶联核素;67Cu标记的放射性药物,Clarity Pharmaceuticals(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;中国无申报;Potential First-in-Class,67Cu标记的放射性药物;多肽偶联核素,神经母细胞瘤,I/II期临床,2019/7/17,Active,肿瘤领域;罕见疾病领域,DR062471,澳大利亚,phase 2,I/II期临床,2018/3/1,phase 2,1,TRUE,TRUE,FALSE,[],['Clarity Pharmaceuticals'],1,['Clarity Pharmaceuticals(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
67Cu-SARTATE,67Cu-SARTATE,67Cu-SARTATE;67Cu-MeCOSar-Tyr3-octreotate;67Cu-CuSarTATE,神经内分泌肿瘤,neuroendocrine tumors,SSTR,anti-SSTR多肽偶联核素;67Cu标记的放射性药物,Clarity Pharmaceuticals(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;中国无申报;Potential First-in-Class,67Cu标记的放射性药物;多肽偶联核素,神经内分泌肿瘤,I/II期临床,,Active,肿瘤领域;罕见疾病领域,DR062471,澳大利亚,phase 2,I/II期临床,2018/3/1,phase 2,1,TRUE,TRUE,FALSE,[],['Clarity Pharmaceuticals'],1,['Clarity Pharmaceuticals(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
67Cu-SARTATE,67Cu-SARTATE,67Cu-SARTATE;67Cu-MeCOSar-Tyr3-octreotate;67Cu-CuSarTATE,脑膜瘤,Meningioma,SSTR,anti-SSTR多肽偶联核素;67Cu标记的放射性药物,Clarity Pharmaceuticals(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;中国无申报;Potential First-in-Class,67Cu标记的放射性药物;多肽偶联核素,脑膜瘤,I/II期临床,2018/3/1,Active,肿瘤领域,DR062471,澳大利亚,phase 2,I/II期临床,2018/3/1,phase 2,1,TRUE,FALSE,FALSE,[],['Clarity Pharmaceuticals'],1,['Clarity Pharmaceuticals(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
BT5528,BT5528,BT5528,实体瘤,solid tumors,EphA2,多肽偶联药物,Bicycle Therapeutics(原研),创新药,化药,多肽;偶联药物,环肽;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];受体酪氨酸激酶;Potential First-in-Class;可降解连接子,多肽偶联药物,实体瘤,I/II期临床,2019/11/27,Active,肿瘤领域,DR052083,欧洲,phase 2,I/II期临床,2019/11/27,phase 2,1,TRUE,FALSE,FALSE,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
IDP-121,IDP-121,IDP-121,小细胞肺癌,small cell lung cancer,c-Myc,c-Myc抑制剂,IDP Pharma(原研),创新药,化药,多肽,环肽;差异化疾病;难成药靶点,抑制剂,小细胞肺癌(差异化疾病),I/II期临床,2025/12/18,Active,肿瘤领域;罕见疾病领域,DR053886,欧洲,phase 2,I/II期临床,2021/10/19,phase 2,1,TRUE,TRUE,FALSE,[],['IDP Pharma'],1,['IDP Pharma(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
IDP-121,IDP-121,IDP-121,血液系统肿瘤,hematological tumors,c-Myc,c-Myc抑制剂,IDP Pharma(原研),创新药,化药,多肽,环肽;差异化疾病;难成药靶点,抑制剂,血液系统肿瘤,I/II期临床,2023/10/26,Active,肿瘤领域;血液领域,DR053886,欧洲,phase 2,I/II期临床,2021/10/19,phase 2,1,TRUE,FALSE,FALSE,[],['IDP Pharma'],1,['IDP Pharma(原研)'],肿瘤领域,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,2,2,Oncology,Oncology,Hematology,
IDP-121,IDP-121,IDP-121,慢性淋巴细胞白血病,chronic lymphocytic leukemia,c-Myc,c-Myc抑制剂,IDP Pharma(原研),创新药,化药,多肽,环肽;差异化疾病;难成药靶点,抑制剂,慢性淋巴细胞白血病(差异化疾病),I/II期临床,2021/10/19,Active,肿瘤领域;血液领域;罕见疾病领域,DR053886,欧洲,phase 2,I/II期临床,2021/10/19,phase 2,1,TRUE,TRUE,FALSE,[],['IDP Pharma'],1,['IDP Pharma(原研)'],肿瘤领域,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,2,2,Oncology,Oncology,Hematology,
IDP-121,IDP-121,IDP-121,弥漫性大B细胞淋巴瘤,Diffuse large B-cell lymphoma,c-Myc,c-Myc抑制剂,IDP Pharma(原研),创新药,化药,多肽,环肽;差异化疾病;难成药靶点,抑制剂,弥漫性大B细胞淋巴瘤,I/II期临床,2021/10/19,Active,肿瘤领域;血液领域;罕见疾病领域,DR053886,欧洲,phase 2,I/II期临床,2021/10/19,phase 2,1,TRUE,TRUE,FALSE,[],['IDP Pharma'],1,['IDP Pharma(原研)'],肿瘤领域,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,2,2,Oncology,Oncology,Hematology,
IDP-121,IDP-121,IDP-121,多发性骨髓瘤,multiple myeloma,c-Myc,c-Myc抑制剂,IDP Pharma(原研),创新药,化药,多肽,环肽;差异化疾病;难成药靶点,抑制剂,多发性骨髓瘤(差异化疾病),I/II期临床,2021/10/19,Active,肿瘤领域;血液领域;罕见疾病领域,DR053886,欧洲,phase 2,I/II期临床,2021/10/19,phase 2,1,TRUE,TRUE,FALSE,[],['IDP Pharma'],1,['IDP Pharma(原研)'],肿瘤领域,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,2,2,Oncology,Oncology,Hematology,
IDP-121,IDP-121,IDP-121,B细胞淋巴瘤,B cell lymphoma,c-Myc,c-Myc抑制剂,IDP Pharma(原研),创新药,化药,多肽,环肽;差异化疾病;难成药靶点,抑制剂,B细胞淋巴瘤,I/II期临床,2024/12/30,Active,肿瘤领域;血液领域,DR053886,欧洲,phase 2,I/II期临床,2021/10/19,phase 2,1,TRUE,FALSE,FALSE,[],['IDP Pharma'],1,['IDP Pharma(原研)'],肿瘤领域,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,2,2,Oncology,Oncology,Hematology,
IDP-121,IDP-121,IDP-121,双重打击淋巴瘤,double hit lymphoma,c-Myc,c-Myc抑制剂,IDP Pharma(原研),创新药,化药,多肽,环肽;差异化疾病;难成药靶点,抑制剂,双重打击淋巴瘤(差异化疾病),I/II期临床,,Active,血液领域;肿瘤领域,DR053886,欧洲,phase 2,I/II期临床,2021/10/19,phase 2,1,TRUE,FALSE,FALSE,[],['IDP Pharma'],1,['IDP Pharma(原研)'],肿瘤领域,"['血液领域', '肿瘤领域']",2,血液领域,肿瘤领域,,2,2,Oncology,Hematology,Oncology,
BT7480,BT7480,BT7480,实体瘤,solid tumors,nectin-4;4-1BB,4-1BB激动剂;nectin-4配体,Bicycle Therapeutics(原研),创新药,化药,多肽,环肽;Potential First-in-Class;肿瘤免疫,激动剂;配体,实体瘤,I/II期临床,2021/12/20,Active,肿瘤领域,DR000382,欧洲,phase 2,I/II期临床,2021/12/20,phase 2,1,TRUE,FALSE,FALSE,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
64Cu-FBP8,64Cu-FBP8,64Cu-FBP8;[64Cu]FBP8,PET显像,PET imaging,fibrin,64Cu标记的放射性示踪剂;anti-fibrin多肽偶联核素,Massachusetts General Hospital(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,64Cu标记的放射性示踪剂;多肽偶联核素,PET显像,I/II期临床,2022/4/20,Active,诊断试剂领域,DR054395,美国,phase 2,I/II期临床,2022/4/20,phase 2,1,TRUE,FALSE,FALSE,[],['Massachusetts General Hospital'],1,['Massachusetts General Hospital(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,2,2,Diagnostic Reagents,Diagnostic Reagents,,
64Cu-FBP8,64Cu-FBP8,64Cu-FBP8;[64Cu]FBP8,阿尔茨海默病性痴呆,Alzheimer's disease dementia,fibrin,64Cu标记的放射性示踪剂;anti-fibrin多肽偶联核素,Massachusetts General Hospital(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,64Cu标记的放射性示踪剂;多肽偶联核素,阿尔茨海默病性痴呆,I/II期临床,2022/4/20,Active,神经领域,DR054395,美国,phase 2,I/II期临床,2022/4/20,phase 2,1,TRUE,FALSE,FALSE,[],['Massachusetts General Hospital'],1,['Massachusetts General Hospital(原研)'],神经领域,['神经领域'],1,神经领域,,,2,2,Neurology,Neurology,,
64Cu-FBP8,64Cu-FBP8,64Cu-FBP8;[64Cu]FBP8,血栓(抗凝或抗血小板),Thrombosis (anticoagulant or antiplatelet),fibrin,64Cu标记的放射性示踪剂;anti-fibrin多肽偶联核素,Massachusetts General Hospital(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,64Cu标记的放射性示踪剂;多肽偶联核素,血栓(抗凝或抗血小板),I期临床,2019/2/5,Active,心脑血管领域,DR054395,美国,phase 1,I/II期临床,2022/4/20,phase 2,1,TRUE,FALSE,FALSE,[],['Massachusetts General Hospital'],1,['Massachusetts General Hospital(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,2,1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
177Lu-LNC1010,177Lu-LNC1010,177Lu-LNC1010;177Lu-EB-TATE-01,实体瘤,solid tumors,SSTR2,177Lu标记的放射性药物;anti-SSTR2多肽偶联核素,蓝纳成生物(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,实体瘤,I期临床,,Active,肿瘤领域,DR015637,中国(内地),phase 1,I/II期临床,2022/6/8,phase 2,1,TRUE,FALSE,FALSE,[],['蓝纳成生物'],1,['蓝纳成生物(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,1,Oncology,Oncology,,
177Lu-LNC1010,177Lu-LNC1010,177Lu-LNC1010;177Lu-EB-TATE-01,胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,SSTR2,177Lu标记的放射性药物;anti-SSTR2多肽偶联核素,蓝纳成生物(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,胃肠胰神经内分泌肿瘤(差异化疾病),I期临床,2024/8/28,Active,肿瘤领域;罕见疾病领域,DR015637,中国(内地),phase 1,I/II期临床,2022/6/8,phase 2,1,TRUE,TRUE,FALSE,[],['蓝纳成生物'],1,['蓝纳成生物(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,1,Oncology,Oncology,,
68Ga-FAPI-RGD,68Ga-FAPI-RGD,68Ga-FAPI-RGD;68Ga-FAP-RGD,癌症,cancer,αvβ3;FAP,anti-αvβ3×FAP多肽偶联核素;68Ga标记的PET药物,--,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,癌症,I/II期临床,2022/8/25,Active,肿瘤领域,DR036681,,phase 2,I/II期临床,2022/8/25,phase 2,0,TRUE,FALSE,FALSE,[],[],0,[],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
68Ga-FAPI-RGD,68Ga-FAPI-RGD,68Ga-FAPI-RGD;68Ga-FAP-RGD,PET显像,PET imaging,αvβ3;FAP,anti-αvβ3×FAP多肽偶联核素;68Ga标记的PET药物,--,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,PET显像,I/II期临床,2022/8/25,Active,诊断试剂领域,DR036681,,phase 2,I/II期临床,2022/8/25,phase 2,0,TRUE,FALSE,FALSE,[],[],0,[],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,2,2,Diagnostic Reagents,Diagnostic Reagents,,
68Ga-FAPI-RGD,68Ga-FAPI-RGD,68Ga-FAPI-RGD;68Ga-FAP-RGD,肿瘤,tumor,αvβ3;FAP,anti-αvβ3×FAP多肽偶联核素;68Ga标记的PET药物,--,创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,肿瘤,I期临床,2024/10/15,Active,肿瘤领域,DR036681,,phase 1,I/II期临床,2022/8/25,phase 2,0,TRUE,FALSE,FALSE,[],[],0,[],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,1,Oncology,Oncology,,
90Y-pentixather,90Y-pentixather,90Y-pentixather;[90Y]Y-PentixaTher;[90Y]Y-PTT;PTT101,多发性骨髓瘤,multiple myeloma,CXCR4,90Y标记的放射性药物,Eckert & Ziegler;PentixaPharm(原研);Technische Universität München,创新药,化药,小分子;放射性药物,环肽;治疗用放射性药物;G蛋白偶联受体;Potential First-in-Class,90Y标记的放射性药物,多发性骨髓瘤,I/II期临床,2023/1/26,Active,肿瘤领域;血液领域;罕见疾病领域,DR024649,欧洲,phase 2,I/II期临床,2023/1/26,phase 2,3,TRUE,TRUE,FALSE,[],['PentixaPharm'],1,"['Eckert & Ziegler', 'PentixaPharm(原研)', 'Technische Universität München']",肿瘤领域,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,2,2,Oncology,Oncology,Hematology,
90Y-pentixather,90Y-pentixather,90Y-pentixather;[90Y]Y-PentixaTher;[90Y]Y-PTT;PTT101,原发性中枢神经系统淋巴瘤,primary central nervous system lymphoma,CXCR4,90Y标记的放射性药物,Eckert & Ziegler;PentixaPharm(原研);Technische Universität München,创新药,化药,小分子;放射性药物,环肽;治疗用放射性药物;G蛋白偶联受体;Potential First-in-Class,90Y标记的放射性药物,原发性中枢神经系统淋巴瘤,I/II期临床,2023/11/15,Active,肿瘤领域;血液领域,DR024649,欧洲,phase 2,I/II期临床,2023/1/26,phase 2,3,TRUE,FALSE,FALSE,[],['PentixaPharm'],1,"['Eckert & Ziegler', 'PentixaPharm(原研)', 'Technische Universität München']",肿瘤领域,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,2,2,Oncology,Oncology,Hematology,
90Y-pentixather,90Y-pentixather,90Y-pentixather;[90Y]Y-PentixaTher;[90Y]Y-PTT;PTT101,继发性中枢神经系统淋巴瘤,secondary central nervous system lymphoma,CXCR4,90Y标记的放射性药物,Eckert & Ziegler;PentixaPharm(原研);Technische Universität München,创新药,化药,小分子;放射性药物,环肽;治疗用放射性药物;G蛋白偶联受体;Potential First-in-Class,90Y标记的放射性药物,继发性中枢神经系统淋巴瘤,I/II期临床,2023/11/15,Active,肿瘤领域;血液领域;罕见疾病领域,DR024649,欧洲,phase 2,I/II期临床,2023/1/26,phase 2,3,TRUE,TRUE,FALSE,[],['PentixaPharm'],1,"['Eckert & Ziegler', 'PentixaPharm(原研)', 'Technische Universität München']",肿瘤领域,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,2,2,Oncology,Oncology,Hematology,
90Y-pentixather,90Y-pentixather,90Y-pentixather;[90Y]Y-PentixaTher;[90Y]Y-PTT;PTT101,T细胞非霍奇金淋巴瘤,T-cell non-Hodgkin lymphoma,CXCR4,90Y标记的放射性药物,Eckert & Ziegler;PentixaPharm(原研);Technische Universität München,创新药,化药,小分子;放射性药物,环肽;治疗用放射性药物;G蛋白偶联受体;Potential First-in-Class,90Y标记的放射性药物,T细胞非霍奇金淋巴瘤,I/II期临床,2023/1/26,Active,肿瘤领域;血液领域,DR024649,欧洲,phase 2,I/II期临床,2023/1/26,phase 2,3,TRUE,FALSE,FALSE,[],['PentixaPharm'],1,"['Eckert & Ziegler', 'PentixaPharm(原研)', 'Technische Universität München']",肿瘤领域,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,2,2,Oncology,Oncology,Hematology,
177Lu-DPI-4452,177Lu-DPI-4452,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91,非小细胞肺癌,non-small cell lung cancer,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,非小细胞肺癌(差异化疾病),I/II期临床,2024/3/25,Active,肿瘤领域,DR056890,欧洲,phase 2,I/II期临床,2023/1/31,phase 2,3,TRUE,FALSE,FALSE,[],['3B Pharmaceuticals'],1,"['Debiopharm', 'ITM Isotope', '3B Pharmaceuticals(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
177Lu-DPI-4452,177Lu-DPI-4452,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91,三阴性乳腺癌,triple negative breast cancer,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,三阴性乳腺癌(差异化疾病),I/II期临床,2024/3/25,Active,肿瘤领域,DR056890,欧洲,phase 2,I/II期临床,2023/1/31,phase 2,3,TRUE,FALSE,FALSE,[],['3B Pharmaceuticals'],1,"['Debiopharm', 'ITM Isotope', '3B Pharmaceuticals(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
177Lu-DPI-4452,177Lu-DPI-4452,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91,头颈癌,Head and neck cancer,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,头颈癌(差异化疾病),I/II期临床,2024/3/25,Active,肿瘤领域,DR056890,欧洲,phase 2,I/II期临床,2023/1/31,phase 2,3,TRUE,FALSE,FALSE,[],['3B Pharmaceuticals'],1,"['Debiopharm', 'ITM Isotope', '3B Pharmaceuticals(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
177Lu-DPI-4452,177Lu-DPI-4452,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91,尿路上皮癌,urothelial carcinoma,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,尿路上皮癌(差异化疾病),I/II期临床,2024/3/25,Active,肿瘤领域,DR056890,欧洲,phase 2,I/II期临床,2023/1/31,phase 2,3,TRUE,FALSE,FALSE,[],['3B Pharmaceuticals'],1,"['Debiopharm', 'ITM Isotope', '3B Pharmaceuticals(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
177Lu-DPI-4452,177Lu-DPI-4452,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91,肾病,kidney disease,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,肾病(差异化疾病),I/II期临床,2024/3/25,Active,泌尿生殖领域,DR056890,欧洲,phase 2,I/II期临床,2023/1/31,phase 2,3,TRUE,FALSE,FALSE,[],['3B Pharmaceuticals'],1,"['Debiopharm', 'ITM Isotope', '3B Pharmaceuticals(原研)']",泌尿生殖领域,['泌尿生殖领域'],1,泌尿生殖领域,,,2,2,Genitourinary,Genitourinary,,
177Lu-DPI-4452,177Lu-DPI-4452,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91,结直肠癌,colorectal cancer,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,结直肠癌(差异化疾病),I/II期临床,2023/1/31,Active,肿瘤领域,DR056890,欧洲,phase 2,I/II期临床,2023/1/31,phase 2,3,TRUE,FALSE,FALSE,[],['3B Pharmaceuticals'],1,"['Debiopharm', 'ITM Isotope', '3B Pharmaceuticals(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
177Lu-DPI-4452,177Lu-DPI-4452,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91,胰腺导管癌,pancreatic ductal carcinoma,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,胰腺导管癌(差异化疾病),I/II期临床,2023/1/31,Active,肿瘤领域,DR056890,欧洲,phase 2,I/II期临床,2023/1/31,phase 2,3,TRUE,FALSE,FALSE,[],['3B Pharmaceuticals'],1,"['Debiopharm', 'ITM Isotope', '3B Pharmaceuticals(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
177Lu-DPI-4452,177Lu-DPI-4452,177Lu-DPI-4452;Debio 0228;[177Lu]Lu-DPI-4452;ITM-91,肾透明细胞癌,clear cell renal cell carcinoma,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,肾透明细胞癌,I/II期临床,2023/1/31,Active,肿瘤领域,DR056890,欧洲,phase 2,I/II期临床,2023/1/31,phase 2,3,TRUE,FALSE,FALSE,[],['3B Pharmaceuticals'],1,"['Debiopharm', 'ITM Isotope', '3B Pharmaceuticals(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
68Ga-DPI-4452,68Ga-DPI-4452,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,非小细胞肺癌,non-small cell lung cancer,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,非小细胞肺癌(差异化疾病),I/II期临床,2024/3/25,Active,肿瘤领域,DR014717,欧洲,phase 2,I/II期临床,2023/1/31,phase 2,3,TRUE,FALSE,FALSE,[],['3B Pharmaceuticals'],1,"['Debiopharm', 'ITM Isotope', '3B Pharmaceuticals(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
68Ga-DPI-4452,68Ga-DPI-4452,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,三阴性乳腺癌,triple negative breast cancer,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,三阴性乳腺癌(差异化疾病),I/II期临床,2024/3/25,Active,肿瘤领域,DR014717,欧洲,phase 2,I/II期临床,2023/1/31,phase 2,3,TRUE,FALSE,FALSE,[],['3B Pharmaceuticals'],1,"['Debiopharm', 'ITM Isotope', '3B Pharmaceuticals(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
68Ga-DPI-4452,68Ga-DPI-4452,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,头颈癌,Head and neck cancer,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,头颈癌(差异化疾病),I/II期临床,2024/3/25,Active,肿瘤领域,DR014717,欧洲,phase 2,I/II期临床,2023/1/31,phase 2,3,TRUE,FALSE,FALSE,[],['3B Pharmaceuticals'],1,"['Debiopharm', 'ITM Isotope', '3B Pharmaceuticals(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
68Ga-DPI-4452,68Ga-DPI-4452,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,尿路上皮癌,urothelial carcinoma,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,尿路上皮癌(差异化疾病),I/II期临床,2024/3/25,Active,肿瘤领域,DR014717,欧洲,phase 2,I/II期临床,2023/1/31,phase 2,3,TRUE,FALSE,FALSE,[],['3B Pharmaceuticals'],1,"['Debiopharm', 'ITM Isotope', '3B Pharmaceuticals(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
68Ga-DPI-4452,68Ga-DPI-4452,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,肾病,kidney disease,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,肾病(差异化疾病),I/II期临床,2024/3/25,Active,泌尿生殖领域,DR014717,欧洲,phase 2,I/II期临床,2023/1/31,phase 2,3,TRUE,FALSE,FALSE,[],['3B Pharmaceuticals'],1,"['Debiopharm', 'ITM Isotope', '3B Pharmaceuticals(原研)']",泌尿生殖领域,['泌尿生殖领域'],1,泌尿生殖领域,,,2,2,Genitourinary,Genitourinary,,
68Ga-DPI-4452,68Ga-DPI-4452,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,PET显像,PET imaging,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,PET显像,I/II期临床,,Active,诊断试剂领域,DR014717,欧洲,phase 2,I/II期临床,2023/1/31,phase 2,3,TRUE,FALSE,FALSE,[],['3B Pharmaceuticals'],1,"['Debiopharm', 'ITM Isotope', '3B Pharmaceuticals(原研)']",诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,2,2,Diagnostic Reagents,Diagnostic Reagents,,
68Ga-DPI-4452,68Ga-DPI-4452,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,结直肠癌,colorectal cancer,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,结直肠癌(差异化疾病),I/II期临床,2023/1/31,Active,肿瘤领域,DR014717,欧洲,phase 2,I/II期临床,2023/1/31,phase 2,3,TRUE,FALSE,FALSE,[],['3B Pharmaceuticals'],1,"['Debiopharm', 'ITM Isotope', '3B Pharmaceuticals(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
68Ga-DPI-4452,68Ga-DPI-4452,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,胰腺导管癌,pancreatic ductal carcinoma,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,胰腺导管癌(差异化疾病),I/II期临床,2023/1/31,Active,肿瘤领域,DR014717,欧洲,phase 2,I/II期临床,2023/1/31,phase 2,3,TRUE,FALSE,FALSE,[],['3B Pharmaceuticals'],1,"['Debiopharm', 'ITM Isotope', '3B Pharmaceuticals(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
68Ga-DPI-4452,68Ga-DPI-4452,68Ga-DPI-4452;[68Ga]Ga-DPI-4452;Debio 0328;ITM-94D;ITM-94,肾透明细胞癌,clear cell renal cell carcinoma,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,Debiopharm;ITM Isotope;3B Pharmaceuticals(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,肾透明细胞癌,I/II期临床,2023/1/31,Active,肿瘤领域,DR014717,欧洲,phase 2,I/II期临床,2023/1/31,phase 2,3,TRUE,FALSE,FALSE,[],['3B Pharmaceuticals'],1,"['Debiopharm', 'ITM Isotope', '3B Pharmaceuticals(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
FOG-001,FOG-001,FOG-001,实体瘤,solid tumors,β-cat;TCF4,β-cat×TCF4蛋白蛋白相互作用抑制剂,Parabilis Medicines(原研),创新药,化药,多肽,环肽;Potential First-in-Class;Wnt信号通路,蛋白蛋白相互作用抑制剂,实体瘤,I/II期临床,2023/6/26,Active,肿瘤领域,DR033337,美国,phase 2,I/II期临床,2023/6/26,phase 2,1,TRUE,FALSE,FALSE,[],['Parabilis Medicines'],1,['Parabilis Medicines(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
FOG-001,FOG-001,FOG-001,非小细胞肺癌,non-small cell lung cancer,β-cat;TCF4,β-cat×TCF4蛋白蛋白相互作用抑制剂,Parabilis Medicines(原研),创新药,化药,多肽,环肽;Potential First-in-Class;Wnt信号通路,蛋白蛋白相互作用抑制剂,非小细胞肺癌,I/II期临床,,Active,肿瘤领域,DR033337,美国,phase 2,I/II期临床,2023/6/26,phase 2,1,TRUE,FALSE,FALSE,[],['Parabilis Medicines'],1,['Parabilis Medicines(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
FOG-001,FOG-001,FOG-001,胃癌,stomach cancer,β-cat;TCF4,β-cat×TCF4蛋白蛋白相互作用抑制剂,Parabilis Medicines(原研),创新药,化药,多肽,环肽;Potential First-in-Class;Wnt信号通路,蛋白蛋白相互作用抑制剂,胃癌,I/II期临床,,Active,肿瘤领域,DR033337,美国,phase 2,I/II期临床,2023/6/26,phase 2,1,TRUE,FALSE,FALSE,[],['Parabilis Medicines'],1,['Parabilis Medicines(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
FOG-001,FOG-001,FOG-001,结直肠癌,colorectal cancer,β-cat;TCF4,β-cat×TCF4蛋白蛋白相互作用抑制剂,Parabilis Medicines(原研),创新药,化药,多肽,环肽;Potential First-in-Class;Wnt信号通路,蛋白蛋白相互作用抑制剂,结直肠癌,I/II期临床,,Active,肿瘤领域,DR033337,美国,phase 2,I/II期临床,2023/6/26,phase 2,1,TRUE,FALSE,FALSE,[],['Parabilis Medicines'],1,['Parabilis Medicines(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
FOG-001,FOG-001,FOG-001,胃食管交界处癌,gastroesophageal junction cancer,β-cat;TCF4,β-cat×TCF4蛋白蛋白相互作用抑制剂,Parabilis Medicines(原研),创新药,化药,多肽,环肽;Potential First-in-Class;Wnt信号通路,蛋白蛋白相互作用抑制剂,胃食管交界处癌,I/II期临床,,Active,肿瘤领域,DR033337,美国,phase 2,I/II期临床,2023/6/26,phase 2,1,TRUE,FALSE,FALSE,[],['Parabilis Medicines'],1,['Parabilis Medicines(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
FOG-001,FOG-001,FOG-001,硬纤维瘤,desmoid tumor,β-cat;TCF4,β-cat×TCF4蛋白蛋白相互作用抑制剂,Parabilis Medicines(原研),创新药,化药,多肽,环肽;Potential First-in-Class;Wnt信号通路,蛋白蛋白相互作用抑制剂,硬纤维瘤,I/II期临床,,Active,肿瘤领域;罕见疾病领域,DR033337,美国,phase 2,I/II期临床,2023/6/26,phase 2,1,TRUE,TRUE,FALSE,[],['Parabilis Medicines'],1,['Parabilis Medicines(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
177Lu-pentixather,177Lu-pentixather,177Lu-pentixather;[177Lu]pentixather;(177)Lu-pentixather,急性淋巴细胞白血病,acute lymphoblastic leukemia,CXCR4,177Lu标记的放射性药物,Scintomics(原研),创新药,化药,小分子;放射性药物,环肽;差异化疾病;治疗用放射性药物;G蛋白偶联受体;Potential First-in-Class,177Lu标记的放射性药物,急性淋巴细胞白血病(差异化疾病),I/II期临床,2024/11/21,Active,肿瘤领域;血液领域;罕见疾病领域,DR007291,欧洲,phase 2,I/II期临床,2024/4/10,phase 2,1,TRUE,TRUE,FALSE,[],['Scintomics'],1,['Scintomics(原研)'],肿瘤领域,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,2,2,Oncology,Oncology,Hematology,
177Lu-pentixather,177Lu-pentixather,177Lu-pentixather;[177Lu]pentixather;(177)Lu-pentixather,急性髓系白血病,acute myeloid leukemia,CXCR4,177Lu标记的放射性药物,Scintomics(原研),创新药,化药,小分子;放射性药物,环肽;差异化疾病;治疗用放射性药物;G蛋白偶联受体;Potential First-in-Class,177Lu标记的放射性药物,急性髓系白血病(差异化疾病),I/II期临床,2024/11/21,Active,肿瘤领域;血液领域;罕见疾病领域,DR007291,欧洲,phase 2,I/II期临床,2024/4/10,phase 2,1,TRUE,TRUE,FALSE,[],['Scintomics'],1,['Scintomics(原研)'],肿瘤领域,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,2,2,Oncology,Oncology,Hematology,
177Lu-pentixather,177Lu-pentixather,177Lu-pentixather;[177Lu]pentixather;(177)Lu-pentixather,急性白血病,acute leukemia,CXCR4,177Lu标记的放射性药物,Scintomics(原研),创新药,化药,小分子;放射性药物,环肽;差异化疾病;治疗用放射性药物;G蛋白偶联受体;Potential First-in-Class,177Lu标记的放射性药物,急性白血病,I/II期临床,2024/4/10,Active,肿瘤领域;血液领域,DR007291,欧洲,phase 2,I/II期临床,2024/4/10,phase 2,1,TRUE,FALSE,FALSE,[],['Scintomics'],1,['Scintomics(原研)'],肿瘤领域,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,2,2,Oncology,Oncology,Hematology,
177Lu-pentixather,177Lu-pentixather,177Lu-pentixather;[177Lu]pentixather;(177)Lu-pentixather,多发性骨髓瘤,multiple myeloma,CXCR4,177Lu标记的放射性药物,Scintomics(原研),创新药,化药,小分子;放射性药物,环肽;差异化疾病;治疗用放射性药物;G蛋白偶联受体;Potential First-in-Class,177Lu标记的放射性药物,多发性骨髓瘤(差异化疾病),I期临床,,Active,肿瘤领域;血液领域;罕见疾病领域,DR007291,欧洲,phase 1,I/II期临床,2024/4/10,phase 2,1,TRUE,TRUE,FALSE,[],['Scintomics'],1,['Scintomics(原研)'],肿瘤领域,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,2,1,Oncology,Oncology,Hematology,
61Cu-NODAGA-LM3,61Cu-NODAGA-LM3,61Cu-NODAGA-LM3,PET显像,PET imaging,SSTR2,61Cu标记的PET药物;anti-SSTR2多肽偶联核素,University Hospital of Basel(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,61Cu标记的PET药物;多肽偶联核素,PET显像,I/II期临床,2024/6/12,Active,诊断试剂领域,DR067671,欧洲,phase 2,I/II期临床,2024/6/12,phase 2,1,TRUE,FALSE,FALSE,[],['University Hospital of Basel'],1,['University Hospital of Basel(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,2,2,Diagnostic Reagents,Diagnostic Reagents,,
61Cu-NODAGA-LM3,61Cu-NODAGA-LM3,61Cu-NODAGA-LM3,胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,SSTR2,61Cu标记的PET药物;anti-SSTR2多肽偶联核素,University Hospital of Basel(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,61Cu标记的PET药物;多肽偶联核素,胃肠胰神经内分泌肿瘤,I/II期临床,2024/6/12,Active,肿瘤领域;罕见疾病领域,DR067671,欧洲,phase 2,I/II期临床,2024/6/12,phase 2,1,TRUE,TRUE,FALSE,[],['University Hospital of Basel'],1,['University Hospital of Basel(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
[18F]-FET-βAG-TOCA,[18F]-FET-βAG-TOCA,[18F]-FET-βAG-TOCA,PET显像,PET imaging,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,Imperial College London(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,18F标记的PET药物;多肽偶联核素,PET显像,I/II期临床,2024/6/13,Active,诊断试剂领域,DR067736,欧洲,phase 2,I/II期临床,2024/6/13,phase 2,1,TRUE,FALSE,FALSE,[],['Imperial College London'],1,['Imperial College London(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,2,2,Diagnostic Reagents,Diagnostic Reagents,,
[18F]-FET-βAG-TOCA,[18F]-FET-βAG-TOCA,[18F]-FET-βAG-TOCA,神经内分泌肿瘤,neuroendocrine tumors,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,Imperial College London(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,18F标记的PET药物;多肽偶联核素,神经内分泌肿瘤,I/II期临床,2024/6/13,Active,肿瘤领域;罕见疾病领域,DR067736,欧洲,phase 2,I/II期临床,2024/6/13,phase 2,1,TRUE,TRUE,FALSE,[],['Imperial College London'],1,['Imperial College London(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
[18F]AlF-NOTA-PCP2,[18F]AlF-NOTA-PCP2,[18F]AlF-NOTA-PCP2,肿瘤,tumor,PDL1,18F标记的PET药物,山东省肿瘤医院(原研),创新药,化药,放射性药物;其他,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class;肿瘤免疫,18F标记的PET药物,肿瘤,I/II期临床,,Active,肿瘤领域,DR071215,中国(内地),phase 2,I/II期临床,2024/11/15,phase 2,1,TRUE,FALSE,FALSE,[],['山东省肿瘤医院'],1,['山东省肿瘤医院(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
[18F]AlF-NOTA-PCP2,[18F]AlF-NOTA-PCP2,[18F]AlF-NOTA-PCP2,非小细胞肺癌,non-small cell lung cancer,PDL1,18F标记的PET药物,山东省肿瘤医院(原研),创新药,化药,放射性药物;其他,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class;肿瘤免疫,18F标记的PET药物,非小细胞肺癌(差异化疾病),I/II期临床,2024/11/15,Active,肿瘤领域,DR071215,中国(内地),phase 2,I/II期临床,2024/11/15,phase 2,1,TRUE,FALSE,FALSE,[],['山东省肿瘤医院'],1,['山东省肿瘤医院(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
[18F]AlF-NOTA-PCP2,[18F]AlF-NOTA-PCP2,[18F]AlF-NOTA-PCP2,食管癌,Esophageal cancer,PDL1,18F标记的PET药物,山东省肿瘤医院(原研),创新药,化药,放射性药物;其他,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class;肿瘤免疫,18F标记的PET药物,食管癌(差异化疾病),I/II期临床,2024/11/15,Active,肿瘤领域,DR071215,中国(内地),phase 2,I/II期临床,2024/11/15,phase 2,1,TRUE,FALSE,FALSE,[],['山东省肿瘤医院'],1,['山东省肿瘤医院(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
[18F]AlF-NOTA-PCP2,[18F]AlF-NOTA-PCP2,[18F]AlF-NOTA-PCP2,胶质母细胞瘤,glioblastoma,PDL1,18F标记的PET药物,山东省肿瘤医院(原研),创新药,化药,放射性药物;其他,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class;肿瘤免疫,18F标记的PET药物,胶质母细胞瘤(差异化疾病),I/II期临床,2024/11/15,Active,肿瘤领域;罕见疾病领域,DR071215,中国(内地),phase 2,I/II期临床,2024/11/15,phase 2,1,TRUE,TRUE,FALSE,[],['山东省肿瘤医院'],1,['山东省肿瘤医院(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
[18F]AlF-NOTA-PCP2,[18F]AlF-NOTA-PCP2,[18F]AlF-NOTA-PCP2,PET显像,PET imaging,PDL1,18F标记的PET药物,山东省肿瘤医院(原研),创新药,化药,放射性药物;其他,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class;肿瘤免疫,18F标记的PET药物,PET显像,I/II期临床,2024/11/15,Active,诊断试剂领域,DR071215,中国(内地),phase 2,I/II期临床,2024/11/15,phase 2,1,TRUE,FALSE,FALSE,[],['山东省肿瘤医院'],1,['山东省肿瘤医院(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,2,2,Diagnostic Reagents,Diagnostic Reagents,,
[18F]AlF-NOTA-PCP2,[18F]AlF-NOTA-PCP2,[18F]AlF-NOTA-PCP2,头颈部鳞状细胞癌,Head and neck squamous cell carcinoma,PDL1,18F标记的PET药物,山东省肿瘤医院(原研),创新药,化药,放射性药物;其他,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class;肿瘤免疫,18F标记的PET药物,头颈部鳞状细胞癌(差异化疾病),I/II期临床,2024/11/15,Active,肿瘤领域,DR071215,中国(内地),phase 2,I/II期临床,2024/11/15,phase 2,1,TRUE,FALSE,FALSE,[],['山东省肿瘤医院'],1,['山东省肿瘤医院(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
[203Pb]Pb-PSV359,[203Pb]Pb-PSV359,[203Pb]Pb-PSV359,实体瘤,solid tumors,FAP,203Pb标记的放射性示踪剂;anti-FAP多肽偶联核素,Perspective Therapeutics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,203Pb标记的放射性示踪剂;多肽偶联核素,实体瘤,I/II期临床,2024/11/29,Active,肿瘤领域,DR071474,美国,phase 2,I/II期临床,2024/11/29,phase 2,1,TRUE,FALSE,FALSE,[],['Perspective Therapeutics'],1,['Perspective Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
[203Pb]Pb-PSV359,[203Pb]Pb-PSV359,[203Pb]Pb-PSV359,胃癌,stomach cancer,FAP,203Pb标记的放射性示踪剂;anti-FAP多肽偶联核素,Perspective Therapeutics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,203Pb标记的放射性示踪剂;多肽偶联核素,胃癌,I/II期临床,2024/11/29,Active,肿瘤领域,DR071474,美国,phase 2,I/II期临床,2024/11/29,phase 2,1,TRUE,FALSE,FALSE,[],['Perspective Therapeutics'],1,['Perspective Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
[203Pb]Pb-PSV359,[203Pb]Pb-PSV359,[203Pb]Pb-PSV359,食管癌,Esophageal cancer,FAP,203Pb标记的放射性示踪剂;anti-FAP多肽偶联核素,Perspective Therapeutics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,203Pb标记的放射性示踪剂;多肽偶联核素,食管癌,I/II期临床,2024/11/29,Active,肿瘤领域,DR071474,美国,phase 2,I/II期临床,2024/11/29,phase 2,1,TRUE,FALSE,FALSE,[],['Perspective Therapeutics'],1,['Perspective Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
[203Pb]Pb-PSV359,[203Pb]Pb-PSV359,[203Pb]Pb-PSV359,头颈癌,Head and neck cancer,FAP,203Pb标记的放射性示踪剂;anti-FAP多肽偶联核素,Perspective Therapeutics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,203Pb标记的放射性示踪剂;多肽偶联核素,头颈癌,I/II期临床,2024/11/29,Active,肿瘤领域,DR071474,美国,phase 2,I/II期临床,2024/11/29,phase 2,1,TRUE,FALSE,FALSE,[],['Perspective Therapeutics'],1,['Perspective Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
[203Pb]Pb-PSV359,[203Pb]Pb-PSV359,[203Pb]Pb-PSV359,卵巢癌,ovarian cancer,FAP,203Pb标记的放射性示踪剂;anti-FAP多肽偶联核素,Perspective Therapeutics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,203Pb标记的放射性示踪剂;多肽偶联核素,卵巢癌,I/II期临床,2024/11/29,Active,肿瘤领域;罕见疾病领域,DR071474,美国,phase 2,I/II期临床,2024/11/29,phase 2,1,TRUE,TRUE,FALSE,[],['Perspective Therapeutics'],1,['Perspective Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
[203Pb]Pb-PSV359,[203Pb]Pb-PSV359,[203Pb]Pb-PSV359,SPECT显像,SPECT imaging,FAP,203Pb标记的放射性示踪剂;anti-FAP多肽偶联核素,Perspective Therapeutics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,203Pb标记的放射性示踪剂;多肽偶联核素,SPECT显像,I/II期临床,,Active,诊断试剂领域,DR071474,美国,phase 2,I/II期临床,2024/11/29,phase 2,1,TRUE,FALSE,FALSE,[],['Perspective Therapeutics'],1,['Perspective Therapeutics(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,2,2,Diagnostic Reagents,Diagnostic Reagents,,
[203Pb]Pb-PSV359,[203Pb]Pb-PSV359,[203Pb]Pb-PSV359,结直肠癌,colorectal cancer,FAP,203Pb标记的放射性示踪剂;anti-FAP多肽偶联核素,Perspective Therapeutics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,203Pb标记的放射性示踪剂;多肽偶联核素,结直肠癌,I/II期临床,2024/11/29,Active,肿瘤领域,DR071474,美国,phase 2,I/II期临床,2024/11/29,phase 2,1,TRUE,FALSE,FALSE,[],['Perspective Therapeutics'],1,['Perspective Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
[203Pb]Pb-PSV359,[203Pb]Pb-PSV359,[203Pb]Pb-PSV359,胰腺导管癌,pancreatic ductal carcinoma,FAP,203Pb标记的放射性示踪剂;anti-FAP多肽偶联核素,Perspective Therapeutics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,203Pb标记的放射性示踪剂;多肽偶联核素,胰腺导管癌,I/II期临床,2024/11/29,Active,肿瘤领域,DR071474,美国,phase 2,I/II期临床,2024/11/29,phase 2,1,TRUE,FALSE,FALSE,[],['Perspective Therapeutics'],1,['Perspective Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
[212Pb]Pb-PSV359,[212Pb]Pb-PSV359,[212Pb]Pb-PSV359,实体瘤,solid tumors,FAP,212Pb标记的放射性药物;anti-FAP多肽偶联核素,Perspective Therapeutics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Potential First-in-Class,212Pb标记的放射性药物;多肽偶联核素,实体瘤,I/II期临床,2024/11/29,Active,肿瘤领域,DR071475,美国,phase 2,I/II期临床,2024/11/29,phase 2,1,TRUE,FALSE,FALSE,[],['Perspective Therapeutics'],1,['Perspective Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
[212Pb]Pb-PSV359,[212Pb]Pb-PSV359,[212Pb]Pb-PSV359,胃癌,stomach cancer,FAP,212Pb标记的放射性药物;anti-FAP多肽偶联核素,Perspective Therapeutics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Potential First-in-Class,212Pb标记的放射性药物;多肽偶联核素,胃癌,I/II期临床,2024/11/29,Active,肿瘤领域,DR071475,美国,phase 2,I/II期临床,2024/11/29,phase 2,1,TRUE,FALSE,FALSE,[],['Perspective Therapeutics'],1,['Perspective Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
[212Pb]Pb-PSV359,[212Pb]Pb-PSV359,[212Pb]Pb-PSV359,食管癌,Esophageal cancer,FAP,212Pb标记的放射性药物;anti-FAP多肽偶联核素,Perspective Therapeutics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Potential First-in-Class,212Pb标记的放射性药物;多肽偶联核素,食管癌,I/II期临床,2024/11/29,Active,肿瘤领域,DR071475,美国,phase 2,I/II期临床,2024/11/29,phase 2,1,TRUE,FALSE,FALSE,[],['Perspective Therapeutics'],1,['Perspective Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
[212Pb]Pb-PSV359,[212Pb]Pb-PSV359,[212Pb]Pb-PSV359,头颈癌,Head and neck cancer,FAP,212Pb标记的放射性药物;anti-FAP多肽偶联核素,Perspective Therapeutics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Potential First-in-Class,212Pb标记的放射性药物;多肽偶联核素,头颈癌,I/II期临床,2024/11/29,Active,肿瘤领域,DR071475,美国,phase 2,I/II期临床,2024/11/29,phase 2,1,TRUE,FALSE,FALSE,[],['Perspective Therapeutics'],1,['Perspective Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
[212Pb]Pb-PSV359,[212Pb]Pb-PSV359,[212Pb]Pb-PSV359,卵巢癌,ovarian cancer,FAP,212Pb标记的放射性药物;anti-FAP多肽偶联核素,Perspective Therapeutics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Potential First-in-Class,212Pb标记的放射性药物;多肽偶联核素,卵巢癌,I/II期临床,2024/11/29,Active,肿瘤领域;罕见疾病领域,DR071475,美国,phase 2,I/II期临床,2024/11/29,phase 2,1,TRUE,TRUE,FALSE,[],['Perspective Therapeutics'],1,['Perspective Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
[212Pb]Pb-PSV359,[212Pb]Pb-PSV359,[212Pb]Pb-PSV359,结直肠癌,colorectal cancer,FAP,212Pb标记的放射性药物;anti-FAP多肽偶联核素,Perspective Therapeutics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Potential First-in-Class,212Pb标记的放射性药物;多肽偶联核素,结直肠癌,I/II期临床,2024/11/29,Active,肿瘤领域,DR071475,美国,phase 2,I/II期临床,2024/11/29,phase 2,1,TRUE,FALSE,FALSE,[],['Perspective Therapeutics'],1,['Perspective Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
[212Pb]Pb-PSV359,[212Pb]Pb-PSV359,[212Pb]Pb-PSV359,胰腺导管癌,pancreatic ductal carcinoma,FAP,212Pb标记的放射性药物;anti-FAP多肽偶联核素,Perspective Therapeutics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Potential First-in-Class,212Pb标记的放射性药物;多肽偶联核素,胰腺导管癌,I/II期临床,2024/11/29,Active,肿瘤领域,DR071475,美国,phase 2,I/II期临床,2024/11/29,phase 2,1,TRUE,FALSE,FALSE,[],['Perspective Therapeutics'],1,['Perspective Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
225Ac-SSO110,225Ac-SSO110,225Ac-SSO110;225Ac-satoreotide,小细胞肺癌,small cell lung cancer,SSTR2,225Ac标记的放射性药物;anti-SSTR2多肽偶联核素,Ariceum Therapeutics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;225Ac标记的放射性药物,小细胞肺癌,I/II期临床,2025/4/22,Active,肿瘤领域;罕见疾病领域,DR068742,欧洲,phase 2,I/II期临床,2025/4/22,phase 2,1,TRUE,TRUE,FALSE,[],['Ariceum Therapeutics'],1,['Ariceum Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
225Ac-SSO110,225Ac-SSO110,225Ac-SSO110;225Ac-satoreotide,Merkel细胞瘤,Merkel cell tumor,SSTR2,225Ac标记的放射性药物;anti-SSTR2多肽偶联核素,Ariceum Therapeutics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;225Ac标记的放射性药物,Merkel细胞瘤(差异化疾病),I/II期临床,2025/4/22,Active,肿瘤领域;罕见疾病领域,DR068742,欧洲,phase 2,I/II期临床,2025/4/22,phase 2,1,TRUE,TRUE,FALSE,[],['Ariceum Therapeutics'],1,['Ariceum Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
225Ac-SSO110,225Ac-SSO110,225Ac-SSO110;225Ac-satoreotide,肿瘤,tumor,SSTR2,225Ac标记的放射性药物;anti-SSTR2多肽偶联核素,Ariceum Therapeutics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;225Ac标记的放射性药物,肿瘤,临床前,,Active,肿瘤领域,DR068742,欧洲,pre-clinical,I/II期临床,2025/4/22,phase 2,1,TRUE,FALSE,FALSE,[],['Ariceum Therapeutics'],1,['Ariceum Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,-1,Oncology,Oncology,,
177Lu-DOTA-EB-TATE,177Lu-DOTA-EB-TATE,177Lu-DOTA-EB-TATE;EBTATE;177Lu-EBTATE,许特尔细胞瘤,Hütter cell tumor,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,National Institutes of Health(原研);Molecular Targeting Technologies,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,许特尔细胞瘤(差异化疾病),I/II期临床,2025/5/28,Active,肿瘤领域,DR062226,美国,phase 2,I/II期临床,2025/5/28,phase 2,2,TRUE,FALSE,FALSE,[],['National Institutes of Health'],1,"['National Institutes of Health(原研)', 'Molecular Targeting Technologies']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
177Lu-DOTA-EB-TATE,177Lu-DOTA-EB-TATE,177Lu-DOTA-EB-TATE;EBTATE;177Lu-EBTATE,神经内分泌肿瘤,neuroendocrine tumors,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,National Institutes of Health(原研);Molecular Targeting Technologies,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,神经内分泌肿瘤,I期临床,2017/10/12,Active,肿瘤领域;罕见疾病领域,DR062226,美国,phase 1,I/II期临床,2025/5/28,phase 2,2,TRUE,TRUE,FALSE,[],['National Institutes of Health'],1,"['National Institutes of Health(原研)', 'Molecular Targeting Technologies']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,1,Oncology,Oncology,,
177Lu-DOTA-EB-TATE,177Lu-DOTA-EB-TATE,177Lu-DOTA-EB-TATE;EBTATE;177Lu-EBTATE,鼻咽癌,Nasopharyngeal cancer,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,National Institutes of Health(原研);Molecular Targeting Technologies,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,鼻咽癌,申报临床,,Active,肿瘤领域;罕见疾病领域,DR062226,美国,ind,I/II期临床,2025/5/28,phase 2,2,TRUE,TRUE,FALSE,[],['National Institutes of Health'],1,"['National Institutes of Health(原研)', 'Molecular Targeting Technologies']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,0,Oncology,Oncology,,
177Lu-DOTA-EB-TATE,177Lu-DOTA-EB-TATE,177Lu-DOTA-EB-TATE;EBTATE;177Lu-EBTATE,甲状腺癌,Thyroid cancer,SSTR,anti-SSTR多肽偶联核素;177Lu标记的放射性药物,National Institutes of Health(原研);Molecular Targeting Technologies,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,甲状腺癌,申报临床,,Active,肿瘤领域,DR062226,美国,ind,I/II期临床,2025/5/28,phase 2,2,TRUE,FALSE,FALSE,[],['National Institutes of Health'],1,"['National Institutes of Health(原研)', 'Molecular Targeting Technologies']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,0,Oncology,Oncology,,
镓[68Ga]氧奥曲肽,gallium [68Ga] oxodotreotide,镓[68Ga]氧奥曲肽;gallium [68Ga] oxodotreotide,小细胞肺癌,small cell lung cancer,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Novartis(Top20 MNC)(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,多肽偶联核素;68Ga标记的PET药物,小细胞肺癌,I/II期临床,2025/6/3,Active,肿瘤领域;罕见疾病领域,DR072714,欧洲,phase 2,I/II期临床,2025/6/3,phase 2,1,TRUE,TRUE,TRUE,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
镓[68Ga]氧奥曲肽,gallium [68Ga] oxodotreotide,镓[68Ga]氧奥曲肽;gallium [68Ga] oxodotreotide,未知/待定,unknown/pending,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Novartis(Top20 MNC)(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,多肽偶联核素;68Ga标记的PET药物,未知/待定,申报临床,,Active,其他领域,DR072714,欧洲,ind,I/II期临床,2025/6/3,phase 2,1,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],其他领域,['其他领域'],1,其他领域,,,2,0,Others,Others,,
镓[68Ga]氧奥曲肽,gallium [68Ga] oxodotreotide,镓[68Ga]氧奥曲肽;gallium [68Ga] oxodotreotide,PET显像,PET imaging,SSTR,anti-SSTR多肽偶联核素;68Ga标记的PET药物,Novartis(Top20 MNC)(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,多肽偶联核素;68Ga标记的PET药物,PET显像,申报临床,2025/1/1,Active,诊断试剂领域,DR072714,欧洲,ind,I/II期临床,2025/6/3,phase 2,1,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,2,0,Diagnostic Reagents,Diagnostic Reagents,,
64Cu-NODAGA-LM3,64Cu-NODAGA-LM3,64Cu-NODAGA-LM3;(64)Cu-NODAGA-LM3,PET显像,PET imaging,SSTR2,64Cu标记的放射性示踪剂;anti-SSTR2多肽偶联核素,University Hospital of Basel(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;64Cu标记的放射性示踪剂,PET显像(差异化疾病),I/II期临床,,Active,诊断试剂领域,DR057503,欧洲,phase 2,I/II期临床,,phase 2,1,TRUE,FALSE,FALSE,[],['University Hospital of Basel'],1,['University Hospital of Basel(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,2,2,Diagnostic Reagents,Diagnostic Reagents,,
64Cu-NODAGA-LM3,64Cu-NODAGA-LM3,64Cu-NODAGA-LM3;(64)Cu-NODAGA-LM3,胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,SSTR2,64Cu标记的放射性示踪剂;anti-SSTR2多肽偶联核素,University Hospital of Basel(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;64Cu标记的放射性示踪剂,胃肠胰神经内分泌肿瘤(差异化疾病),I/II期临床,,Active,肿瘤领域;罕见疾病领域,DR057503,欧洲,phase 2,I/II期临床,,phase 2,1,TRUE,TRUE,FALSE,[],['University Hospital of Basel'],1,['University Hospital of Basel(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,2,2,Oncology,Oncology,,
NeuroSTAT,NeuroSTAT (cyclosporine),NeuroSTAT;NeuroSTAT (环孢素);NeuroSTAT (cyclosporine);OWL-1410,外伤性脑损伤,traumatic brain injury,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Abliva(Pharming)(原研);Owl Therapeutics,微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶;中国无申报,抑制剂;分子胶,外伤性脑损伤,I/II期临床,,Active,神经领域,DR062199,欧洲,phase 2,I/II期临床,,phase 2,2,TRUE,FALSE,FALSE,[],['Abliva(Pharming)'],1,"['Abliva(Pharming)(原研)', 'Owl Therapeutics']",神经领域,['神经领域'],1,神经领域,,,2,2,Neurology,Neurology,,
68Ga-DOTA-JR11,68Ga-DOTA-JR11,68Ga-DOTA-JR11,PET显像,PET imaging,SSTR2,68Ga标记的PET药物;anti-SSTR2多肽偶联核素,University Hospital Freiburg(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,PET显像,I期临床,2020/12/30,Active,诊断试剂领域,DR018989,欧洲,phase 1,I期临床,2015/11/20,phase 1,1,TRUE,FALSE,FALSE,[],['University Hospital Freiburg'],1,['University Hospital Freiburg(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,
68Ga-DOTA-JR11,68Ga-DOTA-JR11,68Ga-DOTA-JR11,神经内分泌肿瘤,neuroendocrine tumors,SSTR2,68Ga标记的PET药物;anti-SSTR2多肽偶联核素,University Hospital Freiburg(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,神经内分泌肿瘤,I期临床,2015/11/20,Active,肿瘤领域;罕见疾病领域,DR018989,欧洲,phase 1,I期临床,2015/11/20,phase 1,1,TRUE,TRUE,FALSE,[],['University Hospital Freiburg'],1,['University Hospital Freiburg(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
68Ga-DOTA-JR11,68Ga-DOTA-JR11,68Ga-DOTA-JR11,肿瘤性骨软化症,neoplastic osteomalacia,SSTR2,68Ga标记的PET药物;anti-SSTR2多肽偶联核素,University Hospital Freiburg(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,肿瘤性骨软化症(差异化疾病),I期临床,2020/12/30,Active,骨骼肌肉领域;肿瘤领域;罕见疾病领域,DR018989,欧洲,phase 1,I期临床,2015/11/20,phase 1,1,TRUE,TRUE,FALSE,[],['University Hospital Freiburg'],1,['University Hospital Freiburg(原研)'],肿瘤领域,"['骨骼肌肉领域', '肿瘤领域']",2,骨骼肌肉领域,肿瘤领域,,1,1,Oncology,Musculoskeletal,Oncology,
[18F]FP-R01-MG-F2,[18F]FP-R01-MG-F2,[18F]FP-R01-MG-F2,胰腺癌,pancreatic cancer,αvβ6,anti-αvβ6多肽偶联核素;18F标记的PET药物,Stanford University(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,18F标记的PET药物;多肽偶联核素,胰腺癌,I期临床,2016/2/17,Active,肿瘤领域;罕见疾病领域,DR062395,美国,phase 1,I期临床,2016/2/17,phase 1,1,TRUE,TRUE,FALSE,[],['Stanford University'],1,['Stanford University(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
[18F]FP-R01-MG-F2,[18F]FP-R01-MG-F2,[18F]FP-R01-MG-F2,PET显像,PET imaging,αvβ6,anti-αvβ6多肽偶联核素;18F标记的PET药物,Stanford University(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,18F标记的PET药物;多肽偶联核素,PET显像,I期临床,2016/2/17,Active,诊断试剂领域,DR062395,美国,phase 1,I期临床,2016/2/17,phase 1,1,TRUE,FALSE,FALSE,[],['Stanford University'],1,['Stanford University(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,
68Ga-NOTA-3PTATE-RGD,68Ga-NOTA-3PTATE-RGD,68Ga-NOTA-3PTATE-RGD,甲状腺癌,Thyroid cancer,αvβ3;SSTR2,anti-αvβ3×SSTR2多肽偶联核素;68Ga标记的PET药物,天津医科大学(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,甲状腺癌,I期临床,2024/10/9,Active,肿瘤领域,DR002634,中国(内地),phase 1,I期临床,2016/6/29,phase 1,1,TRUE,FALSE,FALSE,[],['天津医科大学'],1,['天津医科大学(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
68Ga-NOTA-3PTATE-RGD,68Ga-NOTA-3PTATE-RGD,68Ga-NOTA-3PTATE-RGD,脑膜瘤,Meningioma,αvβ3;SSTR2,anti-αvβ3×SSTR2多肽偶联核素;68Ga标记的PET药物,天津医科大学(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,脑膜瘤,I期临床,2024/10/9,Active,肿瘤领域,DR002634,中国(内地),phase 1,I期临床,2016/6/29,phase 1,1,TRUE,FALSE,FALSE,[],['天津医科大学'],1,['天津医科大学(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
68Ga-DOTA-Siglec-9,68Ga-DOTA-Siglec-9,68Ga-DOTA-Siglec-9,PET显像,PET imaging,VAP-1,anti-VAP-1多肽偶联核素;68Ga标记的PET药物,University of Turku(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,PET显像,I期临床,2018/11/27,Active,诊断试剂领域,DR057506,欧洲,phase 1,I期临床,2018/11/27,phase 1,1,TRUE,FALSE,FALSE,[],['University of Turku'],1,['University of Turku(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,
68Ga-DOTA-Siglec-9,68Ga-DOTA-Siglec-9,68Ga-DOTA-Siglec-9,炎症(未指明),Inflammation (unspecified),VAP-1,anti-VAP-1多肽偶联核素;68Ga标记的PET药物,University of Turku(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,炎症(未指明),临床前,,Active,免疫领域,DR057506,欧洲,pre-clinical,I期临床,2018/11/27,phase 1,1,TRUE,FALSE,FALSE,[],['University of Turku'],1,['University of Turku(原研)'],免疫领域,['免疫领域'],1,免疫领域,,,1,-1,Immunology,Immunology,,
[18F]BMS-986229,[18F]BMS-986229,[18F]BMS-986229;18F-BMS-986229,胃癌,stomach cancer,PDL1,18F标记的PET药物;anti-PDL1多肽偶联核素,Bristol-Myers Squibb(Top20 MNC)(原研);PeptiDream,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;中国无申报;Potential First-in-Class;肿瘤免疫,18F标记的PET药物;多肽偶联核素,胃癌(差异化疾病),I期临床,,Active,肿瘤领域,DR022833,美国,phase 1,I期临床,2019/11/13,phase 1,2,TRUE,FALSE,TRUE,['Bristol-Myers Squibb'],['Bristol-Myers Squibb'],1,"['Bristol-Myers Squibb(Top20 MNC)(原研)', 'PeptiDream']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
[18F]BMS-986229,[18F]BMS-986229,[18F]BMS-986229;18F-BMS-986229,食管癌,Esophageal cancer,PDL1,18F标记的PET药物;anti-PDL1多肽偶联核素,Bristol-Myers Squibb(Top20 MNC)(原研);PeptiDream,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;中国无申报;Potential First-in-Class;肿瘤免疫,18F标记的PET药物;多肽偶联核素,食管癌,I期临床,,Active,肿瘤领域,DR022833,美国,phase 1,I期临床,2019/11/13,phase 1,2,TRUE,FALSE,TRUE,['Bristol-Myers Squibb'],['Bristol-Myers Squibb'],1,"['Bristol-Myers Squibb(Top20 MNC)(原研)', 'PeptiDream']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
[18F]BMS-986229,[18F]BMS-986229,[18F]BMS-986229;18F-BMS-986229,PET显像,PET imaging,PDL1,18F标记的PET药物;anti-PDL1多肽偶联核素,Bristol-Myers Squibb(Top20 MNC)(原研);PeptiDream,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;中国无申报;Potential First-in-Class;肿瘤免疫,18F标记的PET药物;多肽偶联核素,PET显像,I期临床,,Active,诊断试剂领域,DR022833,美国,phase 1,I期临床,2019/11/13,phase 1,2,TRUE,FALSE,TRUE,['Bristol-Myers Squibb'],['Bristol-Myers Squibb'],1,"['Bristol-Myers Squibb(Top20 MNC)(原研)', 'PeptiDream']",诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,
[18F]BMS-986229,[18F]BMS-986229,[18F]BMS-986229;18F-BMS-986229,胃食管交界处癌,gastroesophageal junction cancer,PDL1,18F标记的PET药物;anti-PDL1多肽偶联核素,Bristol-Myers Squibb(Top20 MNC)(原研);PeptiDream,创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;中国无申报;Potential First-in-Class;肿瘤免疫,18F标记的PET药物;多肽偶联核素,胃食管交界处癌(差异化疾病),I期临床,2019/11/13,Active,肿瘤领域,DR022833,美国,phase 1,I期临床,2019/11/13,phase 1,2,TRUE,FALSE,TRUE,['Bristol-Myers Squibb'],['Bristol-Myers Squibb'],1,"['Bristol-Myers Squibb(Top20 MNC)(原研)', 'PeptiDream']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
ALS-205,ALS-205,ALS-205;PMX205,帕金森病,Parkinson's disease,C5aR,C5aR拮抗剂,University of Queensland(原研);Alsonex;Promics(原研),创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;中国无申报,拮抗剂,帕金森病(差异化疾病),I期临床,2019/11/25,Active,神经领域,DR060769,澳大利亚,phase 1,I期临床,2019/11/25,phase 1,3,TRUE,FALSE,FALSE,[],"['University of Queensland', 'Promics']",2,"['University of Queensland(原研)', 'Alsonex', 'Promics(原研)']",神经领域,['神经领域'],1,神经领域,,,1,1,Neurology,Neurology,,
ALS-205,ALS-205,ALS-205;PMX205,肌萎缩侧索硬化症,amyotrophic lateral sclerosis,C5aR,C5aR拮抗剂,University of Queensland(原研);Alsonex;Promics(原研),创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;中国无申报,拮抗剂,肌萎缩侧索硬化症(差异化疾病),I期临床,2022/6/29,Active,神经领域;罕见疾病领域,DR060769,澳大利亚,phase 1,I期临床,2019/11/25,phase 1,3,TRUE,TRUE,FALSE,[],"['University of Queensland', 'Promics']",2,"['University of Queensland(原研)', 'Alsonex', 'Promics(原研)']",神经领域,['神经领域'],1,神经领域,,,1,1,Neurology,Neurology,,
ALS-205,ALS-205,ALS-205;PMX205,亨廷顿氏病,Huntington's disease,C5aR,C5aR拮抗剂,University of Queensland(原研);Alsonex;Promics(原研),创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;中国无申报,拮抗剂,亨廷顿氏病(差异化疾病),临床前,,Active,神经领域;罕见疾病领域,DR060769,澳大利亚,pre-clinical,I期临床,2019/11/25,phase 1,3,TRUE,TRUE,FALSE,[],"['University of Queensland', 'Promics']",2,"['University of Queensland(原研)', 'Alsonex', 'Promics(原研)']",神经领域,['神经领域'],1,神经领域,,,1,-1,Neurology,Neurology,,
18F-WL12,18F-WL12,18F-WL12,实体瘤,solid tumors,PDL1,18F标记的PET药物;anti-PDL1多肽偶联核素,北京大学肿瘤医院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;肿瘤免疫,18F标记的PET药物;多肽偶联核素,实体瘤,I期临床,,Active,肿瘤领域,DR011153,中国(内地),phase 1,I期临床,2020/3/11,phase 1,1,TRUE,FALSE,FALSE,[],['北京大学肿瘤医院'],1,['北京大学肿瘤医院(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
zosurabalpin,zosurabalpin,zosurabalpin;RG6006;Abx MCP;RO7223280,鲍曼不动杆菌-醋酸钙不动杆菌复合体感染,Acinetobacter baumannii-Acinetobacter calaceticus complex infection,Lpt,抗生素,Roche(Top20 MNC)(原研),创新药,化药,小分子,环肽;Potential First-in-Class,抗生素,鲍曼不动杆菌-醋酸钙不动杆菌复合体感染,I期临床,2023/1/6,Active,感染领域,DR041385,欧洲,phase 1,I期临床,2020/10/28,phase 1,1,TRUE,FALSE,TRUE,['Roche'],['Roche'],1,['Roche(Top20 MNC)(原研)'],感染领域,['感染领域'],1,感染领域,,,1,1,Infectious Diseases,Infectious Diseases,,
zosurabalpin,zosurabalpin,zosurabalpin;RG6006;Abx MCP;RO7223280,鲍曼不动杆菌感染,Acinetobacter baumannii infection,Lpt,抗生素,Roche(Top20 MNC)(原研),创新药,化药,小分子,环肽;Potential First-in-Class,抗生素,鲍曼不动杆菌感染,I期临床,,Active,感染领域,DR041385,欧洲,phase 1,I期临床,2020/10/28,phase 1,1,TRUE,FALSE,TRUE,['Roche'],['Roche'],1,['Roche(Top20 MNC)(原研)'],感染领域,['感染领域'],1,感染领域,,,1,1,Infectious Diseases,Infectious Diseases,,
zosurabalpin,zosurabalpin,zosurabalpin;RG6006;Abx MCP;RO7223280,感染,Infect,Lpt,抗生素,Roche(Top20 MNC)(原研),创新药,化药,小分子,环肽;Potential First-in-Class,抗生素,感染,申报临床,2022/7/14,Active,感染领域,DR041385,欧洲,ind,I期临床,2020/10/28,phase 1,1,TRUE,FALSE,TRUE,['Roche'],['Roche'],1,['Roche(Top20 MNC)(原研)'],感染领域,['感染领域'],1,感染领域,,,1,0,Infectious Diseases,Infectious Diseases,,
Soralimixin,Soralimixin,Soralimixin;QPX9003;BRII-693,细菌感染,bacterial infection,not available,多粘菌素类抗生素,健康元;腾盛博药;Monash University(原研)(无权益);Qpex Biopharma(Shionogi)(无权益),创新药,化药,多肽,环肽,多粘菌素类抗生素,细菌感染,I期临床,2021/3/22,Active,感染领域,DR044020,澳大利亚,phase 1,I期临床,2021/3/22,phase 1,4,TRUE,FALSE,FALSE,[],['Monash University'],1,"['健康元', '腾盛博药', 'Monash University(原研)(无权益)', 'Qpex Biopharma(Shionogi)(无权益)']",感染领域,['感染领域'],1,感染领域,,,1,1,Infectious Diseases,Infectious Diseases,,
Soralimixin,Soralimixin,Soralimixin;QPX9003;BRII-693,感染,Infect,not available,多粘菌素类抗生素,健康元;腾盛博药;Monash University(原研)(无权益);Qpex Biopharma(Shionogi)(无权益),创新药,化药,多肽,环肽,多粘菌素类抗生素,感染,申报临床,2024/7/20,Active,感染领域,DR044020,澳大利亚,ind,I期临床,2021/3/22,phase 1,4,TRUE,FALSE,FALSE,[],['Monash University'],1,"['健康元', '腾盛博药', 'Monash University(原研)(无权益)', 'Qpex Biopharma(Shionogi)(无权益)']",感染领域,['感染领域'],1,感染领域,,,1,0,Infectious Diseases,Infectious Diseases,,
[68Ga]VMT02,[68Ga]VMT02,[68Ga]VMT02,黑色素瘤,melanoma,MC1R,anti-MC1R多肽偶联核素;68Ga标记的PET药物,Viewpoint Molecular Targeting(Perspective Therapeutics)(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class;Melanogenesis,68Ga标记的PET药物;多肽偶联核素,黑色素瘤,I期临床,,Active,肿瘤领域;罕见疾病领域,DR053782,美国,phase 1,I期临床,2021/5/27,phase 1,1,TRUE,TRUE,FALSE,[],['Viewpoint Molecular Targeting(Perspective Therapeutics)'],1,['Viewpoint Molecular Targeting(Perspective Therapeutics)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
177Lu-AB-3PRGD2,177Lu-AB-3PRGD2,177Lu-AB-3PRGD2,实体瘤,solid tumors,αvβ3,177Lu标记的放射性药物;anti-αvβ3多肽偶联核素,北京大学(原研),创新药,生物,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,177Lu标记的放射性药物;多肽偶联核素,实体瘤,I期临床,2024/4/19,Active,肿瘤领域,DR065756,中国(内地),phase 1,I期临床,2021/8/19,phase 1,1,TRUE,FALSE,FALSE,[],['北京大学'],1,['北京大学(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
177Lu-AB-3PRGD2,177Lu-AB-3PRGD2,177Lu-AB-3PRGD2,非小细胞肺癌,non-small cell lung cancer,αvβ3,177Lu标记的放射性药物;anti-αvβ3多肽偶联核素,北京大学(原研),创新药,生物,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,177Lu标记的放射性药物;多肽偶联核素,非小细胞肺癌,I期临床,2021/8/19,Active,肿瘤领域,DR065756,中国(内地),phase 1,I期临床,2021/8/19,phase 1,1,TRUE,FALSE,FALSE,[],['北京大学'],1,['北京大学(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
177Lu-AB-3PRGD2,177Lu-AB-3PRGD2,177Lu-AB-3PRGD2,神经内分泌肿瘤,neuroendocrine tumors,αvβ3,177Lu标记的放射性药物;anti-αvβ3多肽偶联核素,北京大学(原研),创新药,生物,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,177Lu标记的放射性药物;多肽偶联核素,神经内分泌肿瘤(差异化疾病),I期临床,2024/10/9,Active,肿瘤领域;罕见疾病领域,DR065756,中国(内地),phase 1,I期临床,2021/8/19,phase 1,1,TRUE,TRUE,FALSE,[],['北京大学'],1,['北京大学(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
Tdura,Tdura,Tdura;99mTc-Duramycin,SPECT显像,SPECT imaging,not available,含锝放射性示踪剂;多肽偶联核素,Molecular Targeting Technologies(原研);University of Antwerp(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;中国无申报,含锝放射性示踪剂;多肽偶联核素,SPECT显像,I期临床,2022/1/4,Active,诊断试剂领域,DR034924,美国;欧洲,phase 1,I期临床,2022/1/4,phase 1,2,TRUE,FALSE,FALSE,[],"['Molecular Targeting Technologies', 'University of Antwerp']",2,"['Molecular Targeting Technologies(原研)', 'University of Antwerp(原研)']",诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,
Tdura,Tdura,Tdura;99mTc-Duramycin,结肠癌,colon cancer,not available,含锝放射性示踪剂;多肽偶联核素,Molecular Targeting Technologies(原研);University of Antwerp(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;中国无申报,含锝放射性示踪剂;多肽偶联核素,结肠癌,I期临床,,Active,肿瘤领域,DR034924,美国;欧洲,phase 1,I期临床,2022/1/4,phase 1,2,TRUE,FALSE,FALSE,[],"['Molecular Targeting Technologies', 'University of Antwerp']",2,"['Molecular Targeting Technologies(原研)', 'University of Antwerp(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
Oph1,Oph1 (0.5% Cyclosporine A),Oph1;Oph1 (0.5%环孢素滴眼液);Oph1 (0.5% Cyclosporine A);OPH-100,干眼病,dry eye disease,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,OphRx(原研),微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶;中国无申报,抑制剂;分子胶,干眼病,I期临床,2022/1/11,Active,眼科领域,DR033775,以色列,phase 1,I期临床,2022/1/11,phase 1,1,TRUE,FALSE,FALSE,[],['OphRx'],1,['OphRx(原研)'],眼科领域,['眼科领域'],1,眼科领域,,,1,1,Ophthalmology,Ophthalmology,,
PA-001,PA-001,PA-001,新型冠状病毒感染,novel coronavirus infection,SARS-CoV-2 S protein,,PeptiDream(原研),创新药,化药,多肽,环肽,其他,新型冠状病毒感染,I期临床,2022/2/7,Active,感染领域,DR035773,日本,phase 1,I期临床,2022/2/7,phase 1,1,TRUE,FALSE,FALSE,[],['PeptiDream'],1,['PeptiDream(原研)'],感染领域,['感染领域'],1,感染领域,,,1,1,Infectious Diseases,Infectious Diseases,,
68Ga-N188,68Ga-N188,68Ga-N188;[68Ga]N188,肺癌,lung cancer,nectin-4,anti-nectin-4多肽偶联核素;68Ga标记的PET药物,北京大学肿瘤医院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,肺癌(差异化疾病),I期临床,2024/10/18,Active,肿瘤领域,DR013319,中国(内地),phase 1,I期临床,2022/4/11,phase 1,1,TRUE,FALSE,FALSE,[],['北京大学肿瘤医院'],1,['北京大学肿瘤医院(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
68Ga-N188,68Ga-N188,68Ga-N188;[68Ga]N188,尿路上皮癌,urothelial carcinoma,nectin-4,anti-nectin-4多肽偶联核素;68Ga标记的PET药物,北京大学肿瘤医院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,尿路上皮癌,I期临床,2022/4/11,Active,肿瘤领域,DR013319,中国(内地),phase 1,I期临床,2022/4/11,phase 1,1,TRUE,FALSE,FALSE,[],['北京大学肿瘤医院'],1,['北京大学肿瘤医院(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
68Ga-N188,68Ga-N188,68Ga-N188;[68Ga]N188,PET显像,PET imaging,nectin-4,anti-nectin-4多肽偶联核素;68Ga标记的PET药物,北京大学肿瘤医院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,PET显像,I期临床,2022/4/11,Active,诊断试剂领域,DR013319,中国(内地),phase 1,I期临床,2022/4/11,phase 1,1,TRUE,FALSE,FALSE,[],['北京大学肿瘤医院'],1,['北京大学肿瘤医院(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,
161Tb-DOTA-LM3,161Tb-DOTA-LM3,161Tb-DOTA-LM3,胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,SSTR2,161Tb标记的放射性药物;anti-SSTR2多肽偶联核素,Paul Scherrer Institute(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;Potential First-in-Class,161Tb标记的放射性药物;多肽偶联核素,胃肠胰神经内分泌肿瘤,I期临床,2022/5/3,Active,肿瘤领域;罕见疾病领域,DR003476,欧洲,phase 1,I期临床,2022/5/3,phase 1,1,TRUE,TRUE,FALSE,[],['Paul Scherrer Institute'],1,['Paul Scherrer Institute(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
68Ga-pentixather,68Ga-pentixather,68Ga-pentixather,多发性骨髓瘤,multiple myeloma,CXCR4,68Ga标记的PET药物,北京协和医院(原研),创新药,化药,小分子;放射性药物,环肽;差异化疾病;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物,多发性骨髓瘤(差异化疾病),I期临床,2022/5/6,Active,肿瘤领域;血液领域;罕见疾病领域,DR055770,中国(内地),phase 1,I期临床,2022/5/6,phase 1,1,TRUE,TRUE,FALSE,[],['北京协和医院'],1,['北京协和医院(原研)'],肿瘤领域,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,1,1,Oncology,Oncology,Hematology,
68Ga-pentixather,68Ga-pentixather,68Ga-pentixather,PET显像,PET imaging,CXCR4,68Ga标记的PET药物,北京协和医院(原研),创新药,化药,小分子;放射性药物,环肽;差异化疾病;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,68Ga标记的PET药物,PET显像,I期临床,2022/5/6,Active,诊断试剂领域,DR055770,中国(内地),phase 1,I期临床,2022/5/6,phase 1,1,TRUE,FALSE,FALSE,[],['北京协和医院'],1,['北京协和医院(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,
PHIN-214,PHIN-214,PHIN-214,肝硬化,Cirrhosis,AVPR1A,AVPR1A部分激动剂,PharmaIN(原研),创新药,化药,多肽,环肽;Potential First-in-Class,部分激动剂,肝硬化,I期临床,2022/8/8,Active,消化领域,DR021763,美国,phase 1,I期临床,2022/8/8,phase 1,1,TRUE,FALSE,FALSE,[],['PharmaIN'],1,['PharmaIN(原研)'],消化领域,['消化领域'],1,消化领域,,,1,1,Digestive System,Digestive System,,
PHIN-214,PHIN-214,PHIN-214,低血压,hypotension,AVPR1A,AVPR1A部分激动剂,PharmaIN(原研),创新药,化药,多肽,环肽;Potential First-in-Class,部分激动剂,低血压,临床前,,Active,心脑血管领域,DR021763,美国,pre-clinical,I期临床,2022/8/8,phase 1,1,TRUE,FALSE,FALSE,[],['PharmaIN'],1,['PharmaIN(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,1,-1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
203Pb-pentixather,203Pb-pentixather,203Pb-pentixather,小细胞肺癌,small cell lung cancer,CXCR4,203Pb标记的放射性示踪剂,University of Iowa(原研),创新药,化药,小分子;放射性药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,203Pb标记的放射性示踪剂,小细胞肺癌,I期临床,2022/9/28,Active,肿瘤领域;罕见疾病领域,DR013617,美国,phase 1,I期临床,2022/9/28,phase 1,1,TRUE,TRUE,FALSE,[],['University of Iowa'],1,['University of Iowa(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
203Pb-pentixather,203Pb-pentixather,203Pb-pentixather,SPECT显像,SPECT imaging,CXCR4,203Pb标记的放射性示踪剂,University of Iowa(原研),创新药,化药,小分子;放射性药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,203Pb标记的放射性示踪剂,SPECT显像,I期临床,,Active,诊断试剂领域,DR013617,美国,phase 1,I期临床,2022/9/28,phase 1,1,TRUE,FALSE,FALSE,[],['University of Iowa'],1,['University of Iowa(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,
203Pb-pentixather,203Pb-pentixather,203Pb-pentixather,肺类癌,lung carcinoid,CXCR4,203Pb标记的放射性示踪剂,University of Iowa(原研),创新药,化药,小分子;放射性药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,203Pb标记的放射性示踪剂,肺类癌,I期临床,2022/9/28,Active,肿瘤领域;罕见疾病领域,DR013617,美国,phase 1,I期临床,2022/9/28,phase 1,1,TRUE,TRUE,FALSE,[],['University of Iowa'],1,['University of Iowa(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
212Pb-pentixather,212Pb-pentixather,212Pb-pentixather,小细胞肺癌,small cell lung cancer,CXCR4,212Pb标记的放射性药物,University of Iowa(原研),创新药,化药,小分子;放射性药物,环肽;治疗用放射性药物;G蛋白偶联受体;Potential First-in-Class,212Pb标记的放射性药物,小细胞肺癌,I期临床,2022/9/28,Active,肿瘤领域;罕见疾病领域,DR028994,美国,phase 1,I期临床,2022/9/28,phase 1,1,TRUE,TRUE,FALSE,[],['University of Iowa'],1,['University of Iowa(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
212Pb-pentixather,212Pb-pentixather,212Pb-pentixather,肺类癌,lung carcinoid,CXCR4,212Pb标记的放射性药物,University of Iowa(原研),创新药,化药,小分子;放射性药物,环肽;治疗用放射性药物;G蛋白偶联受体;Potential First-in-Class,212Pb标记的放射性药物,肺类癌,I期临床,2022/9/28,Active,肿瘤领域;罕见疾病领域,DR028994,美国,phase 1,I期临床,2022/9/28,phase 1,1,TRUE,TRUE,FALSE,[],['University of Iowa'],1,['University of Iowa(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
[18F]AlF-NOTA-FAPI-04,[18F]AlF-NOTA-FAPI-04,[18F]AlF-NOTA-FAPI-04;Al18F-NOTA-FAPI-04,癌症,cancer,FAP,18F标记的PET药物,四川省肿瘤医院(原研),创新药,化药,放射性药物;其他,环肽;差异化疾病;诊断用放射性药物,18F标记的PET药物,癌症,I期临床,2025/1/26,Active,肿瘤领域,DR057496,中国(内地),phase 1,I期临床,2022/10/12,phase 1,1,TRUE,FALSE,FALSE,[],['四川省肿瘤医院'],1,['四川省肿瘤医院(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
[18F]AlF-NOTA-FAPI-04,[18F]AlF-NOTA-FAPI-04,[18F]AlF-NOTA-FAPI-04;Al18F-NOTA-FAPI-04,肾炎,Nephritis,FAP,18F标记的PET药物,四川省肿瘤医院(原研),创新药,化药,放射性药物;其他,环肽;差异化疾病;诊断用放射性药物,18F标记的PET药物,肾炎(差异化疾病),I期临床,2023/3/2,Active,泌尿生殖领域,DR057496,中国(内地),phase 1,I期临床,2022/10/12,phase 1,1,TRUE,FALSE,FALSE,[],['四川省肿瘤医院'],1,['四川省肿瘤医院(原研)'],泌尿生殖领域,['泌尿生殖领域'],1,泌尿生殖领域,,,1,1,Genitourinary,Genitourinary,,
[18F]AlF-NOTA-FAPI-04,[18F]AlF-NOTA-FAPI-04,[18F]AlF-NOTA-FAPI-04;Al18F-NOTA-FAPI-04,PET显像,PET imaging,FAP,18F标记的PET药物,四川省肿瘤医院(原研),创新药,化药,放射性药物;其他,环肽;差异化疾病;诊断用放射性药物,18F标记的PET药物,PET显像,I期临床,2022/10/12,Active,诊断试剂领域,DR057496,中国(内地),phase 1,I期临床,2022/10/12,phase 1,1,TRUE,FALSE,FALSE,[],['四川省肿瘤医院'],1,['四川省肿瘤医院(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,
[18F]AlF-NOTA-FAPI-04,[18F]AlF-NOTA-FAPI-04,[18F]AlF-NOTA-FAPI-04;Al18F-NOTA-FAPI-04,肾纤维化,renal fibrosis,FAP,18F标记的PET药物,四川省肿瘤医院(原研),创新药,化药,放射性药物;其他,环肽;差异化疾病;诊断用放射性药物,18F标记的PET药物,肾纤维化,I期临床,2023/3/2,Active,泌尿生殖领域,DR057496,中国(内地),phase 1,I期临床,2022/10/12,phase 1,1,TRUE,FALSE,FALSE,[],['四川省肿瘤医院'],1,['四川省肿瘤医院(原研)'],泌尿生殖领域,['泌尿生殖领域'],1,泌尿生殖领域,,,1,1,Genitourinary,Genitourinary,,
[68Ga]-trivehexin,[68Ga]-trivehexin,[68Ga]-trivehexin;RAD301;68Ga-trivehexin,癌症,cancer,αvβ6,anti-αvβ6多肽偶联核素;68Ga标记的PET药物,Radiopharm Theranostics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,多肽偶联核素;68Ga标记的PET药物,癌症,I期临床,2023/4/28,Active,肿瘤领域,DR027025,澳大利亚,phase 1,I期临床,2023/4/5,phase 1,1,TRUE,FALSE,FALSE,[],['Radiopharm Theranostics'],1,['Radiopharm Theranostics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
[68Ga]-trivehexin,[68Ga]-trivehexin,[68Ga]-trivehexin;RAD301;68Ga-trivehexin,PET显像,PET imaging,αvβ6,anti-αvβ6多肽偶联核素;68Ga标记的PET药物,Radiopharm Theranostics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,多肽偶联核素;68Ga标记的PET药物,PET显像,I期临床,2023/4/5,Active,诊断试剂领域,DR027025,澳大利亚,phase 1,I期临床,2023/4/5,phase 1,1,TRUE,FALSE,FALSE,[],['Radiopharm Theranostics'],1,['Radiopharm Theranostics(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,
[68Ga]-trivehexin,[68Ga]-trivehexin,[68Ga]-trivehexin;RAD301;68Ga-trivehexin,胰腺导管癌,pancreatic ductal carcinoma,αvβ6,anti-αvβ6多肽偶联核素;68Ga标记的PET药物,Radiopharm Theranostics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,多肽偶联核素;68Ga标记的PET药物,胰腺导管癌,I期临床,2023/4/5,Active,肿瘤领域,DR027025,澳大利亚,phase 1,I期临床,2023/4/5,phase 1,1,TRUE,FALSE,FALSE,[],['Radiopharm Theranostics'],1,['Radiopharm Theranostics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
[18F]AlF-NOTA-pentixather,[18F]AlF-NOTA-pentixather,[18F]AlF-NOTA-pentixather,醛固酮过多症,Hyperaldosteronism,CXCR4,18F标记的PET药物,Technische Universität München(原研),创新药,化药,小分子;放射性药物,环肽;诊断用放射性药物;G蛋白偶联受体,18F标记的PET药物,醛固酮过多症,I期临床,2023/4/18,Active,内分泌及代谢领域,DR021166,欧洲,phase 1,I期临床,2023/4/18,phase 1,1,TRUE,FALSE,FALSE,[],['Technische Universität München'],1,['Technische Universität München(原研)'],内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,1,1,Endocrinology & Metabolism,Endocrinology & Metabolism,,
[18F]AlF-NOTA-pentixather,[18F]AlF-NOTA-pentixather,[18F]AlF-NOTA-pentixather,PET显像,PET imaging,CXCR4,18F标记的PET药物,Technische Universität München(原研),创新药,化药,小分子;放射性药物,环肽;诊断用放射性药物;G蛋白偶联受体,18F标记的PET药物,PET显像,I期临床,2023/4/18,Active,诊断试剂领域,DR021166,欧洲,phase 1,I期临床,2023/4/18,phase 1,1,TRUE,FALSE,FALSE,[],['Technische Universität München'],1,['Technische Universität München(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,
AZP-3813,AZP-3813,AZP-3813,肢端肥大症,acromegaly,GHR,GHR拮抗剂,PeptiDream(原研);Amolyt Pharma(AstraZeneca)(Top20 MNC),创新药,化药,多肽,环肽;中国无申报,拮抗剂,肢端肥大症,I期临床,2023/4/24,Active,内分泌及代谢领域;罕见疾病领域,DR024370,日本,phase 1,I期临床,2023/4/24,phase 1,2,TRUE,TRUE,TRUE,['Amolyt Pharma(AstraZeneca)'],['PeptiDream'],1,"['PeptiDream(原研)', 'Amolyt Pharma(AstraZeneca)(Top20 MNC)']",内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,1,1,Endocrinology & Metabolism,Endocrinology & Metabolism,,
TB-B002,TB-B002,TB-B002;TB-B002D,特发性肺纤维化,idiopathic pulmonary fibrosis,not available,抑制剂,图微安创(原研),创新药,化药,多肽,环肽,抑制剂,特发性肺纤维化,I期临床,2023/5/6,Active,呼吸领域;罕见疾病领域,DR014128,中国(内地),phase 1,I期临床,2023/5/6,phase 1,1,TRUE,TRUE,FALSE,[],['图微安创'],1,['图微安创(原研)'],呼吸领域,['呼吸领域'],1,呼吸领域,,,1,1,Respiratory,Respiratory,,
TB-B002,TB-B002,TB-B002;TB-B002D,肺损伤,lung damage,not available,抑制剂,图微安创(原研),创新药,化药,多肽,环肽,抑制剂,肺损伤,申报临床,2023/8/25,Active,呼吸领域,DR014128,中国(内地),ind,I期临床,2023/5/6,phase 1,1,TRUE,FALSE,FALSE,[],['图微安创'],1,['图微安创(原研)'],呼吸领域,['呼吸领域'],1,呼吸领域,,,1,0,Respiratory,Respiratory,,
TE-8214,TE-8214,TE-8214,肢端肥大症,acromegaly,somatostatin,somatostatin类似物,免疫功坊(原研),创新药,化药,多肽,环肽,类似物,肢端肥大症,I期临床,2024/4/18,Active,内分泌及代谢领域;罕见疾病领域,DR015375,中国(港澳台),phase 1,I期临床,2024/4/18,phase 1,1,TRUE,TRUE,FALSE,[],['免疫功坊'],1,['免疫功坊(原研)'],内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,1,1,Endocrinology & Metabolism,Endocrinology & Metabolism,,
TE-8214,TE-8214,TE-8214,神经内分泌肿瘤,neuroendocrine tumors,somatostatin,somatostatin类似物,免疫功坊(原研),创新药,化药,多肽,环肽,类似物,神经内分泌肿瘤,临床前,,Active,肿瘤领域;罕见疾病领域,DR015375,中国(港澳台),pre-clinical,I期临床,2024/4/18,phase 1,1,TRUE,TRUE,FALSE,[],['免疫功坊'],1,['免疫功坊(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,-1,Oncology,Oncology,,
64Cu-PD-32766,64Cu-PD-32766,64Cu-PD-32766,PET显像,PET imaging,CAIX,64Cu标记的放射性示踪剂;anti-CAIX多肽偶联核素,PeptiDream(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;64Cu标记的放射性示踪剂,PET显像,I期临床,2024/4/24,Active,诊断试剂领域,DR068744,日本,phase 1,I期临床,2024/4/24,phase 1,1,TRUE,FALSE,FALSE,[],['PeptiDream'],1,['PeptiDream(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,
64Cu-PD-32766,64Cu-PD-32766,64Cu-PD-32766,肾透明细胞癌,clear cell renal cell carcinoma,CAIX,64Cu标记的放射性示踪剂;anti-CAIX多肽偶联核素,PeptiDream(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;64Cu标记的放射性示踪剂,肾透明细胞癌,I期临床,2024/4/24,Active,肿瘤领域,DR068744,日本,phase 1,I期临床,2024/4/24,phase 1,1,TRUE,FALSE,FALSE,[],['PeptiDream'],1,['PeptiDream(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
68Ga-FAPI-JH04,68Ga-FAPI-JH04,68Ga-FAPI-JH04;68Ga-JH04,癌症,cancer,FAP,68Ga标记的PET药物,福建医科大学附属第一医院(原研),创新药,其他,放射性药物;其他,环肽;诊断用放射性药物,68Ga标记的PET药物,癌症,I期临床,2024/5/31,Active,肿瘤领域,DR067575,中国(内地),phase 1,I期临床,2024/5/31,phase 1,1,TRUE,FALSE,FALSE,[],['福建医科大学附属第一医院'],1,['福建医科大学附属第一医院(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
68Ga-FAPI-JH04,68Ga-FAPI-JH04,68Ga-FAPI-JH04;68Ga-JH04,PET显像,PET imaging,FAP,68Ga标记的PET药物,福建医科大学附属第一医院(原研),创新药,其他,放射性药物;其他,环肽;诊断用放射性药物,68Ga标记的PET药物,PET显像,I期临床,2024/5/31,Active,诊断试剂领域,DR067575,中国(内地),phase 1,I期临床,2024/5/31,phase 1,1,TRUE,FALSE,FALSE,[],['福建医科大学附属第一医院'],1,['福建医科大学附属第一医院(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,
[177Lu]Lu-NNS309,[177Lu]Lu-NNS309,[177Lu]Lu-NNS309;177Lu-NNS309;177Lu-FXX489,非小细胞肺癌,non-small cell lung cancer,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);PeptiDream(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;中国无申报,177Lu标记的放射性药物;多肽偶联核素,非小细胞肺癌,I期临床,2024/8/20,Active,肿瘤领域,DR069256,欧洲;日本,phase 1,I期临床,2024/8/20,phase 1,2,TRUE,FALSE,TRUE,['Novartis'],"['Novartis', 'PeptiDream']",2,"['Novartis(Top20 MNC)(原研)', 'PeptiDream(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
[177Lu]Lu-NNS309,[177Lu]Lu-NNS309,[177Lu]Lu-NNS309;177Lu-NNS309;177Lu-FXX489,HR阳性乳腺癌,HR positive breast cancer,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);PeptiDream(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;中国无申报,177Lu标记的放射性药物;多肽偶联核素,HR阳性乳腺癌(差异化疾病),I期临床,2024/8/20,Active,肿瘤领域,DR069256,欧洲;日本,phase 1,I期临床,2024/8/20,phase 1,2,TRUE,FALSE,TRUE,['Novartis'],"['Novartis', 'PeptiDream']",2,"['Novartis(Top20 MNC)(原研)', 'PeptiDream(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
[177Lu]Lu-NNS309,[177Lu]Lu-NNS309,[177Lu]Lu-NNS309;177Lu-NNS309;177Lu-FXX489,三阴性乳腺癌,triple negative breast cancer,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);PeptiDream(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;中国无申报,177Lu标记的放射性药物;多肽偶联核素,三阴性乳腺癌(差异化疾病),I期临床,2024/8/20,Active,肿瘤领域,DR069256,欧洲;日本,phase 1,I期临床,2024/8/20,phase 1,2,TRUE,FALSE,TRUE,['Novartis'],"['Novartis', 'PeptiDream']",2,"['Novartis(Top20 MNC)(原研)', 'PeptiDream(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
[177Lu]Lu-NNS309,[177Lu]Lu-NNS309,[177Lu]Lu-NNS309;177Lu-NNS309;177Lu-FXX489,结直肠癌,colorectal cancer,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);PeptiDream(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;中国无申报,177Lu标记的放射性药物;多肽偶联核素,结直肠癌(差异化疾病),I期临床,2024/8/20,Active,肿瘤领域,DR069256,欧洲;日本,phase 1,I期临床,2024/8/20,phase 1,2,TRUE,FALSE,TRUE,['Novartis'],"['Novartis', 'PeptiDream']",2,"['Novartis(Top20 MNC)(原研)', 'PeptiDream(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
[177Lu]Lu-NNS309,[177Lu]Lu-NNS309,[177Lu]Lu-NNS309;177Lu-NNS309;177Lu-FXX489,胰腺导管癌,pancreatic ductal carcinoma,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研);PeptiDream(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;中国无申报,177Lu标记的放射性药物;多肽偶联核素,胰腺导管癌,I期临床,2024/8/20,Active,肿瘤领域,DR069256,欧洲;日本,phase 1,I期临床,2024/8/20,phase 1,2,TRUE,FALSE,TRUE,['Novartis'],"['Novartis', 'PeptiDream']",2,"['Novartis(Top20 MNC)(原研)', 'PeptiDream(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
CID-078,CID-078,CID-078;CID-016;CIR7-7321;CIR-7321,实体瘤,solid tumors,cyclin A;cyclin B,cyclin A抑制剂;cyclin B抑制剂,Circle Pharma(原研);Vall d'Hebron Institute of Oncology(原研),创新药,化药,多肽,环肽;细胞周期;差异化疾病;中国无申报;Potential First-in-Class;2025 AACR新机会,抑制剂,实体瘤,I期临床,2024/10/15,Active,肿瘤领域,DR013158,美国;欧洲,phase 1,I期临床,2024/8/29,phase 1,2,TRUE,FALSE,FALSE,[],"['Circle Pharma', ""Vall d'Hebron Institute of Oncology""]",2,"['Circle Pharma(原研)', ""Vall d'Hebron Institute of Oncology(原研)""]",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
CID-078,CID-078,CID-078;CID-016;CIR7-7321;CIR-7321,肺癌,lung cancer,cyclin A;cyclin B,cyclin A抑制剂;cyclin B抑制剂,Circle Pharma(原研);Vall d'Hebron Institute of Oncology(原研),创新药,化药,多肽,环肽;细胞周期;差异化疾病;中国无申报;Potential First-in-Class;2025 AACR新机会,抑制剂,肺癌,I期临床,2024/8/29,Active,肿瘤领域,DR013158,美国;欧洲,phase 1,I期临床,2024/8/29,phase 1,2,TRUE,FALSE,FALSE,[],"['Circle Pharma', ""Vall d'Hebron Institute of Oncology""]",2,"['Circle Pharma(原研)', ""Vall d'Hebron Institute of Oncology(原研)""]",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
CID-078,CID-078,CID-078;CID-016;CIR7-7321;CIR-7321,小细胞肺癌,small cell lung cancer,cyclin A;cyclin B,cyclin A抑制剂;cyclin B抑制剂,Circle Pharma(原研);Vall d'Hebron Institute of Oncology(原研),创新药,化药,多肽,环肽;细胞周期;差异化疾病;中国无申报;Potential First-in-Class;2025 AACR新机会,抑制剂,小细胞肺癌(差异化疾病),I期临床,2025/6/16,Active,肿瘤领域;罕见疾病领域,DR013158,美国;欧洲,phase 1,I期临床,2024/8/29,phase 1,2,TRUE,TRUE,FALSE,[],"['Circle Pharma', ""Vall d'Hebron Institute of Oncology""]",2,"['Circle Pharma(原研)', ""Vall d'Hebron Institute of Oncology(原研)""]",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
CID-078,CID-078,CID-078;CID-016;CIR7-7321;CIR-7321,三阴性乳腺癌,triple negative breast cancer,cyclin A;cyclin B,cyclin A抑制剂;cyclin B抑制剂,Circle Pharma(原研);Vall d'Hebron Institute of Oncology(原研),创新药,化药,多肽,环肽;细胞周期;差异化疾病;中国无申报;Potential First-in-Class;2025 AACR新机会,抑制剂,三阴性乳腺癌(差异化疾病),I期临床,2024/8/29,Active,肿瘤领域,DR013158,美国;欧洲,phase 1,I期临床,2024/8/29,phase 1,2,TRUE,FALSE,FALSE,[],"['Circle Pharma', ""Vall d'Hebron Institute of Oncology""]",2,"['Circle Pharma(原研)', ""Vall d'Hebron Institute of Oncology(原研)""]",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
CID-078,CID-078,CID-078;CID-016;CIR7-7321;CIR-7321,神经内分泌肿瘤,neuroendocrine tumors,cyclin A;cyclin B,cyclin A抑制剂;cyclin B抑制剂,Circle Pharma(原研);Vall d'Hebron Institute of Oncology(原研),创新药,化药,多肽,环肽;细胞周期;差异化疾病;中国无申报;Potential First-in-Class;2025 AACR新机会,抑制剂,神经内分泌肿瘤(差异化疾病),I期临床,2024/8/29,Active,肿瘤领域;罕见疾病领域,DR013158,美国;欧洲,phase 1,I期临床,2024/8/29,phase 1,2,TRUE,TRUE,FALSE,[],"['Circle Pharma', ""Vall d'Hebron Institute of Oncology""]",2,"['Circle Pharma(原研)', ""Vall d'Hebron Institute of Oncology(原研)""]",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
CID-078,CID-078,CID-078;CID-016;CIR7-7321;CIR-7321,癌症,cancer,cyclin A;cyclin B,cyclin A抑制剂;cyclin B抑制剂,Circle Pharma(原研);Vall d'Hebron Institute of Oncology(原研),创新药,化药,多肽,环肽;细胞周期;差异化疾病;中国无申报;Potential First-in-Class;2025 AACR新机会,抑制剂,癌症,临床前,,Active,肿瘤领域,DR013158,美国;欧洲,pre-clinical,I期临床,2024/8/29,phase 1,2,TRUE,FALSE,FALSE,[],"['Circle Pharma', ""Vall d'Hebron Institute of Oncology""]",2,"['Circle Pharma(原研)', ""Vall d'Hebron Institute of Oncology(原研)""]",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,-1,Oncology,Oncology,,
CID-078,CID-078,CID-078;CID-016;CIR7-7321;CIR-7321,非小细胞肺癌,non-small cell lung cancer,cyclin A;cyclin B,cyclin A抑制剂;cyclin B抑制剂,Circle Pharma(原研);Vall d'Hebron Institute of Oncology(原研),创新药,化药,多肽,环肽;细胞周期;差异化疾病;中国无申报;Potential First-in-Class;2025 AACR新机会,抑制剂,非小细胞肺癌(差异化疾病),临床前,,Active,肿瘤领域,DR013158,美国;欧洲,pre-clinical,I期临床,2024/8/29,phase 1,2,TRUE,FALSE,FALSE,[],"['Circle Pharma', ""Vall d'Hebron Institute of Oncology""]",2,"['Circle Pharma(原研)', ""Vall d'Hebron Institute of Oncology(原研)""]",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,-1,Oncology,Oncology,,
CID-078,CID-078,CID-078;CID-016;CIR7-7321;CIR-7321,乳腺癌,breast cancer,cyclin A;cyclin B,cyclin A抑制剂;cyclin B抑制剂,Circle Pharma(原研);Vall d'Hebron Institute of Oncology(原研),创新药,化药,多肽,环肽;细胞周期;差异化疾病;中国无申报;Potential First-in-Class;2025 AACR新机会,抑制剂,乳腺癌,临床前,,Active,肿瘤领域,DR013158,美国;欧洲,pre-clinical,I期临床,2024/8/29,phase 1,2,TRUE,FALSE,FALSE,[],"['Circle Pharma', ""Vall d'Hebron Institute of Oncology""]",2,"['Circle Pharma(原研)', ""Vall d'Hebron Institute of Oncology(原研)""]",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,-1,Oncology,Oncology,,
NN6537-7650,NN6537-7650,NN6537-7650;NN6537,心力衰竭,heart failure,CNP,CNP类似物,Novo Nordisk(Top20 MNC)(原研),创新药,化药,多肽,环肽,类似物,心力衰竭,I期临床,2024/10/3,Active,心脑血管领域,DR070230,欧洲,phase 1,I期临床,2024/10/3,phase 1,1,TRUE,FALSE,TRUE,['Novo Nordisk'],['Novo Nordisk'],1,['Novo Nordisk(Top20 MNC)(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,1,1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
177Lu-JH04,177Lu-JH04,177Lu-JH04;JH004;[177Lu]JH040182,肿瘤,tumor,FAP,anti-FAP多肽偶联核素;177Lu标记的放射性药物,晶核生物(原研),创新药,化药,小分子;多肽;放射性药物;偶联药物,环肽;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,肿瘤,I期临床,2024/10/10,Active,肿瘤领域,DR069733,中国(内地),phase 1,I期临床,2024/10/10,phase 1,1,TRUE,FALSE,FALSE,[],['晶核生物'],1,['晶核生物(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
[18F]AlF-ETN,[18F]AlF-ETN,[18F]AlF-ETN,实体瘤,solid tumors,EphA2,18F标记的PET药物;anti-EphA2多肽偶联核素,北京大学第一医院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;受体酪氨酸激酶;Potential First-in-Class,多肽偶联核素;18F标记的PET药物,实体瘤,I期临床,2024/10/14,Active,肿瘤领域,DR070403,中国(内地),phase 1,I期临床,2024/10/14,phase 1,1,TRUE,FALSE,FALSE,[],['北京大学第一医院'],1,['北京大学第一医院(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
[18F]AlF-ETN,[18F]AlF-ETN,[18F]AlF-ETN,PET显像,PET imaging,EphA2,18F标记的PET药物;anti-EphA2多肽偶联核素,北京大学第一医院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;受体酪氨酸激酶;Potential First-in-Class,多肽偶联核素;18F标记的PET药物,PET显像,I期临床,2024/10/14,Active,诊断试剂领域,DR070403,中国(内地),phase 1,I期临床,2024/10/14,phase 1,1,TRUE,FALSE,FALSE,[],['北京大学第一医院'],1,['北京大学第一医院(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,
ZP9830,ZP9830,ZP9830;ZP 9830,自身免疫性疾病,autoimmune disease,Kv1.3,Kv1.3阻断剂,Zealand Pharma(原研),创新药,化药,多肽,环肽,阻断剂,自身免疫性疾病,I期临床,2024/11/12,Active,免疫领域,DR065642,欧洲,phase 1,I期临床,2024/11/12,phase 1,1,TRUE,FALSE,FALSE,[],['Zealand Pharma'],1,['Zealand Pharma(原研)'],免疫领域,['免疫领域'],1,免疫领域,,,1,1,Immunology,Immunology,,
ZP9830,ZP9830,ZP9830;ZP 9830,炎症性肠病,inflammatory bowel disease,Kv1.3,Kv1.3阻断剂,Zealand Pharma(原研),创新药,化药,多肽,环肽,阻断剂,炎症性肠病,临床前,,Active,免疫领域;消化领域,DR065642,欧洲,pre-clinical,I期临床,2024/11/12,phase 1,1,TRUE,FALSE,FALSE,[],['Zealand Pharma'],1,['Zealand Pharma(原研)'],免疫领域,"['免疫领域', '消化领域']",2,免疫领域,消化领域,,1,-1,Immunology,Immunology,Digestive System,
68Ga-MMP14,68Ga-MMP14,68Ga-MMP14,实体瘤,solid tumors,MMP14,anti-MMP14多肽偶联核素;68Ga标记的PET药物,北京大学肿瘤医院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,实体瘤,I期临床,2024/12/6,Active,肿瘤领域,DR071612,中国(内地),phase 1,I期临床,2024/12/6,phase 1,1,TRUE,FALSE,FALSE,[],['北京大学肿瘤医院'],1,['北京大学肿瘤医院(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
68Ga-MMP14,68Ga-MMP14,68Ga-MMP14,PET显像,PET imaging,MMP14,anti-MMP14多肽偶联核素;68Ga标记的PET药物,北京大学肿瘤医院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,PET显像,I期临床,2024/12/6,Active,诊断试剂领域,DR071612,中国(内地),phase 1,I期临床,2024/12/6,phase 1,1,TRUE,FALSE,FALSE,[],['北京大学肿瘤医院'],1,['北京大学肿瘤医院(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,
225Ac-RAYZ-8009,225Ac-RAYZ-8009,225Ac-RAYZ-8009;RYZ801,肝细胞癌,hepatocellular carcinoma,GPC3,225Ac标记的放射性药物;anti-GPC3多肽偶联核素,PeptiDream(原研);RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;中国无申报;Potential First-in-Class;Wnt信号通路,多肽偶联核素;225Ac标记的放射性药物,肝细胞癌(差异化疾病),I期临床,2024/12/10,Active,肿瘤领域,DR030874,美国;日本,phase 1,I期临床,2024/12/10,phase 1,2,TRUE,FALSE,TRUE,['RayzeBio(Bristol-Myers Squibb)'],"['PeptiDream', 'RayzeBio(Bristol-Myers Squibb)']",2,"['PeptiDream(原研)', 'RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
[68Ga]-RYZ-GPC3,[68Ga]-RYZ-GPC3,[68Ga]-RYZ-GPC3;RYZ811,肝细胞癌,hepatocellular carcinoma,GPC3,anti-GPC3多肽偶联核素;68Ga标记的PET药物,RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class;Wnt信号通路,多肽偶联核素;68Ga标记的PET药物,肝细胞癌(差异化疾病),I期临床,2024/12/10,Active,肿瘤领域,DR036238,美国,phase 1,I期临床,2024/12/10,phase 1,1,TRUE,FALSE,TRUE,['RayzeBio(Bristol-Myers Squibb)'],['RayzeBio(Bristol-Myers Squibb)'],1,['RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
[68Ga]-RYZ-GPC3,[68Ga]-RYZ-GPC3,[68Ga]-RYZ-GPC3;RYZ811,PET显像,PET imaging,GPC3,anti-GPC3多肽偶联核素;68Ga标记的PET药物,RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class;Wnt信号通路,多肽偶联核素;68Ga标记的PET药物,PET显像,I期临床,,Active,诊断试剂领域,DR036238,美国,phase 1,I期临床,2024/12/10,phase 1,1,TRUE,FALSE,TRUE,['RayzeBio(Bristol-Myers Squibb)'],['RayzeBio(Bristol-Myers Squibb)'],1,['RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,
68Ga-3BP-3940,68Ga-3BP-3940,68Ga-3BP-3940,实体瘤,solid tumors,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,3B Pharmaceuticals(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,实体瘤,I期临床,2025/4/24,Active,肿瘤领域,DR078864,欧洲,phase 1,I期临床,2025/4/24,phase 1,1,TRUE,FALSE,FALSE,[],['3B Pharmaceuticals'],1,['3B Pharmaceuticals(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
68Ga-3BP-3940,68Ga-3BP-3940,68Ga-3BP-3940,PET显像,PET imaging,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,3B Pharmaceuticals(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,PET显像,I期临床,,Active,诊断试剂领域,DR078864,欧洲,phase 1,I期临床,2025/4/24,phase 1,1,TRUE,FALSE,FALSE,[],['3B Pharmaceuticals'],1,['3B Pharmaceuticals(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,
13N-oxytocin,13N-oxytocin,13N-oxytocin,PET显像,PET imaging,OXTR,13N标记的PET药物;anti-OXTR多肽偶联核素,Tonix Pharmaceuticals(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,13N标记的PET药物;多肽偶联核素,PET显像,I期临床,2025/5/2,Active,诊断试剂领域,DR079142,美国,phase 1,I期临床,2025/5/2,phase 1,1,TRUE,FALSE,FALSE,[],['Tonix Pharmaceuticals'],1,['Tonix Pharmaceuticals(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,
FAP-2286,FAP-2286,FAP-2286,实体瘤,solid tumors,FAP,FAP抑制剂,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),创新药,化药,多肽,环肽;差异化疾病,抑制剂,实体瘤,I期临床,,Active,肿瘤领域,DR062105,欧洲,phase 1,I期临床,2025/5/12,phase 1,3,TRUE,FALSE,TRUE,['Novartis'],['3B Pharmaceuticals'],1,"['Novartis(Top20 MNC)', '3B Pharmaceuticals(原研)', 'Clovis Oncology(无权益)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
FAP-2286,FAP-2286,FAP-2286,骨转移疼痛,bone metastasis pain,FAP,FAP抑制剂,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),创新药,化药,多肽,环肽;差异化疾病,抑制剂,骨转移疼痛(差异化疾病),I期临床,2025/5/12,Active,肿瘤领域,DR062105,欧洲,phase 1,I期临床,2025/5/12,phase 1,3,TRUE,FALSE,TRUE,['Novartis'],['3B Pharmaceuticals'],1,"['Novartis(Top20 MNC)', '3B Pharmaceuticals(原研)', 'Clovis Oncology(无权益)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
AUBE00,AUBE00,AUBE00,实体瘤,solid tumors,KRAS,KRAS抑制剂,Chugai Pharmaceutical(Top20 MNC)(原研),创新药,化药,其他,环肽;难成药靶点,抑制剂,实体瘤,I期临床,2025/5/12,Active,肿瘤领域,DR080098,日本,phase 1,I期临床,2025/5/12,phase 1,1,TRUE,FALSE,TRUE,['Chugai Pharmaceutical'],['Chugai Pharmaceutical'],1,['Chugai Pharmaceutical(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
68Ga-CCZ01048,68Ga-CCZ01048,68Ga-CCZ01048,黑色素瘤,melanoma,MSH;MC1R,MSH类似物;anti-MC1R多肽偶联核素;68Ga标记的PET药物,BC Cancer(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;中国无申报;Potential First-in-Class;Melanogenesis;瘦素-黑皮素通路,类似物;多肽偶联核素;68Ga标记的PET药物,黑色素瘤,I期临床,2025/5/22,Active,肿瘤领域;罕见疾病领域,DR080251,加拿大,phase 1,I期临床,2025/5/22,phase 1,1,TRUE,TRUE,FALSE,[],['BC Cancer'],1,['BC Cancer(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
68Ga-CCZ01048,68Ga-CCZ01048,68Ga-CCZ01048,诊断试剂,diagnostic reagents,MSH;MC1R,MSH类似物;anti-MC1R多肽偶联核素;68Ga标记的PET药物,BC Cancer(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;中国无申报;Potential First-in-Class;Melanogenesis;瘦素-黑皮素通路,类似物;多肽偶联核素;68Ga标记的PET药物,诊断试剂,I期临床,2025/5/22,Active,诊断试剂领域,DR080251,加拿大,phase 1,I期临床,2025/5/22,phase 1,1,TRUE,FALSE,FALSE,[],['BC Cancer'],1,['BC Cancer(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,
MC-339,MC-339,MC-339;MC339;225Ac-ETN029;ESP359;225Ac-CTP002096,实体瘤,solid tumors,DLL3,anti-DLL3多肽偶联核素;225Ac标记的放射性药物,Mariana Oncology(Novartis)(Top20 MNC)(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Notch信号通路;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,实体瘤,I期临床,2025/6/5,Active,肿瘤领域,DR007854,美国,phase 1,I期临床,2025/6/5,phase 1,1,TRUE,FALSE,TRUE,['Mariana Oncology(Novartis)'],['Mariana Oncology(Novartis)'],1,['Mariana Oncology(Novartis)(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
MC-339,MC-339,MC-339;MC339;225Ac-ETN029;ESP359;225Ac-CTP002096,小细胞肺癌,small cell lung cancer,DLL3,anti-DLL3多肽偶联核素;225Ac标记的放射性药物,Mariana Oncology(Novartis)(Top20 MNC)(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Notch信号通路;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,小细胞肺癌,I期临床,2025/6/5,Active,肿瘤领域;罕见疾病领域,DR007854,美国,phase 1,I期临床,2025/6/5,phase 1,1,TRUE,TRUE,TRUE,['Mariana Oncology(Novartis)'],['Mariana Oncology(Novartis)'],1,['Mariana Oncology(Novartis)(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
MC-339,MC-339,MC-339;MC339;225Ac-ETN029;ESP359;225Ac-CTP002096,胃肠胰神经内分泌肿瘤,Gastroenteropancreatic neuroendocrine tumors,DLL3,anti-DLL3多肽偶联核素;225Ac标记的放射性药物,Mariana Oncology(Novartis)(Top20 MNC)(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Notch信号通路;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,胃肠胰神经内分泌肿瘤,I期临床,2025/6/5,Active,肿瘤领域;罕见疾病领域,DR007854,美国,phase 1,I期临床,2025/6/5,phase 1,1,TRUE,TRUE,TRUE,['Mariana Oncology(Novartis)'],['Mariana Oncology(Novartis)'],1,['Mariana Oncology(Novartis)(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
MC-339,MC-339,MC-339;MC339;225Ac-ETN029;ESP359;225Ac-CTP002096,大细胞神经内分泌癌,large cell neuroendocrine carcinoma,DLL3,anti-DLL3多肽偶联核素;225Ac标记的放射性药物,Mariana Oncology(Novartis)(Top20 MNC)(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Notch信号通路;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,大细胞神经内分泌癌,I期临床,2025/6/5,Active,肿瘤领域;罕见疾病领域,DR007854,美国,phase 1,I期临床,2025/6/5,phase 1,1,TRUE,TRUE,TRUE,['Mariana Oncology(Novartis)'],['Mariana Oncology(Novartis)'],1,['Mariana Oncology(Novartis)(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
MC-339,MC-339,MC-339;MC339;225Ac-ETN029;ESP359;225Ac-CTP002096,神经内分泌前列腺癌,neuroendocrine prostate cancer,DLL3,anti-DLL3多肽偶联核素;225Ac标记的放射性药物,Mariana Oncology(Novartis)(Top20 MNC)(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Notch信号通路;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,神经内分泌前列腺癌,I期临床,2025/6/5,Active,肿瘤领域,DR007854,美国,phase 1,I期临床,2025/6/5,phase 1,1,TRUE,FALSE,TRUE,['Mariana Oncology(Novartis)'],['Mariana Oncology(Novartis)'],1,['Mariana Oncology(Novartis)(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
MC-339,MC-339,MC-339;MC339;225Ac-ETN029;ESP359;225Ac-CTP002096,肺神经内分泌肿瘤,Pulmonary neuroendocrine tumors,DLL3,anti-DLL3多肽偶联核素;225Ac标记的放射性药物,Mariana Oncology(Novartis)(Top20 MNC)(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Notch信号通路;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,肺神经内分泌肿瘤,I期临床,2025/6/5,Active,肿瘤领域;罕见疾病领域,DR007854,美国,phase 1,I期临床,2025/6/5,phase 1,1,TRUE,TRUE,TRUE,['Mariana Oncology(Novartis)'],['Mariana Oncology(Novartis)'],1,['Mariana Oncology(Novartis)(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
TT-P34,TT-P34,TT-P34,帕金森病,Parkinson's disease,CREB,CREB激活剂,Teitur Trophics(原研),创新药,化药,多肽,环肽;Potential First-in-Class,激活剂,帕金森病,I期临床,2025/6/13,Active,神经领域,DR047339,欧洲,phase 1,I期临床,2025/6/13,phase 1,1,TRUE,FALSE,FALSE,[],['Teitur Trophics'],1,['Teitur Trophics(原研)'],神经领域,['神经领域'],1,神经领域,,,1,1,Neurology,Neurology,,
TT-P34,TT-P34,TT-P34,亨廷顿氏病,Huntington's disease,CREB,CREB激活剂,Teitur Trophics(原研),创新药,化药,多肽,环肽;Potential First-in-Class,激活剂,亨廷顿氏病,临床前,,Active,神经领域;罕见疾病领域,DR047339,欧洲,pre-clinical,I期临床,2025/6/13,phase 1,1,TRUE,TRUE,FALSE,[],['Teitur Trophics'],1,['Teitur Trophics(原研)'],神经领域,['神经领域'],1,神经领域,,,1,-1,Neurology,Neurology,,
TT-P34,TT-P34,TT-P34,额颞叶痴呆,frontotemporal dementia,CREB,CREB激活剂,Teitur Trophics(原研),创新药,化药,多肽,环肽;Potential First-in-Class,激活剂,额颞叶痴呆,临床前,,Active,神经领域;罕见疾病领域,DR047339,欧洲,pre-clinical,I期临床,2025/6/13,phase 1,1,TRUE,TRUE,FALSE,[],['Teitur Trophics'],1,['Teitur Trophics(原研)'],神经领域,['神经领域'],1,神经领域,,,1,-1,Neurology,Neurology,,
68Ga-nectin-4 bicyclic peptide,68Ga-nectin-4 bicyclic peptide,68Ga-nectin-4 bicyclic peptide,实体瘤,solid tumors,nectin-4,anti-nectin-4多肽偶联核素;68Ga标记的PET药物,苏州大学附属第一医院(原研),创新药,其他,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,实体瘤,I期临床,2025/7/9,Active,肿瘤领域,DR082017,中国(内地),phase 1,I期临床,2025/7/9,phase 1,1,TRUE,FALSE,FALSE,[],['苏州大学附属第一医院'],1,['苏州大学附属第一医院(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
68Ga-nectin-4 bicyclic peptide,68Ga-nectin-4 bicyclic peptide,68Ga-nectin-4 bicyclic peptide,PET显像,PET imaging,nectin-4,anti-nectin-4多肽偶联核素;68Ga标记的PET药物,苏州大学附属第一医院(原研),创新药,其他,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,PET显像,I期临床,2025/7/9,Active,诊断试剂领域,DR082017,中国(内地),phase 1,I期临床,2025/7/9,phase 1,1,TRUE,FALSE,FALSE,[],['苏州大学附属第一医院'],1,['苏州大学附属第一医院(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,
68Ga-DOTA-WL12,68Ga-DOTA-WL12,68Ga-DOTA-WL12,头颈癌,Head and neck cancer,PDL1,anti-PDL1多肽偶联核素;68Ga标记的PET药物,复旦大学附属华山医院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;肿瘤免疫,68Ga标记的PET药物;多肽偶联核素,头颈癌(差异化疾病),I期临床,2025/7/30,Active,肿瘤领域,DR082669,中国(内地),phase 1,I期临床,2025/7/30,phase 1,1,TRUE,FALSE,FALSE,[],['复旦大学附属华山医院'],1,['复旦大学附属华山医院(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
68Ga-DOTA-WL12,68Ga-DOTA-WL12,68Ga-DOTA-WL12,PET显像,PET imaging,PDL1,anti-PDL1多肽偶联核素;68Ga标记的PET药物,复旦大学附属华山医院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;肿瘤免疫,68Ga标记的PET药物;多肽偶联核素,PET显像,I期临床,2025/7/30,Active,诊断试剂领域,DR082669,中国(内地),phase 1,I期临床,2025/7/30,phase 1,1,TRUE,FALSE,FALSE,[],['复旦大学附属华山医院'],1,['复旦大学附属华山医院(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,
68Ga-DOTA-WL12,68Ga-DOTA-WL12,68Ga-DOTA-WL12,非小细胞肺癌,non-small cell lung cancer,PDL1,anti-PDL1多肽偶联核素;68Ga标记的PET药物,复旦大学附属华山医院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;肿瘤免疫,68Ga标记的PET药物;多肽偶联核素,非小细胞肺癌(差异化疾病),临床前,,Active,肿瘤领域,DR082669,中国(内地),pre-clinical,I期临床,2025/7/30,phase 1,1,TRUE,FALSE,FALSE,[],['复旦大学附属华山医院'],1,['复旦大学附属华山医院(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,-1,Oncology,Oncology,,
[18F]DK222,[18F]DK222,[18F]DK222;PMI06,尿路上皮癌,urothelial carcinoma,PDL1,18F标记的PET药物;anti-PDL1多肽偶联核素,Johns Hopkins University;Precision Molecular(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;肿瘤免疫,18F标记的PET药物;多肽偶联核素,尿路上皮癌(差异化疾病),I期临床,2025/8/24,Active,肿瘤领域,DR056475,美国,phase 1,I期临床,2025/8/24,phase 1,2,TRUE,FALSE,FALSE,[],['Precision Molecular'],1,"['Johns Hopkins University', 'Precision Molecular(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
18F-SiTATE,18F-SiTATE (LMU Munich),18F-SiTATE;18F-SiTATE (LMU Munich);[18F]SiTATE,神经母细胞瘤,Neuroblastoma,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,Ludwig Maximilian University of Munich(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,18F标记的PET药物;多肽偶联核素,神经母细胞瘤,I期临床,2025/9/26,Active,肿瘤领域;罕见疾病领域,DR081193,欧洲,phase 1,I期临床,2025/9/26,phase 1,1,TRUE,TRUE,FALSE,[],['Ludwig Maximilian University of Munich'],1,['Ludwig Maximilian University of Munich(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
18F-SiTATE,18F-SiTATE (LMU Munich),18F-SiTATE;18F-SiTATE (LMU Munich);[18F]SiTATE,抑郁症,depression,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,Ludwig Maximilian University of Munich(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,18F标记的PET药物;多肽偶联核素,抑郁症,I期临床,2025/9/26,Active,精神领域,DR081193,欧洲,phase 1,I期临床,2025/9/26,phase 1,1,TRUE,FALSE,FALSE,[],['Ludwig Maximilian University of Munich'],1,['Ludwig Maximilian University of Munich(原研)'],精神领域,['精神领域'],1,精神领域,,,1,1,Psychiatry,Psychiatry,,
18F-SiTATE,18F-SiTATE (LMU Munich),18F-SiTATE;18F-SiTATE (LMU Munich);[18F]SiTATE,不孕不育,Infertility,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,Ludwig Maximilian University of Munich(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,18F标记的PET药物;多肽偶联核素,不孕不育,I期临床,2025/9/26,Active,泌尿生殖领域,DR081193,欧洲,phase 1,I期临床,2025/9/26,phase 1,1,TRUE,FALSE,FALSE,[],['Ludwig Maximilian University of Munich'],1,['Ludwig Maximilian University of Munich(原研)'],泌尿生殖领域,['泌尿生殖领域'],1,泌尿生殖领域,,,1,1,Genitourinary,Genitourinary,,
18F-SiTATE,18F-SiTATE (LMU Munich),18F-SiTATE;18F-SiTATE (LMU Munich);[18F]SiTATE,嗜铬细胞瘤,Pheochromocytoma,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,Ludwig Maximilian University of Munich(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,18F标记的PET药物;多肽偶联核素,嗜铬细胞瘤,I期临床,2025/9/26,Active,肿瘤领域;罕见疾病领域,DR081193,欧洲,phase 1,I期临床,2025/9/26,phase 1,1,TRUE,TRUE,FALSE,[],['Ludwig Maximilian University of Munich'],1,['Ludwig Maximilian University of Munich(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
18F-SiTATE,18F-SiTATE (LMU Munich),18F-SiTATE;18F-SiTATE (LMU Munich);[18F]SiTATE,骨转移疼痛,bone metastasis pain,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,Ludwig Maximilian University of Munich(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,18F标记的PET药物;多肽偶联核素,骨转移疼痛,I期临床,2025/9/26,Active,肿瘤领域,DR081193,欧洲,phase 1,I期临床,2025/9/26,phase 1,1,TRUE,FALSE,FALSE,[],['Ludwig Maximilian University of Munich'],1,['Ludwig Maximilian University of Munich(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
18F-SiTATE,18F-SiTATE (LMU Munich),18F-SiTATE;18F-SiTATE (LMU Munich);[18F]SiTATE,副神经节瘤,paraganglioma,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,Ludwig Maximilian University of Munich(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,18F标记的PET药物;多肽偶联核素,副神经节瘤,I期临床,2025/9/26,Active,肿瘤领域;罕见疾病领域,DR081193,欧洲,phase 1,I期临床,2025/9/26,phase 1,1,TRUE,TRUE,FALSE,[],['Ludwig Maximilian University of Munich'],1,['Ludwig Maximilian University of Munich(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
18F-SiTATE,18F-SiTATE (LMU Munich),18F-SiTATE;18F-SiTATE (LMU Munich);[18F]SiTATE,PET显像,PET imaging,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,Ludwig Maximilian University of Munich(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,18F标记的PET药物;多肽偶联核素,PET显像,临床前,,Active,诊断试剂领域,DR081193,欧洲,pre-clinical,I期临床,2025/9/26,phase 1,1,TRUE,FALSE,FALSE,[],['Ludwig Maximilian University of Munich'],1,['Ludwig Maximilian University of Munich(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,1,-1,Diagnostic Reagents,Diagnostic Reagents,,
18F-SiTATE,18F-SiTATE (LMU Munich),18F-SiTATE;18F-SiTATE (LMU Munich);[18F]SiTATE,脑膜瘤,Meningioma,SSTR,anti-SSTR多肽偶联核素;18F标记的PET药物,Ludwig Maximilian University of Munich(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,18F标记的PET药物;多肽偶联核素,脑膜瘤(差异化疾病),临床前,,Active,肿瘤领域,DR081193,欧洲,pre-clinical,I期临床,2025/9/26,phase 1,1,TRUE,FALSE,FALSE,[],['Ludwig Maximilian University of Munich'],1,['Ludwig Maximilian University of Munich(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,-1,Oncology,Oncology,,
225Ac-DOTA-LM3,225Ac-DOTA-LM3,225Ac-DOTA-LM3,神经内分泌肿瘤,neuroendocrine tumors,SSTR2,225Ac标记的放射性药物;anti-SSTR2多肽偶联核素,Università Cattolica del Sacro Cuore(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物,多肽偶联核素;225Ac标记的放射性药物,神经内分泌肿瘤,I期临床,,Active,肿瘤领域;罕见疾病领域,DR089738,欧洲,phase 1,I期临床,,phase 1,1,TRUE,TRUE,FALSE,[],['Università Cattolica del Sacro Cuore'],1,['Università Cattolica del Sacro Cuore(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
CAM4071,CAM4071 (pasireotide FluidCrystal® long-acting injection),CAM4071;CAM4071 (帕瑞肽FluidCrystal®长效注射剂）;CAM4071 (pasireotide FluidCrystal® long-acting injection),肢端肥大症,acromegaly,somatostatin,somatostatin类似物,Camurus(原研),微创新,化药,多肽,环肽,类似物,肢端肥大症,I期临床,,Active,内分泌及代谢领域;罕见疾病领域,DR018258,欧洲,phase 1,I期临床,,phase 1,1,TRUE,TRUE,FALSE,[],['Camurus'],1,['Camurus(原研)'],内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,1,1,Endocrinology & Metabolism,Endocrinology & Metabolism,,
CAM4071,CAM4071 (pasireotide FluidCrystal® long-acting injection),CAM4071;CAM4071 (帕瑞肽FluidCrystal®长效注射剂）;CAM4071 (pasireotide FluidCrystal® long-acting injection),库欣综合征,Cushing's syndrome,somatostatin,somatostatin类似物,Camurus(原研),微创新,化药,多肽,环肽,类似物,库欣综合征,I期临床,,Active,内分泌及代谢领域;罕见疾病领域,DR018258,欧洲,phase 1,I期临床,,phase 1,1,TRUE,TRUE,FALSE,[],['Camurus'],1,['Camurus(原研)'],内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,1,1,Endocrinology & Metabolism,Endocrinology & Metabolism,,
CsA-SNU2001,CsA-SNU2001,CsA-SNU2001;SNU2101,干眼病,dry eye disease,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,CAMP Therapeutics(原研),微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶;中国无申报,抑制剂;分子胶,干眼病,I期临床,,Active,眼科领域,DR075599,韩国,phase 1,I期临床,,phase 1,1,TRUE,FALSE,FALSE,[],['CAMP Therapeutics'],1,['CAMP Therapeutics(原研)'],眼科领域,['眼科领域'],1,眼科领域,,,1,1,Ophthalmology,Ophthalmology,,
NVI-100,NVI-100 (AXN-001),NVI-100;NVI-100 (AXN-001);FE205030,偏头痛,Migraine,CGRP receptor,CGRP receptor拮抗剂,Ferring Pharmaceuticals(原研);Nuvie Bio,创新药,化药,多肽,环肽;G蛋白偶联受体;中国无申报,拮抗剂,偏头痛,I期临床,,Active,麻醉镇痛领域;神经领域,DR072945,欧洲,phase 1,I期临床,,phase 1,2,TRUE,FALSE,FALSE,[],['Ferring Pharmaceuticals'],1,"['Ferring Pharmaceuticals(原研)', 'Nuvie Bio']",麻醉镇痛领域,"['麻醉镇痛领域', '神经领域']",2,麻醉镇痛领域,神经领域,,1,1,Anesthesia & Analgesia,Anesthesia & Analgesia,Neurology,
ZP BNP,ZP BNP (nesiritide patch),ZP BNP;ZP BNP (奈西立肽贴剂);ZP BNP (nesiritide patch),急性失代偿性心力衰竭,acute decompensated heart failure,BNP,重组BNP,Zosano Pharma(原研),微创新,生物,多肽,环肽,重组,急性失代偿性心力衰竭,I期临床,,Active,心脑血管领域,DR059743,美国,phase 1,I期临床,,phase 1,1,TRUE,FALSE,FALSE,[],['Zosano Pharma'],1,['Zosano Pharma(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,1,1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
[68Ga]-BCY25286,[68Ga]-BCY25286,[68Ga]-BCY25286,PET显像,PET imaging,MMP14,anti-MMP14多肽偶联核素;68Ga标记的PET药物,Bicycle Therapeutics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,多肽偶联核素;68Ga标记的PET药物,PET显像,I期临床,,Active,诊断试剂领域,DR077676,欧洲,phase 1,I期临床,,phase 1,1,TRUE,FALSE,FALSE,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,
[68Ga]-BCY25286,[68Ga]-BCY25286,[68Ga]-BCY25286,肺腺癌,lung adenocarcinoma,MMP14,anti-MMP14多肽偶联核素;68Ga标记的PET药物,Bicycle Therapeutics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物,多肽偶联核素;68Ga标记的PET药物,肺腺癌(差异化疾病),I期临床,,Active,肿瘤领域,DR077676,欧洲,phase 1,I期临床,,phase 1,1,TRUE,FALSE,FALSE,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
[68Ga]Ga-C1-FAP-2286,[68Ga]Ga-C1-FAP-2286,[68Ga]Ga-C1-FAP-2286,肿瘤,tumor,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,南方医科大学南方医院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,肿瘤,I期临床,,Active,肿瘤领域,DR081012,中国(内地),phase 1,I期临床,,phase 1,1,TRUE,FALSE,FALSE,[],['南方医科大学南方医院'],1,['南方医科大学南方医院(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
[68Ga]Ga-C1-FAP-2286,[68Ga]Ga-C1-FAP-2286,[68Ga]Ga-C1-FAP-2286,PET显像,PET imaging,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,南方医科大学南方医院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,PET显像,I期临床,,Active,诊断试剂领域,DR081012,中国(内地),phase 1,I期临床,,phase 1,1,TRUE,FALSE,FALSE,[],['南方医科大学南方医院'],1,['南方医科大学南方医院(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,
[68Ga]PSV377,[68Ga]PSV377,[68Ga]PSV377;[68Ga]Ga-PSV377,癌症,cancer,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,Perspective Therapeutics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,多肽偶联核素;68Ga标记的PET药物,癌症,I期临床,,Active,肿瘤领域,DR089770,美国,phase 1,I期临床,,phase 1,1,TRUE,FALSE,FALSE,[],['Perspective Therapeutics'],1,['Perspective Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
[68Ga]PSV377,[68Ga]PSV377,[68Ga]PSV377;[68Ga]Ga-PSV377,PET显像,PET imaging,FAP,anti-FAP多肽偶联核素;68Ga标记的PET药物,Perspective Therapeutics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,多肽偶联核素;68Ga标记的PET药物,PET显像,I期临床,,Active,诊断试剂领域,DR089770,美国,phase 1,I期临床,,phase 1,1,TRUE,FALSE,FALSE,[],['Perspective Therapeutics'],1,['Perspective Therapeutics(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,1,1,Diagnostic Reagents,Diagnostic Reagents,,
lanreotide acetate CRF,lanreotide acetate controlled release formulation,lanreotide acetate CRF;醋酸兰瑞肽控释注射剂;lanreotide acetate controlled release formulation,神经内分泌肿瘤,neuroendocrine tumors,somatostatin,somatostatin类似物,ASCIL Biopharm(原研),微创新,化药,多肽,环肽;中国无申报,类似物,神经内分泌肿瘤,I期临床,,Active,肿瘤领域;罕见疾病领域,DR009210,澳大利亚,phase 1,I期临床,,phase 1,1,TRUE,TRUE,FALSE,[],['ASCIL Biopharm'],1,['ASCIL Biopharm(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
octreotide acetate CR,octreotide acetate CR (octreotide controlled release formulation）,octreotide acetate CR;octreotide acetate CR (奥曲肽控释注射剂）;octreotide acetate CR (octreotide controlled release formulation）;octreotide acetate CRF,神经内分泌肿瘤,neuroendocrine tumors,somatostatin,somatostatin类似物,ASCIL Biopharm(原研),微创新,化药,多肽,环肽;中国无申报,类似物,神经内分泌肿瘤,I期临床,,Active,肿瘤领域;罕见疾病领域,DR059890,澳大利亚,phase 1,I期临床,,phase 1,1,TRUE,TRUE,FALSE,[],['ASCIL Biopharm'],1,['ASCIL Biopharm(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,1,1,Oncology,Oncology,,
GP-033,GP-033,GP-033,炎症性肠病,inflammatory bowel disease,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,济群医药(原研),微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,炎症性肠病,申报临床,2024/3/30,Active,免疫领域;消化领域,DR014293,中国(内地),ind,申报临床,2024/1/10,ind,1,TRUE,FALSE,FALSE,[],['济群医药'],1,['济群医药(原研)'],免疫领域,"['免疫领域', '消化领域']",2,免疫领域,消化领域,,0,0,Immunology,Immunology,Digestive System,
GP-033,GP-033,GP-033,克罗恩病,Crohn's disease,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,济群医药(原研),微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,克罗恩病,申报临床,2024/3/30,Active,消化领域;免疫领域,DR014293,中国(内地),ind,申报临床,2024/1/10,ind,1,TRUE,FALSE,FALSE,[],['济群医药'],1,['济群医药(原研)'],消化领域,"['消化领域', '免疫领域']",2,消化领域,免疫领域,,0,0,Digestive System,Digestive System,Immunology,
GP-033,GP-033,GP-033,溃疡性结肠炎,ulcerative colitis,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,济群医药(原研),微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,溃疡性结肠炎,申报临床,2024/1/10,Active,免疫领域;消化领域,DR014293,中国(内地),ind,申报临床,2024/1/10,ind,1,TRUE,FALSE,FALSE,[],['济群医药'],1,['济群医药(原研)'],免疫领域,"['免疫领域', '消化领域']",2,免疫领域,消化领域,,0,0,Immunology,Immunology,Digestive System,
[225Ac]Ac-DOTATOC,[225Ac]Ac-DOTATOC,[225Ac]Ac-DOTATOC,胰腺神经内分泌肿瘤,pancreatic neuroendocrine tumors,SSTR,anti-SSTR多肽偶联核素;225Ac标记的放射性药物,Nantes University Hospital(原研);Angers University(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,225Ac标记的放射性药物;多肽偶联核素,胰腺神经内分泌肿瘤(差异化疾病),临床前,2024/9/13,Active,肿瘤领域;罕见疾病领域,DR081531,欧洲,pre-clinical,临床前,2024/9/13,pre-clinical,2,TRUE,TRUE,FALSE,[],"['Nantes University Hospital', 'Angers University']",2,"['Nantes University Hospital(原研)', 'Angers University(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
[18F]AlF-NOTA-A6P,[18F]AlF-NOTA-A6P,[18F]AlF-NOTA-A6P,PET显像,PET imaging,ITGA6,18F标记的PET药物;anti-ITGA6多肽偶联核素,江南大学附属医院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;18F标记的PET药物,PET显像,临床前,2024/10/17,Active,诊断试剂领域,DR081455,中国(内地),pre-clinical,临床前,2024/10/17,pre-clinical,1,TRUE,FALSE,FALSE,[],['江南大学附属医院'],1,['江南大学附属医院(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
[18F]AlF-NOTA-A6P,[18F]AlF-NOTA-A6P,[18F]AlF-NOTA-A6P,结直肠癌,colorectal cancer,ITGA6,18F标记的PET药物;anti-ITGA6多肽偶联核素,江南大学附属医院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;18F标记的PET药物,结直肠癌,临床前,2024/10/17,Active,肿瘤领域,DR081455,中国(内地),pre-clinical,临床前,2024/10/17,pre-clinical,1,TRUE,FALSE,FALSE,[],['江南大学附属医院'],1,['江南大学附属医院(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
[225Ac]Ac-EBTATE,[225Ac]Ac-EBTATE,[225Ac]Ac-EBTATE,小细胞肺癌,small cell lung cancer,SSTR2,225Ac标记的放射性药物;anti-SSTR2多肽偶联核素,University of Saskatchewan(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;中国无申报,多肽偶联核素;225Ac标记的放射性药物,小细胞肺癌,临床前,2024/12/4,Active,肿瘤领域;罕见疾病领域,DR081419,加拿大,pre-clinical,临床前,2024/12/4,pre-clinical,1,TRUE,TRUE,FALSE,[],['University of Saskatchewan'],1,['University of Saskatchewan(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
[225Ac]Ac-EBTATE,[225Ac]Ac-EBTATE,[225Ac]Ac-EBTATE,胰腺神经内分泌肿瘤,pancreatic neuroendocrine tumors,SSTR2,225Ac标记的放射性药物;anti-SSTR2多肽偶联核素,University of Saskatchewan(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;中国无申报,多肽偶联核素;225Ac标记的放射性药物,胰腺神经内分泌肿瘤(差异化疾病),临床前,2024/12/4,Active,肿瘤领域;罕见疾病领域,DR081419,加拿大,pre-clinical,临床前,2024/12/4,pre-clinical,1,TRUE,TRUE,FALSE,[],['University of Saskatchewan'],1,['University of Saskatchewan(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
myostatin therapeutic peptide,myostatin therapeutic peptide (Kawasaki Medical School),myostatin therapeutic peptide;myostatin therapeutic peptide (Kawasaki Medical School),肥胖,obesity,myostatin,myostatin抑制剂,PeptiDream(原研);Kawasaki Medical School(原研),创新药,化药,多肽,环肽;TGF-β信号通路,抑制剂,肥胖,临床前,2024/12/12,Active,内分泌及代谢领域,DR011921,日本,pre-clinical,临床前,2024/12/12,pre-clinical,2,TRUE,FALSE,FALSE,[],"['PeptiDream', 'Kawasaki Medical School']",2,"['PeptiDream(原研)', 'Kawasaki Medical School(原研)']",内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,-1,-1,Endocrinology & Metabolism,Endocrinology & Metabolism,,
myostatin therapeutic peptide,myostatin therapeutic peptide (Kawasaki Medical School),myostatin therapeutic peptide;myostatin therapeutic peptide (Kawasaki Medical School),假肥大性肌营养不良,Duchenne muscular dystrophy,myostatin,myostatin抑制剂,PeptiDream(原研);Kawasaki Medical School(原研),创新药,化药,多肽,环肽;TGF-β信号通路,抑制剂,假肥大性肌营养不良,临床前,,Active,骨骼肌肉领域;罕见疾病领域,DR011921,日本,pre-clinical,临床前,2024/12/12,pre-clinical,2,TRUE,TRUE,FALSE,[],"['PeptiDream', 'Kawasaki Medical School']",2,"['PeptiDream(原研)', 'Kawasaki Medical School(原研)']",骨骼肌肉领域,['骨骼肌肉领域'],1,骨骼肌肉领域,,,-1,-1,Musculoskeletal,Musculoskeletal,,
MCR环肽,MCR cyclic peptide (wepon),MCR环肽;MCR环肽 (wepon);MCR cyclic peptide (wepon),肥胖,obesity,MC4R,MC4R激动剂,万邦德制药(原研),创新药,化药,小分子,环肽;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,肥胖,临床前,2025/3/29,Active,内分泌及代谢领域,DR077260,中国(内地),pre-clinical,临床前,2025/3/29,pre-clinical,1,TRUE,FALSE,FALSE,[],['万邦德制药'],1,['万邦德制药(原研)'],内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,-1,-1,Endocrinology & Metabolism,Endocrinology & Metabolism,,
[149Tb]Tb-DOTA-LM3,[149Tb]Tb-DOTA-LM3,[149Tb]Tb-DOTA-LM3,肿瘤,tumor,SSTR2,149Tb标记的放射性药物;anti-SSTR2多肽偶联核素,Paul Scherrer Institute(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;149Tb标记的放射性药物,肿瘤,临床前,2025/3/31,Active,肿瘤领域,DR081317,欧洲,pre-clinical,临床前,2025/3/31,pre-clinical,1,TRUE,FALSE,FALSE,[],['Paul Scherrer Institute'],1,['Paul Scherrer Institute(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
[149Tb]Tb-DOTATATE,[149Tb]Tb-DOTATATE,[149Tb]Tb-DOTATATE,肿瘤,tumor,SSTR,anti-SSTR多肽偶联核素;149Tb标记的放射性药物,Paul Scherrer Institute(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;149Tb标记的放射性药物,肿瘤,临床前,2025/3/31,Active,肿瘤领域,DR081316,欧洲,pre-clinical,临床前,2025/3/31,pre-clinical,1,TRUE,FALSE,FALSE,[],['Paul Scherrer Institute'],1,['Paul Scherrer Institute(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
Al18F-NOTA-FAP-2286,Al18F-NOTA-FAP-2286,Al18F-NOTA-FAP-2286,前列腺癌,prostate cancer,FAP,anti-FAP多肽偶联核素;18F标记的PET药物,贵州医科大学(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,前列腺癌,临床前,2025/4/23,Active,肿瘤领域,DR081166,中国(内地),pre-clinical,临床前,2025/4/23,pre-clinical,1,TRUE,FALSE,FALSE,[],['贵州医科大学'],1,['贵州医科大学(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
Al18F-NOTA-FAP-2286,Al18F-NOTA-FAP-2286,Al18F-NOTA-FAP-2286,PET显像,PET imaging,FAP,anti-FAP多肽偶联核素;18F标记的PET药物,贵州医科大学(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,PET显像,临床前,2025/4/23,Active,诊断试剂领域,DR081166,中国(内地),pre-clinical,临床前,2025/4/23,pre-clinical,1,TRUE,FALSE,FALSE,[],['贵州医科大学'],1,['贵州医科大学(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
177Lu-PD-29875,177Lu-PD-29875,177Lu-PD-29875,胰腺癌,pancreatic cancer,CLDN18.2,177Lu标记的放射性药物;anti-CLDN18.2多肽偶联核素,PeptiDream(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,胰腺癌,临床前,2025/4/27,Active,肿瘤领域;罕见疾病领域,DR081156,日本,pre-clinical,临床前,2025/4/27,pre-clinical,1,TRUE,TRUE,FALSE,[],['PeptiDream'],1,['PeptiDream(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
[18F]AlF-NOTA-SC,[18F]AlF-NOTA-SC,[18F]AlF-NOTA-SC,肿瘤,tumor,CXCR4,18F标记的PET药物;anti-CXCR4多肽偶联核素,Katholieke Universiteit Leuven(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体,多肽偶联核素;18F标记的PET药物,肿瘤,临床前,2025/4/30,Active,肿瘤领域,DR081435,欧洲,pre-clinical,临床前,2025/4/30,pre-clinical,1,TRUE,FALSE,FALSE,[],['Katholieke Universiteit Leuven'],1,['Katholieke Universiteit Leuven(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
[18F]AlF-NOTA-SC,[18F]AlF-NOTA-SC,[18F]AlF-NOTA-SC,PET显像,PET imaging,CXCR4,18F标记的PET药物;anti-CXCR4多肽偶联核素,Katholieke Universiteit Leuven(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体,多肽偶联核素;18F标记的PET药物,PET显像,临床前,2025/4/30,Active,诊断试剂领域,DR081435,欧洲,pre-clinical,临床前,2025/4/30,pre-clinical,1,TRUE,FALSE,FALSE,[],['Katholieke Universiteit Leuven'],1,['Katholieke Universiteit Leuven(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
[64Cu]CARP-2,[64Cu]CARP-2,[64Cu]CARP-2,肿瘤,tumor,uPAR,anti-uPAR多肽偶联核素;64Cu标记的放射性示踪剂,中国医学科学院&北京协和医学院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽,64Cu标记的放射性示踪剂;多肽偶联核素,肿瘤,临床前,2025/5/19,Active,肿瘤领域,DR081128,中国(内地),pre-clinical,临床前,2025/5/19,pre-clinical,1,TRUE,FALSE,FALSE,[],['中国医学科学院&北京协和医学院'],1,['中国医学科学院&北京协和医学院(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
[64Cu]CARP-2,[64Cu]CARP-2,[64Cu]CARP-2,PET显像,PET imaging,uPAR,anti-uPAR多肽偶联核素;64Cu标记的放射性示踪剂,中国医学科学院&北京协和医学院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽,64Cu标记的放射性示踪剂;多肽偶联核素,PET显像,临床前,2025/5/19,Active,诊断试剂领域,DR081128,中国(内地),pre-clinical,临床前,2025/5/19,pre-clinical,1,TRUE,FALSE,FALSE,[],['中国医学科学院&北京协和医学院'],1,['中国医学科学院&北京协和医学院(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
[18F]AlF-NOTA-(SDM17)2,[18F]AlF-NOTA-(SDM17)2,[18F]AlF-NOTA-(SDM17)2,肿瘤,tumor,αvβ6,anti-αvβ6多肽偶联核素;18F标记的PET药物,南方医科大学(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,18F标记的PET药物;多肽偶联核素,肿瘤,临床前,2025/6/1,Active,肿瘤领域,DR081243,中国(内地),pre-clinical,临床前,2025/6/1,pre-clinical,1,TRUE,FALSE,FALSE,[],['南方医科大学'],1,['南方医科大学(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
[18F]AlF-NOTA-(SDM17)2,[18F]AlF-NOTA-(SDM17)2,[18F]AlF-NOTA-(SDM17)2,PET显像,PET imaging,αvβ6,anti-αvβ6多肽偶联核素;18F标记的PET药物,南方医科大学(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,18F标记的PET药物;多肽偶联核素,PET显像,临床前,2025/6/1,Active,诊断试剂领域,DR081243,中国(内地),pre-clinical,临床前,2025/6/1,pre-clinical,1,TRUE,FALSE,FALSE,[],['南方医科大学'],1,['南方医科大学(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
[99mTc]Tc-HYNIC-cycOn,[99mTc]Tc-HYNIC-cycOn,[99mTc]Tc-HYNIC-cycOn,放射性核素显像,radionuclide imaging,c-Met,anti-c-Met多肽偶联核素;含锝放射性示踪剂,中国药科大学(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;受体酪氨酸激酶;Potential First-in-Class,含锝放射性示踪剂;多肽偶联核素,放射性核素显像,临床前,,Active,诊断试剂领域,DR081209,中国(内地),pre-clinical,临床前,2025/6/22,pre-clinical,1,TRUE,FALSE,FALSE,[],['中国药科大学'],1,['中国药科大学(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
[99mTc]Tc-HYNIC-cycOn,[99mTc]Tc-HYNIC-cycOn,[99mTc]Tc-HYNIC-cycOn,结直肠癌,colorectal cancer,c-Met,anti-c-Met多肽偶联核素;含锝放射性示踪剂,中国药科大学(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;受体酪氨酸激酶;Potential First-in-Class,含锝放射性示踪剂;多肽偶联核素,结直肠癌,临床前,2025/6/22,Active,肿瘤领域,DR081209,中国(内地),pre-clinical,临床前,2025/6/22,pre-clinical,1,TRUE,FALSE,FALSE,[],['中国药科大学'],1,['中国药科大学(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
IL-17A and IL-17F Dual Inhibitor,IL-17A and IL-17F Dual Inhibitor (PeptiDream),IL-17A and IL-17F Dual Inhibitor;IL-17A and IL-17F Dual Inhibitor (PeptiDream),自身免疫性疾病,autoimmune disease,IL-17A;IL-17F,IL-17F抑制剂;IL-17A抑制剂,PeptiDream(原研),创新药,化药,多肽,环肽;Th17通路,抑制剂,自身免疫性疾病,临床前,2025/12/17,Active,免疫领域,DR090431,日本,pre-clinical,临床前,2025/12/17,pre-clinical,1,TRUE,FALSE,FALSE,[],['PeptiDream'],1,['PeptiDream(原研)'],免疫领域,['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,
111In-DPI-4452,111In-DPI-4452,111In-DPI-4452,癌症,cancer,CAIX,含铟放射性示踪剂;anti-CAIX多肽偶联核素,Debiopharm;3B Pharmaceuticals(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,癌症,临床前,,Active,肿瘤领域,DR042206,欧洲,pre-clinical,临床前,,pre-clinical,2,TRUE,FALSE,FALSE,[],['3B Pharmaceuticals'],1,"['Debiopharm', '3B Pharmaceuticals(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
111In-DPI-4452,111In-DPI-4452,111In-DPI-4452,SPECT显像,SPECT imaging,CAIX,含铟放射性示踪剂;anti-CAIX多肽偶联核素,Debiopharm;3B Pharmaceuticals(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,SPECT显像,临床前,,Active,诊断试剂领域,DR042206,欧洲,pre-clinical,临床前,,pre-clinical,2,TRUE,FALSE,FALSE,[],['3B Pharmaceuticals'],1,"['Debiopharm', '3B Pharmaceuticals(原研)']",诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
111In-DPI-4501,111In-DPI-4501,111In-DPI-4501,肾细胞癌,renal cell carcinoma,CAIX,含铟放射性示踪剂;anti-CAIX多肽偶联核素,Debiopharm;3B Pharmaceuticals(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,肾细胞癌(差异化疾病),临床前,,Active,肿瘤领域,DR014701,欧洲,pre-clinical,临床前,,pre-clinical,2,TRUE,FALSE,FALSE,[],['3B Pharmaceuticals'],1,"['Debiopharm', '3B Pharmaceuticals(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
111In-DPI-4501,111In-DPI-4501,111In-DPI-4501,SPECT显像,SPECT imaging,CAIX,含铟放射性示踪剂;anti-CAIX多肽偶联核素,Debiopharm;3B Pharmaceuticals(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,SPECT显像,临床前,,Active,诊断试剂领域,DR014701,欧洲,pre-clinical,临床前,,pre-clinical,2,TRUE,FALSE,FALSE,[],['3B Pharmaceuticals'],1,"['Debiopharm', '3B Pharmaceuticals(原研)']",诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
111In-DPI-4501,111In-DPI-4501,111In-DPI-4501,结直肠癌,colorectal cancer,CAIX,含铟放射性示踪剂;anti-CAIX多肽偶联核素,Debiopharm;3B Pharmaceuticals(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,结直肠癌(差异化疾病),临床前,,Active,肿瘤领域,DR014701,欧洲,pre-clinical,临床前,,pre-clinical,2,TRUE,FALSE,FALSE,[],['3B Pharmaceuticals'],1,"['Debiopharm', '3B Pharmaceuticals(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
111In-FAP-2286,111In-FAP-2286,111In-FAP-2286,实体瘤,solid tumors,FAP,含铟放射性示踪剂;anti-FAP多肽偶联核素,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;中国无申报;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,实体瘤,临床前,,Active,肿瘤领域,DR042207,欧洲,pre-clinical,临床前,,pre-clinical,3,TRUE,FALSE,TRUE,['Novartis'],['3B Pharmaceuticals'],1,"['Novartis(Top20 MNC)', '3B Pharmaceuticals(原研)', 'Clovis Oncology(无权益)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
111In-FAP-2286,111In-FAP-2286,111In-FAP-2286,SPECT显像,SPECT imaging,FAP,含铟放射性示踪剂;anti-FAP多肽偶联核素,Novartis(Top20 MNC);3B Pharmaceuticals(原研);Clovis Oncology(无权益),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;中国无申报;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,SPECT显像,临床前,,Active,诊断试剂领域,DR042207,欧洲,pre-clinical,临床前,,pre-clinical,3,TRUE,FALSE,TRUE,['Novartis'],['3B Pharmaceuticals'],1,"['Novartis(Top20 MNC)', '3B Pharmaceuticals(原研)', 'Clovis Oncology(无权益)']",诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
177 Lu-DOTA-EB-RGD,177 Lu-DOTA-EB-RGD,177 Lu-DOTA-EB-RGD,非小细胞肺癌,non-small cell lung cancer,αvβ3,177Lu标记的放射性药物;anti-αvβ3多肽偶联核素,Molecular Targeting Technologies(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,非小细胞肺癌,临床前,,Active,肿瘤领域,DR025932,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Molecular Targeting Technologies'],1,['Molecular Targeting Technologies(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
177Lu-PD-32766,177Lu-PD-32766,177Lu-PD-32766,PET显像,PET imaging,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,PeptiDream(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,PET显像,临床前,,Active,诊断试剂领域,DR071097,日本,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['PeptiDream'],1,['PeptiDream(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
177Lu-PD-32766,177Lu-PD-32766,177Lu-PD-32766,肾透明细胞癌,clear cell renal cell carcinoma,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,PeptiDream(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物,多肽偶联核素;177Lu标记的放射性药物,肾透明细胞癌,临床前,,Active,肿瘤领域,DR071097,日本,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['PeptiDream'],1,['PeptiDream(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
177Lu-PTR-58,177Lu-PTR-58,177Lu-PTR-58,肿瘤,tumor,SSTR3,anti-SSTR3多肽偶联核素,Starget Pharma(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;诊断用放射性药物;中国无申报;Potential First-in-Class,多肽偶联核素,肿瘤,临床前,,Active,肿瘤领域,DR070791,以色列,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Starget Pharma'],1,['Starget Pharma(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
177Lu-PTR-58,177Lu-PTR-58,177Lu-PTR-58,肉瘤,sarcoma,SSTR3,anti-SSTR3多肽偶联核素,Starget Pharma(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;诊断用放射性药物;中国无申报;Potential First-in-Class,多肽偶联核素,肉瘤(差异化疾病),临床前,,Active,肿瘤领域,DR070791,以色列,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Starget Pharma'],1,['Starget Pharma(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
177Lu-RAYZ-6114,177Lu-RAYZ-6114,177Lu-RAYZ-6114,实体瘤,solid tumors,EphA2,177Lu标记的放射性药物;anti-EphA2多肽偶联核素,PeptiDream(原研);RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;受体酪氨酸激酶;中国无申报;Potential First-in-Class,177Lu标记的放射性药物;多肽偶联核素,实体瘤,临床前,,Active,肿瘤领域,DR076538,美国;日本,pre-clinical,临床前,,pre-clinical,2,TRUE,FALSE,TRUE,['RayzeBio(Bristol-Myers Squibb)'],"['PeptiDream', 'RayzeBio(Bristol-Myers Squibb)']",2,"['PeptiDream(原研)', 'RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
177Lu-RAYZ-6283,177Lu-RAYZ-6283,177Lu-RAYZ-6283,实体瘤,solid tumors,EphA2,177Lu标记的放射性药物;anti-EphA2多肽偶联核素,PeptiDream(原研);RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;受体酪氨酸激酶;中国无申报;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,实体瘤,临床前,,Active,肿瘤领域,DR073584,美国;日本,pre-clinical,临床前,,pre-clinical,2,TRUE,FALSE,TRUE,['RayzeBio(Bristol-Myers Squibb)'],"['PeptiDream', 'RayzeBio(Bristol-Myers Squibb)']",2,"['PeptiDream(原研)', 'RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
225Ac-EBTATE,225Ac-EBTATE,225Ac-EBTATE,小细胞肺癌,small cell lung cancer,SSTR,anti-SSTR多肽偶联核素;225Ac标记的放射性药物,Molecular Targeting Technologies(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;225Ac标记的放射性药物,小细胞肺癌(差异化疾病),临床前,,Active,肿瘤领域;罕见疾病领域,DR071624,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,TRUE,FALSE,[],['Molecular Targeting Technologies'],1,['Molecular Targeting Technologies(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
225Ac-EBTATE,225Ac-EBTATE,225Ac-EBTATE,神经内分泌肿瘤,neuroendocrine tumors,SSTR,anti-SSTR多肽偶联核素;225Ac标记的放射性药物,Molecular Targeting Technologies(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物,多肽偶联核素;225Ac标记的放射性药物,神经内分泌肿瘤,临床前,,Active,肿瘤领域;罕见疾病领域,DR071624,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,TRUE,FALSE,[],['Molecular Targeting Technologies'],1,['Molecular Targeting Technologies(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
225Ac-PD-29875,225Ac-PD-29875,225Ac-PD-29875,胃癌,stomach cancer,CLDN18.2,anti-CLDN18.2多肽偶联核素;225Ac标记的放射性药物,PeptiDream(原研),创新药,其他,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,胃癌,临床前,,Active,肿瘤领域,DR071926,日本,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['PeptiDream'],1,['PeptiDream(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
225Ac-PD-32766,225Ac-PD-32766,225Ac-PD-32766,肾透明细胞癌,clear cell renal cell carcinoma,CAIX,anti-CAIX多肽偶联核素;225Ac标记的放射性药物,PeptiDream(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class,225Ac标记的放射性药物;多肽偶联核素,肾透明细胞癌(差异化疾病),临床前,,Active,肿瘤领域,DR089471,日本,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['PeptiDream'],1,['PeptiDream(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
225Ac-PTR-58,225Ac-PTR-58,225Ac-PTR-58,肝细胞癌,hepatocellular carcinoma,SSTR3,anti-SSTR3多肽偶联核素,Starget Pharma(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;诊断用放射性药物;中国无申报;Potential First-in-Class,多肽偶联核素,肝细胞癌(差异化疾病),临床前,,Active,肿瘤领域,DR070792,以色列,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Starget Pharma'],1,['Starget Pharma(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
225Ac-PTR-58,225Ac-PTR-58,225Ac-PTR-58,黑色素瘤,melanoma,SSTR3,anti-SSTR3多肽偶联核素,Starget Pharma(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;诊断用放射性药物;中国无申报;Potential First-in-Class,多肽偶联核素,黑色素瘤(差异化疾病),临床前,,Active,肿瘤领域;罕见疾病领域,DR070792,以色列,pre-clinical,临床前,,pre-clinical,1,TRUE,TRUE,FALSE,[],['Starget Pharma'],1,['Starget Pharma(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
225Ac-PTR-58,225Ac-PTR-58,225Ac-PTR-58,神经内分泌肿瘤,neuroendocrine tumors,SSTR3,anti-SSTR3多肽偶联核素,Starget Pharma(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;诊断用放射性药物;中国无申报;Potential First-in-Class,多肽偶联核素,神经内分泌肿瘤(差异化疾病),临床前,,Active,肿瘤领域;罕见疾病领域,DR070792,以色列,pre-clinical,临床前,,pre-clinical,1,TRUE,TRUE,FALSE,[],['Starget Pharma'],1,['Starget Pharma(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
225Ac-RAYZ-6114,225Ac-RAYZ-6114,225Ac-RAYZ-6114,实体瘤,solid tumors,EphA2,225Ac标记的放射性药物;anti-EphA2多肽偶联核素,PeptiDream(原研);RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;受体酪氨酸激酶;中国无申报;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,实体瘤,临床前,,Active,肿瘤领域,DR073583,美国;日本,pre-clinical,临床前,,pre-clinical,2,TRUE,FALSE,TRUE,['RayzeBio(Bristol-Myers Squibb)'],"['PeptiDream', 'RayzeBio(Bristol-Myers Squibb)']",2,"['PeptiDream(原研)', 'RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
23-R09 (FAP),23-R09 (FAP),23-R09 (FAP),胰腺癌,pancreatic cancer,FAP,,中晟全肽(原研),创新药,生物,多肽,环肽,其他,胰腺癌,临床前,,Active,肿瘤领域;罕见疾病领域,DR066836,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,TRUE,FALSE,[],['中晟全肽'],1,['中晟全肽(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
23-R09 (FAP),23-R09 (FAP),23-R09 (FAP),消化道癌症,digestive tract cancer,FAP,,中晟全肽(原研),创新药,生物,多肽,环肽,其他,消化道癌症,临床前,,Active,肿瘤领域,DR066836,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['中晟全肽'],1,['中晟全肽(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
23-R09 (TROP2),23-R09 (TROP2),23-R09 (TROP2),三阴性乳腺癌,triple negative breast cancer,TROP2,anti-TROP2多肽偶联核素,中晟全肽(原研),创新药,生物,多肽;放射性药物;偶联药物,环肽;Potential First-in-Class,多肽偶联核素,三阴性乳腺癌,临床前,,Active,肿瘤领域,DR066827,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['中晟全肽'],1,['中晟全肽(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
23-R09 (TROP2/nectin-4),23-R09 (TROP2/nectin-4),23-R09 (TROP2/nectin-4),未知/待定,unknown/pending,nectin-4;TROP2,anti-nectin-4×TROP2多肽偶联核素,中晟全肽(原研),创新药,生物,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Potential First-in-Class,多肽偶联核素,未知/待定,临床前,,Active,其他领域,DR066839,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['中晟全肽'],1,['中晟全肽(原研)'],其他领域,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,
36R-P138,36R-P138,36R-P138,自身免疫性疾病,autoimmune disease,IL-36R,IL-36R抑制剂,Novartis(Top20 MNC)(原研),创新药,化药,多肽,环肽;Potential First-in-Class,抑制剂,自身免疫性疾病,临床前,,Active,免疫领域,DR076820,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],免疫领域,['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,
36R-P192,36R-P192,36R-P192,自身免疫性疾病,autoimmune disease,IL-36R,IL-36R抑制剂,Novartis(Top20 MNC)(原研),创新药,化药,多肽,环肽;Potential First-in-Class,抑制剂,自身免疫性疾病,临床前,,Active,免疫领域,DR076821,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],免疫领域,['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,
64Cu-NOTA-TP-c(RGDfK),64Cu-NOTA-TP-c(RGDfK),64Cu-NOTA-TP-c(RGDfK),胶质母细胞瘤,glioblastoma,αvβ3,64Cu标记的放射性示踪剂;anti-αvβ3多肽偶联核素,Université de Sherbrooke(原研),创新药,其他,放射性药物;多肽;偶联药物,环肽;治疗用放射性药物;中国无申报;Potential First-in-Class,64Cu标记的放射性示踪剂;多肽偶联核素,胶质母细胞瘤,临床前,,Active,肿瘤领域;罕见疾病领域,DR089672,加拿大,pre-clinical,临床前,,pre-clinical,1,TRUE,TRUE,FALSE,[],['Université de Sherbrooke'],1,['Université de Sherbrooke(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
64Cu-PD-29875,64Cu-PD-29875,64Cu-PD-29875,胃癌,stomach cancer,CLDN18.2,64Cu标记的放射性示踪剂;anti-CLDN18.2多肽偶联核素,PeptiDream(原研),创新药,其他,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;64Cu标记的放射性示踪剂,胃癌,临床前,,Active,肿瘤领域,DR071927,日本,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['PeptiDream'],1,['PeptiDream(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
64Cu-PD-29875,64Cu-PD-29875,64Cu-PD-29875,PET显像,PET imaging,CLDN18.2,64Cu标记的放射性示踪剂;anti-CLDN18.2多肽偶联核素,PeptiDream(原研),创新药,其他,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;64Cu标记的放射性示踪剂,PET显像,临床前,,Active,诊断试剂领域,DR071927,日本,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['PeptiDream'],1,['PeptiDream(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
68Ga-DOTA-CEND1,68Ga-DOTA-CEND1,68Ga-DOTA-CEND1,肿瘤,tumor,NRP1,anti-NRP1多肽偶联核素;68Ga标记的PET药物,复旦大学附属肿瘤医院(原研),创新药,其他,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class;肿瘤免疫,68Ga标记的PET药物;多肽偶联核素,肿瘤,临床前,,Active,肿瘤领域,DR089668,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['复旦大学附属肿瘤医院'],1,['复旦大学附属肿瘤医院(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
68Ga-DOTA-CEND1,68Ga-DOTA-CEND1,68Ga-DOTA-CEND1,PET显像,PET imaging,NRP1,anti-NRP1多肽偶联核素;68Ga标记的PET药物,复旦大学附属肿瘤医院(原研),创新药,其他,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class;肿瘤免疫,68Ga标记的PET药物;多肽偶联核素,PET显像,临床前,,Active,诊断试剂领域,DR089668,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['复旦大学附属肿瘤医院'],1,['复旦大学附属肿瘤医院(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
68Ga-EMP-100,68Ga-EMP-100,68Ga-EMP-100;[Ga-68]EMP-100,实体瘤,solid tumors,c-Met,anti-c-Met多肽偶联核素;68Ga标记的PET药物,Edinburgh Molecular Imaging(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;受体酪氨酸激酶;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,实体瘤,临床前,,Active,肿瘤领域,DR021187,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Edinburgh Molecular Imaging'],1,['Edinburgh Molecular Imaging(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
68Ga-EMP-100,68Ga-EMP-100,68Ga-EMP-100;[Ga-68]EMP-100,PET显像,PET imaging,c-Met,anti-c-Met多肽偶联核素;68Ga标记的PET药物,Edinburgh Molecular Imaging(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;受体酪氨酸激酶;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,PET显像,临床前,,Active,诊断试剂领域,DR021187,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Edinburgh Molecular Imaging'],1,['Edinburgh Molecular Imaging(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
68Ga-NOTA-XH05,68Ga-NOTA-XH05,68Ga-NOTA-XH05,黑色素瘤,melanoma,LAG3,anti-LAG3多肽偶联核素;68Ga标记的PET药物,同济医学院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class;肿瘤免疫,68Ga标记的PET药物;多肽偶联核素,黑色素瘤,临床前,,Active,肿瘤领域;罕见疾病领域,DR081119,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,TRUE,FALSE,[],['同济医学院'],1,['同济医学院(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
68Ga-NOTA-XH05,68Ga-NOTA-XH05,68Ga-NOTA-XH05,PET显像,PET imaging,LAG3,anti-LAG3多肽偶联核素;68Ga标记的PET药物,同济医学院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class;肿瘤免疫,68Ga标记的PET药物;多肽偶联核素,PET显像,临床前,,Active,诊断试剂领域,DR081119,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['同济医学院'],1,['同济医学院(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
90Y-CM600,90Y-CM600,90Y-CM600,肿瘤,tumor,fibrin,90Y标记的放射性药物;anti-fibrin多肽偶联核素,Massachusetts General Hospital(原研);Collagen Medical(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Potential First-in-Class,90Y标记的放射性药物;多肽偶联核素,肿瘤,临床前,,Active,肿瘤领域,DR072127,美国,pre-clinical,临床前,,pre-clinical,2,TRUE,FALSE,FALSE,[],"['Massachusetts General Hospital', 'Collagen Medical']",2,"['Massachusetts General Hospital(原研)', 'Collagen Medical(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
99mTc-PentixaTec,99mTc-PentixaTec,99mTc-PentixaTec;[99mTc]Tc-PentixaTec,癌症,cancer,CXCR4,含锝放射性示踪剂;anti-CXCR4多肽偶联核素,Technische Universität München(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,多肽偶联核素;含锝放射性示踪剂,癌症,临床前,,Active,肿瘤领域,DR081187,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Technische Universität München'],1,['Technische Universität München(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
99mTc-PentixaTec,99mTc-PentixaTec,99mTc-PentixaTec;[99mTc]Tc-PentixaTec,SPECT显像,SPECT imaging,CXCR4,含锝放射性示踪剂;anti-CXCR4多肽偶联核素,Technische Universität München(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,多肽偶联核素;含锝放射性示踪剂,SPECT显像,临床前,,Active,诊断试剂领域,DR081187,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Technische Universität München'],1,['Technische Universität München(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
ABZ-706,ABZ-706,ABZ-706;177Lu-RAYZ-8009,肝细胞癌,hepatocellular carcinoma,GPC3,177Lu标记的放射性药物;anti-GPC3多肽偶联核素,RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研);PeptiDream(原研)(无权益);艾博兹医药(无权益),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;中国无申报;Potential First-in-Class;Wnt信号通路,多肽偶联核素;177Lu标记的放射性药物,肝细胞癌(差异化疾病),临床前,,Active,肿瘤领域,DR011510,美国;日本,pre-clinical,临床前,,pre-clinical,3,TRUE,FALSE,TRUE,['RayzeBio(Bristol-Myers Squibb)'],"['RayzeBio(Bristol-Myers Squibb)', 'PeptiDream']",2,"['RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研)', 'PeptiDream(原研)(无权益)', '艾博兹医药(无权益)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
AP-01,AP-01 (Apmonia Therapeutics),AP-01;AP-01 (Apmonia Therapeutics);TAX2 peptide;TAX2,实体瘤,solid tumors,CD47;THBS1,CD47×THBS1蛋白蛋白相互作用抑制剂,Apmonia Therapeutics(原研),创新药,其他,多肽,环肽;肿瘤相关巨噬细胞;Potential First-in-Class;肿瘤免疫,蛋白蛋白相互作用抑制剂,实体瘤,临床前,,Active,肿瘤领域,DR008397,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Apmonia Therapeutics'],1,['Apmonia Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
ARAspheres,ARAspheres (225Ac-RGD-Alginate Nanospheres),ARAspheres;ARAspheres (225Ac-RGD-Alginate Nanospheres),胶质母细胞瘤,glioblastoma,integrin,225Ac标记的放射性药物,Blue Wave Therapeutics(原研),创新药,化药,放射性药物,环肽;治疗用放射性药物;Potential First-in-Class,225Ac标记的放射性药物,胶质母细胞瘤,临床前,,Active,肿瘤领域;罕见疾病领域,DR089758,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,TRUE,FALSE,[],['Blue Wave Therapeutics'],1,['Blue Wave Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
Ano-3/3s,Ano-3/3s,Ano-3/3s,黑色素瘤,melanoma,not available,多肽偶联药物,上海中医药大学(原研),创新药,化药,多肽;偶联药物,环肽,多肽偶联药物,黑色素瘤,临床前,,Active,肿瘤领域;罕见疾病领域,DR052461,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,TRUE,FALSE,[],['上海中医药大学'],1,['上海中医药大学(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
BE-43547A2,BE-43547A2,BE-43547A2,胰腺癌,pancreatic cancer,EEF1A1,EEF1A1抑制剂,--,创新药,化药,多肽,环肽;差异化疾病,抑制剂,胰腺癌(差异化疾病),临床前,,Active,肿瘤领域;罕见疾病领域,DR011350,,pre-clinical,临床前,,pre-clinical,0,TRUE,TRUE,FALSE,[],[],0,[],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
BMN 333,BMN 333,BMN 333,骨骼肌肉疾病,musculoskeletal diseases,,,BioMarin Pharmaceutical(原研),微创新,其他,多肽,环肽,,骨骼肌肉疾病,临床前,,Active,骨骼肌肉领域,DR007946,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['BioMarin Pharmaceutical'],1,['BioMarin Pharmaceutical(原研)'],骨骼肌肉领域,['骨骼肌肉领域'],1,骨骼肌肉领域,,,-1,-1,Musculoskeletal,Musculoskeletal,,
BT1769,BT1769,BT1769,骨肉瘤,Osteosarcoma,MMP14,多肽偶联药物,Bicycle Therapeutics(原研),创新药,化药,多肽;偶联药物,环肽;payload [海兔毒素衍生物：MMAE];差异化疾病;Potential First-in-Class;可降解连接子,多肽偶联药物,骨肉瘤(差异化疾病),临床前,,Active,肿瘤领域;罕见疾病领域,DR059741,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,TRUE,FALSE,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
BT7455,BT7455,BT7455;BCY12491,肿瘤,tumor,EphA2;4-1BB,EphA2配体;4-1BB激动剂,Bicycle Therapeutics(原研),创新药,化药,多肽,环肽;受体酪氨酸激酶;Potential First-in-Class;肿瘤免疫,配体;激动剂,肿瘤,临床前,,Active,肿瘤领域,DR004683,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
Bicycle 46,Bicycle 46,Bicycle 46,哮喘,asthma,TSLP,TSLP抑制剂,Bicycle Therapeutics(原研),创新药,化药,多肽,环肽;Th2通路;Potential First-in-Class,抑制剂,哮喘,临床前,,Active,呼吸领域,DR045043,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],呼吸领域,['呼吸领域'],1,呼吸领域,,,-1,-1,Respiratory,Respiratory,,
C4m-3127,C4m-3127,C4m-3127,未知/待定,unknown/pending,CTLA4,CTLA4抑制剂,GeneFrontier(原研),创新药,化药,多肽,环肽;Treg细胞;Potential First-in-Class,抑制剂,未知/待定,临床前,,Active,其他领域,DR050438,日本,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['GeneFrontier'],1,['GeneFrontier(原研)'],其他领域,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,
C5 Inhibitor,C5 Inhibitor (Nimble Therapeutics),C5 Inhibitor;C5 Inhibitor (Nimble Therapeutics),重症肌无力,myasthenia gravis,C5,C5抑制剂,Nimble Therapeutics(AbbVie)(Top20 MNC)(原研),创新药,化药,多肽,环肽,抑制剂,重症肌无力,临床前,,Active,罕见疾病领域;免疫领域,DR071874,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,TRUE,TRUE,['Nimble Therapeutics(AbbVie)'],['Nimble Therapeutics(AbbVie)'],1,['Nimble Therapeutics(AbbVie)(Top20 MNC)(原研)'],免疫领域,['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,
CAR Peptide,CAR Peptide (Vascular BioSciences),CAR Peptide;CAR Peptide (Vascular BioSciences);CARSKNKDC,菌血症,bacteremia,not available,,Vascular Biosciences(原研),创新药,化药,多肽,环肽,其他,菌血症,临床前,,Active,感染领域,DR036908,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Vascular Biosciences'],1,['Vascular Biosciences(原研)'],感染领域,['感染领域'],1,感染领域,,,-1,-1,Infectious Diseases,Infectious Diseases,,
CAR Peptide,CAR Peptide (Vascular BioSciences),CAR Peptide;CAR Peptide (Vascular BioSciences);CARSKNKDC,肺动脉高压,pulmonary hypertension,not available,,Vascular Biosciences(原研),创新药,化药,多肽,环肽,其他,肺动脉高压,临床前,,Active,心脑血管领域;罕见疾病领域,DR036908,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,TRUE,FALSE,[],['Vascular Biosciences'],1,['Vascular Biosciences(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,-1,-1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
CAR Peptide,CAR Peptide (Vascular BioSciences),CAR Peptide;CAR Peptide (Vascular BioSciences);CARSKNKDC,新型冠状病毒感染,novel coronavirus infection,not available,,Vascular Biosciences(原研),创新药,化药,多肽,环肽,其他,新型冠状病毒感染,临床前,,Active,感染领域,DR036908,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Vascular Biosciences'],1,['Vascular Biosciences(原研)'],感染领域,['感染领域'],1,感染领域,,,-1,-1,Infectious Diseases,Infectious Diseases,,
CBT-005,CBT-005 (Cbiomex),CBT-005;CBT-005 (Cbiomex),软骨发育不全,Achondroplasia,NPRB,NPRB激动剂,C-BIOMEX(原研),创新药,化药,多肽,环肽;中国无申报;Potential First-in-Class,激动剂,软骨发育不全,临床前,,Active,骨骼肌肉领域;罕见疾病领域,DR009364,韩国,pre-clinical,临床前,,pre-clinical,1,TRUE,TRUE,FALSE,[],['C-BIOMEX'],1,['C-BIOMEX(原研)'],骨骼肌肉领域,['骨骼肌肉领域'],1,骨骼肌肉领域,,,-1,-1,Musculoskeletal,Musculoskeletal,,
CN119285702A,CN119285702A,CN119285702A,癌症,cancer,EphA2,EphA2抑制剂,禾泰健宇(原研),创新药,化药,多肽,环肽;受体酪氨酸激酶;Potential First-in-Class,抑制剂,癌症,临床前,,Active,肿瘤领域,DR084791,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['禾泰健宇'],1,['禾泰健宇(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
CN119303102A,CN119303102A,CN119303102A,癌症,cancer,EphA2;nectin-4,多肽偶联药物,博瑞医药(原研),创新药,化药,多肽;偶联药物,环肽;受体酪氨酸激酶;Potential First-in-Class,多肽偶联药物,癌症,临床前,,Active,肿瘤领域,DR084448,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['博瑞医药'],1,['博瑞医药(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
CN119390770A,CN119390770A,CN119390770A,肿瘤,tumor,nectin-4,18F标记的PET药物;anti-nectin-4多肽偶联核素,云南白药(原研);北京大学第一医院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,18F标记的PET药物;多肽偶联核素,肿瘤,临床前,,Active,肿瘤领域,DR086286,中国(内地),pre-clinical,临床前,,pre-clinical,2,TRUE,FALSE,FALSE,[],"['云南白药', '北京大学第一医院']",2,"['云南白药(原研)', '北京大学第一医院(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
CN119390848A,CN119390848A,CN119390848A,神经退行性疾病,neurodegenerative diseases,PSD95,PSD95抑制剂,中晟全肽(原研),创新药,化药,多肽,环肽;差异化疾病,抑制剂,神经退行性疾病(差异化疾病),临床前,,Active,神经领域,DR084804,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['中晟全肽'],1,['中晟全肽(原研)'],神经领域,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,
CN119390848A,CN119390848A,CN119390848A,缺血性卒中,ischemic stroke,PSD95,PSD95抑制剂,中晟全肽(原研),创新药,化药,多肽,环肽;差异化疾病,抑制剂,缺血性卒中,临床前,,Active,心脑血管领域,DR084804,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['中晟全肽'],1,['中晟全肽(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,-1,-1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
CN119552215A,CN119552215A,CN119552215A,肿瘤,tumor,SSTR2,多肽偶联药物,星洲生物(原研),创新药,化药,多肽;偶联药物,环肽,多肽偶联药物,肿瘤,临床前,,Active,肿瘤领域,DR083998,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['星洲生物'],1,['星洲生物(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
CN119638783A,CN119638783A,CN119638783A,细菌感染,bacterial infection,APHs,多肽类抗生素,上海交通大学(原研),创新药,化药,多肽,环肽;Potential First-in-Class,多肽类抗生素,细菌感染,临床前,,Active,感染领域,DR085370,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['上海交通大学'],1,['上海交通大学(原研)'],感染领域,['感染领域'],1,感染领域,,,-1,-1,Infectious Diseases,Infectious Diseases,,
CN119701000A,CN119701000A,CN119701000A,葡萄球菌感染,Staph infection,S. aureus,多肽偶联药物,第四军医大学(原研),创新药,化药,多肽;偶联药物,环肽;payload [利福霉素类抗生素：dmDNA31];Potential First-in-Class,多肽偶联药物,葡萄球菌感染,临床前,,Active,感染领域,DR090138,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['第四军医大学'],1,['第四军医大学(原研)'],感染领域,['感染领域'],1,感染领域,,,-1,-1,Infectious Diseases,Infectious Diseases,,
CN119751581A,CN119751581A,CN119751581A,癌症,cancer,EphA2,177Lu标记的放射性药物;anti-EphA2多肽偶联核素,上海交通大学(原研);南京市第一医院(原研),创新药,生物,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;受体酪氨酸激酶;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,癌症,临床前,,Active,肿瘤领域,DR086866,中国(内地),pre-clinical,临床前,,pre-clinical,2,TRUE,FALSE,FALSE,[],"['上海交通大学', '南京市第一医院']",2,"['上海交通大学(原研)', '南京市第一医院(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
CN119874812A,CN119874812A,CN119874812A,癌症,cancer,nectin-4,anti-nectin-4多肽偶联核素;68Ga标记的PET药物,范恩柯尔(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽,68Ga标记的PET药物;多肽偶联核素,癌症,临床前,,Active,肿瘤领域,DR083609,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['范恩柯尔'],1,['范恩柯尔(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
CN119874812A,CN119874812A,CN119874812A,PET显像,PET imaging,nectin-4,anti-nectin-4多肽偶联核素;68Ga标记的PET药物,范恩柯尔(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽,68Ga标记的PET药物;多肽偶联核素,PET显像,临床前,,Active,诊断试剂领域,DR083609,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['范恩柯尔'],1,['范恩柯尔(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
CN119874840A,CN119874840A,CN119874840A,癌症,cancer,EphA2,177Lu标记的放射性药物;anti-EphA2多肽偶联核素,晶核生物(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;受体酪氨酸激酶;Potential First-in-Class,177Lu标记的放射性药物;多肽偶联核素,癌症,临床前,,Active,肿瘤领域,DR084744,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['晶核生物'],1,['晶核生物(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
CN119978071A,CN119978071A,CN119978071A,疼痛,pain,NPFFR1,NPFFR1激动剂,中晟全肽(原研),创新药,化药,多肽,环肽;G蛋白偶联受体;Potential First-in-Class,激动剂,疼痛,临床前,,Active,麻醉镇痛领域,DR084841,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['中晟全肽'],1,['中晟全肽(原研)'],麻醉镇痛领域,['麻醉镇痛领域'],1,麻醉镇痛领域,,,-1,-1,Anesthesia & Analgesia,Anesthesia & Analgesia,,
CN120004985A,CN120004985A,CN120004985A,肿瘤,tumor,uPA,64Cu标记的放射性示踪剂;anti-uPA多肽偶联核素,中国医学科学院药物研究所(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;64Cu标记的放射性示踪剂,肿瘤,临床前,,Active,肿瘤领域,DR090531,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['中国医学科学院药物研究所'],1,['中国医学科学院药物研究所(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
CN120004985A,CN120004985A,CN120004985A,PET显像,PET imaging,uPA,64Cu标记的放射性示踪剂;anti-uPA多肽偶联核素,中国医学科学院药物研究所(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;64Cu标记的放射性示踪剂,PET显像,临床前,,Active,诊断试剂领域,DR090531,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['中国医学科学院药物研究所'],1,['中国医学科学院药物研究所(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
CN120058842A,CN120058842A,CN120058842A,肿瘤,tumor,uPAR,anti-uPAR多肽偶联核素;64Cu标记的放射性示踪剂,中国医学科学院药物研究所(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,肿瘤,临床前,,Active,肿瘤领域,DR090536,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['中国医学科学院药物研究所'],1,['中国医学科学院药物研究所(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
CN120058842A,CN120058842A,CN120058842A,PET显像,PET imaging,uPAR,anti-uPAR多肽偶联核素;64Cu标记的放射性示踪剂,中国医学科学院药物研究所(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,多肽偶联核素;64Cu标记的放射性示踪剂,PET显像,临床前,,Active,诊断试剂领域,DR090536,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['中国医学科学院药物研究所'],1,['中国医学科学院药物研究所(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
CN120136966A,CN120136966A,CN120136966A,细菌感染,bacterial infection,not available,脂肽类抗生素,上海交通大学(原研),创新药,化药,多肽,环肽,脂肽类抗生素,细菌感染,临床前,,Active,感染领域,DR085395,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['上海交通大学'],1,['上海交通大学(原研)'],感染领域,['感染领域'],1,感染领域,,,-1,-1,Infectious Diseases,Infectious Diseases,,
CN120230182A,CN120230182A,CN120230182A,肿瘤,tumor,CAIX,anti-CAIX多肽偶联核素;18F标记的PET药物,北京大学肿瘤医院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;18F标记的PET药物,肿瘤,临床前,,Active,肿瘤领域,DR084489,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['北京大学肿瘤医院'],1,['北京大学肿瘤医院(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
CN120230182A,CN120230182A,CN120230182A,PET显像,PET imaging,CAIX,anti-CAIX多肽偶联核素;18F标记的PET药物,北京大学肿瘤医院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,多肽偶联核素;18F标记的PET药物,PET显像,临床前,,Active,诊断试剂领域,DR084489,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['北京大学肿瘤医院'],1,['北京大学肿瘤医院(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
CN120535589A,CN120535589A,CN120535589A,肿瘤,tumor,ACE2;FAP,68Ga标记的PET药物;anti-ACE2×FAP多肽偶联核素,北京大学肿瘤医院(原研),创新药,化药,放射性药物;多肽;偶联药物,环肽;肾素-血管紧张素-醛固酮系统;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,肿瘤,临床前,,Active,肿瘤领域,DR084887,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['北京大学肿瘤医院'],1,['北京大学肿瘤医院(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
CN120535589A,CN120535589A,CN120535589A,PET显像,PET imaging,ACE2;FAP,68Ga标记的PET药物;anti-ACE2×FAP多肽偶联核素,北京大学肿瘤医院(原研),创新药,化药,放射性药物;多肽;偶联药物,环肽;肾素-血管紧张素-醛固酮系统;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,PET显像,临床前,,Active,诊断试剂领域,DR084887,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['北京大学肿瘤医院'],1,['北京大学肿瘤医院(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
CN120757611A,CN120757611A,CN120757611A,肾细胞癌,renal cell carcinoma,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,南方医科大学南方医院(原研),创新药,化药,放射性药物;多肽;偶联药物,环肽;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,肾细胞癌,临床前,,Active,肿瘤领域,DR087164,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['南方医科大学南方医院'],1,['南方医科大学南方医院(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
CN120757611A,CN120757611A,CN120757611A,PET显像,PET imaging,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,南方医科大学南方医院(原研),创新药,化药,放射性药物;多肽;偶联药物,环肽;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,PET显像,临床前,,Active,诊断试剂领域,DR087164,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['南方医科大学南方医院'],1,['南方医科大学南方医院(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
CN120757611A,CN120757611A,CN120757611A,肾透明细胞癌,clear cell renal cell carcinoma,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,南方医科大学南方医院(原研),创新药,化药,放射性药物;多肽;偶联药物,环肽;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,肾透明细胞癌,临床前,,Active,肿瘤领域,DR087164,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['南方医科大学南方医院'],1,['南方医科大学南方医院(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
CN120818068A,CN120818068A,CN120818068A,疼痛,pain,μ opioid receptor;Nav1.8,μ opioid receptor×Nav1.8-白蛋白融合蛋白;μ opioid receptor激动剂;Nav1.8抑制剂,新乡医学院(原研),创新药,生物,多肽;融合蛋白,环肽;G蛋白偶联受体;Potential First-in-Class,激动剂;抑制剂;白蛋白融合蛋白,疼痛,临床前,,Active,麻醉镇痛领域,DR088047,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['新乡医学院'],1,['新乡医学院(原研)'],麻醉镇痛领域,['麻醉镇痛领域'],1,麻醉镇痛领域,,,-1,-1,Anesthesia & Analgesia,Anesthesia & Analgesia,,
CN120837693A,CN120837693A,CN120837693A,PET显像,PET imaging,EphA2,anti-EphA2多肽偶联核素;68Ga标记的PET药物,复旦大学附属肿瘤医院(原研),创新药,化药,放射性药物;多肽;偶联药物,环肽;诊断用放射性药物;受体酪氨酸激酶;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,PET显像,临床前,,Active,诊断试剂领域,DR088530,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['复旦大学附属肿瘤医院'],1,['复旦大学附属肿瘤医院(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
CN120865351A,CN120865351A,CN120865351A,阵发性睡眠性血红蛋白尿症,paroxysmal nocturnal hemoglobinuria,C5,C5抑制剂,普康唯新(原研),创新药,化药,多肽,环肽;差异化疾病,抑制剂,阵发性睡眠性血红蛋白尿症,临床前,,Active,罕见疾病领域;血液领域,DR088535,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,TRUE,FALSE,[],['普康唯新'],1,['普康唯新(原研)'],血液领域,['血液领域'],1,血液领域,,,-1,-1,Hematology,Hematology,,
CN120865351A,CN120865351A,CN120865351A,非典型溶血尿毒综合征,atypical hemolytic uremic syndrome,C5,C5抑制剂,普康唯新(原研),创新药,化药,多肽,环肽;差异化疾病,抑制剂,非典型溶血尿毒综合征(差异化疾病),临床前,,Active,罕见疾病领域;泌尿生殖领域,DR088535,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,TRUE,FALSE,[],['普康唯新'],1,['普康唯新(原研)'],泌尿生殖领域,['泌尿生殖领域'],1,泌尿生殖领域,,,-1,-1,Genitourinary,Genitourinary,,
CN121005762A,CN121005762A,CN121005762A,焦虑症,anxiety disorder,NMDA receptor;PSD95,NMDA receptor×PSD95蛋白蛋白相互作用抑制剂,拜西欧斯(原研),创新药,化药,多肽,环肽;Potential First-in-Class,蛋白蛋白相互作用抑制剂,焦虑症,临床前,,Active,精神领域,DR090117,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['拜西欧斯'],1,['拜西欧斯(原研)'],精神领域,['精神领域'],1,精神领域,,,-1,-1,Psychiatry,Psychiatry,,
CN121005762A,CN121005762A,CN121005762A,神经退行性疾病,neurodegenerative diseases,NMDA receptor;PSD95,NMDA receptor×PSD95蛋白蛋白相互作用抑制剂,拜西欧斯(原研),创新药,化药,多肽,环肽;Potential First-in-Class,蛋白蛋白相互作用抑制剂,神经退行性疾病,临床前,,Active,神经领域,DR090117,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['拜西欧斯'],1,['拜西欧斯(原研)'],神经领域,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,
CN121005762A,CN121005762A,CN121005762A,癫痫,epilepsy,NMDA receptor;PSD95,NMDA receptor×PSD95蛋白蛋白相互作用抑制剂,拜西欧斯(原研),创新药,化药,多肽,环肽;Potential First-in-Class,蛋白蛋白相互作用抑制剂,癫痫,临床前,,Active,神经领域,DR090117,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['拜西欧斯'],1,['拜西欧斯(原研)'],神经领域,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,
CN121045338A,CN121045338A,CN121045338A,肾透明细胞癌,clear cell renal cell carcinoma,CAIX,anti-CAIX多肽偶联核素;177Lu标记的放射性药物,原子高科(原研),创新药,化药,放射性药物;多肽;偶联药物,环肽;治疗用放射性药物,177Lu标记的放射性药物;多肽偶联核素,肾透明细胞癌,临床前,,Active,肿瘤领域,DR090461,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['原子高科'],1,['原子高科(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
CN121045338A-1,CN121045338A-1,CN121045338A-1,肾透明细胞癌,clear cell renal cell carcinoma,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,原子高科(原研),创新药,生物,多肽;放射性药物;偶联药物,环肽,多肽偶联核素;68Ga标记的PET药物,肾透明细胞癌,临床前,,Active,肿瘤领域,DR090564,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['原子高科'],1,['原子高科(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
CN2097,CN2097,CN2097,快乐木偶综合症,happy puppet syndrome,PSD95,PSD95抑制剂,Aingeal therapeutics(原研),创新药,化药,多肽,环肽;差异化疾病,抑制剂,快乐木偶综合症(差异化疾病),临床前,,Active,罕见疾病领域,DR036352,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,TRUE,FALSE,[],['Aingeal therapeutics'],1,['Aingeal therapeutics(原研)'],,[],0,,,,-1,-1,,,,
CN2097,CN2097,CN2097,外伤性脑损伤,traumatic brain injury,PSD95,PSD95抑制剂,Aingeal therapeutics(原研),创新药,化药,多肽,环肽;差异化疾病,抑制剂,外伤性脑损伤,临床前,,Active,神经领域,DR036352,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Aingeal therapeutics'],1,['Aingeal therapeutics(原研)'],神经领域,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,
CN2097,CN2097,CN2097,难治性抑郁症,treatment-resistant depression,PSD95,PSD95抑制剂,Aingeal therapeutics(原研),创新药,化药,多肽,环肽;差异化疾病,抑制剂,难治性抑郁症(差异化疾病),临床前,,Active,精神领域,DR036352,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Aingeal therapeutics'],1,['Aingeal therapeutics(原研)'],精神领域,['精神领域'],1,精神领域,,,-1,-1,Psychiatry,Psychiatry,,
CP7-FP13-2,CP7-FP13-2,CP7-FP13-2,葡萄球菌感染,Staph infection,not available,,南方医科大学(原研),创新药,化药,多肽,环肽,其他,葡萄球菌感染,临床前,,Active,感染领域,DR026410,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['南方医科大学'],1,['南方医科大学(原研)'],感染领域,['感染领域'],1,感染领域,,,-1,-1,Infectious Diseases,Infectious Diseases,,
CPX-101,CPX-101,CPX-101,骨关节炎,osteoarthritis,BMP7,BMP7类似物,Chondropeptix(原研),创新药,其他,多肽,环肽;TGF-β信号通路;Potential First-in-Class,类似物,骨关节炎,临床前,,Active,骨骼肌肉领域,DR029351,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Chondropeptix'],1,['Chondropeptix(原研)'],骨骼肌肉领域,['骨骼肌肉领域'],1,骨骼肌肉领域,,,-1,-1,Musculoskeletal,Musculoskeletal,,
CRRL191,CRRL191,CRRL191,高血压,hypertension,NPR1,NPR1激活剂,Mayo Clinic(原研),创新药,化药,多肽,环肽,激活剂,高血压,临床前,,Active,心脑血管领域,DR073668,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Mayo Clinic'],1,['Mayo Clinic(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,-1,-1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
CRRL269,CRRL269,CRRL269,急性肾损伤,acute kidney injury,NPR1,NPR1激活剂,Mayo Clinic(原研),创新药,化药,多肽,环肽;差异化疾病,激活剂,急性肾损伤(差异化疾病),临床前,,Active,泌尿生殖领域,DR052784,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Mayo Clinic'],1,['Mayo Clinic(原研)'],泌尿生殖领域,['泌尿生殖领域'],1,泌尿生殖领域,,,-1,-1,Genitourinary,Genitourinary,,
CRRL555,CRRL555,CRRL555,高血压,hypertension,ANP,ANP类似物,Mayo Clinic(原研),创新药,化药,多肽,环肽;Potential First-in-Class,类似物,高血压,临床前,,Active,心脑血管领域,DR073078,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Mayo Clinic'],1,['Mayo Clinic(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,-1,-1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
CXCR4-targeting radiopharmaceutical,CXCR4-targeting radiopharmaceutical (Alpha-9),CXCR4-targeting radiopharmaceutical;CXCR4-targeting radiopharmaceutical (Alpha-9),肿瘤,tumor,CXCR4,,Alpha-9(原研),创新药,其他,多肽,环肽;G蛋白偶联受体,其他,肿瘤,临床前,,Active,肿瘤领域,DR044356,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Alpha-9'],1,['Alpha-9(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
CXJ-2,CXJ-2,CXJ-2,肝纤维化,liver fibrosis,elastin-binding protein,elastin-binding protein抑制剂,中山大学(原研),创新药,化药,多肽,环肽;Potential First-in-Class,抑制剂,肝纤维化,临床前,,Active,消化领域,DR063621,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['中山大学'],1,['中山大学(原研)'],消化领域,['消化领域'],1,消化领域,,,-1,-1,Digestive System,Digestive System,,
Colistin Cyclops,Colistin Cyclops (inhaled colistin),Colistin Cyclops;Colistin Cyclops (粘菌素吸入粉);Colistin Cyclops (inhaled colistin),肺部感染,lung infection,not available,多粘菌素类抗生素,PureIMS(原研),微创新,化药,其他,环肽,多粘菌素类抗生素,肺部感染,临床前,,Active,感染领域;呼吸领域,DR075147,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['PureIMS'],1,['PureIMS(原研)'],感染领域,"['感染领域', '呼吸领域']",2,感染领域,呼吸领域,,-1,-1,Infectious Diseases,Infectious Diseases,Respiratory,
Colistin Cyclops,Colistin Cyclops (inhaled colistin),Colistin Cyclops;Colistin Cyclops (粘菌素吸入粉);Colistin Cyclops (inhaled colistin),囊性纤维化,cystic fibrosis,not available,多粘菌素类抗生素,PureIMS(原研),微创新,化药,其他,环肽,多粘菌素类抗生素,囊性纤维化,临床前,,Active,呼吸领域;罕见疾病领域,DR075147,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,TRUE,FALSE,[],['PureIMS'],1,['PureIMS(原研)'],呼吸领域,['呼吸领域'],1,呼吸领域,,,-1,-1,Respiratory,Respiratory,,
Colistin Cyclops,Colistin Cyclops (inhaled colistin),Colistin Cyclops;Colistin Cyclops (粘菌素吸入粉);Colistin Cyclops (inhaled colistin),绿脓杆菌感染,Pseudomonas aeruginosa infection,not available,多粘菌素类抗生素,PureIMS(原研),微创新,化药,其他,环肽,多粘菌素类抗生素,绿脓杆菌感染,临床前,,Active,感染领域,DR075147,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['PureIMS'],1,['PureIMS(原研)'],感染领域,['感染领域'],1,感染领域,,,-1,-1,Infectious Diseases,Infectious Diseases,,
Cp1,Cp1 (Changhai Hospital),Cp1;Cp1 (长海医院);Cp1 (Changhai Hospital),脓毒症,sepsis,C5a,C5a阻断剂,上海长海医院(原研),创新药,其他,多肽,环肽;差异化疾病;Potential First-in-Class,阻断剂,脓毒症(差异化疾病),临床前,,Active,感染领域,DR088698,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['上海长海医院'],1,['上海长海医院(原研)'],感染领域,['感染领域'],1,感染领域,,,-1,-1,Infectious Diseases,Infectious Diseases,,
Cyclin A targeting macrocyclic compound,Cyclin A targeting macrocyclic compound (Circle Pharma),Cyclin A targeting macrocyclic compound;Cyclin A targeting macrocyclic compound (Circle Pharma),小细胞肺癌,small cell lung cancer,cyclin A,cyclin A抑制剂,Circle Pharma(原研),创新药,化药,多肽,环肽;细胞周期;Potential First-in-Class,抑制剂,小细胞肺癌,临床前,,Active,肿瘤领域;罕见疾病领域,DR036896,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,TRUE,FALSE,[],['Circle Pharma'],1,['Circle Pharma(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
Cyclopeptides,Cyclopeptides (advanceCOR),Cyclopeptides;Cyclopeptides (advanceCOR),格雷夫斯病,Graves' disease,TSHR,,advanceCOR(原研),创新药,生物,多肽,环肽,其他,格雷夫斯病,临床前,,Active,免疫领域;内分泌及代谢领域,DR052507,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['advanceCOR'],1,['advanceCOR(原研)'],免疫领域,"['免疫领域', '内分泌及代谢领域']",2,免疫领域,内分泌及代谢领域,,-1,-1,Immunology,Immunology,Endocrinology & Metabolism,
DYV024,DYV024 (cyclosporine transdermal delivery),DYV024;DYV024 (环孢素透皮递送);DYV024 (cyclosporine transdermal delivery),银屑病,psoriasis,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Dyve Biosciences(原研),微创新,化药,小分子,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,银屑病,临床前,,Active,免疫领域;皮肤领域,DR052450,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Dyve Biosciences'],1,['Dyve Biosciences(原研)'],免疫领域,"['免疫领域', '皮肤领域']",2,免疫领域,皮肤领域,,-1,-1,Immunology,Immunology,Dermatology,
EGFR-targeted cyclic peptides project,EGFR-targeted cyclic peptides project (GeneFrontier),EGFR-targeted cyclic peptides project;EGFR-targeted cyclic peptides project (GeneFrontier),未知/待定,unknown/pending,EGFR,,GeneFrontier(原研),创新药,化药,多肽,环肽;受体酪氨酸激酶,其他,未知/待定,临床前,,Active,其他领域,DR088904,日本,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['GeneFrontier'],1,['GeneFrontier(原研)'],其他领域,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,
Enniatin A ,Enniatin A (Augusta University),Enniatin A ;Enniatin A (Augusta University),三阴性乳腺癌,triple negative breast cancer,not available,,University of Notre Dame(原研);Augusta University(原研),创新药,其他,其他,环肽,其他,三阴性乳腺癌,临床前,,Active,肿瘤领域,DR084296,美国,pre-clinical,临床前,,pre-clinical,2,TRUE,FALSE,FALSE,[],"['University of Notre Dame', 'Augusta University']",2,"['University of Notre Dame(原研)', 'Augusta University(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
EphA2-68Ga imaging agent,EphA2-68Ga imaging agent (Bicycle),EphA2-68Ga imaging agent;EphA2-68Ga imaging agent (Bicycle),PET显像,PET imaging,EphA2,anti-EphA2多肽偶联核素;68Ga标记的PET药物,Bicycle Therapeutics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;受体酪氨酸激酶;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,PET显像,临床前,,Active,诊断试剂领域,DR073753,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
Erk2-targeted cyclic peptides project,Erk2-targeted cyclic peptides project (GeneFrontier),Erk2-targeted cyclic peptides project;Erk2-targeted cyclic peptides project (GeneFrontier),未知/待定,unknown/pending,ERK2,,GeneFrontier(原研),创新药,化药,多肽,环肽;MAPK信号通路,其他,未知/待定,临床前,,Active,其他领域,DR088905,日本,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['GeneFrontier'],1,['GeneFrontier(原研)'],其他领域,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,
FNDR-20364,FNDR-20364,FNDR-20364;NF1001,非结核分枝杆菌肺病,non-tuberculous mycobacterial lung disease,not available,多肽类抗生素,FNDR(原研);NCPOR(原研),创新药,化药,多肽,环肽;差异化疾病;中国无申报,多肽类抗生素,非结核分枝杆菌肺病(差异化疾病),临床前,,Active,罕见疾病领域;感染领域;呼吸领域,DR073504,印度,pre-clinical,临床前,,pre-clinical,2,TRUE,TRUE,FALSE,[],"['FNDR', 'NCPOR']",2,"['FNDR(原研)', 'NCPOR(原研)']",感染领域,"['感染领域', '呼吸领域']",2,感染领域,呼吸领域,,-1,-1,Infectious Diseases,Infectious Diseases,Respiratory,
FOXA1 inhibitor,FOXA1 inhibitor (Curve Therapeutics),FOXA1 inhibitor;FOXA1 inhibitor (Curve Therapeutics),乳腺癌,breast cancer,FOXA1,FOXA1抑制剂,Curve Therapeutics(原研),创新药,化药,小分子,环肽;Potential First-in-Class,抑制剂,乳腺癌,临床前,,Active,肿瘤领域,DR015043,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Curve Therapeutics'],1,['Curve Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
FP-002,FP-002 (octreotide),FP-002;FP-002 (奥曲肽);FP-002 (octreotide);FP-008,肢端肥大症,acromegaly,somatostatin,somatostatin类似物,逸达生物(原研),微创新,化药,多肽,环肽,类似物,肢端肥大症,临床前,,Active,内分泌及代谢领域;罕见疾病领域,DR017674,中国(港澳台),pre-clinical,临床前,,pre-clinical,1,TRUE,TRUE,FALSE,[],['逸达生物'],1,['逸达生物(原研)'],内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,-1,-1,Endocrinology & Metabolism,Endocrinology & Metabolism,,
FP-002,FP-002 (octreotide),FP-002;FP-002 (奥曲肽);FP-002 (octreotide);FP-008,糖尿病视网膜病变,diabetic retinopathy,somatostatin,somatostatin类似物,逸达生物(原研),微创新,化药,多肽,环肽,类似物,糖尿病视网膜病变,临床前,,Active,眼科领域,DR017674,中国(港澳台),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['逸达生物'],1,['逸达生物(原研)'],眼科领域,['眼科领域'],1,眼科领域,,,-1,-1,Ophthalmology,Ophthalmology,,
FPP29,FPP29,FPP29,肝癌,liver cancer,FOXM1,FOXM1 PROTAC,西南交通大学(原研),创新药,化药,多肽;降解类药物,环肽;E3 ligase [VHL];Potential First-in-Class,PROTAC,肝癌,临床前,,Active,肿瘤领域,DR083401,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['西南交通大学'],1,['西南交通大学(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
HER2-targeted cyclic peptides project,HER2-targeted cyclic peptides project (GeneFrontier),HER2-targeted cyclic peptides project;HER2-targeted cyclic peptides project (GeneFrontier),未知/待定,unknown/pending,HER2,,GeneFrontier(原研),创新药,化药,多肽,环肽;受体酪氨酸激酶,其他,未知/待定,临床前,,Active,其他领域,DR088903,日本,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['GeneFrontier'],1,['GeneFrontier(原研)'],其他领域,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,
IL-11/IL-11Rα inhibitor,IL-11/IL-11Rα inhibitor (Takeda Pharmaceuticals),IL-11/IL-11Rα inhibitor;IL-11/IL-11Rα inhibitor (Takeda Pharmaceuticals),炎症(未指明),Inflammation (unspecified),IL-11;IL-11RA,IL-11×IL-11RA蛋白蛋白相互作用抑制剂,Takeda Pharmaceuticals(Top20 MNC)(原研),创新药,化药,多肽,环肽;Potential First-in-Class,蛋白蛋白相互作用抑制剂,炎症(未指明),临床前,,Active,免疫领域,DR072761,日本,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,TRUE,['Takeda Pharmaceuticals'],['Takeda Pharmaceuticals'],1,['Takeda Pharmaceuticals(Top20 MNC)(原研)'],免疫领域,['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,
IL-11/IL-11Rα inhibitor,IL-11/IL-11Rα inhibitor (Takeda Pharmaceuticals),IL-11/IL-11Rα inhibitor;IL-11/IL-11Rα inhibitor (Takeda Pharmaceuticals),纤维化(未指明),Fibrosis (unspecified),IL-11;IL-11RA,IL-11×IL-11RA蛋白蛋白相互作用抑制剂,Takeda Pharmaceuticals(Top20 MNC)(原研),创新药,化药,多肽,环肽;Potential First-in-Class,蛋白蛋白相互作用抑制剂,纤维化(未指明),临床前,,Active,其他领域,DR072761,日本,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,TRUE,['Takeda Pharmaceuticals'],['Takeda Pharmaceuticals'],1,['Takeda Pharmaceuticals(Top20 MNC)(原研)'],其他领域,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,
IL-23R Inhibitor,IL-23R Inhibitor (Nimble Therapeutics),IL-23R Inhibitor;IL-23R Inhibitor (Nimble Therapeutics),银屑病,psoriasis,IL-23R,IL-23R抑制剂,Nimble Therapeutics(AbbVie)(Top20 MNC)(原研),创新药,化药,多肽,环肽;Th17通路,抑制剂,银屑病,临床前,,Active,免疫领域;皮肤领域,DR071873,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,TRUE,['Nimble Therapeutics(AbbVie)'],['Nimble Therapeutics(AbbVie)'],1,['Nimble Therapeutics(AbbVie)(Top20 MNC)(原研)'],免疫领域,"['免疫领域', '皮肤领域']",2,免疫领域,皮肤领域,,-1,-1,Immunology,Immunology,Dermatology,
IL-6-targeted cyclic peptides project,IL-6-targeted cyclic peptides project (GeneFrontier),IL-6-targeted cyclic peptides project;IL-6-targeted cyclic peptides project (GeneFrontier),未知/待定,unknown/pending,IL-6,IL-6抑制剂,GeneFrontier(原研),创新药,化药,多肽,环肽;Potential First-in-Class,抑制剂,未知/待定,临床前,,Active,其他领域,DR088906,日本,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['GeneFrontier'],1,['GeneFrontier(原研)'],其他领域,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,
IL17 therapeutic MPC,IL17 therapeutic MPC (PeptiDream),IL17 therapeutic MPC;IL17 therapeutic MPC (PeptiDream),自身免疫性疾病,autoimmune disease,IL-17,多肽偶联药物,PeptiDream(原研),创新药,化药,多肽;偶联药物,环肽;Th17通路;Potential First-in-Class,多肽偶联药物,自身免疫性疾病,临床前,,Active,免疫领域,DR060945,日本,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['PeptiDream'],1,['PeptiDream(原研)'],免疫领域,['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,
IT-01,IT-01,IT-01,肿瘤,tumor,TIM3,TIM3抑制剂,Interprotein(原研),创新药,化药,多肽,环肽;Potential First-in-Class;肿瘤免疫,抑制剂,肿瘤,临床前,,Active,肿瘤领域,DR035071,日本,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Interprotein'],1,['Interprotein(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
IT-201,IT-201,IT-201,肿瘤,tumor,TIM3,TIM3抑制剂,Interprotein(原研),创新药,化药,多肽,环肽;Potential First-in-Class;肿瘤免疫,抑制剂,肿瘤,临床前,,Active,肿瘤领域,DR023651,日本,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Interprotein'],1,['Interprotein(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
IT-202,IT-202,IT-202,肿瘤,tumor,TIM3,TIM3抑制剂,Interprotein(原研),创新药,化药,多肽,环肽;Potential First-in-Class;肿瘤免疫,抑制剂,肿瘤,临床前,,Active,肿瘤领域,DR035073,日本,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Interprotein'],1,['Interprotein(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
IT-203,IT-203,IT-203,肿瘤,tumor,TIM3,TIM3抑制剂,Interprotein(原研),创新药,化药,多肽,环肽;Potential First-in-Class;肿瘤免疫,抑制剂,肿瘤,临床前,,Active,肿瘤领域,DR013523,日本,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Interprotein'],1,['Interprotein(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
IT-205,IT-205,IT-205,肿瘤,tumor,TIM3,TIM3抑制剂,Interprotein(原研),创新药,化药,多肽,环肽;Potential First-in-Class;肿瘤免疫,抑制剂,肿瘤,临床前,,Active,肿瘤领域,DR035072,日本,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Interprotein'],1,['Interprotein(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
JMKX2301,JMKX2301,JMKX2301,未知/待定,unknown/pending,not available,多肽偶联药物,济煜医药(原研),创新药,其他,多肽;偶联药物,环肽,多肽偶联药物,未知/待定,临床前,,Active,其他领域,DR088411,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['济煜医药'],1,['济煜医药(原研)'],其他领域,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,
JVA-4001,JVA-4001,JVA-4001,阿片成瘾,opiate addiction,κ opioid receptor,κ opioid receptor拮抗剂,University of Florida(原研),创新药,化药,多肽,环肽;G蛋白偶联受体,拮抗剂,阿片成瘾,临床前,,Active,精神领域,DR025052,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['University of Florida'],1,['University of Florida(原研)'],精神领域,['精神领域'],1,精神领域,,,-1,-1,Psychiatry,Psychiatry,,
JWP24,JWP24,JWP24,癌症,cancer,MAGEA4,MAGEA4抑制剂,University of North Carolina at Chapel Hill(原研),创新药,化药,多肽,环肽;Potential First-in-Class,抑制剂,癌症,临床前,,Active,肿瘤领域,DR086918,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['University of North Carolina at Chapel Hill'],1,['University of North Carolina at Chapel Hill(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
KROS-401,KROS-401,KROS-401,三阴性乳腺癌,triple negative breast cancer,IL-4Rα,IL-4Rα抑制剂,Kairos Pharma(原研),创新药,化药,多肽,环肽;Th2通路;差异化疾病;Potential First-in-Class,抑制剂,三阴性乳腺癌(差异化疾病),临床前,,Active,肿瘤领域,DR033240,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Kairos Pharma'],1,['Kairos Pharma(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
KROS-401,KROS-401,KROS-401,阿尔茨海默病,Alzheimer's disease,IL-4Rα,IL-4Rα抑制剂,Kairos Pharma(原研),创新药,化药,多肽,环肽;Th2通路;差异化疾病;Potential First-in-Class,抑制剂,阿尔茨海默病(差异化疾病),临床前,,Active,神经领域,DR033240,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Kairos Pharma'],1,['Kairos Pharma(原研)'],神经领域,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,
KS-133,KS-133,KS-133,精神分裂症,Schizophrenia,VIPR2,VIPR2拮抗剂,Ichimaru Pharcos(原研),创新药,化药,多肽,环肽;G蛋白偶联受体;Potential First-in-Class,拮抗剂,精神分裂症,临床前,,Active,精神领域,DR005772,日本,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Ichimaru Pharcos'],1,['Ichimaru Pharcos(原研)'],精神领域,['精神领域'],1,精神领域,,,-1,-1,Psychiatry,Psychiatry,,
LAS200813,LAS200813,LAS200813,呼吸系统疾病,respiratory diseases,Nrf2;Keap1,Nrf2×Keap1蛋白蛋白相互作用抑制剂,AstraZeneca(Top20 MNC);Almirall(原研),创新药,化药,多肽,环肽;Keap1-Nrf2通路;Potential First-in-Class,蛋白蛋白相互作用抑制剂,呼吸系统疾病,临床前,,Active,呼吸领域,DR035180,欧洲,pre-clinical,临床前,,pre-clinical,2,TRUE,FALSE,TRUE,['AstraZeneca'],['Almirall'],1,"['AstraZeneca(Top20 MNC)', 'Almirall(原研)']",呼吸领域,['呼吸领域'],1,呼吸领域,,,-1,-1,Respiratory,Respiratory,,
LYTAP-001,LYTAP-001,LYTAP-001,炎症(未指明),Inflammation (unspecified),EGFR,EGFR降解剂,Filamon(原研),创新药,化药,多肽;降解类药物,环肽;受体酪氨酸激酶;中国无申报;Potential First-in-Class,降解剂,炎症(未指明),临床前,,Active,免疫领域,DR076530,澳大利亚,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Filamon'],1,['Filamon(原研)'],免疫领域,['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,
MAI-516,MAI-516,MAI-516,结直肠癌,colorectal cancer,activated protein C;ARHGEF4,activated protein C×ARHGEF4蛋白蛋白相互作用抑制剂,上海大学(原研),创新药,化药,多肽,环肽;Potential First-in-Class,蛋白蛋白相互作用抑制剂,结直肠癌,临床前,,Active,肿瘤领域,DR086913,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['上海大学'],1,['上海大学(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
MCB_D2,MCB_D2 (University of Washington),MCB_D2;MCB_D2 (University of Washington),未知/待定,unknown/pending,Mcl-1,Mcl-1结合剂,University of Washington(原研),创新药,化药,多肽,环肽;细胞凋亡;Potential First-in-Class,结合剂,未知/待定,临床前,,Active,其他领域,DR087809,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['University of Washington'],1,['University of Washington(原研)'],其他领域,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,
MT1-MMP targeting BDC,MT1-MMP targeting BDC (BicycleTx),MT1-MMP targeting BDC;MT1-MMP targeting BDC (BicycleTx),非小细胞肺癌,non-small cell lung cancer,MMP14,多肽偶联药物,Bicycle Therapeutics(原研),创新药,化药,多肽;偶联药物,环肽;payload [海兔毒素衍生物：MMAE];差异化疾病;linker [VC];Potential First-in-Class;可降解连接子,多肽偶联药物,非小细胞肺癌(差异化疾病),临床前,,Active,肿瘤领域,DR087521,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
MT1-MMP-68Ga imaging agent,MT1-MMP-68Ga imaging agent (Bicycle),MT1-MMP-68Ga imaging agent;MT1-MMP-68Ga imaging agent (Bicycle),PET显像,PET imaging,MMP14,anti-MMP14多肽偶联核素;68Ga标记的PET药物,Bicycle Therapeutics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,68Ga标记的PET药物;多肽偶联核素,PET显像,临床前,,Active,诊断试剂领域,DR073754,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
NAI-112,NAI-112,NAI-112,疼痛,pain,not available,,Naicons(原研),创新药,化药,多肽,环肽,其他,疼痛,临床前,,Active,麻醉镇痛领域,DR010852,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Naicons'],1,['Naicons(原研)'],麻醉镇痛领域,['麻醉镇痛领域'],1,麻醉镇痛领域,,,-1,-1,Anesthesia & Analgesia,Anesthesia & Analgesia,,
NBP14,NBP14,NBP14,阿尔茨海默病,Alzheimer's disease,α7 receptor,α7 receptor抑制剂,Neuro-Bio(原研),创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体,抑制剂,阿尔茨海默病(差异化疾病),临床前,,Active,神经领域,DR009912,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Neuro-Bio'],1,['Neuro-Bio(原研)'],神经领域,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,
NK-TICA,NK-TICA,NK-TICA;BCY17226,肿瘤,tumor,EphA2;NKp46,EphA2×NKp46结合剂,Bicycle Therapeutics(原研),创新药,化药,多肽,环肽;NK cell engager;NK细胞;受体酪氨酸激酶;Potential First-in-Class,结合剂,肿瘤,临床前,,Active,肿瘤领域,DR084292,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
NL301,NL301 (cyclosporine eye drop),NL301;NL301 (环孢素滴眼液);NL301 (cyclosporine eye drop),干眼病,dry eye disease,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,诺思兰德(原研),微创新,化药,多肽,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,干眼病,临床前,,Active,眼科领域,DR087637,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['诺思兰德'],1,['诺思兰德(原研)'],眼科领域,['眼科领域'],1,眼科领域,,,-1,-1,Ophthalmology,Ophthalmology,,
NPA7,NPA7,NPA7,心血管疾病,cardiovascular disease,Mas receptor,Mas receptor激活剂,Mayo Clinic(原研),创新药,化药,多肽,环肽;肾素-血管紧张素-醛固酮系统;G蛋白偶联受体,激活剂,心血管疾病,临床前,,Active,心脑血管领域,DR047403,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Mayo Clinic'],1,['Mayo Clinic(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,-1,-1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
NanoRomi,NanoRomi (romidepsin nanoparticle),NanoRomi;NanoRomi (romidepsin nanoparticle),T细胞淋巴瘤,T cell lymphoma,HDAC,HDAC抑制剂,University of Virginia(原研),微创新,化药,小分子,环肽;表观遗传,抑制剂,T细胞淋巴瘤,临床前,,Active,肿瘤领域;血液领域;罕见疾病领域,DR086152,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,TRUE,FALSE,[],['University of Virginia'],1,['University of Virginia(原研)'],肿瘤领域,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,-1,-1,Oncology,Oncology,Hematology,
OMN-51,OMN-51,OMN-51,细菌感染,bacterial infection,not available,,Omnix Medical(原研),创新药,化药,多肽,环肽;中国无申报,其他,细菌感染,临床前,,Active,感染领域,DR047574,以色列,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Omnix Medical'],1,['Omnix Medical(原研)'],感染领域,['感染领域'],1,感染领域,,,-1,-1,Infectious Diseases,Infectious Diseases,,
ORYN 1051,ORYN 1051,ORYN 1051,克罗恩病,Crohn's disease,not available,,Oryn Therapeutics(原研),创新药,化药,多肽,环肽,其他,克罗恩病,临床前,,Active,消化领域;免疫领域,DR009768,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Oryn Therapeutics'],1,['Oryn Therapeutics(原研)'],消化领域,"['消化领域', '免疫领域']",2,消化领域,免疫领域,,-1,-1,Digestive System,Digestive System,Immunology,
ORYN 1051,ORYN 1051,ORYN 1051,溃疡性结肠炎,ulcerative colitis,not available,,Oryn Therapeutics(原研),创新药,化药,多肽,环肽,其他,溃疡性结肠炎,临床前,,Active,免疫领域;消化领域,DR009768,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Oryn Therapeutics'],1,['Oryn Therapeutics(原研)'],免疫领域,"['免疫领域', '消化领域']",2,免疫领域,消化领域,,-1,-1,Immunology,Immunology,Digestive System,
ORYN 1053,ORYN 1053,ORYN 1053,肿瘤,tumor,not available,,Oryn Therapeutics(原研),创新药,化药,多肽,环肽,其他,肿瘤,临床前,,Active,肿瘤领域,DR042056,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Oryn Therapeutics'],1,['Oryn Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
ORYN 1064,ORYN 1064,ORYN 1064,细菌感染,bacterial infection,not available,,Oryn Therapeutics(原研),创新药,化药,多肽,环肽,其他,细菌感染,临床前,,Active,感染领域,DR020136,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Oryn Therapeutics'],1,['Oryn Therapeutics(原研)'],感染领域,['感染领域'],1,感染领域,,,-1,-1,Infectious Diseases,Infectious Diseases,,
P1-1,P1-1,P1-1,肝纤维化,liver fibrosis,GPR55,GPR55拮抗剂,中山大学(原研);图微安创(原研),创新药,化药,多肽,环肽;差异化疾病;Potential First-in-Class,拮抗剂,肝纤维化(差异化疾病),临床前,,Active,消化领域,DR068670,中国(内地),pre-clinical,临床前,,pre-clinical,2,TRUE,FALSE,FALSE,[],"['中山大学', '图微安创']",2,"['中山大学(原研)', '图微安创(原研)']",消化领域,['消化领域'],1,消化领域,,,-1,-1,Digestive System,Digestive System,,
PBP3s inhibitor,PBP3s inhibitor (Bicycle Therapeutics),PBP3s inhibitor;PBP3s inhibitor (Bicycle Therapeutics),细菌感染,bacterial infection,PBP3,PBP3抑制剂,Bicycle Therapeutics(原研),创新药,化药,多肽,环肽;Potential First-in-Class,抑制剂,细菌感染,临床前,,Active,感染领域,DR087523,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],感染领域,['感染领域'],1,感染领域,,,-1,-1,Infectious Diseases,Infectious Diseases,,
PD-K(111In-DOTA)-RGD,PD-K(111In-DOTA)-RGD,PD-K(111In-DOTA)-RGD,胰腺导管癌,pancreatic ductal carcinoma,αvβ6;αvβ3,anti-αvβ3×αvβ6多肽偶联核素;含铟放射性示踪剂,National Cancer Center Japan(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,胰腺导管癌,临床前,,Active,肿瘤领域,DR089733,日本,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['National Cancer Center Japan'],1,['National Cancer Center Japan(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
PD-K(177Lu-DOTA)-c(RGDfK),PD-K(177Lu-DOTA)-c(RGDfK),PD-K(177Lu-DOTA)-c(RGDfK),胰腺导管癌,pancreatic ductal carcinoma,αvβ6;αvβ3,anti-αvβ3×αvβ6多肽偶联核素;177Lu标记的放射性药物,National Cancer Center Japan(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,胰腺导管癌,临床前,,Active,肿瘤领域,DR089726,日本,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['National Cancer Center Japan'],1,['National Cancer Center Japan(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
PD-K(225Ac-DOTA)-c(RGDfK),PD-K(225Ac-DOTA)-c(RGDfK),PD-K(225Ac-DOTA)-c(RGDfK),胰腺导管癌,pancreatic ductal carcinoma,αvβ6;αvβ3,anti-αvβ3×αvβ6多肽偶联核素;225Ac标记的放射性药物,National Cancer Center Japan(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,胰腺导管癌,临床前,,Active,肿瘤领域,DR089727,日本,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['National Cancer Center Japan'],1,['National Cancer Center Japan(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
PG-004,PG-004,PG-004,未知/待定,unknown/pending,BMP7;BMP4,BMP4抑制剂;BMP7抑制剂,PeptiGrowth(原研),创新药,化药,多肽,环肽;TGF-β信号通路;Potential First-in-Class,抑制剂,未知/待定,临床前,,Active,其他领域,DR060120,日本,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['PeptiGrowth'],1,['PeptiGrowth(原研)'],其他领域,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,
PG-005,PG-005,PG-005,未知/待定,unknown/pending,BMP7,BMP7抑制剂,PeptiGrowth(原研),创新药,化药,多肽,环肽;TGF-β信号通路;Potential First-in-Class,抑制剂,未知/待定,临床前,,Active,其他领域,DR013348,日本,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['PeptiGrowth'],1,['PeptiGrowth(原研)'],其他领域,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,
PG-006,PG-006,PG-006,未知/待定,unknown/pending,BMP4,BMP4抑制剂,PeptiGrowth(原研),创新药,化药,多肽,环肽;Potential First-in-Class,抑制剂,未知/待定,临床前,,Active,其他领域,DR013349,日本,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['PeptiGrowth'],1,['PeptiGrowth(原研)'],其他领域,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,
PG-007,PG-007,PG-007,未知/待定,unknown/pending,VEGFR2,VEGFR2激动剂,PeptiGrowth(原研),创新药,化药,多肽,环肽;受体酪氨酸激酶;Potential First-in-Class,激动剂,未知/待定,临床前,,Active,其他领域,DR043547,日本,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['PeptiGrowth'],1,['PeptiGrowth(原研)'],其他领域,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,
PG-008,PG-008,PG-008,未知/待定,unknown/pending,WNT3A,WNT3A类似物,PeptiGrowth(原研),创新药,化药,多肽,环肽;Potential First-in-Class,类似物,未知/待定,临床前,,Active,其他领域,DR077632,日本,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['PeptiGrowth'],1,['PeptiGrowth(原研)'],其他领域,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,
PG-010,PG-010,PG-010,未知/待定,unknown/pending,TPO receptor,TPO receptor激动剂,PeptiGrowth(原研),创新药,化药,多肽,环肽,激动剂,未知/待定,临床前,,Active,其他领域,DR077635,日本,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['PeptiGrowth'],1,['PeptiGrowth(原研)'],其他领域,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,
PG-012,PG-012,PG-012,未知/待定,unknown/pending,FGFR2,FGFR2激动剂,PeptiGrowth(原研),创新药,化药,多肽,环肽;受体酪氨酸激酶;Potential First-in-Class,激动剂,未知/待定,临床前,,Active,其他领域,DR077636,日本,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['PeptiGrowth'],1,['PeptiGrowth(原研)'],其他领域,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,
PHIN-1314,PHIN-1314,PHIN-1314,实体瘤,solid tumors,CNP,CNP类似物,PharmaIN(原研),创新药,化药,多肽,环肽,类似物,实体瘤,临床前,,Active,肿瘤领域,DR036407,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['PharmaIN'],1,['PharmaIN(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
PHIN-1314,PHIN-1314,PHIN-1314,纤维化(未指明),Fibrosis (unspecified),CNP,CNP类似物,PharmaIN(原研),创新药,化药,多肽,环肽,类似物,纤维化(未指明),临床前,,Active,其他领域,DR036407,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['PharmaIN'],1,['PharmaIN(原研)'],其他领域,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,
PLX138,PLX138,"PLX138;[Gln6,14]CNP-38",软骨发育不全,Achondroplasia,CNP,CNP类似物,ProLynx(原研),创新药,化药,多肽,环肽,类似物,软骨发育不全,临床前,,Active,骨骼肌肉领域;罕见疾病领域,DR025062,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,TRUE,FALSE,[],['ProLynx'],1,['ProLynx(原研)'],骨骼肌肉领域,['骨骼肌肉领域'],1,骨骼肌肉领域,,,-1,-1,Musculoskeletal,Musculoskeletal,,
PN23114,PN23114,PN23114,遗传性血色素沉着病,hereditary hemochromatosis,Hepc,Hepc模拟物,Protagonist Therapeutics(原研),创新药,化药,多肽,环肽;铁代谢,模拟物,遗传性血色素沉着病,临床前,,Active,罕见疾病领域;内分泌及代谢领域,DR073535,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,TRUE,FALSE,[],['Protagonist Therapeutics'],1,['Protagonist Therapeutics(原研)'],内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,-1,-1,Endocrinology & Metabolism,Endocrinology & Metabolism,,
POL7306,POL7306,POL7306,细菌感染,bacterial infection,BamA,BamA抑制剂,Polyphor(Spexis)(原研),创新药,化药,小分子,环肽;Potential First-in-Class,抑制剂,细菌感染,临床前,,Active,感染领域,DR029380,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Polyphor(Spexis)'],1,['Polyphor(Spexis)(原研)'],感染领域,['感染领域'],1,感染领域,,,-1,-1,Infectious Diseases,Infectious Diseases,,
PT-2,PT-2 (oral octreotide),PT-2;PT-2 (口服奥曲肽);PT-2 (oral octreotide),类癌,carcinoid,somatostatin,somatostatin类似物,Imagine Pharma(原研),微创新,化药,多肽,环肽,类似物,类癌,临床前,,Active,肿瘤领域;罕见疾病领域,DR074468,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,TRUE,FALSE,[],['Imagine Pharma'],1,['Imagine Pharma(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
PT-2,PT-2 (oral octreotide),PT-2;PT-2 (口服奥曲肽);PT-2 (oral octreotide),类癌综合征,carcinoid syndrome,somatostatin,somatostatin类似物,Imagine Pharma(原研),微创新,化药,多肽,环肽,类似物,类癌综合征,临床前,,Active,肿瘤领域;罕见疾病领域,DR074468,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,TRUE,FALSE,[],['Imagine Pharma'],1,['Imagine Pharma(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
Pb-BCY20603,Pb-BCY20603,Pb-BCY20603,癌症,cancer,MMP14,212Pb标记的放射性药物;anti-MMP14多肽偶联核素,Bicycle Therapeutics(原研);Orano Med,创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;中国无申报;Potential First-in-Class,212Pb标记的放射性药物;多肽偶联核素,癌症,临床前,,Active,肿瘤领域,DR055166,欧洲,pre-clinical,临床前,,pre-clinical,2,TRUE,FALSE,FALSE,[],['Bicycle Therapeutics'],1,"['Bicycle Therapeutics(原研)', 'Orano Med']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
RAY0221,RAY0221,RAY0221,糖尿病,diabetes,GIPR;GLP-1R;GCGR,GIPR激动剂;GLP-1R激动剂;GCGR激动剂,众生睿创(原研),创新药,化药,多肽,环肽;肠促胰岛素通路,激动剂,糖尿病,临床前,,Active,内分泌及代谢领域,DR049182,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['众生睿创'],1,['众生睿创(原研)'],内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,-1,-1,Endocrinology & Metabolism,Endocrinology & Metabolism,,
RAY0221,RAY0221,RAY0221,肥胖,obesity,GIPR;GLP-1R;GCGR,GIPR激动剂;GLP-1R激动剂;GCGR激动剂,众生睿创(原研),创新药,化药,多肽,环肽;肠促胰岛素通路,激动剂,肥胖,临床前,,Active,内分泌及代谢领域,DR049182,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['众生睿创'],1,['众生睿创(原研)'],内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,-1,-1,Endocrinology & Metabolism,Endocrinology & Metabolism,,
RAY0221,RAY0221,RAY0221,代谢相关脂肪性肝炎,Metabolic related steatohepatitis,GIPR;GLP-1R;GCGR,GIPR激动剂;GLP-1R激动剂;GCGR激动剂,众生睿创(原研),创新药,化药,多肽,环肽;肠促胰岛素通路,激动剂,代谢相关脂肪性肝炎,临床前,,Active,消化领域,DR049182,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['众生睿创'],1,['众生睿创(原研)'],消化领域,['消化领域'],1,消化领域,,,-1,-1,Digestive System,Digestive System,,
RGD-VC-CA,RGD-VC-CA,RGD-VC-CA,癌症,cancer,not available,多肽偶联药物,中国科学院深圳先进技术研究院(原研),创新药,化药,多肽;偶联药物,环肽,多肽偶联药物,癌症,临床前,,Active,肿瘤领域,DR052476,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['中国科学院深圳先进技术研究院'],1,['中国科学院深圳先进技术研究院(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
SAG602,SAG602,SAG602,癌症,cancer,Muc1,多肽偶联药物,羿肽生物(原研),创新药,化药,多肽;偶联药物,环肽;Potential First-in-Class,多肽偶联药物,癌症,临床前,,Active,肿瘤领域,DR080142,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['羿肽生物'],1,['羿肽生物(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
SAG602,SAG602,SAG602,光学成像剂,optical imaging agent,Muc1,多肽偶联药物,羿肽生物(原研),创新药,化药,多肽;偶联药物,环肽;Potential First-in-Class,多肽偶联药物,光学成像剂,临床前,,Active,诊断试剂领域,DR080142,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['羿肽生物'],1,['羿肽生物(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
SBL-PX1-206,SBL-PX1-206,SBL-PX1-206,心血管疾病,cardiovascular disease,PANX1,PANX1抑制剂,Vrije Universiteit Brussel(原研),创新药,化药,多肽,环肽,抑制剂,心血管疾病,临床前,,Active,心脑血管领域,DR060134,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Vrije Universiteit Brussel'],1,['Vrije Universiteit Brussel(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,-1,-1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
SBL-PX1-42,SBL-PX1-42,SBL-PX1-42,心血管疾病,cardiovascular disease,PANX1,PANX1抑制剂,Vrije Universiteit Brussel(原研),创新药,化药,多肽,环肽,抑制剂,心血管疾病,临床前,,Active,心脑血管领域,DR030511,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Vrije Universiteit Brussel'],1,['Vrije Universiteit Brussel(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,-1,-1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
SBL-PX1-44,SBL-PX1-44,SBL-PX1-44,心血管疾病,cardiovascular disease,PANX1,PANX1抑制剂,Vrije Universiteit Brussel(原研),创新药,化药,多肽,环肽,抑制剂,心血管疾病,临床前,,Active,心脑血管领域,DR060133,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Vrije Universiteit Brussel'],1,['Vrije Universiteit Brussel(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,-1,-1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
SG5035,SG5035,SG5035,侵袭性念珠菌病,Invasive candidiasis,glucan synthase,glucan synthase抑制剂,祥根生物(原研),创新药,化药,多肽,环肽,抑制剂,侵袭性念珠菌病,临床前,,Active,感染领域,DR076774,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['祥根生物'],1,['祥根生物(原研)'],感染领域,['感染领域'],1,感染领域,,,-1,-1,Infectious Diseases,Infectious Diseases,,
SP-002,SP-002 (cyclosporin nanoparticles),SP-002;SP-002 (环孢素纳米粒);SP-002 (cyclosporin nanoparticles),肢体缺血性疾病,limb ischemic disease,CaN;NTCP;Cyp,NTCP抑制剂;CaN×Cyp分子胶,Sentan Pharma(原研),微创新,化药,小分子,环肽;胆汁酸通路;非降解型分子胶,抑制剂;分子胶,肢体缺血性疾病,临床前,,Active,心脑血管领域,DR044515,日本,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Sentan Pharma'],1,['Sentan Pharma(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,-1,-1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
SVC112,SVC112,SVC112,头颈部鳞状细胞癌,Head and neck squamous cell carcinoma,not available,,SuviCa(原研),创新药,化药,多肽,环肽,其他,头颈部鳞状细胞癌,临床前,,Active,肿瘤领域,DR047485,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['SuviCa'],1,['SuviCa(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
SYNB011128,SYNB011128,SYNB011128,癌症,cancer,CAIX;EGFR,多肽偶联药物,元思生肽(原研),创新药,化药,多肽;偶联药物,环肽;payload [海兔毒素衍生物：MMAE];受体酪氨酸激酶;Potential First-in-Class;可降解连接子,多肽偶联药物,癌症,临床前,,Active,肿瘤领域,DR078617,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['元思生肽'],1,['元思生肽(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
SYNB021225,SYNB021225,SYNB021225,肿瘤,tumor,KRAS,KRAS抑制剂,元思生肽(原研),创新药,化药,多肽,环肽;难成药靶点,抑制剂,肿瘤,临床前,,Active,肿瘤领域,DR078820,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['元思生肽'],1,['元思生肽(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
ShK-235,ShK-235,ShK-235;LrS235,类风湿性关节炎,rheumatoid arthritis,Kv1.3,Kv1.3抑制剂,Baylor College of Medicine(原研),创新药,生物,多肽,环肽;差异化疾病,抑制剂,类风湿性关节炎(差异化疾病),临床前,,Active,免疫领域;骨骼肌肉领域,DR037473,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Baylor College of Medicine'],1,['Baylor College of Medicine(原研)'],免疫领域,"['免疫领域', '骨骼肌肉领域']",2,免疫领域,骨骼肌肉领域,,-1,-1,Immunology,Immunology,Musculoskeletal,
Syn3,Syn3,Syn3,快乐木偶综合症,happy puppet syndrome,BDNF,BDNF增强剂,Aingeal therapeutics(原研),创新药,化药,多肽,环肽;Potential First-in-Class,增强剂,快乐木偶综合症,临床前,,Active,罕见疾病领域,DR024934,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,TRUE,FALSE,[],['Aingeal therapeutics'],1,['Aingeal therapeutics(原研)'],,[],0,,,,-1,-1,,,,
Syn3,Syn3,Syn3,外伤性脑损伤,traumatic brain injury,BDNF,BDNF增强剂,Aingeal therapeutics(原研),创新药,化药,多肽,环肽;Potential First-in-Class,增强剂,外伤性脑损伤,临床前,,Active,神经领域,DR024934,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Aingeal therapeutics'],1,['Aingeal therapeutics(原研)'],神经领域,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,
Syn3,Syn3,Syn3,难治性抑郁症,treatment-resistant depression,BDNF,BDNF增强剂,Aingeal therapeutics(原研),创新药,化药,多肽,环肽;Potential First-in-Class,增强剂,难治性抑郁症,临床前,,Active,精神领域,DR024934,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Aingeal therapeutics'],1,['Aingeal therapeutics(原研)'],精神领域,['精神领域'],1,精神领域,,,-1,-1,Psychiatry,Psychiatry,,
Synova macrocyclic peptide,Synova macrocyclic peptide (Syneron Bio),Synova macrocyclic peptide;Synova macrocyclic peptide (元思生肽);Synova macrocyclic peptide (Syneron Bio),自身免疫性疾病,autoimmune disease,not available,,AstraZeneca(Top20 MNC);元思生肽(原研),创新药,其他,多肽,环肽;中国无申报,其他,自身免疫性疾病,临床前,,Active,免疫领域,DR076824,中国(内地),pre-clinical,临床前,,pre-clinical,2,TRUE,FALSE,TRUE,['AstraZeneca'],['元思生肽'],1,"['AstraZeneca(Top20 MNC)', '元思生肽(原研)']",免疫领域,['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,
Synova macrocyclic peptide,Synova macrocyclic peptide (Syneron Bio),Synova macrocyclic peptide;Synova macrocyclic peptide (元思生肽);Synova macrocyclic peptide (Syneron Bio),代谢疾病,Metabolic diseases,not available,,AstraZeneca(Top20 MNC);元思生肽(原研),创新药,其他,多肽,环肽;中国无申报,其他,代谢疾病,临床前,,Active,内分泌及代谢领域,DR076824,中国(内地),pre-clinical,临床前,,pre-clinical,2,TRUE,FALSE,TRUE,['AstraZeneca'],['元思生肽'],1,"['AstraZeneca(Top20 MNC)', '元思生肽(原研)']",内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,-1,-1,Endocrinology & Metabolism,Endocrinology & Metabolism,,
T20K,T20K,T20K,多发性硬化症相关视神经炎,Multiple sclerosis-related optic neuritis,IL-2,,Cyxone(原研),创新药,化药,多肽,环肽,其他,多发性硬化症相关视神经炎,临床前,,Active,神经领域;罕见疾病领域,DR044285,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,TRUE,FALSE,[],['Cyxone'],1,['Cyxone(原研)'],神经领域,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,
TB513,TB513,TB513,肿瘤,tumor,SIRPα,多肽偶联药物,Twinpig Biolab(原研),创新药,化药,多肽;偶联药物,环肽;肿瘤相关巨噬细胞;中国无申报;Potential First-in-Class;肿瘤免疫,多肽偶联药物,肿瘤,临床前,,Active,肿瘤领域,DR087533,韩国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Twinpig Biolab'],1,['Twinpig Biolab(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
TB551,TB551,TB551;TB522,胰腺癌,pancreatic cancer,not available,多肽偶联药物,Twinpig Biolab(原研),创新药,化药,多肽;偶联药物,环肽;中国无申报,多肽偶联药物,胰腺癌,临床前,,Active,肿瘤领域;罕见疾病领域,DR045211,韩国,pre-clinical,临床前,,pre-clinical,1,TRUE,TRUE,FALSE,[],['Twinpig Biolab'],1,['Twinpig Biolab(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
TB712,TB712,TB712;TB711,肿瘤,tumor,CD18;STAT6,多肽偶联药物;反义疗法,Twinpig Biolab(原研),创新药,化药,核酸;多肽;偶联药物,环肽;JAK-STAT信号通路;小核酸;中国无申报;Potential First-in-Class,反义疗法;多肽偶联药物,肿瘤,临床前,,Active,肿瘤领域,DR084301,韩国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Twinpig Biolab'],1,['Twinpig Biolab(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
TBR521,TBR521,TBR521,癌症,cancer,FAP,多肽偶联药物,Twinpig Biolab(原研),创新药,化药,多肽;偶联药物,环肽;中国无申报,多肽偶联药物,癌症,临床前,,Active,肿瘤领域,DR087539,韩国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Twinpig Biolab'],1,['Twinpig Biolab(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
TBR551,TBR551,TBR551,癌症,cancer,nectin-4,多肽偶联药物,Twinpig Biolab(原研),创新药,化药,多肽;偶联药物,环肽;中国无申报,多肽偶联药物,癌症,临床前,,Active,肿瘤领域,DR087542,韩国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Twinpig Biolab'],1,['Twinpig Biolab(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
TBR552,TBR552,TBR552,癌症,cancer,TROP2,多肽偶联药物,Twinpig Biolab(原研),创新药,化药,多肽;偶联药物,环肽;中国无申报;Potential First-in-Class,多肽偶联药物,癌症,临床前,,Active,肿瘤领域,DR087544,韩国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Twinpig Biolab'],1,['Twinpig Biolab(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
TBR553,TBR553,TBR553,癌症,cancer,ROR1,多肽偶联药物,Twinpig Biolab(原研),创新药,化药,多肽;偶联药物,环肽;受体酪氨酸激酶;中国无申报;Potential First-in-Class;Wnt信号通路,多肽偶联药物,癌症,临床前,,Active,肿瘤领域,DR087545,韩国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Twinpig Biolab'],1,['Twinpig Biolab(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
TLR3 targeted Bicycle,TLR3 targeted Bicycle (Bicycle Therapeutics),TLR3 targeted Bicycle;TLR3 targeted Bicycle (Bicycle Therapeutics),实体瘤,solid tumors,TLR3,TLR3调节剂,Genentech(Roche)(Top20 MNC);Bicycle Therapeutics(原研),创新药,化药,多肽,环肽;Toll样受体信号通路;中国无申报;Potential First-in-Class;肿瘤免疫,调节剂,实体瘤,临床前,,Active,肿瘤领域,DR075803,欧洲,pre-clinical,临床前,,pre-clinical,2,TRUE,FALSE,TRUE,['Genentech(Roche)'],['Bicycle Therapeutics'],1,"['Genentech(Roche)(Top20 MNC)', 'Bicycle Therapeutics(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
TNF-α-targeted cyclic peptides project,TNF-α-targeted cyclic peptides project (GeneFrontier),TNF-α-targeted cyclic peptides project;TNF-α-targeted cyclic peptides project (GeneFrontier),未知/待定,unknown/pending,TNF-α,,GeneFrontier(原研),创新药,化药,多肽,环肽,其他,未知/待定,临床前,,Active,其他领域,DR088907,日本,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['GeneFrontier'],1,['GeneFrontier(原研)'],其他领域,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,
TT-241X,TT-241X,TT-241X,神经痛,neuralgia,not available,,Teitur Trophics(原研),创新药,化药,多肽,环肽,其他,神经痛,临床前,,Active,麻醉镇痛领域,DR011058,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Teitur Trophics'],1,['Teitur Trophics(原研)'],麻醉镇痛领域,['麻醉镇痛领域'],1,麻醉镇痛领域,,,-1,-1,Anesthesia & Analgesia,Anesthesia & Analgesia,,
Tye-1002,Tye-1002,Tye-1002,小细胞肺癌,small cell lung cancer,SSTR2,多肽偶联药物,泰尔康生物(原研),创新药,化药,多肽;偶联药物,环肽;差异化疾病,多肽偶联药物,小细胞肺癌,临床前,,Active,肿瘤领域;罕见疾病领域,DR034168,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,TRUE,FALSE,[],['泰尔康生物'],1,['泰尔康生物(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
Tye-1002,Tye-1002,Tye-1002,鼻咽癌,Nasopharyngeal cancer,SSTR2,多肽偶联药物,泰尔康生物(原研),创新药,化药,多肽;偶联药物,环肽;差异化疾病,多肽偶联药物,鼻咽癌(差异化疾病),临床前,,Active,肿瘤领域;罕见疾病领域,DR034168,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,TRUE,FALSE,[],['泰尔康生物'],1,['泰尔康生物(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
Tye-1002,Tye-1002,Tye-1002,神经内分泌肿瘤,neuroendocrine tumors,SSTR2,多肽偶联药物,泰尔康生物(原研),创新药,化药,多肽;偶联药物,环肽;差异化疾病,多肽偶联药物,神经内分泌肿瘤,临床前,,Active,肿瘤领域;罕见疾病领域,DR034168,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,TRUE,FALSE,[],['泰尔康生物'],1,['泰尔康生物(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
Tye-2001,Tye-2001,Tye-2001;Tye2001,器官移植,organ transplant,CaN;SSTR2;FKBP12,多肽偶联药物;CaN×FKBP12分子胶,泰尔康生物(原研),创新药,化药,多肽;偶联药物,环肽;Potential First-in-Class,多肽偶联药物;分子胶,器官移植,临床前,,Active,其他领域,DR059368,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['泰尔康生物'],1,['泰尔康生物(原研)'],其他领域,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,
ULT3,ULT3,ULT3,细菌感染,bacterial infection,P. aeruginosa;S. aureus;E. coli;K. pneumoniae;A. baumannii,多肽类抗生素,Ultupharma(原研),创新药,生物,多肽,环肽;Potential First-in-Class,多肽类抗生素,细菌感染,临床前,,Active,感染领域,DR008548,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Ultupharma'],1,['Ultupharma(原研)'],感染领域,['感染领域'],1,感染领域,,,-1,-1,Infectious Diseases,Infectious Diseases,,
UNP-6457,UNP-6457,UNP-6457,未知/待定,unknown/pending,MDM2;p53,MDM2×p53蛋白蛋白相互作用抑制剂,Unnatural Products(原研),创新药,化药,多肽,环肽;细胞凋亡;泛素-蛋白酶体系统;合成致死;难成药靶点;p53信号通路,蛋白蛋白相互作用抑制剂,未知/待定,临床前,,Active,其他领域,DR061184,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Unnatural Products'],1,['Unnatural Products(原研)'],其他领域,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,
US2025122242A1,US2025122242A1,US2025122242A1,阿尔茨海默病,Alzheimer's disease,Aβ,Aβ聚集抑制剂,WARF(原研),创新药,化药,多肽,环肽;Amyloid beta通路,聚集抑制剂,阿尔茨海默病,临床前,,Active,神经领域,DR084136,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['WARF'],1,['WARF(原研)'],神经领域,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,
US2025145665A1,US2025145665A1,US2025145665A1,自身免疫性疾病,autoimmune disease,TNF-α,TNF-α抑制剂,Bristol-Myers Squibb(Top20 MNC)(原研),创新药,化药,多肽,环肽,抑制剂,自身免疫性疾病,临床前,,Active,免疫领域,DR084139,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,TRUE,['Bristol-Myers Squibb'],['Bristol-Myers Squibb'],1,['Bristol-Myers Squibb(Top20 MNC)(原研)'],免疫领域,['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,
US2025145665A1,US2025145665A1,US2025145665A1,炎症(未指明),Inflammation (unspecified),TNF-α,TNF-α抑制剂,Bristol-Myers Squibb(Top20 MNC)(原研),创新药,化药,多肽,环肽,抑制剂,炎症(未指明),临床前,,Active,免疫领域,DR084139,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,TRUE,['Bristol-Myers Squibb'],['Bristol-Myers Squibb'],1,['Bristol-Myers Squibb(Top20 MNC)(原研)'],免疫领域,['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,
VIAN-c4551,VIAN-c4551,VIAN-c4551,湿性年龄相关性黄斑变性,Wet age-related macular degeneration,Ang2;VEGF,Ang2×VEGF抑制剂,ViAn Therapeutics(原研),创新药,化药,多肽,环肽;Potential First-in-Class,抑制剂,湿性年龄相关性黄斑变性,临床前,,Active,眼科领域,DR074000,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['ViAn Therapeutics'],1,['ViAn Therapeutics(原研)'],眼科领域,['眼科领域'],1,眼科领域,,,-1,-1,Ophthalmology,Ophthalmology,,
VIAN-c4551,VIAN-c4551,VIAN-c4551,糖尿病黄斑水肿,diabetic macular edema,Ang2;VEGF,Ang2×VEGF抑制剂,ViAn Therapeutics(原研),创新药,化药,多肽,环肽;Potential First-in-Class,抑制剂,糖尿病黄斑水肿,临床前,,Active,眼科领域,DR074000,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['ViAn Therapeutics'],1,['ViAn Therapeutics(原研)'],眼科领域,['眼科领域'],1,眼科领域,,,-1,-1,Ophthalmology,Ophthalmology,,
VIAN-c4551,VIAN-c4551,VIAN-c4551,糖尿病视网膜病变,diabetic retinopathy,Ang2;VEGF,Ang2×VEGF抑制剂,ViAn Therapeutics(原研),创新药,化药,多肽,环肽;Potential First-in-Class,抑制剂,糖尿病视网膜病变,临床前,,Active,眼科领域,DR074000,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['ViAn Therapeutics'],1,['ViAn Therapeutics(原研)'],眼科领域,['眼科领域'],1,眼科领域,,,-1,-1,Ophthalmology,Ophthalmology,,
VRP-034,VRP-034,VRP-034;VRP-034 (Polymyxin B),细菌感染,bacterial infection,not available,多粘菌素类抗生素,Venus Remedies(原研),微创新,化药,其他,环肽;中国无申报,多粘菌素类抗生素,细菌感染,临床前,,Active,感染领域,DR050842,印度,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Venus Remedies'],1,['Venus Remedies(原研)'],感染领域,['感染领域'],1,感染领域,,,-1,-1,Infectious Diseases,Infectious Diseases,,
WN561,WN561,WN561,心血管疾病,cardiovascular disease,APLNR,APLNR激动剂,浙江大学医学院附属邵逸夫医院(原研),创新药,化药,多肽,环肽;G蛋白偶联受体,激动剂,心血管疾病,临床前,,Active,心脑血管领域,DR061928,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['浙江大学医学院附属邵逸夫医院'],1,['浙江大学医学院附属邵逸夫医院(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,-1,-1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
WO2021007436A1,WO2021007436A1,WO2021007436A1,癌症,cancer,Bcl-2;PD1;TNF-α,Bcl-2抑制剂;TNF-α抑制剂;PD1抑制剂,拓创生物(原研),创新药,化药,多肽,环肽;细胞凋亡;Potential First-in-Class;难成药靶点;肿瘤免疫,抑制剂,癌症,临床前,,Active,肿瘤领域,DR075019,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['拓创生物'],1,['拓创生物(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2022034057A1,WO2022034057A1,WO2022034057A1,糖尿病,diabetes,RARRES2,RARRES2类似物,Bayer(Top20 MNC)(原研),创新药,化药,多肽,环肽;Potential First-in-Class,类似物,糖尿病,临床前,,Active,内分泌及代谢领域,DR072334,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,TRUE,['Bayer'],['Bayer'],1,['Bayer(Top20 MNC)(原研)'],内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,-1,-1,Endocrinology & Metabolism,Endocrinology & Metabolism,,
WO2022096394A1,WO2022096394A1,WO2022096394A1,心肌再灌注损伤,myocardial reperfusion injury,MASP,MASP抑制剂,Bayer(Top20 MNC)(原研),创新药,化药,多肽,环肽;Potential First-in-Class,抑制剂,心肌再灌注损伤,临床前,,Active,心脑血管领域,DR072399,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,TRUE,['Bayer'],['Bayer'],1,['Bayer(Top20 MNC)(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,-1,-1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
WO2022096394A1,WO2022096394A1,WO2022096394A1,肾脏缺血再灌注损伤,renal ischemia-reperfusion injury,MASP,MASP抑制剂,Bayer(Top20 MNC)(原研),创新药,化药,多肽,环肽;Potential First-in-Class,抑制剂,肾脏缺血再灌注损伤,临床前,,Active,泌尿生殖领域,DR072399,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,TRUE,['Bayer'],['Bayer'],1,['Bayer(Top20 MNC)(原研)'],泌尿生殖领域,['泌尿生殖领域'],1,泌尿生殖领域,,,-1,-1,Genitourinary,Genitourinary,,
WO2022115799A1,WO2022115799A1,WO2022115799A1,结直肠癌,colorectal cancer,GC-C,anti-GC-C多肽偶联核素;225Ac标记的放射性药物,RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,结直肠癌,临床前,,Active,肿瘤领域,DR075156,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,TRUE,['RayzeBio(Bristol-Myers Squibb)'],['RayzeBio(Bristol-Myers Squibb)'],1,['RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2022129254A1,WO2022129254A1,WO2022129254A1,糖尿病,diabetes,amylin,amylin类似物,MedImmune(AstraZeneca)(Top20 MNC)(原研),微创新,化药,多肽,环肽,类似物,糖尿病,临床前,,Active,内分泌及代谢领域,DR072408,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,TRUE,['MedImmune(AstraZeneca)'],['MedImmune(AstraZeneca)'],1,['MedImmune(AstraZeneca)(Top20 MNC)(原研)'],内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,-1,-1,Endocrinology & Metabolism,Endocrinology & Metabolism,,
WO2022129254A1,WO2022129254A1,WO2022129254A1,肥胖,obesity,amylin,amylin类似物,MedImmune(AstraZeneca)(Top20 MNC)(原研),微创新,化药,多肽,环肽,类似物,肥胖,临床前,,Active,内分泌及代谢领域,DR072408,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,TRUE,['MedImmune(AstraZeneca)'],['MedImmune(AstraZeneca)'],1,['MedImmune(AstraZeneca)(Top20 MNC)(原研)'],内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,-1,-1,Endocrinology & Metabolism,Endocrinology & Metabolism,,
WO2022212947A1,WO2022212947A1,WO2022212947A1,癌症,cancer,KRAS G12D,KRAS G12D抑制剂,Indi Molecular(原研),创新药,化药,多肽,环肽;难成药靶点;Ras-Raf信号通路,抑制剂,癌症,临床前,,Active,肿瘤领域,DR075973,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Indi Molecular'],1,['Indi Molecular(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2022223969A1,WO2022223969A1,WO2022223969A1,癌症,cancer,P-sel,P-sel抑制剂,Bicycle Therapeutics(原研),创新药,化药,多肽,环肽;差异化疾病;CLR信号通路,抑制剂,癌症,临床前,,Active,肿瘤领域,DR081393,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2022223969A1,WO2022223969A1,WO2022223969A1,镰状细胞病,sickle cell disease,P-sel,P-sel抑制剂,Bicycle Therapeutics(原研),创新药,化药,多肽,环肽;差异化疾病;CLR信号通路,抑制剂,镰状细胞病,临床前,,Active,血液领域;罕见疾病领域,DR081393,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,TRUE,FALSE,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],血液领域,['血液领域'],1,血液领域,,,-1,-1,Hematology,Hematology,,
WO2022223969A1,WO2022223969A1,WO2022223969A1,新型冠状病毒感染,novel coronavirus infection,P-sel,P-sel抑制剂,Bicycle Therapeutics(原研),创新药,化药,多肽,环肽;差异化疾病;CLR信号通路,抑制剂,新型冠状病毒感染(差异化疾病),临床前,,Active,感染领域,DR081393,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],感染领域,['感染领域'],1,感染领域,,,-1,-1,Infectious Diseases,Infectious Diseases,,
WO2022253051A1,WO2022253051A1,WO2022253051A1,肿瘤,tumor,nectin-4,多肽偶联药物,药明康德(原研),创新药,化药,多肽;偶联药物,环肽,多肽偶联药物,肿瘤,临床前,,Active,肿瘤领域,DR073933,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['药明康德'],1,['药明康德(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2023020485A1,WO2023020485A1,WO2023020485A1,实体瘤,solid tumors,EphA2,多肽偶联药物,药明康德(原研),创新药,化药,多肽;偶联药物,环肽;payload [海兔毒素衍生物：MMAE];受体酪氨酸激酶,多肽偶联药物,实体瘤,临床前,,Active,肿瘤领域,DR077827,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['药明康德'],1,['药明康德(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2023026994A1,WO2023026994A1,WO2023026994A1,假肥大性肌营养不良,Duchenne muscular dystrophy,dystrophin;TfR,多肽偶联药物,Takeda Pharmaceuticals(Top20 MNC)(原研),创新药,化药,核酸;多肽;偶联药物,环肽;铁代谢;Potential First-in-Class,多肽偶联药物,假肥大性肌营养不良,临床前,,Active,骨骼肌肉领域;罕见疾病领域,DR072159,日本,pre-clinical,临床前,,pre-clinical,1,TRUE,TRUE,TRUE,['Takeda Pharmaceuticals'],['Takeda Pharmaceuticals'],1,['Takeda Pharmaceuticals(Top20 MNC)(原研)'],骨骼肌肉领域,['骨骼肌肉领域'],1,骨骼肌肉领域,,,-1,-1,Musculoskeletal,Musculoskeletal,,
WO2023048151A1,WO2023048151A1,WO2023048151A1,新型冠状病毒感染,novel coronavirus infection,SARS-CoV-2 S protein,SARS-CoV-2 S protein抑制剂,Shionogi(原研);Hokkaido University(原研),创新药,化药,多肽,环肽,抑制剂,新型冠状病毒感染,临床前,,Active,感染领域,DR078680,日本,pre-clinical,临床前,,pre-clinical,2,TRUE,FALSE,FALSE,[],"['Shionogi', 'Hokkaido University']",2,"['Shionogi(原研)', 'Hokkaido University(原研)']",感染领域,['感染领域'],1,感染领域,,,-1,-1,Infectious Diseases,Infectious Diseases,,
WO2023056368A1,WO2023056368A1,WO2023056368A1,男性避孕,male contraception,DDX25,DDX25抑制剂,Department of Health and Human Services(原研),创新药,化药,多肽,环肽;Potential First-in-Class,抑制剂,男性避孕,临床前,,Active,泌尿生殖领域,DR075188,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Department of Health and Human Services'],1,['Department of Health and Human Services(原研)'],泌尿生殖领域,['泌尿生殖领域'],1,泌尿生殖领域,,,-1,-1,Genitourinary,Genitourinary,,
WO2023061482A1,WO2023061482A1,WO2023061482A1,肿瘤,tumor,EphA2,多肽偶联药物,海思科(原研),创新药,化药,多肽;偶联药物,环肽;受体酪氨酸激酶,多肽偶联药物,肿瘤,临床前,,Active,肿瘤领域,DR076750,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['海思科'],1,['海思科(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2023066314A1,WO2023066314A1,WO2023066314A1,肿瘤,tumor,nectin-4,多肽偶联药物,海思科(原研),创新药,化药,多肽;偶联药物,环肽,多肽偶联药物,肿瘤,临床前,,Active,肿瘤领域,DR074311,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['海思科'],1,['海思科(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2023069332A1,WO2023069332A1,WO2023069332A1,癌症,cancer,eIF4E,eIF4E抑制剂,Merck & Co.(Top20 MNC)(原研),创新药,化药,多肽,环肽;Potential First-in-Class,抑制剂,癌症,临床前,,Active,肿瘤领域,DR072181,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,TRUE,['Merck & Co.'],['Merck & Co.'],1,['Merck & Co.(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2023084234A1,WO2023084234A1,WO2023084234A1,新型冠状病毒感染,novel coronavirus infection,ACE2,ACE2结合剂,Bicycle Therapeutics(原研),创新药,生物,多肽,环肽;肾素-血管紧张素-醛固酮系统,结合剂,新型冠状病毒感染,临床前,,Active,感染领域,DR073249,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],感染领域,['感染领域'],1,感染领域,,,-1,-1,Infectious Diseases,Infectious Diseases,,
WO2023088236A1,WO2023088236A1,WO2023088236A1,癌症,cancer,MMP14,多肽偶联药物,海思科(原研),创新药,化药,多肽;偶联药物,环肽;Potential First-in-Class,多肽偶联药物,癌症,临床前,,Active,肿瘤领域,DR076760,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['海思科'],1,['海思科(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2023098072A1,WO2023098072A1,WO2023098072A1,肿瘤,tumor,nectin-4,177Lu标记的放射性药物;anti-nectin-4多肽偶联核素,北京大学第一医院(原研),创新药,生物,多肽;放射性药物;偶联药物,环肽;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,肿瘤,临床前,,Active,肿瘤领域,DR074317,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['北京大学第一医院'],1,['北京大学第一医院(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2023111350A2,WO2023111350A2,WO2023111350A2,癌症,cancer,CAIX,anti-CAIX多肽偶联核素;225Ac标记的放射性药物,3B Pharmaceuticals(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,癌症,临床前,,Active,肿瘤领域,DR081398,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['3B Pharmaceuticals'],1,['3B Pharmaceuticals(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2023111350A2,WO2023111350A2,WO2023111350A2,SPECT显像,SPECT imaging,CAIX,anti-CAIX多肽偶联核素;225Ac标记的放射性药物,3B Pharmaceuticals(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,SPECT显像(差异化疾病),临床前,,Active,诊断试剂领域,DR081398,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['3B Pharmaceuticals'],1,['3B Pharmaceuticals(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
WO2023121699A1,WO2023121699A1,WO2023121699A1,癌症,cancer,CTLA4,CTLA4抑制剂,KSURF(原研),创新药,生物,多肽,环肽;Treg细胞;Potential First-in-Class;肿瘤免疫,抑制剂,癌症,临床前,,Active,肿瘤领域,DR073492,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['KSURF'],1,['KSURF(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2023136342A1,WO2023136342A1,WO2023136342A1,外周动脉疾病,peripheral arterial disease,THBS1,THBS1抑制剂,Daiichi Sankyo(原研);PeptiDream(原研),创新药,化药,多肽,环肽;差异化疾病,抑制剂,外周动脉疾病,临床前,,Active,心脑血管领域,DR081950,日本,pre-clinical,临床前,,pre-clinical,2,TRUE,FALSE,FALSE,[],"['Daiichi Sankyo', 'PeptiDream']",2,"['Daiichi Sankyo(原研)', 'PeptiDream(原研)']",心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,-1,-1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
WO2023136342A1,WO2023136342A1,WO2023136342A1,严重肢体缺血,critical limb ischemia,THBS1,THBS1抑制剂,Daiichi Sankyo(原研);PeptiDream(原研),创新药,化药,多肽,环肽;差异化疾病,抑制剂,严重肢体缺血(差异化疾病),临床前,,Active,心脑血管领域,DR081950,日本,pre-clinical,临床前,,pre-clinical,2,TRUE,FALSE,FALSE,[],"['Daiichi Sankyo', 'PeptiDream']",2,"['Daiichi Sankyo(原研)', 'PeptiDream(原研)']",心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,-1,-1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
WO2023145860A1,WO2023145860A1,WO2023145860A1,肿瘤,tumor,c-Kit,c-Kit激动剂,Ajinomoto(原研),创新药,化药,多肽,环肽;Potential First-in-Class,激动剂,肿瘤,临床前,,Active,肿瘤领域,DR077477,日本,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Ajinomoto'],1,['Ajinomoto(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2023165476A1,WO2023165476A1,WO2023165476A1,肿瘤,tumor,Sortilin,多肽偶联药物,智肽生物(原研),创新药,化药,多肽;偶联药物,环肽,多肽偶联药物,肿瘤,临床前,,Active,肿瘤领域,DR081104,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['智肽生物'],1,['智肽生物(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2023169584A1,WO2023169584A1,WO2023169584A1,癌症,cancer,nectin-4,多肽偶联药物,智肽生物(原研),创新药,化药,多肽;偶联药物,环肽;payload [海兔毒素衍生物：MMAE],多肽偶联药物,癌症,临床前,,Active,肿瘤领域,DR069124,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['智肽生物'],1,['智肽生物(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2023220634A2,WO2023220634A2,WO2023220634A2,癌症,cancer,EGFR,EGFR类似物,University of Pennsylvania(原研);Elicio Therapeutics(原研),创新药,化药,多肽,环肽;受体酪氨酸激酶;Potential First-in-Class,类似物,癌症,临床前,,Active,肿瘤领域,DR077969,美国,pre-clinical,临床前,,pre-clinical,2,TRUE,FALSE,FALSE,[],"['University of Pennsylvania', 'Elicio Therapeutics']",2,"['University of Pennsylvania(原研)', 'Elicio Therapeutics(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2023220836A1,WO2023220836A1,WO2023220836A1,PET显像,PET imaging,SSTR2,125I标记的放射性示踪剂;anti-SSTR2多肽偶联核素,University of Alberta(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;中国无申报;Potential First-in-Class,多肽偶联核素;125I标记的放射性示踪剂,PET显像,临床前,,Active,诊断试剂领域,DR079687,加拿大,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['University of Alberta'],1,['University of Alberta(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
WO2023225661A1,WO2023225661A1,WO2023225661A1,癌症,cancer,PD1;PDL1,PD1×PDL1蛋白蛋白相互作用抑制剂,Bristol-Myers Squibb(Top20 MNC)(原研),创新药,化药,多肽,环肽;肿瘤免疫,蛋白蛋白相互作用抑制剂,癌症,临床前,,Active,肿瘤领域,DR044937,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,TRUE,['Bristol-Myers Squibb'],['Bristol-Myers Squibb'],1,['Bristol-Myers Squibb(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2023228186A1,WO2023228186A1,WO2023228186A1,癌症,cancer,EGFR,EGFR结合剂,Ariel Precision Medicine(原研),创新药,化药,多肽,环肽;受体酪氨酸激酶;Potential First-in-Class,结合剂,癌症,临床前,,Active,肿瘤领域,DR077977,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Ariel Precision Medicine'],1,['Ariel Precision Medicine(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2023244554A1,WO2023244554A1,WO2023244554A1,动脉粥样硬化,atherosclerosis,IL-1β,IL-1β抑制剂,Merck & Co.(Top20 MNC)(原研),创新药,化药,多肽,环肽;差异化疾病;Potential First-in-Class,抑制剂,动脉粥样硬化(差异化疾病),临床前,,Active,心脑血管领域,DR045025,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,TRUE,['Merck & Co.'],['Merck & Co.'],1,['Merck & Co.(Top20 MNC)(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,-1,-1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
WO2023245016A1,WO2023245016A1,WO2023245016A1,皮肤病,skin disease,IL-13,IL-13抑制剂,B.A.I. Biosciences(原研),创新药,化药,多肽,环肽;Th2通路;Potential First-in-Class,抑制剂,皮肤病,临床前,,Active,皮肤领域,DR027504,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['B.A.I. Biosciences'],1,['B.A.I. Biosciences(原研)'],皮肤领域,['皮肤领域'],1,皮肤领域,,,-1,-1,Dermatology,Dermatology,,
WO2024003313A1,WO2024003313A1,WO2024003313A1,炎症性肠病,inflammatory bowel disease,IL-23R,IL-23R拮抗剂,Sanofi(Top20 MNC)(原研),创新药,化药,多肽,环肽;Th17通路,拮抗剂,炎症性肠病,临床前,,Active,免疫领域;消化领域,DR027562,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,TRUE,['Sanofi'],['Sanofi'],1,['Sanofi(Top20 MNC)(原研)'],免疫领域,"['免疫领域', '消化领域']",2,免疫领域,消化领域,,-1,-1,Immunology,Immunology,Digestive System,
WO2024010957A2,WO2024010957A2,WO2024010957A2,肿瘤,tumor,nectin-4,含铟放射性示踪剂;anti-nectin-4多肽偶联核素,Aktis Oncology(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,肿瘤,临床前,,Active,肿瘤领域,DR081404,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Aktis Oncology'],1,['Aktis Oncology(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2024010957A2,WO2024010957A2,WO2024010957A2,SPECT显像,SPECT imaging,nectin-4,含铟放射性示踪剂;anti-nectin-4多肽偶联核素,Aktis Oncology(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,SPECT显像,临床前,,Active,诊断试剂领域,DR081404,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Aktis Oncology'],1,['Aktis Oncology(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
WO2024015958A1,WO2024015958A1,WO2024015958A1,自身免疫性疾病,autoimmune disease,IL-23R,IL-23R拮抗剂,Janssen Biotech(Johnson & Johnson)(Top20 MNC)(原研),创新药,化药,多肽,环肽;Th17通路,拮抗剂,自身免疫性疾病,临床前,,Active,免疫领域,DR061912,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,TRUE,['Janssen Biotech(Johnson & Johnson)'],['Janssen Biotech(Johnson & Johnson)'],1,['Janssen Biotech(Johnson & Johnson)(Top20 MNC)(原研)'],免疫领域,['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,
WO2024020159A1,WO2024020159A1,WO2024020159A1,癌症,cancer,KRAS G12D,KRAS G12D抑制剂,Merck & Co.(Top20 MNC)(原研),创新药,化药,多肽,环肽;难成药靶点;Ras-Raf信号通路,抑制剂,癌症,临床前,,Active,肿瘤领域,DR061920,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,TRUE,['Merck & Co.'],['Merck & Co.'],1,['Merck & Co.(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2024043250A1,WO2024043250A1,WO2024043250A1,癌症,cancer,MDMX,MDMX抑制剂,Fujifilm(原研),创新药,化药,多肽,环肽;Potential First-in-Class;p53信号通路,抑制剂,癌症,临床前,,Active,肿瘤领域,DR081963,日本,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Fujifilm'],1,['Fujifilm(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2024052431A1,WO2024052431A1,WO2024052431A1,前列腺癌,prostate cancer,PSMA,anti-PSMA多肽偶联核素;含铟放射性示踪剂,3B Pharmaceuticals(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,前列腺癌,临床前,,Active,肿瘤领域,DR081408,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['3B Pharmaceuticals'],1,['3B Pharmaceuticals(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2024052431A1,WO2024052431A1,WO2024052431A1,SPECT显像,SPECT imaging,PSMA,anti-PSMA多肽偶联核素;含铟放射性示踪剂,3B Pharmaceuticals(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;Potential First-in-Class,多肽偶联核素;含铟放射性示踪剂,SPECT显像,临床前,,Active,诊断试剂领域,DR081408,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['3B Pharmaceuticals'],1,['3B Pharmaceuticals(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
WO2024083224A1,WO2024083224A1,WO2024083224A1,癌症,cancer,CCKBR;SSTR2,177Lu标记的放射性药物;anti-CCKBR×SSTR2多肽偶联核素,辐联科技(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,癌症,临床前,,Active,肿瘤领域,DR081414,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['辐联科技'],1,['辐联科技(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2024094747A1,WO2024094747A1,WO2024094747A1,心力衰竭,heart failure,CNP,CNP类似物,Novo Nordisk(Top20 MNC)(原研),创新药,化药,多肽,环肽,类似物,心力衰竭,临床前,,Active,心脑血管领域,DR067282,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,TRUE,['Novo Nordisk'],['Novo Nordisk'],1,['Novo Nordisk(Top20 MNC)(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,-1,-1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
WO2024101386A1,WO2024101386A1,WO2024101386A1,癌症,cancer,KRAS,KRAS抑制剂,Chugai Pharmaceutical(Top20 MNC)(原研),创新药,化药,多肽,环肽;难成药靶点,抑制剂,癌症,临床前,,Active,肿瘤领域,DR067444,日本,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,TRUE,['Chugai Pharmaceutical'],['Chugai Pharmaceutical'],1,['Chugai Pharmaceutical(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2024114762A1,WO2024114762A1,WO2024114762A1,自身免疫性疾病,autoimmune disease,IL-23R,IL-23R抑制剂,翰森制药(原研),创新药,化药,多肽,环肽;Th17通路,抑制剂,自身免疫性疾病,临床前,,Active,免疫领域,DR067818,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['翰森制药'],1,['翰森制药(原研)'],免疫领域,['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,
WO2024163691A1,WO2024163691A1,WO2024163691A1,自身免疫性疾病,autoimmune disease,TNFR1,TNFR1抑制剂,Merck & Co.(Top20 MNC)(原研),创新药,化药,多肽,环肽;细胞凋亡;差异化疾病,抑制剂,自身免疫性疾病,临床前,,Active,免疫领域,DR069427,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,TRUE,['Merck & Co.'],['Merck & Co.'],1,['Merck & Co.(Top20 MNC)(原研)'],免疫领域,['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,
WO2024163691A1,WO2024163691A1,WO2024163691A1,自身炎症性疾病,autoinflammatory disease,TNFR1,TNFR1抑制剂,Merck & Co.(Top20 MNC)(原研),创新药,化药,多肽,环肽;细胞凋亡;差异化疾病,抑制剂,自身炎症性疾病(差异化疾病),临床前,,Active,罕见疾病领域;免疫领域,DR069427,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,TRUE,TRUE,['Merck & Co.'],['Merck & Co.'],1,['Merck & Co.(Top20 MNC)(原研)'],免疫领域,['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,
WO2024182044A1,WO2024182044A1,WO2024182044A1,炎症(未指明),Inflammation (unspecified),Nrf2,Nrf2激活剂,Mayo Clinic(原研),创新药,化药,多肽,环肽;Keap1-Nrf2通路,激活剂,炎症(未指明),临床前,,Active,免疫领域,DR069977,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Mayo Clinic'],1,['Mayo Clinic(原研)'],免疫领域,['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,
WO2024188291A1,WO2024188291A1,WO2024188291A1,卵巢癌,ovarian cancer,HER2,anti-HER2多肽偶联核素;68Ga标记的PET药物,上海药物研究所(原研);Northeastern University(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;受体酪氨酸激酶;中国无申报,多肽偶联核素;68Ga标记的PET药物,卵巢癌(差异化疾病),临床前,,Active,肿瘤领域;罕见疾病领域,DR070183,美国;中国(内地),pre-clinical,临床前,,pre-clinical,2,TRUE,TRUE,FALSE,[],"['上海药物研究所', 'Northeastern University']",2,"['上海药物研究所(原研)', 'Northeastern University(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2024188291A1,WO2024188291A1,WO2024188291A1,PET显像,PET imaging,HER2,anti-HER2多肽偶联核素;68Ga标记的PET药物,上海药物研究所(原研);Northeastern University(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;诊断用放射性药物;受体酪氨酸激酶;中国无申报,多肽偶联核素;68Ga标记的PET药物,PET显像,临床前,,Active,诊断试剂领域,DR070183,美国;中国(内地),pre-clinical,临床前,,pre-clinical,2,TRUE,FALSE,FALSE,[],"['上海药物研究所', 'Northeastern University']",2,"['上海药物研究所(原研)', 'Northeastern University(原研)']",诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
WO2024189611A1,WO2024189611A1,WO2024189611A1,骨质疏松症,osteoporosis,calcitonin,calcitonin类似物,Yissum(原研),创新药,化药,多肽,环肽;中国无申报,类似物,骨质疏松症,临床前,,Active,骨骼肌肉领域;内分泌及代谢领域,DR070268,以色列,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Yissum'],1,['Yissum(原研)'],骨骼肌肉领域,"['骨骼肌肉领域', '内分泌及代谢领域']",2,骨骼肌肉领域,内分泌及代谢领域,,-1,-1,Musculoskeletal,Musculoskeletal,Endocrinology & Metabolism,
WO2024195709A1,WO2024195709A1,WO2024195709A1,癌症,cancer,FGFR,FGFR抑制剂,Fujifilm(原研),创新药,化药,多肽,环肽;受体酪氨酸激酶,抑制剂,癌症,临床前,,Active,肿瘤领域,DR070420,日本,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Fujifilm'],1,['Fujifilm(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2024199103A1,WO2024199103A1,WO2024199103A1,骨质疏松症,osteoporosis,calcitonin,calcitonin类似物,奥达生物(原研),创新药,化药,多肽,环肽,类似物,骨质疏松症,临床前,,Active,骨骼肌肉领域;内分泌及代谢领域,DR070368,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['奥达生物'],1,['奥达生物(原研)'],骨骼肌肉领域,"['骨骼肌肉领域', '内分泌及代谢领域']",2,骨骼肌肉领域,内分泌及代谢领域,,-1,-1,Musculoskeletal,Musculoskeletal,Endocrinology & Metabolism,
WO2024199103A1,WO2024199103A1,WO2024199103A1,骨病,bone disease,calcitonin,calcitonin类似物,奥达生物(原研),创新药,化药,多肽,环肽,类似物,骨病,临床前,,Active,骨骼肌肉领域,DR070368,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['奥达生物'],1,['奥达生物(原研)'],骨骼肌肉领域,['骨骼肌肉领域'],1,骨骼肌肉领域,,,-1,-1,Musculoskeletal,Musculoskeletal,,
WO2024227437A1,WO2024227437A1,WO2024227437A1,银屑病,psoriasis,IL-23R,IL-23R抑制剂,海思科(原研),创新药,化药,多肽,环肽;Th17通路,抑制剂,银屑病,临床前,,Active,免疫领域;皮肤领域,DR071166,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['海思科'],1,['海思科(原研)'],免疫领域,"['免疫领域', '皮肤领域']",2,免疫领域,皮肤领域,,-1,-1,Immunology,Immunology,Dermatology,
WO2024227437A1,WO2024227437A1,WO2024227437A1,炎症性肠病,inflammatory bowel disease,IL-23R,IL-23R抑制剂,海思科(原研),创新药,化药,多肽,环肽;Th17通路,抑制剂,炎症性肠病,临床前,,Active,免疫领域;消化领域,DR071166,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['海思科'],1,['海思科(原研)'],免疫领域,"['免疫领域', '消化领域']",2,免疫领域,消化领域,,-1,-1,Immunology,Immunology,Digestive System,
WO2024227437A1,WO2024227437A1,WO2024227437A1,克罗恩病,Crohn's disease,IL-23R,IL-23R抑制剂,海思科(原研),创新药,化药,多肽,环肽;Th17通路,抑制剂,克罗恩病,临床前,,Active,消化领域;免疫领域,DR071166,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['海思科'],1,['海思科(原研)'],消化领域,"['消化领域', '免疫领域']",2,消化领域,免疫领域,,-1,-1,Digestive System,Digestive System,Immunology,
WO2024230246A1,WO2024230246A1,WO2024230246A1,肿瘤,tumor,FAP,anti-FAP多肽偶联核素,纽瑞特医疗(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;Potential First-in-Class,多肽偶联核素,肿瘤,临床前,,Active,肿瘤领域,DR071565,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['纽瑞特医疗'],1,['纽瑞特医疗(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2024235273A1,WO2024235273A1,WO2024235273A1,癌症,cancer,CXCR4;FAP,anti-CXCR4×FAP多肽偶联核素,远大医药(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;G蛋白偶联受体;Potential First-in-Class,多肽偶联核素,癌症,临床前,,Active,肿瘤领域,DR071750,中国(港澳台),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['远大医药'],1,['远大医药(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2024238623A1,WO2024238623A1,WO2024238623A1,阿尔茨海默病,Alzheimer's disease,LRRK2,LRRK2变构抑制剂,University of Georgia(原研),创新药,化药,多肽,环肽;差异化疾病,变构抑制剂,阿尔茨海默病,临床前,,Active,神经领域,DR071723,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['University of Georgia'],1,['University of Georgia(原研)'],神经领域,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,
WO2024238623A1,WO2024238623A1,WO2024238623A1,帕金森病,Parkinson's disease,LRRK2,LRRK2变构抑制剂,University of Georgia(原研),创新药,化药,多肽,环肽;差异化疾病,变构抑制剂,帕金森病,临床前,,Active,神经领域,DR071723,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['University of Georgia'],1,['University of Georgia(原研)'],神经领域,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,
WO2024238623A1,WO2024238623A1,WO2024238623A1,亨廷顿氏病,Huntington's disease,LRRK2,LRRK2变构抑制剂,University of Georgia(原研),创新药,化药,多肽,环肽;差异化疾病,变构抑制剂,亨廷顿氏病(差异化疾病),临床前,,Active,神经领域;罕见疾病领域,DR071723,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,TRUE,FALSE,[],['University of Georgia'],1,['University of Georgia(原研)'],神经领域,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,
WO2024238623A1,WO2024238623A1,WO2024238623A1,肌萎缩侧索硬化症,amyotrophic lateral sclerosis,LRRK2,LRRK2变构抑制剂,University of Georgia(原研),创新药,化药,多肽,环肽;差异化疾病,变构抑制剂,肌萎缩侧索硬化症(差异化疾病),临床前,,Active,神经领域;罕见疾病领域,DR071723,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,TRUE,FALSE,[],['University of Georgia'],1,['University of Georgia(原研)'],神经领域,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,
WO2024238623A1,WO2024238623A1,WO2024238623A1,神经系统疾病,neurological disease,LRRK2,LRRK2变构抑制剂,University of Georgia(原研),创新药,化药,多肽,环肽;差异化疾病,变构抑制剂,神经系统疾病,临床前,,Active,神经领域,DR071723,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['University of Georgia'],1,['University of Georgia(原研)'],神经领域,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,
WO2024243509A1,WO2024243509A1,WO2024243509A1,神经退行性疾病,neurodegenerative diseases,LRRK2;FADD,LRRK2×FADD蛋白蛋白相互作用抑制剂,UGARF(原研),创新药,化药,多肽,环肽;Potential First-in-Class,蛋白蛋白相互作用抑制剂,神经退行性疾病,临床前,,Active,神经领域,DR071797,,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['UGARF'],1,['UGARF(原研)'],神经领域,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,
WO2024243509A1,WO2024243509A1,WO2024243509A1,阿尔茨海默病,Alzheimer's disease,LRRK2;FADD,LRRK2×FADD蛋白蛋白相互作用抑制剂,UGARF(原研),创新药,化药,多肽,环肽;Potential First-in-Class,蛋白蛋白相互作用抑制剂,阿尔茨海默病,临床前,,Active,神经领域,DR071797,,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['UGARF'],1,['UGARF(原研)'],神经领域,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,
WO2024243509A1,WO2024243509A1,WO2024243509A1,帕金森病,Parkinson's disease,LRRK2;FADD,LRRK2×FADD蛋白蛋白相互作用抑制剂,UGARF(原研),创新药,化药,多肽,环肽;Potential First-in-Class,蛋白蛋白相互作用抑制剂,帕金森病,临床前,,Active,神经领域,DR071797,,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['UGARF'],1,['UGARF(原研)'],神经领域,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,
WO2024243509A1,WO2024243509A1,WO2024243509A1,亨廷顿氏病,Huntington's disease,LRRK2;FADD,LRRK2×FADD蛋白蛋白相互作用抑制剂,UGARF(原研),创新药,化药,多肽,环肽;Potential First-in-Class,蛋白蛋白相互作用抑制剂,亨廷顿氏病,临床前,,Active,神经领域;罕见疾病领域,DR071797,,pre-clinical,临床前,,pre-clinical,1,TRUE,TRUE,FALSE,[],['UGARF'],1,['UGARF(原研)'],神经领域,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,
WO2024243509A1,WO2024243509A1,WO2024243509A1,肌萎缩侧索硬化症,amyotrophic lateral sclerosis,LRRK2;FADD,LRRK2×FADD蛋白蛋白相互作用抑制剂,UGARF(原研),创新药,化药,多肽,环肽;Potential First-in-Class,蛋白蛋白相互作用抑制剂,肌萎缩侧索硬化症,临床前,,Active,神经领域;罕见疾病领域,DR071797,,pre-clinical,临床前,,pre-clinical,1,TRUE,TRUE,FALSE,[],['UGARF'],1,['UGARF(原研)'],神经领域,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,
WO2024248042A1,WO2024248042A1,WO2024248042A1,重症肌无力,myasthenia gravis,MuSK,MuSK激动剂,National Hospital Organization(原研),创新药,化药,多肽,环肽;受体酪氨酸激酶;Potential First-in-Class;Wnt信号通路,激动剂,重症肌无力,临床前,,Active,罕见疾病领域;免疫领域,DR071830,日本,pre-clinical,临床前,,pre-clinical,1,TRUE,TRUE,FALSE,[],['National Hospital Organization'],1,['National Hospital Organization(原研)'],免疫领域,['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,
WO2024259132A1,WO2024259132A1,WO2024259132A1,癌症,cancer,DLL3,anti-DLL3多肽偶联核素,Mariana Oncology(Novartis)(Top20 MNC)(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;Notch信号通路;Potential First-in-Class,多肽偶联核素,癌症,临床前,,Active,肿瘤领域,DR072524,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,TRUE,['Mariana Oncology(Novartis)'],['Mariana Oncology(Novartis)'],1,['Mariana Oncology(Novartis)(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2025007839A1,WO2025007839A1,WO2025007839A1,肿瘤,tumor,nectin-4,多肽偶联药物,韦恩生物(原研),创新药,化药,多肽;偶联药物,环肽,多肽偶联药物,肿瘤,临床前,,Active,肿瘤领域,DR073180,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['韦恩生物'],1,['韦恩生物(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2025011611A1,WO2025011611A1,WO2025011611A1,癌症,cancer,FAP,anti-FAP多肽偶联核素,恒瑞医药(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;Potential First-in-Class,多肽偶联核素,癌症,临床前,,Active,肿瘤领域,DR073838,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['恒瑞医药'],1,['恒瑞医药(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2025067477A1,WO2025067477A1,WO2025067477A1,鲍曼不动杆菌感染,Acinetobacter baumannii infection,A. baumannii,抗生素,人福医药(原研),创新药,化药,多肽,环肽;差异化疾病;Potential First-in-Class,抗生素,鲍曼不动杆菌感染(差异化疾病),临床前,,Active,感染领域,DR077776,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['人福医药'],1,['人福医药(原研)'],感染领域,['感染领域'],1,感染领域,,,-1,-1,Infectious Diseases,Infectious Diseases,,
WO2025068348A1,WO2025068348A1,WO2025068348A1,癌症,cancer,PD1;CXCR4,CXCR4抑制剂;PD1抑制剂,University of Michigan(原研);Johns Hopkins University(原研);Cedars-Sinai(原研);Spexis(原研),创新药,化药,多肽,环肽;G蛋白偶联受体;中国无申报;Potential First-in-Class;肿瘤免疫,抑制剂,癌症,临床前,,Active,肿瘤领域,DR077780,美国;欧洲,pre-clinical,临床前,,pre-clinical,4,TRUE,FALSE,FALSE,[],"['University of Michigan', 'Johns Hopkins University', 'Cedars-Sinai', 'Spexis']",4,"['University of Michigan(原研)', 'Johns Hopkins University(原研)', 'Cedars-Sinai(原研)', 'Spexis(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2025073871A1,WO2025073871A1,WO2025073871A1,癌症,cancer,TfR1,多肽偶联药物,Bicycle Therapeutics(原研),创新药,化药,多肽;偶联药物,环肽;铁代谢;Potential First-in-Class,多肽偶联药物,癌症,临床前,,Active,肿瘤领域,DR078215,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2025073871A1,WO2025073871A1,WO2025073871A1,癫痫,epilepsy,TfR1,多肽偶联药物,Bicycle Therapeutics(原研),创新药,化药,多肽;偶联药物,环肽;铁代谢;Potential First-in-Class,多肽偶联药物,癫痫,临床前,,Active,神经领域,DR078215,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],神经领域,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,
WO2025073871A1,WO2025073871A1,WO2025073871A1,眼科疾病,Eye diseases,TfR1,多肽偶联药物,Bicycle Therapeutics(原研),创新药,化药,多肽;偶联药物,环肽;铁代谢;Potential First-in-Class,多肽偶联药物,眼科疾病,临床前,,Active,眼科领域,DR078215,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],眼科领域,['眼科领域'],1,眼科领域,,,-1,-1,Ophthalmology,Ophthalmology,,
WO2025073871A1,WO2025073871A1,WO2025073871A1,神经系统疾病,neurological disease,TfR1,多肽偶联药物,Bicycle Therapeutics(原研),创新药,化药,多肽;偶联药物,环肽;铁代谢;Potential First-in-Class,多肽偶联药物,神经系统疾病,临床前,,Active,神经领域,DR078215,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],神经领域,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,
WO2025077823A1,WO2025077823A1,WO2025077823A1,癌症,cancer,αvβ3,多肽偶联药物,海思科(原研),创新药,化药,多肽;偶联药物,环肽;Potential First-in-Class,多肽偶联药物,癌症,临床前,,Active,肿瘤领域,DR078571,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['海思科'],1,['海思科(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2025079064A1,WO2025079064A1,WO2025079064A1,类风湿性关节炎,rheumatoid arthritis,IL-17;IL-17R,IL-17×IL-17R蛋白蛋白相互作用抑制剂,Pepticom(原研),创新药,化药,小分子,环肽;Th17通路;中国无申报;Potential First-in-Class,蛋白蛋白相互作用抑制剂,类风湿性关节炎,临床前,,Active,免疫领域;骨骼肌肉领域,DR078579,以色列,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Pepticom'],1,['Pepticom(原研)'],免疫领域,"['免疫领域', '骨骼肌肉领域']",2,免疫领域,骨骼肌肉领域,,-1,-1,Immunology,Immunology,Musculoskeletal,
WO2025079064A1,WO2025079064A1,WO2025079064A1,多发性硬化症,multiple sclerosis,IL-17;IL-17R,IL-17×IL-17R蛋白蛋白相互作用抑制剂,Pepticom(原研),创新药,化药,小分子,环肽;Th17通路;中国无申报;Potential First-in-Class,蛋白蛋白相互作用抑制剂,多发性硬化症,临床前,,Active,神经领域;免疫领域;罕见疾病领域,DR078579,以色列,pre-clinical,临床前,,pre-clinical,1,TRUE,TRUE,FALSE,[],['Pepticom'],1,['Pepticom(原研)'],神经领域,"['神经领域', '免疫领域']",2,神经领域,免疫领域,,-1,-1,Neurology,Neurology,Immunology,
WO2025079064A1,WO2025079064A1,WO2025079064A1,银屑病,psoriasis,IL-17;IL-17R,IL-17×IL-17R蛋白蛋白相互作用抑制剂,Pepticom(原研),创新药,化药,小分子,环肽;Th17通路;中国无申报;Potential First-in-Class,蛋白蛋白相互作用抑制剂,银屑病,临床前,,Active,免疫领域;皮肤领域,DR078579,以色列,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Pepticom'],1,['Pepticom(原研)'],免疫领域,"['免疫领域', '皮肤领域']",2,免疫领域,皮肤领域,,-1,-1,Immunology,Immunology,Dermatology,
WO2025079064A1,WO2025079064A1,WO2025079064A1,斑块状银屑病,plaque psoriasis,IL-17;IL-17R,IL-17×IL-17R蛋白蛋白相互作用抑制剂,Pepticom(原研),创新药,化药,小分子,环肽;Th17通路;中国无申报;Potential First-in-Class,蛋白蛋白相互作用抑制剂,斑块状银屑病,临床前,,Active,免疫领域;皮肤领域,DR078579,以色列,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Pepticom'],1,['Pepticom(原研)'],免疫领域,"['免疫领域', '皮肤领域']",2,免疫领域,皮肤领域,,-1,-1,Immunology,Immunology,Dermatology,
WO2025079064A1,WO2025079064A1,WO2025079064A1,系统性红斑狼疮,systemic lupus erythematosus,IL-17;IL-17R,IL-17×IL-17R蛋白蛋白相互作用抑制剂,Pepticom(原研),创新药,化药,小分子,环肽;Th17通路;中国无申报;Potential First-in-Class,蛋白蛋白相互作用抑制剂,系统性红斑狼疮,临床前,,Active,免疫领域;皮肤领域,DR078579,以色列,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Pepticom'],1,['Pepticom(原研)'],免疫领域,"['免疫领域', '皮肤领域']",2,免疫领域,皮肤领域,,-1,-1,Immunology,Immunology,Dermatology,
WO2025082283A1,WO2025082283A1,WO2025082283A1,肿瘤,tumor,FAP,FAP抑制剂,科伦博泰(原研),创新药,化药,多肽,环肽;差异化疾病,抑制剂,肿瘤,临床前,,Active,肿瘤领域,DR078895,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['科伦博泰'],1,['科伦博泰(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2025082283A1,WO2025082283A1,WO2025082283A1,诊断试剂,diagnostic reagents,FAP,FAP抑制剂,科伦博泰(原研),创新药,化药,多肽,环肽;差异化疾病,抑制剂,诊断试剂(差异化疾病),临床前,,Active,诊断试剂领域,DR078895,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['科伦博泰'],1,['科伦博泰(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
WO2025105948A1,WO2025105948A1,WO2025105948A1,肿瘤,tumor,PDL1,含锝放射性示踪剂;anti-PDL1多肽偶联核素,Instituto Nacional de Investigaciones Nucleares(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;中国无申报;Potential First-in-Class;肿瘤免疫,含锝放射性示踪剂;多肽偶联核素,肿瘤,临床前,,Active,肿瘤领域,DR080180,墨西哥,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Instituto Nacional de Investigaciones Nucleares'],1,['Instituto Nacional de Investigaciones Nucleares(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2025105948A1,WO2025105948A1,WO2025105948A1,SPECT显像,SPECT imaging,PDL1,含锝放射性示踪剂;anti-PDL1多肽偶联核素,Instituto Nacional de Investigaciones Nucleares(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;中国无申报;Potential First-in-Class;肿瘤免疫,含锝放射性示踪剂;多肽偶联核素,SPECT显像,临床前,,Active,诊断试剂领域,DR080180,墨西哥,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Instituto Nacional de Investigaciones Nucleares'],1,['Instituto Nacional de Investigaciones Nucleares(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
WO2025106567A1,WO2025106567A1,WO2025106567A1,心力衰竭,heart failure,BNP,BNP类似物,Antlia Bioscience(原研),创新药,化药,多肽,环肽;Potential First-in-Class,类似物,心力衰竭,临床前,,Active,心脑血管领域,DR080184,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Antlia Bioscience'],1,['Antlia Bioscience(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,-1,-1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
WO2025106567A1,WO2025106567A1,WO2025106567A1,代谢疾病,Metabolic diseases,BNP,BNP类似物,Antlia Bioscience(原研),创新药,化药,多肽,环肽;Potential First-in-Class,类似物,代谢疾病,临床前,,Active,内分泌及代谢领域,DR080184,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Antlia Bioscience'],1,['Antlia Bioscience(原研)'],内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,-1,-1,Endocrinology & Metabolism,Endocrinology & Metabolism,,
WO2025106567A1,WO2025106567A1,WO2025106567A1,肺病,pulmonary disease,BNP,BNP类似物,Antlia Bioscience(原研),创新药,化药,多肽,环肽;Potential First-in-Class,类似物,肺病,临床前,,Active,呼吸领域,DR080184,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Antlia Bioscience'],1,['Antlia Bioscience(原研)'],呼吸领域,['呼吸领域'],1,呼吸领域,,,-1,-1,Respiratory,Respiratory,,
WO2025112214A1,WO2025112214A1,WO2025112214A1,癌症,cancer,αvβ3,多肽偶联药物,碳云智能(原研),创新药,化药,多肽;偶联药物,环肽;Potential First-in-Class,多肽偶联药物,癌症,临床前,,Active,肿瘤领域,DR080677,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['碳云智能'],1,['碳云智能(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2025113628A1,WO2025113628A1,WO2025113628A1,癌症,cancer,SSTR2,177Lu标记的放射性药物;anti-SSTR2多肽偶联核素,辐联科技(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;177Lu标记的放射性药物,癌症,临床前,,Active,肿瘤领域,DR080759,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['辐联科技'],1,['辐联科技(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2025113628A1,WO2025113628A1,WO2025113628A1,PET显像,PET imaging,SSTR2,177Lu标记的放射性药物;anti-SSTR2多肽偶联核素,辐联科技(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病,多肽偶联核素;177Lu标记的放射性药物,PET显像(差异化疾病),临床前,,Active,诊断试剂领域,DR080759,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['辐联科技'],1,['辐联科技(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
WO2025117586A1,WO2025117586A1,WO2025117586A1,癌症,cancer,DLL3,anti-DLL3多肽偶联核素;177Lu标记的放射性药物,Mariana Oncology(Novartis)(Top20 MNC)(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;Notch信号通路;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,癌症,临床前,,Active,肿瘤领域,DR080706,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,TRUE,['Mariana Oncology(Novartis)'],['Mariana Oncology(Novartis)'],1,['Mariana Oncology(Novartis)(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2025121943A1,WO2025121943A1,WO2025121943A1,结肠癌,colon cancer,CD51,多肽偶联药物,Soonchunhyang University(原研),创新药,化药,多肽;偶联药物,环肽;差异化疾病;中国无申报;Potential First-in-Class,多肽偶联药物,结肠癌(差异化疾病),临床前,,Active,肿瘤领域,DR081040,韩国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Soonchunhyang University'],1,['Soonchunhyang University(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2025122525A1,WO2025122525A1,WO2025122525A1,心力衰竭,heart failure,IgG,IgG降解剂,Biohaven Pharmaceuticals(Pfizer)(Top20 MNC)(原研),创新药,化药,多肽;降解类药物,环肽;差异化疾病,降解剂,心力衰竭(差异化疾病),临床前,,Active,心脑血管领域,DR081010,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,TRUE,['Biohaven Pharmaceuticals(Pfizer)'],['Biohaven Pharmaceuticals(Pfizer)'],1,['Biohaven Pharmaceuticals(Pfizer)(Top20 MNC)(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,-1,-1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
WO2025122525A1,WO2025122525A1,WO2025122525A1,扩张型心肌病,dilated cardiomyopathy,IgG,IgG降解剂,Biohaven Pharmaceuticals(Pfizer)(Top20 MNC)(原研),创新药,化药,多肽;降解类药物,环肽;差异化疾病,降解剂,扩张型心肌病(差异化疾病),临床前,,Active,心脑血管领域;罕见疾病领域,DR081010,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,TRUE,TRUE,['Biohaven Pharmaceuticals(Pfizer)'],['Biohaven Pharmaceuticals(Pfizer)'],1,['Biohaven Pharmaceuticals(Pfizer)(Top20 MNC)(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,-1,-1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
WO2025137441A,WO2025137441A,WO2025137441A,肿瘤,tumor,SSTR2,64Cu标记的放射性示踪剂;anti-SSTR2多肽偶联核素,RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽,多肽偶联核素;64Cu标记的放射性示踪剂,肿瘤,临床前,,Active,肿瘤领域,DR081688,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,TRUE,['RayzeBio(Bristol-Myers Squibb)'],['RayzeBio(Bristol-Myers Squibb)'],1,['RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2025137441A1,WO2025137441A1,WO2025137441A1,肿瘤,tumor,SSTR2,anti-SSTR2多肽偶联核素;68Ga标记的PET药物,RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,多肽偶联核素;68Ga标记的PET药物,肿瘤,临床前,,Active,肿瘤领域,DR081687,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,TRUE,['RayzeBio(Bristol-Myers Squibb)'],['RayzeBio(Bristol-Myers Squibb)'],1,['RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2025151982A1,WO2025151982A1,WO2025151982A1,前列腺癌,prostate cancer,PSMA;SSTR2,anti-PSMA×SSTR2多肽偶联核素;68Ga标记的PET药物,北京协和医院(原研);北京师范大学(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,前列腺癌,临床前,,Active,肿瘤领域,DR082544,中国(内地),pre-clinical,临床前,,pre-clinical,2,TRUE,FALSE,FALSE,[],"['北京协和医院', '北京师范大学']",2,"['北京协和医院(原研)', '北京师范大学(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2025151982A1,WO2025151982A1,WO2025151982A1,PET显像,PET imaging,PSMA;SSTR2,anti-PSMA×SSTR2多肽偶联核素;68Ga标记的PET药物,北京协和医院(原研);北京师范大学(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,PET显像,临床前,,Active,诊断试剂领域,DR082544,中国(内地),pre-clinical,临床前,,pre-clinical,2,TRUE,FALSE,FALSE,[],"['北京协和医院', '北京师范大学']",2,"['北京协和医院(原研)', '北京师范大学(原研)']",诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
WO2025153102A1,WO2025153102A1,WO2025153102A1,肿瘤,tumor,αvβ3,177Lu标记的放射性药物;anti-αvβ3多肽偶联核素,深景医药(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽,多肽偶联核素;177Lu标记的放射性药物,肿瘤,临床前,,Active,肿瘤领域,DR082564,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['深景医药'],1,['深景医药(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2025160448A1,WO2025160448A1,WO2025160448A1,癌症,cancer,B7-H3,anti-B7-H3多肽偶联核素;225Ac标记的放射性药物,Mariana Oncology(Novartis)(Top20 MNC)(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;Potential First-in-Class,多肽偶联核素;225Ac标记的放射性药物,癌症,临床前,,Active,肿瘤领域,DR082865,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,TRUE,['Mariana Oncology(Novartis)'],['Mariana Oncology(Novartis)'],1,['Mariana Oncology(Novartis)(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2025191093A1,WO2025191093A1,WO2025191093A1,癌症,cancer,CRAF,CRAF抑制剂,University of Glasgow(原研),创新药,化药,多肽,环肽;差异化疾病;Potential First-in-Class;Ras-Raf信号通路,抑制剂,癌症,临床前,,Active,肿瘤领域,DR085518,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['University of Glasgow'],1,['University of Glasgow(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2025191093A1,WO2025191093A1,WO2025191093A1,自身免疫性疾病,autoimmune disease,CRAF,CRAF抑制剂,University of Glasgow(原研),创新药,化药,多肽,环肽;差异化疾病;Potential First-in-Class;Ras-Raf信号通路,抑制剂,自身免疫性疾病(差异化疾病),临床前,,Active,免疫领域,DR085518,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['University of Glasgow'],1,['University of Glasgow(原研)'],免疫领域,['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,
WO2025193569A1,WO2025193569A1,WO2025193569A1,癌症,cancer,LAG3;MHC-II,LAG3×MHC-II蛋白蛋白相互作用抑制剂,Bristol-Myers Squibb(Top20 MNC)(原研),创新药,化药,多肽,环肽;Potential First-in-Class;肿瘤免疫,蛋白蛋白相互作用抑制剂,癌症,临床前,,Active,肿瘤领域,DR085669,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,TRUE,['Bristol-Myers Squibb'],['Bristol-Myers Squibb'],1,['Bristol-Myers Squibb(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2025199179A2,WO2025199179A2,WO2025199179A2,饮食障碍,eating disorder,oxytocin,oxytocin类似物,Tonix Pharmaceuticals(原研),创新药,生物,多肽,环肽;差异化疾病,类似物,饮食障碍(差异化疾病),临床前,,Active,精神领域,DR086088,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Tonix Pharmaceuticals'],1,['Tonix Pharmaceuticals(原研)'],精神领域,['精神领域'],1,精神领域,,,-1,-1,Psychiatry,Psychiatry,,
WO2025199179A2,WO2025199179A2,WO2025199179A2,头痛,Headache,oxytocin,oxytocin类似物,Tonix Pharmaceuticals(原研),创新药,生物,多肽,环肽;差异化疾病,类似物,头痛(差异化疾病),临床前,,Active,麻醉镇痛领域,DR086088,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Tonix Pharmaceuticals'],1,['Tonix Pharmaceuticals(原研)'],麻醉镇痛领域,['麻醉镇痛领域'],1,麻醉镇痛领域,,,-1,-1,Anesthesia & Analgesia,Anesthesia & Analgesia,,
WO2025214417A1,WO2025214417A1,WO2025214417A1,癌症,cancer,EGFR,EGFR抑制剂,元思生肽(原研),创新药,化药,多肽,环肽;受体酪氨酸激酶,抑制剂,癌症,临床前,,Active,肿瘤领域,DR087082,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['元思生肽'],1,['元思生肽(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2025218677A1,WO2025218677A1,WO2025218677A1,肿瘤,tumor,αvβ6;αvβ3;FAP,anti-αvβ6×αvβ3×FAP多肽偶联核素;68Ga标记的PET药物,范恩柯尔(原研),创新药,化药,放射性药物;多肽;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,肿瘤,临床前,,Active,肿瘤领域,DR087567,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['范恩柯尔'],1,['范恩柯尔(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2025218677A1,WO2025218677A1,WO2025218677A1,PET显像,PET imaging,αvβ6;αvβ3;FAP,anti-αvβ6×αvβ3×FAP多肽偶联核素;68Ga标记的PET药物,范恩柯尔(原研),创新药,化药,放射性药物;多肽;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,PET显像,临床前,,Active,诊断试剂领域,DR087567,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['范恩柯尔'],1,['范恩柯尔(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
WO2025218677A1-1,WO2025218677A1-1,WO2025218677A1-1,肿瘤,tumor,αvβ6;αvβ3;FAP,177Lu标记的放射性药物;anti-αvβ6×αvβ3×FAP多肽偶联核素,范恩柯尔(原研),创新药,化药,放射性药物;多肽;偶联药物,环肽;治疗用放射性药物;Potential First-in-Class,177Lu标记的放射性药物;多肽偶联核素,肿瘤,临床前,,Active,肿瘤领域,DR087569,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['范恩柯尔'],1,['范恩柯尔(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2025224598A1,WO2025224598A1,WO2025224598A1,癌症,cancer,HER2,anti-HER2多肽偶联核素;177Lu标记的放射性药物,Novartis(Top20 MNC)(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;受体酪氨酸激酶;Potential First-in-Class,多肽偶联核素;177Lu标记的放射性药物,癌症,临床前,,Active,肿瘤领域,DR088078,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,TRUE,['Novartis'],['Novartis'],1,['Novartis(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2025228156A1,WO2025228156A1,WO2025228156A1,高尿酸血症,hyperuricemia,URAT1,多肽偶联药物;siRNA疗法,炫景生物(原研),创新药,化药,核酸;多肽;偶联药物,环肽;小核酸;Potential First-in-Class;尿酸代谢通路,siRNA疗法;多肽偶联药物,高尿酸血症,临床前,,Active,内分泌及代谢领域,DR088580,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['炫景生物'],1,['炫景生物(原研)'],内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,-1,-1,Endocrinology & Metabolism,Endocrinology & Metabolism,,
WO2025232577A1,WO2025232577A1,WO2025232577A1,早产,premature birth,OXTR,OXTR拮抗剂,羚诺生物(原研),创新药,化药,多肽,环肽;G蛋白偶联受体,拮抗剂,早产,临床前,,Active,泌尿生殖领域,DR089039,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['羚诺生物'],1,['羚诺生物(原研)'],泌尿生殖领域,['泌尿生殖领域'],1,泌尿生殖领域,,,-1,-1,Genitourinary,Genitourinary,,
WO2025236772A1,WO2025236772A1,WO2025236772A1,糖尿病,diabetes,melanocortin receptor,melanocortin receptor激动剂,万邦德制药(原研),创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;Potential First-in-Class,激动剂,糖尿病(差异化疾病),临床前,,Active,内分泌及代谢领域,DR089479,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['万邦德制药'],1,['万邦德制药(原研)'],内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,-1,-1,Endocrinology & Metabolism,Endocrinology & Metabolism,,
WO2025236772A1,WO2025236772A1,WO2025236772A1,肥胖,obesity,melanocortin receptor,melanocortin receptor激动剂,万邦德制药(原研),创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;Potential First-in-Class,激动剂,肥胖(差异化疾病),临床前,,Active,内分泌及代谢领域,DR089479,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['万邦德制药'],1,['万邦德制药(原研)'],内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,-1,-1,Endocrinology & Metabolism,Endocrinology & Metabolism,,
WO2025236772A1,WO2025236772A1,WO2025236772A1,血脂异常,dyslipidemia,melanocortin receptor,melanocortin receptor激动剂,万邦德制药(原研),创新药,化药,多肽,环肽;差异化疾病;G蛋白偶联受体;Potential First-in-Class,激动剂,血脂异常(差异化疾病),临床前,,Active,心脑血管领域,DR089479,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['万邦德制药'],1,['万邦德制药(原研)'],心脑血管领域,['心脑血管领域'],1,心脑血管领域,,,-1,-1,Cardiovascular & Cerebrovascular,Cardiovascular & Cerebrovascular,,
WO2025245483A1,WO2025245483A1,WO2025245483A1,肥胖,obesity,MC4R,MC4R激动剂,Flagship Pioneering(原研),创新药,化药,多肽,环肽;G蛋白偶联受体;瘦素-黑皮素通路,激动剂,肥胖,临床前,,Active,内分泌及代谢领域,DR089783,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Flagship Pioneering'],1,['Flagship Pioneering(原研)'],内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,-1,-1,Endocrinology & Metabolism,Endocrinology & Metabolism,,
WO2025246257A1,WO2025246257A1,WO2025246257A1,癌症,cancer,PPID;PPIA,PPIA抑制剂;PPID抑制剂,睿诺医疗科技(原研),创新药,生物,多肽,环肽;Potential First-in-Class,抑制剂,癌症,临床前,,Active,肿瘤领域,DR090011,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['睿诺医疗科技'],1,['睿诺医疗科技(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
WO2025249754A1,WO2025249754A1,WO2025249754A1,炎症(未指明),Inflammation (unspecified),IL-1β,IL-1β抑制剂,EyebioKorea(原研),创新药,化药,小分子,环肽;中国无申报;Potential First-in-Class,抑制剂,炎症(未指明),临床前,,Active,免疫领域,DR090094,韩国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['EyebioKorea'],1,['EyebioKorea(原研)'],免疫领域,['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,
WO2025255635A1,WO2025255635A1,WO2025255635A1,糖尿病,diabetes,MC5R,MC5R激动剂,Monash University(原研),创新药,生物,多肽,环肽;G蛋白偶联受体;中国无申报,激动剂,糖尿病,临床前,,Active,内分泌及代谢领域,DR090722,澳大利亚,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Monash University'],1,['Monash University(原研)'],内分泌及代谢领域,['内分泌及代谢领域'],1,内分泌及代谢领域,,,-1,-1,Endocrinology & Metabolism,Endocrinology & Metabolism,,
WP-101,WP-101,WP-101,尿路感染,urinary tract infection,not available,多肽类抗生素,WellPep(原研),创新药,化药,多肽,环肽;差异化疾病;中国无申报,多肽类抗生素,尿路感染(差异化疾病),临床前,,Active,感染领域;泌尿生殖领域,DR084192,韩国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['WellPep'],1,['WellPep(原研)'],感染领域,"['感染领域', '泌尿生殖领域']",2,感染领域,泌尿生殖领域,,-1,-1,Infectious Diseases,Infectious Diseases,Genitourinary,
WP-101,WP-101,WP-101,脓毒症,sepsis,not available,多肽类抗生素,WellPep(原研),创新药,化药,多肽,环肽;差异化疾病;中国无申报,多肽类抗生素,脓毒症,临床前,,Active,感染领域,DR084192,韩国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['WellPep'],1,['WellPep(原研)'],感染领域,['感染领域'],1,感染领域,,,-1,-1,Infectious Diseases,Infectious Diseases,,
WP-101,WP-101,WP-101,肺炎,pneumonia,not available,多肽类抗生素,WellPep(原研),创新药,化药,多肽,环肽;差异化疾病;中国无申报,多肽类抗生素,肺炎,临床前,,Active,呼吸领域,DR084192,韩国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['WellPep'],1,['WellPep(原研)'],呼吸领域,['呼吸领域'],1,呼吸领域,,,-1,-1,Respiratory,Respiratory,,
XTR024,XTR024,XTR024,小细胞肺癌,small cell lung cancer,SSTR,225Ac标记的放射性药物,先通医药(原研),创新药,其他,放射性药物;其他,环肽;治疗用放射性药物;Potential First-in-Class,225Ac标记的放射性药物,小细胞肺癌,临床前,,Active,肿瘤领域;罕见疾病领域,DR080227,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,TRUE,FALSE,[],['先通医药'],1,['先通医药(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
XTR024,XTR024,XTR024,神经内分泌肿瘤,neuroendocrine tumors,SSTR,225Ac标记的放射性药物,先通医药(原研),创新药,其他,放射性药物;其他,环肽;治疗用放射性药物;Potential First-in-Class,225Ac标记的放射性药物,神经内分泌肿瘤,临床前,,Active,肿瘤领域;罕见疾病领域,DR080227,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,TRUE,FALSE,[],['先通医药'],1,['先通医药(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
ZP10068,ZP10068,ZP10068,炎症(未指明),Inflammation (unspecified),C3,C3抑制剂,Alexion Pharmaceuticals(AstraZeneca)(Top20 MNC);Zealand Pharma(原研),创新药,化药,多肽,环肽;中国无申报,抑制剂,炎症(未指明),临床前,,Active,免疫领域,DR025543,欧洲,pre-clinical,临床前,,pre-clinical,2,TRUE,FALSE,TRUE,['Alexion Pharmaceuticals(AstraZeneca)'],['Zealand Pharma'],1,"['Alexion Pharmaceuticals(AstraZeneca)(Top20 MNC)', 'Zealand Pharma(原研)']",免疫领域,['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,
[111In]In-BCY18469,[111In]In-BCY18469,[111In]In-BCY18469,肿瘤,tumor,EphA2,含铟放射性示踪剂;anti-EphA2多肽偶联核素,Bicycle Therapeutics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;受体酪氨酸激酶;Potential First-in-Class,含铟放射性示踪剂;多肽偶联核素,肿瘤,临床前,,Active,肿瘤领域,DR074871,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
[111In]In-BCY18469,[111In]In-BCY18469,[111In]In-BCY18469,SPECT显像,SPECT imaging,EphA2,含铟放射性示踪剂;anti-EphA2多肽偶联核素,Bicycle Therapeutics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;受体酪氨酸激酶;Potential First-in-Class,含铟放射性示踪剂;多肽偶联核素,SPECT显像,临床前,,Active,诊断试剂领域,DR074871,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
[161Tb]Tb-DOTATATE,[161Tb]Tb-DOTATATE,[161Tb]Tb-DOTATATE,神经母细胞瘤,Neuroblastoma,SSTR2,161Tb标记的放射性药物,Uppsala University(原研),创新药,化药,多肽;放射性药物,环肽;治疗用放射性药物;Potential First-in-Class,161Tb标记的放射性药物,神经母细胞瘤,临床前,,Active,肿瘤领域;罕见疾病领域,DR089674,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,TRUE,FALSE,[],['Uppsala University'],1,['Uppsala University(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
[161Tb]Tb-DPI-4452,[161Tb]Tb-DPI-4452,[161Tb]Tb-DPI-4452,胰腺导管癌,pancreatic ductal carcinoma,CAIX,161Tb标记的放射性药物;anti-CAIX多肽偶联核素,Katholieke Universiteit Leuven(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;Potential First-in-Class,多肽偶联核素;161Tb标记的放射性药物,胰腺导管癌,临床前,,Active,肿瘤领域,DR089695,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Katholieke Universiteit Leuven'],1,['Katholieke Universiteit Leuven(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
[177Lu]Lu-BCY18469,[177Lu]Lu-BCY18469,[177Lu]Lu-BCY18469,肿瘤,tumor,EphA2,177Lu标记的放射性药物;anti-EphA2多肽偶联核素,Bicycle Therapeutics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;受体酪氨酸激酶;Potential First-in-Class,177Lu标记的放射性药物;多肽偶联核素,肿瘤,临床前,,Active,肿瘤领域,DR074872,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
[177Lu]Lu-RYZ-GPC3,[177Lu]Lu-RYZ-GPC3,[177Lu]Lu-RYZ-GPC3,神经内分泌前列腺癌,neuroendocrine prostate cancer,GPC3,177Lu标记的放射性药物;anti-GPC3多肽偶联核素,RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Potential First-in-Class;Wnt信号通路,177Lu标记的放射性药物;多肽偶联核素,神经内分泌前列腺癌(差异化疾病),临床前,,Active,肿瘤领域,DR081253,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,TRUE,['RayzeBio(Bristol-Myers Squibb)'],['RayzeBio(Bristol-Myers Squibb)'],1,['RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
[18F]AlF-NOTA-IMB,[18F]AlF-NOTA-IMB,[18F]AlF-NOTA-IMB,癌症,cancer,PDL1,18F标记的PET药物;anti-PDL1多肽偶联核素,南京医科大学(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;肿瘤免疫,多肽偶联核素;18F标记的PET药物,癌症,临床前,,Active,肿瘤领域,DR081308,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['南京医科大学'],1,['南京医科大学(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
[18F]AlF-NOTA-IMB,[18F]AlF-NOTA-IMB,[18F]AlF-NOTA-IMB,PET显像,PET imaging,PDL1,18F标记的PET药物;anti-PDL1多肽偶联核素,南京医科大学(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;肿瘤免疫,多肽偶联核素;18F标记的PET药物,PET显像,临床前,,Active,诊断试剂领域,DR081308,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['南京医科大学'],1,['南京医科大学(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
[18F]AlF-NOTA-IPB-GPC3P,[18F]AlF-NOTA-IPB-GPC3P,[18F]AlF-NOTA-IPB-GPC3P,肿瘤,tumor,GPC3,18F标记的PET药物;anti-GPC3多肽偶联核素,南方医科大学南方医院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class;Wnt信号通路,多肽偶联核素;18F标记的PET药物,肿瘤,临床前,,Active,肿瘤领域,DR081216,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['南方医科大学南方医院'],1,['南方医科大学南方医院(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
[18F]AlF-NOTA-IPB-GPC3P,[18F]AlF-NOTA-IPB-GPC3P,[18F]AlF-NOTA-IPB-GPC3P,PET显像,PET imaging,GPC3,18F标记的PET药物;anti-GPC3多肽偶联核素,南方医科大学南方医院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class;Wnt信号通路,多肽偶联核素;18F标记的PET药物,PET显像,临床前,,Active,诊断试剂领域,DR081216,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['南方医科大学南方医院'],1,['南方医科大学南方医院(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
[225Ac]Ac-RYZ-GPC3,[225Ac]Ac-RYZ-GPC3,[225Ac]Ac-RYZ-GPC3,神经内分泌前列腺癌,neuroendocrine prostate cancer,GPC3,225Ac标记的放射性药物;anti-GPC3多肽偶联核素,RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;差异化疾病;治疗用放射性药物;Wnt信号通路,225Ac标记的放射性药物;多肽偶联核素,神经内分泌前列腺癌(差异化疾病),临床前,,Active,肿瘤领域,DR081255,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,TRUE,['RayzeBio(Bristol-Myers Squibb)'],['RayzeBio(Bristol-Myers Squibb)'],1,['RayzeBio(Bristol-Myers Squibb)(Top20 MNC)(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
[64Cu]Cu-NECT-224,[64Cu]Cu-NECT-224,[64Cu]Cu-NECT-224;[64Cu]Cu-TKR2-24,尿路上皮癌,urothelial carcinoma,nectin-4,64Cu标记的放射性示踪剂;anti-nectin-4多肽偶联核素,Helmholtz-Zentrum Dresden-Rossendorf(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,64Cu标记的放射性示踪剂;多肽偶联核素,尿路上皮癌,临床前,,Active,肿瘤领域,DR086897,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Helmholtz-Zentrum Dresden-Rossendorf'],1,['Helmholtz-Zentrum Dresden-Rossendorf(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
[64Cu]Cu-NECT-224,[64Cu]Cu-NECT-224,[64Cu]Cu-NECT-224;[64Cu]Cu-TKR2-24,PET显像,PET imaging,nectin-4,64Cu标记的放射性示踪剂;anti-nectin-4多肽偶联核素,Helmholtz-Zentrum Dresden-Rossendorf(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,64Cu标记的放射性示踪剂;多肽偶联核素,PET显像,临床前,,Active,诊断试剂领域,DR086897,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Helmholtz-Zentrum Dresden-Rossendorf'],1,['Helmholtz-Zentrum Dresden-Rossendorf(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
[64Cu]Cu-NODAGA-BL34,[64Cu]Cu-NODAGA-BL34,[64Cu]Cu-NODAGA-BL34,肿瘤,tumor,CXCR4,64Cu标记的放射性示踪剂;anti-CXCR4多肽偶联核素,University of British Columbia(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,多肽偶联核素;64Cu标记的放射性示踪剂,肿瘤,临床前,,Active,肿瘤领域,DR089511,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['University of British Columbia'],1,['University of British Columbia(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
[64Cu]Cu-NODAGA-BL34,[64Cu]Cu-NODAGA-BL34,[64Cu]Cu-NODAGA-BL34,PET显像,PET imaging,CXCR4,64Cu标记的放射性示踪剂;anti-CXCR4多肽偶联核素,University of British Columbia(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;G蛋白偶联受体;Potential First-in-Class,多肽偶联核素;64Cu标记的放射性示踪剂,PET显像,临床前,,Active,诊断试剂领域,DR089511,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['University of British Columbia'],1,['University of British Columbia(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
[67Cu]Cu-NODAGA-BL34,[67Cu]Cu-NODAGA-BL34,[67Cu]Cu-NODAGA-BL34,肿瘤,tumor,CXCR4,67Cu标记的放射性药物;anti-CXCR4多肽偶联核素,University of British Columbia(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;G蛋白偶联受体;Potential First-in-Class,67Cu标记的放射性药物;多肽偶联核素,肿瘤,临床前,,Active,肿瘤领域,DR089512,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['University of British Columbia'],1,['University of British Columbia(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
[67Cu]Cu-SAR-bisRGD,[67Cu]Cu-SAR-bisRGD,[67Cu]Cu-SAR-bisRGD,肿瘤,tumor,αvβ3,anti-αvβ3多肽偶联核素;67Cu标记的放射性药物,Memorial Sloan Kettering Cancer Center (MSKCC)(原研);Clarity Pharmaceuticals(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;中国无申报;Potential First-in-Class,多肽偶联核素;67Cu标记的放射性药物,肿瘤,临床前,,Active,肿瘤领域,DR081266,美国;澳大利亚,pre-clinical,临床前,,pre-clinical,2,TRUE,FALSE,FALSE,[],"['Memorial Sloan Kettering Cancer Center (MSKCC)', 'Clarity Pharmaceuticals']",2,"['Memorial Sloan Kettering Cancer Center (MSKCC)(原研)', 'Clarity Pharmaceuticals(原研)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
[68Ga]Ga-B6FA-01,[68Ga]Ga-B6FA-01,[68Ga]Ga-B6FA-01,肿瘤,tumor,αvβ6;FAP,68Ga标记的PET药物,武汉大学中南医院(原研),创新药,化药,小分子;放射性药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物,肿瘤,临床前,,Active,肿瘤领域,DR089673,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['武汉大学中南医院'],1,['武汉大学中南医院(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
[68Ga]Ga-B6FA-01,[68Ga]Ga-B6FA-01,[68Ga]Ga-B6FA-01,PET显像,PET imaging,αvβ6;FAP,68Ga标记的PET药物,武汉大学中南医院(原研),创新药,化药,小分子;放射性药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物,PET显像,临床前,,Active,诊断试剂领域,DR089673,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['武汉大学中南医院'],1,['武汉大学中南医院(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
[68Ga]Ga-BCY18469,[68Ga]Ga-BCY18469,[68Ga]Ga-BCY18469,肿瘤,tumor,EphA2,anti-EphA2多肽偶联核素;68Ga标记的PET药物,Bicycle Therapeutics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;受体酪氨酸激酶;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,肿瘤,临床前,,Active,肿瘤领域,DR074873,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
[68Ga]Ga-BCY18469,[68Ga]Ga-BCY18469,[68Ga]Ga-BCY18469,PET显像,PET imaging,EphA2,anti-EphA2多肽偶联核素;68Ga标记的PET药物,Bicycle Therapeutics(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;受体酪氨酸激酶;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,PET显像,临床前,,Active,诊断试剂领域,DR074873,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Bicycle Therapeutics'],1,['Bicycle Therapeutics(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
[68Ga]Ga-DOTA-Ahx-VGB3,[68Ga]Ga-DOTA-Ahx-VGB3,[68Ga]Ga-DOTA-Ahx-VGB3,乳腺癌,breast cancer,VEGFR1;VEGFR2,anti-VEGFR1×VEGFR2多肽偶联核素;68Ga标记的PET药物,Tehran University of Medical Sciences(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;受体酪氨酸激酶;中国无申报;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,乳腺癌,临床前,,Active,肿瘤领域,DR081199,伊朗,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Tehran University of Medical Sciences'],1,['Tehran University of Medical Sciences(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
[68Ga]Ga-DOTA-Ahx-VGB3,[68Ga]Ga-DOTA-Ahx-VGB3,[68Ga]Ga-DOTA-Ahx-VGB3,PET显像,PET imaging,VEGFR1;VEGFR2,anti-VEGFR1×VEGFR2多肽偶联核素;68Ga标记的PET药物,Tehran University of Medical Sciences(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;受体酪氨酸激酶;中国无申报;Potential First-in-Class,多肽偶联核素;68Ga标记的PET药物,PET显像,临床前,,Active,诊断试剂领域,DR081199,伊朗,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Tehran University of Medical Sciences'],1,['Tehran University of Medical Sciences(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
[68Ga]Ga-DOTA-BP1,[68Ga]Ga-DOTA-BP1,[68Ga]Ga-DOTA-BP1,多发性骨髓瘤,multiple myeloma,BCMA,anti-BCMA多肽偶联核素;68Ga标记的PET药物,北京大学第一医院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,多发性骨髓瘤,临床前,,Active,肿瘤领域;血液领域;罕见疾病领域,DR081101,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,TRUE,FALSE,[],['北京大学第一医院'],1,['北京大学第一医院(原研)'],肿瘤领域,"['肿瘤领域', '血液领域']",2,肿瘤领域,血液领域,,-1,-1,Oncology,Oncology,Hematology,
[68Ga]Ga-DOTA-BP1,[68Ga]Ga-DOTA-BP1,[68Ga]Ga-DOTA-BP1,PET显像,PET imaging,BCMA,anti-BCMA多肽偶联核素;68Ga标记的PET药物,北京大学第一医院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;Potential First-in-Class,68Ga标记的PET药物;多肽偶联核素,PET显像,临床前,,Active,诊断试剂领域,DR081101,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['北京大学第一医院'],1,['北京大学第一医院(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
[68Ga]Ga-ES-02,[68Ga]Ga-ES-02,[68Ga]Ga-ES-02,PET显像,PET imaging,HER2,anti-HER2多肽偶联核素;68Ga标记的PET药物,山东大学齐鲁医院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;受体酪氨酸激酶,多肽偶联核素;68Ga标记的PET药物,PET显像,临床前,,Active,诊断试剂领域,DR081177,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['山东大学齐鲁医院'],1,['山东大学齐鲁医院(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
[68Ga]Ga-ES-02,[68Ga]Ga-ES-02,[68Ga]Ga-ES-02,结直肠癌,colorectal cancer,HER2,anti-HER2多肽偶联核素;68Ga标记的PET药物,山东大学齐鲁医院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物;受体酪氨酸激酶,多肽偶联核素;68Ga标记的PET药物,结直肠癌,临床前,,Active,肿瘤领域,DR081177,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['山东大学齐鲁医院'],1,['山东大学齐鲁医院(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
[68Ga]Ga-RCC78,[68Ga]Ga-RCC78,[68Ga]Ga-RCC78;[68Ga] Ga-RCC78,肾细胞癌,renal cell carcinoma,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,同济医学院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,多肽偶联核素;68Ga标记的PET药物,肾细胞癌,临床前,,Active,肿瘤领域,DR089497,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['同济医学院'],1,['同济医学院(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
[68Ga]Ga-RCC78,[68Ga]Ga-RCC78,[68Ga]Ga-RCC78;[68Ga] Ga-RCC78,PET显像,PET imaging,CAIX,anti-CAIX多肽偶联核素;68Ga标记的PET药物,同济医学院(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;诊断用放射性药物,多肽偶联核素;68Ga标记的PET药物,PET显像,临床前,,Active,诊断试剂领域,DR089497,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['同济医学院'],1,['同济医学院(原研)'],诊断试剂领域,['诊断试剂领域'],1,诊断试剂领域,,,-1,-1,Diagnostic Reagents,Diagnostic Reagents,,
[αTH]EMP-100,[αTH]EMP-100,[αTH]EMP-100,实体瘤,solid tumors,c-Met,anti-c-Met多肽偶联核素;含钍放射性药物,Edinburgh Molecular Imaging(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;受体酪氨酸激酶;Potential First-in-Class,含钍放射性药物;多肽偶联核素,实体瘤,临床前,,Active,肿瘤领域,DR021193,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Edinburgh Molecular Imaging'],1,['Edinburgh Molecular Imaging(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
[βTH]EMP-100,[βTH]EMP-100,[βTH]EMP-100;[βTH]EMP-100 ,实体瘤,solid tumors,c-Met,anti-c-Met多肽偶联核素;含钍放射性药物,Edinburgh Molecular Imaging(原研),创新药,化药,多肽;放射性药物;偶联药物,环肽;治疗用放射性药物;受体酪氨酸激酶;Potential First-in-Class,含钍放射性药物;多肽偶联核素,实体瘤,临床前,,Active,肿瘤领域,DR021191,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Edinburgh Molecular Imaging'],1,['Edinburgh Molecular Imaging(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
alzheimer disease treatment,alzheimer disease treatment (Interprotein),alzheimer disease treatment;alzheimer disease treatment (Interprotein),阿尔茨海默病,Alzheimer's disease,Aβ,,Interprotein(原研),创新药,化药,多肽,环肽;Amyloid beta通路,其他,阿尔茨海默病,临床前,,Active,神经领域,DR050453,日本,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Interprotein'],1,['Interprotein(原研)'],神经领域,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,
anti-TBC peptide,anti-TBC peptide (tuberculosis plectasin),anti-TBC peptide;anti-TBC peptide (tuberculosis plectasin),肺结核,tuberculosis,M.tb,,Hamlet Pharma(原研),创新药,化药,多肽,环肽,其他,肺结核,临床前,,Active,感染领域,DR075136,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Hamlet Pharma'],1,['Hamlet Pharma(原研)'],感染领域,['感染领域'],1,感染领域,,,-1,-1,Infectious Diseases,Infectious Diseases,,
bleeding disorders program,bleeding disorders program (Gubra),bleeding disorders program;bleeding disorders program (Gubra),出血,Bleeding,not available,,Hemab(原研);Gubra(原研),创新药,其他,多肽,环肽,其他,出血,临床前,,Active,其他领域,DR074440,欧洲,pre-clinical,临床前,,pre-clinical,2,TRUE,FALSE,FALSE,[],"['Hemab', 'Gubra']",2,"['Hemab(原研)', 'Gubra(原研)']",其他领域,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,
certepetide-drug conjugate,certepetide-drug conjugate (Catalent),certepetide-drug conjugate;certepetide-drug conjugate (Catalent),实体瘤,solid tumors,CD51,多肽偶联药物,Catalent(Novo Nordisk)(Top20 MNC)(原研);Lisata Therapeutics(无权益),创新药,化药,多肽;偶联药物,环肽;Potential First-in-Class,多肽偶联药物,实体瘤,临床前,,Active,肿瘤领域,DR084115,美国,pre-clinical,临床前,,pre-clinical,2,TRUE,FALSE,TRUE,['Catalent(Novo Nordisk)'],['Catalent(Novo Nordisk)'],1,"['Catalent(Novo Nordisk)(Top20 MNC)(原研)', 'Lisata Therapeutics(无权益)']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
compsorbin,compsorbin,compsorbin;AMY-301,自身免疫性疾病,autoimmune disease,CFH,CFH抑制剂,Amyndas Pharmaceuticals(原研),创新药,化药,多肽,环肽;Potential First-in-Class,抑制剂,自身免疫性疾病,临床前,,Active,免疫领域,DR063167,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Amyndas Pharmaceuticals'],1,['Amyndas Pharmaceuticals(原研)'],免疫领域,['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,
compsorbin,compsorbin,compsorbin;AMY-301,炎症(未指明),Inflammation (unspecified),CFH,CFH抑制剂,Amyndas Pharmaceuticals(原研),创新药,化药,多肽,环肽;Potential First-in-Class,抑制剂,炎症(未指明),临床前,,Active,免疫领域,DR063167,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Amyndas Pharmaceuticals'],1,['Amyndas Pharmaceuticals(原研)'],免疫领域,['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,
cyclic peptide PSD-95 Inhibitors,cyclic peptide PSD-95 Inhibitors (Avilex Pharm),cyclic peptide PSD-95 Inhibitors;cyclic peptide PSD-95 Inhibitors (Avilex Pharm),未知/待定,unknown/pending,PSD95,PSD95抑制剂,Avilex Pharma(原研),创新药,化药,多肽,环肽,抑制剂,未知/待定,临床前,,Active,其他领域,DR025013,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Avilex Pharma'],1,['Avilex Pharma(原研)'],其他领域,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,
cyclic peptide project 40,cyclic peptide project 40 (InnoCare Pharma),cyclic peptide project 40;cyclic peptide project 40 (诺诚健华);cyclic peptide project 40 (InnoCare Pharma),自身免疫性疾病,autoimmune disease,not available,,诺诚健华(原研),创新药,化药,多肽,环肽,其他,自身免疫性疾病,临床前,,Active,免疫领域,DR077456,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['诺诚健华'],1,['诺诚健华(原研)'],免疫领域,['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,
cyclo-CRLLIF,cyclo-CRLLIF,cyclo-CRLLIF,癌症,cancer,HIF-1α;HIF-2α;ARNT,HIF-2α×ARNT蛋白蛋白相互作用抑制剂;HIF-1α×ARNT蛋白蛋白相互作用抑制剂,University of Southampton(原研),创新药,化药,多肽,环肽;HIF信号通路;Potential First-in-Class,蛋白蛋白相互作用抑制剂,癌症,临床前,,Active,肿瘤领域,DR087634,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['University of Southampton'],1,['University of Southampton(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
integrin α4β7 program,integrin α4β7 program (Quantum Intelligence),integrin α4β7 program;integrin α4β7 program (Quantum Intelligence),炎症性肠病,inflammatory bowel disease,α4β7,α4β7拮抗剂,Quantum Intelligence(原研),创新药,化药,多肽,环肽;中国无申报,拮抗剂,炎症性肠病,临床前,,Active,免疫领域;消化领域,DR069280,韩国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Quantum Intelligence'],1,['Quantum Intelligence(原研)'],免疫领域,"['免疫领域', '消化领域']",2,免疫领域,消化领域,,-1,-1,Immunology,Immunology,Digestive System,
macrocyclic peptide 5L1,macrocyclic peptide 5L1 (Shandong University),macrocyclic peptide 5L1;macrocyclic peptide 5L1 (山东大学);macrocyclic peptide 5L1 (Shandong University),癌症,cancer,Mcl-1,Mcl-1抑制剂;Mcl-1分子胶,山东大学(原研);智峪生科,创新药,化药,多肽,环肽;细胞凋亡;非降解型分子胶;Potential First-in-Class,抑制剂;分子胶,癌症,临床前,,Active,肿瘤领域,DR077255,中国(内地),pre-clinical,临床前,,pre-clinical,2,TRUE,FALSE,FALSE,[],['山东大学'],1,"['山东大学(原研)', '智峪生科']",肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
macrocyclic peptide antagonist of IL-11,macrocyclic peptide antagonist of IL-11 (Xuzhou Medical University),macrocyclic peptide antagonist of IL-11;macrocyclic peptide antagonist of IL-11 (Xuzhou Medical University),肾纤维化,renal fibrosis,IL-11,IL-11拮抗剂,徐州医科大学(原研),创新药,化药,多肽,环肽;差异化疾病;Potential First-in-Class,拮抗剂,肾纤维化(差异化疾病),临床前,,Active,泌尿生殖领域,DR084897,中国(内地),pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['徐州医科大学'],1,['徐州医科大学(原研)'],泌尿生殖领域,['泌尿生殖领域'],1,泌尿生殖领域,,,-1,-1,Genitourinary,Genitourinary,,
macrocyclic peptide therapeutics,macrocyclic peptide therapeutics (Pfizer),macrocyclic peptide therapeutics;macrocyclic peptide therapeutics (Pfizer),未知/待定,unknown/pending,not available,,Pfizer(Top20 MNC);Circle Pharma(原研),创新药,化药,多肽,环肽,其他,未知/待定,临床前,,Active,其他领域,DR078876,美国,pre-clinical,临床前,,pre-clinical,2,TRUE,FALSE,TRUE,['Pfizer'],['Circle Pharma'],1,"['Pfizer(Top20 MNC)', 'Circle Pharma(原研)']",其他领域,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,
neurodegenerative disease program,neurodegenerative disease program (Histide),neurodegenerative disease program;neurodegenerative disease program (Histide),神经退行性疾病,neurodegenerative diseases,not available,,Histide(原研),创新药,生物,多肽,环肽,其他,神经退行性疾病,临床前,,Active,神经领域,DR046820,欧洲,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Histide'],1,['Histide(原研)'],神经领域,['神经领域'],1,神经领域,,,-1,-1,Neurology,Neurology,,
non-addictive analgesic peptide,non-addictive analgesic peptide (PreveCeutical),non-addictive analgesic peptide;non-addictive analgesic peptide (PreveCeutical),疼痛,pain,not available,,PreveCeutical Medical(原研),创新药,化药,多肽,环肽;中国无申报,其他,疼痛,临床前,,Active,麻醉镇痛领域,DR014390,加拿大,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['PreveCeutical Medical'],1,['PreveCeutical Medical(原研)'],麻醉镇痛领域,['麻醉镇痛领域'],1,麻醉镇痛领域,,,-1,-1,Anesthesia & Analgesia,Anesthesia & Analgesia,,
oral macrocyclic peptide drugs,oral macrocyclic peptide drugs (Unnatural Products),oral macrocyclic peptide drugs;oral macrocyclic peptide drugs (Unnatural Products),未知/待定,unknown/pending,not available,,Argenx(原研);Unnatural Products(原研),创新药,化药,多肽,环肽;中国无申报,其他,未知/待定,临床前,,Active,其他领域,DR087728,美国;欧洲,pre-clinical,临床前,,pre-clinical,2,TRUE,FALSE,FALSE,[],"['Argenx', 'Unnatural Products']",2,"['Argenx(原研)', 'Unnatural Products(原研)']",其他领域,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,
oral macrocyclic peptides,oral macrocyclic peptides (Dayra Therapeutics),oral macrocyclic peptides;oral macrocyclic peptides (Dayra Therapeutics),免疫相关疾病,immune related diseases,not available,,Biogen(原研);Dayra Therapeutics(原研),创新药,化药,多肽,环肽,其他,免疫相关疾病,临床前,,Active,免疫领域,DR089273,美国,pre-clinical,临床前,,pre-clinical,2,TRUE,FALSE,FALSE,[],"['Biogen', 'Dayra Therapeutics']",2,"['Biogen(原研)', 'Dayra Therapeutics(原研)']",免疫领域,['免疫领域'],1,免疫领域,,,-1,-1,Immunology,Immunology,,
αvβ6 inhibitor,αvβ6 inhibitor (Lassogen),αvβ6 inhibitor;αvβ6 inhibitor (Lassogen),肿瘤,tumor,αvβ6,αvβ6抑制剂,Lassogen(原研),创新药,生物,多肽,环肽;Potential First-in-Class,抑制剂,肿瘤,临床前,,Active,肿瘤领域,DR005870,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Lassogen'],1,['Lassogen(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
αvβ8 inhibitor,αvβ8 inhibitor (Lassogen),αvβ8 inhibitor;αvβ8 inhibitor (Lassogen),肿瘤,tumor,αvβ8,αvβ8抑制剂,Lassogen(原研),创新药,生物,多肽,环肽,抑制剂,肿瘤,临床前,,Active,肿瘤领域,DR053232,美国,pre-clinical,临床前,,pre-clinical,1,TRUE,FALSE,FALSE,[],['Lassogen'],1,['Lassogen(原研)'],肿瘤领域,['肿瘤领域'],1,肿瘤领域,,,-1,-1,Oncology,Oncology,,
多肽偶联核素创新药物,peptide-conjugated nuclide innovations (Anji Biotechnology),多肽偶联核素创新药物;多肽偶联核素创新药物 (安吉生物);peptide-conjugated nuclide innovations (Anji Biotechnology),未知/待定,unknown/pending,not available,多肽偶联药物,安吉生物(原研);纽瑞特医疗,创新药,化药,多肽;偶联药物,环肽,多肽偶联药物,未知/待定,临床前,,Active,其他领域,DR044216,中国(内地),pre-clinical,临床前,,pre-clinical,2,TRUE,FALSE,FALSE,[],['安吉生物'],1,"['安吉生物(原研)', '纽瑞特医疗']",其他领域,['其他领域'],1,其他领域,,,-1,-1,Others,Others,,
